<SEC-DOCUMENT>0001125345-18-000097.txt : 20181107
<SEC-HEADER>0001125345-18-000097.hdr.sgml : 20181107
<ACCEPTANCE-DATETIME>20181107160542
ACCESSION NUMBER:		0001125345-18-000097
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		47
CONFORMED PERIOD OF REPORT:	20180930
FILED AS OF DATE:		20181107
DATE AS OF CHANGE:		20181107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		181166297

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgnx-20180930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2017 Workiva--><!--r:b7316434-03a0-4e88-aa3b-e89ba2bd1bc0,g:5bed0e04-ab87-46dd-8d59-93be05bc483c--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:mgnx="http://macrogenics.com/20180930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"><head><meta http-equiv="Content-Type" content="text/html"></meta>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfNC0xLTEtMS0w_9c3377a5-2377-4ee7-bdc4-1d50adc34b34">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfNS0xLTEtMS0w_e2fbccb0-bf75-4da5-85e2-8fc2aa2ff46f">September 30, 2018</ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfNi0xLTEtMS0w_febdfbb4-25b7-4970-b865-97b883eb15fb">2018</ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfNy0xLTEtMS0w_42032e07-ba2e-4615-a013-76b0083bb74f">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfMTQtMS0xLTEtMA_609ba57e-c11f-4055-8af3-e4dd9432e79a" escape="true">Large Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfMTQtMS0xLTEtODcz_474b2569-5890-4c20-ac91-872171fb7511">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" format="ixt:booleanfalse" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfMTUtMS0xLTEtODc1_87c16290-4959-40c5-b554-92cf7f9d24b8">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RleHRyZWdpb246MTQ3MWIyMjcxYTAxNDZkNTllMjU4NTBmMzAzOTg2ODRfNzE0NjgyNTU4MDY5Mg_362cf4ec-f5cf-4e21-ac7d-9d0512a45b9a">MACROGENICS INC</ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RleHRyZWdpb246MTQ3MWIyMjcxYTAxNDZkNTllMjU4NTBmMzAzOTg2ODRfMjc0ODc3OTA2OTQ5MQ_86e1294e-4904-48a7-9947-0d55c34e2499">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RleHRyZWdpb246MTQ3MWIyMjcxYTAxNDZkNTllMjU4NTBmMzAzOTg2ODRfMjc0ODc3OTA2OTU0Mw_942057ec-6717-486e-ace7-483721cd680d">--12-31</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfMi0xLTEtMS0w_23dcdd2a-5f00-4bb6-915c-a84ad788e63d">0.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfMi0zLTEtMS0w_393c0b9a-379c-4de8-8240-76d323d4701e">0.01</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfMy0xLTEtMS0w_f541d0af-06e7-45c9-9303-1cbf8b046d37">125,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfMy0zLTEtMS0w_45c13a89-4086-47b7-9196-3281eca36c6e">125,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfNC0xLTEtMS0w_61470536-8b9f-48b6-9258-3d5dc2477536">42,248,075</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfNC0zLTEtMS0w_935ed1dd-81d2-4f70-b38c-f3dd24bd9255">36,859,077</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6d547ea0cc684d02aaf167a81f92222e_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzMtMS0xLTEtMA_d5ed95a9-21cd-4c85-aac1-0c2883784cab">67.8</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i52b5b8baf4a04bc0a8515a755c75a5c6_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzMtMy0xLTEtMA_02e461a7-710a-4897-ab15-63b79b0722de">72.2</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie82d67a794864a96916fa3f3a87b1009_D20170101-20170930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzMtNC0xLTEtMA_da304e26-fd93-4fec-a63f-a9ba826d36fd">66.7</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i922b4063c16e435394fae5cdc427b832_D20170101-20170930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzMtNi0xLTEtMA_d7774ac0-179a-4523-ae3c-fb11586adfac">68.3</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6d547ea0cc684d02aaf167a81f92222e_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzQtMS0xLTEtMA_4d7b573a-a0ee-43a6-93d6-ad832575e3ee">2.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i52b5b8baf4a04bc0a8515a755c75a5c6_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzQtMy0xLTEtMA_876cf79e-8f4f-475e-98f2-ced5cb1741a7">3.1</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie82d67a794864a96916fa3f3a87b1009_D20170101-20170930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzQtNC0xLTEtMA_74dc8fa0-36da-473d-96cf-642502101459">1.9</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i922b4063c16e435394fae5cdc427b832_D20170101-20170930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzQtNi0xLTEtMA_f2467f92-5105-4822-b46d-564ac8f16be1">2.3</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mgnx-20180930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i663eb470436c44d0b0424c19e8eab05c_I20181102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i160748b7708d470795cebd2e08cb1b72_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibdc22a390e884f349065805d8e43c679_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44bef5523be840cea494b1c6a9b364fe_D20170701-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44dcd64c130143e7b61b89fe2646000c_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7551c75d6a4793b8ba11659882c30b_D20170101-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a267842ce243189b28090dcf3b6338_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ccb567960f5405fb383ac91138849ca_D20170701-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8497085013f24f54a1464c82acde208c_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca90c5a445d4c77b930deb2ab301751_D20170101-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c071206cf7f4239b167641403572000_D20170701-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a775ac09b1433ab3a29927f84e27f2_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f061d896ab34adea1ec90f8ea217749_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if800a2edba02435c841fd5ce6f7aada7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb6469bec1ea4f8ca65fdad40040b929_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bab00c844a44b45bc42e1f5791cae02_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d979866d3b64e8ba979cb9f915e748f_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5fdced0c8347e9aa3943f81e9837f6_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87517407dd334c3893ac19538b16fd3e_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bedc85266654eaab2882c9503e960e8_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5ededd31534749ab8242be3126e5b2_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib492f638d82e4414a041403e1eddbe3a_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d0da9b4cc14b75991174bfa7e7e7e0_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2083d2f9a48048808e8f2445e7f65ceb_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c61aa06ff0442f384bef16716c9e006_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd177baefb24c5da5f5d762ca97c05a_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i671934b6ca254466884554fbd72599a7_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50ec2c1d0e4f4f05bf9e358137601c56_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic80626a5f83c4f92b03a719528d899b3_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5643f6cec2de4538bc34d86d7a1d42ef_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i588e913554c54d489854f5d7b18643f3_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e44fd3fe174432a63b857d20d62cb9_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5394f3e223d14c0f9d447b8dba062cc7_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a504713132440edac1e257a897cfc5e_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01e4f28d5a2f4d8ba5410cb06f830efb_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc0a6957b1049d1a7fd2aca4546de77_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60a9918f2b454a02a9f52660bcfd9700_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154046cc71f34152877eaec79ccfc61b_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e72fa606524cb6811b76c6b57eb806_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94648d0db7a94b95bcaa11b425cfe7af_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3518f59ae82e4ef582788fe57cbcd3e0_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e9852ab63b4061801c673b10dcb0cd_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e27978db3d429bb2846824cbb065da_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6b9ff22ede4845b89261faf1de4b00_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0fa81042e394b329de76ce95f09cff5_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice63152ef2424cc4a9579cbdc1d6240e_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i723d050a26224f16a353738eb4442e04_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9d77208352f4d25bf386d786bc798cd_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd4f120866b645c4bf3cce8586698473_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaadfc51e828143479b2403579738eaff_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c4cc1bdf234cf987926cd8055b2734_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0eeb462be349aea122b32abf38ffa1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2a21b952a4442dbd5213ed0c13c412_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ef68251110c449f86e8dd7547298305_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d1c05ab7cef41bda60ce9805aa4b8d6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a7580bc237e44bba24dcaac666b17bd_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c92391cb5f04624be95aa6135f9c5e0_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6626efe68b914e4aa0c4c00a038ca6fb_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b810da2b4434106be6a2f4868aa983b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f5d3be38314de693952411eb401367_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8ab2c156a8d47f5b370a57673a58703_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i375187cfa8df4fac956142beb3307c5e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadea8e8fa97d481495bfa26ed8bcb2e8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e22d2b5dd8454fbebfa09f3feb0749_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39b863145a6442bfa00fd78279e2e6d7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ec2edcab7e43d583877d5a7a390b74_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075636ae66df40faaee95c130bcf8ea4_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e13a785a984de8ab85335f4e573536_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if287162bc94548119144a45ef00144e0_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1aa2e56fe0043f790bcc747ebd4cf13_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fac88e6145545bcab342e1996db0e66_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f6af7af270436ebef7bd53a4e07f80_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if828ac34fb81419ca9d1984770c76254_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4af18da1684515ba77f3fadc4081d3_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i866096d237f54e4583f3e604e8c243ec_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i026f26d0cf654febb2e1e5f3037d5afc_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d0a400707884c2198f13e93d13ca5cf_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b8d6b8d41d4fd494c10b56288a758f_D20170426-20170426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-26</xbrli:startDate><xbrli:endDate>2017-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187b1747b6ea4fe7bd1a794a51a3a8bf_I20170426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed9ef592d4e44dd88fcc594f7f2d847_D20170503-20170503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-03</xbrli:startDate><xbrli:endDate>2017-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273fc3440aa24332a0568edcf542e1aa_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c786749d1894dd6a9b452378513440b_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9c327300a84aafaf0a8890a6378c39_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d3c290311249a18501533c07d13527_D20180402-20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-02</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9127f44e472a4031acb85a2e77e5c974_I20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f941ef8b4f48e482ec7ee2d06ebaa3_D20180402-20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-02</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9cd335c9244d9fb051a1a01f207509_I20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e8c9eb9fa140f7bf495f250946e437_D20180402-20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:PublicOfferingandOverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-02</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2f267ad6954342818988358aaec05a_D20171001-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab2d3c47fcb482fb5016a56c6678a2f_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i583cbd7fe1f847cea4b7238b2bc9436a_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia06a043fda544306a7174163d4ba821a_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85e4b6bf29674ed0bb853ac49b61574b_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="performance_obligation"><xbrli:measure>mgnx:performance_obligation</xbrli:measure></xbrli:unit><xbrli:context id="iddfd5052e98f4ca28241b0916f60a7d1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia03651a398b047e6ba26bc530ae802ba_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe8622ead245454683d6cd02732a930e_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e9c20469d344180a7bdbf43ccc98126_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7afec6a50d3e4c49b2fceac1c053cee8_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03336d63cb2e4abf99d71150176d9e2a_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd05ad37dc5648948de2ec1ebeeb9880_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd5dfaa7121c4b398f87a4bf82fe6818_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304e6e07763f45adac1a934bb867bb1b_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadb65054ca38420abd5f2059371dcff6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd2cfd87b18c4510b689cf0331b1d471_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2076bfb4648e47319c3d79dc8b4f052f_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09bb778c2423410098bdc0c426490d87_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ae03eea2c343388670589c0cc8cee6_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="exclusive_license"><xbrli:measure>mgnx:exclusive_license</xbrli:measure></xbrli:unit><xbrli:context id="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e0829991f74feeaba02806ccb252be_D20120901-20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-09-01</xbrli:startDate><xbrli:endDate>2012-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2d8a380170427b92101d51e25a734b_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061c41caf2584f488de00de72d70d359_I20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>mgnx:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i88a4efe1362c4a3db0196262405ad178_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb7ae82b7fd94218adec5b37c3baf521_D20120901-20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-09-01</xbrli:startDate><xbrli:endDate>2012-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bdd4ce1abcb4d84918166baa0aab54f_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib593ee5aff884b09b56907f69f0517e1_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i166c43c2262341ea91348516a28bcbd9_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6a295ad13346be87c34a41d8a59a09_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="component"><xbrli:measure>mgnx:component</xbrli:measure></xbrli:unit><xbrli:context id="ia231899505ea4e26b8ae99393f58f9f8_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f54d23042ce45e3b0f7b1f3527e965c_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d44f7b71fc4200940cf6d3d09f2c3b_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b4e8d5c2cc41a7abc24c33b0b6b4e0_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a09839b03404373938e8002919f2856_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i660cb75a1c0d41c983132bc62bb7d5cd_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52bce1b6baef4facb924a318ed17002f_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23557f80a0a245a690a3b1b11c018cc8_D20180531-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5de7b28e2d4befab1ed1cec48844f6_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i829603c6236e41f2951a9087431df091_D20180531-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77e14b4fd8a549c99d5b94473df0cbdb_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia27a68ad905842ba80b4de3e9d1b929e_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83423a11889045c1bcdec405be3fa546_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i452ee1a0ab714c34ababb41227155f6d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6da7c74defea4d8fb09ed95435cc7a03_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8821603bb64976be6518e29c1c250d_D20170701-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28991436c91f443c8ede9c7a2c47f606_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54aa98e1360041ea8a6f19ceeab7a123_D20170101-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie758ea00f3b045d8aaf61ff77aa1bd5b_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e9f6ff05ac42748139386a1f145650_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib21a72497c3f4f4586fc6f1f696f8ee0_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf2e982e7c3a42d487a756a32a510ac0_I20030228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2003-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib58f57547e3d4bb8a8a5328327afc915_I20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706d5cef31cd430e8365f6915ddcb64f_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ec44ff783b431cb9ed2678498d5f97_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i596e64c58833410299f5dd5853dd7260_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7042cd13db6549e7871f168d9d646e10_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e7fa001b0a43809cae26254818dd0a_D20170701-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i331b887054c54310ba485d67cc56fd98_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1169246d2ee645d2b41f43608d9c7971_D20170101-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie67728928c2f4b7c926568160fbfbb42_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c2c78af9f724b04b7f633e772d609d4_D20170701-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee7edc452a8d41b8a7136478d6aca726_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47470559910c4104a2b667fa430274d6_D20170101-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d547ea0cc684d02aaf167a81f92222e_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b5b8baf4a04bc0a8515a755c75a5c6_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie82d67a794864a96916fa3f3a87b1009_D20170101-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i922b4063c16e435394fae5cdc427b832_D20170101-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:18pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">WASHINGTON, D.C. 20549</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xL2ZyYWc6ZjZiZDE4MzhkMTNkNGIxNGI2MjI3YjMwMjVkNDliNzgvdGV4dHJlZ2lvbjpmNmJkMTgzOGQxM2Q0YjE0YjYyMjdiMzAyNWQ0OWI3OF81NDk3NTU4MTU4MjA_db3b3318-a8fe-43fd-9c5b-8b823422137c" escape="true">10-Q</ix:nonNumeric></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:3.563690%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.436310%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended September&#160;30, 2018&#160;</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:3.563690%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.436310%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;"> to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number: 001-36112</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:24pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:49.683748%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.316252%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Delaware</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">06-1591613</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(State or other jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">incorporation or organization)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">9704 Medical Center Drive</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Rockville, Maryland</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20850&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(Zip code)</span></div></td></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">301-251-5172</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Registrant's telephone number, including area code)</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "accelerated filer," "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:16.740849%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:53.636896%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.547584%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.074671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Non-accelerated filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Emerging growth company     &#9744;</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of November&#160;2, 2018, the number of outstanding shares of the registrant's common stock, par value $0.01 per share, was <ix:nonFraction unitRef="shares" contextRef="i663eb470436c44d0b0424c19e8eab05c_I20181102" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xL2ZyYWc6ZjZiZDE4MzhkMTNkNGIxNGI2MjI3YjMwMjVkNDliNzgvdGV4dHJlZ2lvbjpmNmJkMTgzOGQxM2Q0YjE0YjYyMjdiMzAyNWQ0OWI3OF8xOTA3_903c9f43-35c5-4313-ae35-10bf280212e2">42,259,080</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_27"></div><div style="text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:18pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:22.193548%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:73.806452%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">PART I.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_52">FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_66">Financial Statements</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_78">Consolidated Balance Sheets at September 30, 2018 (unaudited) and December 31, 2017</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_104">Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2018 and September 30, 2017 (unaudited)</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_116">Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and September 30, 2017 (unaudited)</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_129">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_279">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;3.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_363">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;4.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_376">Controls and Procedures</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">PART&#160;II.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_388">OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;1A.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_400">Risk Factors</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;6.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_412">Exhibits</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_426">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i_0_39"></div><div style="text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    our plans to develop and commercialize our product candidates;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    the outcomes of our ongoing and planned clinical trials, including when clinical trials will be initiated and completed and when data will be reported or regulatory filings made;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    our ability to recover the investment in our manufacturing capabilities;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    significant competition in our industry;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    costs of litigation and the failure to successfully defend lawsuits and other claims against us;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    economic, political and other risks associated with our international operations;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    our ability to protect and enforce patents and other intellectual property;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    loss or retirement of key members of management;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    our failure to maintain effective internal controls.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div id="i_0_52"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PART I. FINANCIAL INFORMATION</span></div><div id="i_0_66"></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i_0_78"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:58.205580%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNC0xLTEtMS0w_01a5a890-2f57-42e3-a20d-48de6d902b18">201,807</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNC0zLTEtMS0w_b43fd99f-a1db-4392-bad5-5d77bbb342b0">211,727</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNS0xLTEtMS0w_119ab845-2a1a-49d0-9dbb-cc194f664185">58,336</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNS0zLTEtMS0w_c5352ddb-ef29-48ce-9300-bf584e9cd022">93,394</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNi0xLTEtMS0w_0ac79038-4248-46dd-bcf7-4678d06fc05d">20,970</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNi0zLTEtMS0w_631e4194-fd2a-40c0-a95e-e85e6aa6f81b">13,643</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNy0xLTEtMS0w_7b72df1c-a32f-4b77-aef6-5670b8ab9076">4,315</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNy0zLTEtMS0w_efc9b429-eec8-4f84-98f8-ed0cde6098ba">3,151</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfOC0xLTEtMS0w_256fd5bf-0326-491c-892f-baf04e8373b7">214</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfOC0zLTEtMS0w_ccac1129-d2f3-4bd9-9eaa-ac59fc46b0ec">383</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfOS0xLTEtMS0w_8c378dfd-1087-4e6b-a8d3-eea8a6497d78">285,642</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfOS0zLTEtMS0w_49b920c8-94dc-422b-83d3-10e61bb4a6d1">322,298</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, equipment and software, net&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTAtMS0xLTEtMA_226f753c-6516-4b1f-9c88-6dc552035114">58,649</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTAtMy0xLTEtMA_d1cf40c6-0fe1-4084-a70c-5f5c7fe0d7af">49,983</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTItMS0xLTEtMA_0d4c5ec8-2439-44e5-9701-ba2cbd2f2494">11,065</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTItMy0xLTEtMA_14c95eec-d98f-47ce-a39a-d46c9591a09a">1,602</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTMtMS0xLTEtMA_8ed1d431-4699-43ff-994b-c6274ce59264">355,356</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTMtMy0xLTEtMA_02bd552b-6bc8-4c3e-9a63-375b46fb12c5">373,883</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders' equity&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTctMS0xLTEtMA_74df915a-cbda-4c51-8f4c-0647937d9648">986</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTctMy0xLTEtMA_4d256f77-3d3a-4322-b596-5514bbe00283">2,451</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTgtMS0xLTEtMA_b76f2040-b963-46e5-9d83-a6691b23666c">38,477</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTgtMy0xLTEtMA_ddc14542-0b7c-4000-83b9-7932b7c07c0b">38,581</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTktMS0xLTEtMA_d126fd16-d01c-4f3b-a21e-2892d75fd093">7,377</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTktMy0xLTEtMA_ba56c708-4430-4126-bf04-34ed6794bd8c">7,202</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjAtMS0xLTEtMA_ff581faa-6ba9-4986-abeb-40a47284405c">1,010</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjAtMy0xLTEtMA_173611e3-c70e-4f92-ba0f-36e69a027041">1,048</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease exit liability&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RestructuringReserveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjEtMS0xLTEtMA_044b7e7d-d1d1-45ee-9180-949cf5af146a">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" name="us-gaap:RestructuringReserveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjEtMy0xLTEtMA_21945281-c7b3-4560-9932-0b16611a19a3">298</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjItMS0xLTEtMA_1c47b099-b762-4a13-be12-32dfc816b713">175</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjItMy0xLTEtMA_10ea059b-867f-43bf-bda6-61efe49ac653">175</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjMtMS0xLTEtMA_6ad57b66-e52d-49fc-839c-59f8b63df8f4">48,025</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjMtMy0xLTEtMA_9dbfc26e-e51f-4649-b598-54ffc2b800ef">49,755</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjQtMS0xLTEtMA_9fa4cc9e-d32b-4036-98eb-8e2e7a1e19fc">14,134</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjQtMy0xLTEtMA_050a213e-7a91-4ff2-9633-fd24933d7d90">13,637</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent, net of current portion&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjUtMS0xLTEtMA_1dd74b7b-11fe-44c8-9c65-ac05583b2d64">10,553</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjUtMy0xLTEtMA_822bd73f-f030-42d0-9dd1-edb2993e8927">11,253</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjctMS0xLTEtMA_b9a26fab-e1a2-4e2d-8a19-bc0b97b4390b">72,712</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjctMy0xLTEtMA_d715f962-cc30-44cd-95aa-50314f830332">74,645</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock, $0.01 par value -- 125,000,000 shares authorized, 42,248,075 and 36,859,077 shares outstanding at September 30, 2018 and December 31, 2017, respectively&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjktMS0xLTEtMA_f7be2d78-cd87-406b-aa7e-d69a829a50d8">422</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjktMy0xLTEtMA_e4d01dc5-4c78-4b11-a8bb-01e55d4cfcc1">369</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzAtMS0xLTEtMA_04e93210-f951-433c-b88c-aaa2dbd4c17b">727,849</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzAtMy0xLTEtMA_42579f69-4cc1-4327-aa65-f82974057e87">611,270</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzEtMS0xLTEtMA_fc10cf2c-196d-4f1e-9322-b3523dec3503">445,627</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzEtMy0xLTEtMA_cf8b23cf-7dc0-450c-8251-ff648b26e9e5">312,340</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzItMS0xLTEtMA_72e8c292-bb13-4c3b-b863-b2e0e9aa23f0">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzItMy0xLTEtMA_0b70a78e-f20f-43ef-badf-707b2debbf90">61</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzMtMS0xLTEtMA_2ebb9777-827c-42cb-aceb-2ccb8cfae39e">282,644</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzMtMy0xLTEtMA_c4e041d1-a9bd-447b-bc3e-b89e7db8f293">299,238</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzQtMS0xLTEtMA_6cea2ab6-81d0-4e6b-8dbc-2c9b29bd9ba1">355,356</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzQtMy0xLTEtMA_1e2f7294-6eb5-4c8c-a280-5a6748349b76">373,883</ix:nonFraction>&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">See accompanying notes.</span></div><div id="i_0_104"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:44.198830%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596491%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695906%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.865497%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:25pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:25pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative and other agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibdc22a390e884f349065805d8e43c679_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzMtMS0xLTEtMA_f483b115-8c67-4592-952e-e1e09b557846">20,617</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44bef5523be840cea494b1c6a9b364fe_D20170701-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzMtMy0xLTEtMA_80d7bed7-6661-44c1-b955-07a8a061aad2">1,076</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44dcd64c130143e7b61b89fe2646000c_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzMtNS0xLTEtMA_b87b305f-83f1-4fe8-acd0-477e4bbb7f0a">43,670</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf7551c75d6a4793b8ba11659882c30b_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzMtNy0xLTEtMA_2cab91ff-1e42-4ed9-b3ed-f8a48ab25d35">3,435</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from government agreements&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39a267842ce243189b28090dcf3b6338_D20180701-20180930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzQtMS0xLTEtMA_5bbe088a-3171-4993-8775-4003b946b082">181</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ccb567960f5405fb383ac91138849ca_D20170701-20170930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzQtMy0xLTEtMA_a51a4968-c25c-4da0-b4e5-0bbd0b03490a">587</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8497085013f24f54a1464c82acde208c_D20180101-20180930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzQtNS0xLTEtMA_269d8e84-10de-4811-80cb-c78040aebd22">657</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ca90c5a445d4c77b930deb2ab301751_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzQtNy0xLTEtMA_0d333e4f-8a0f-4494-b844-5b7d46874fa0">1,948</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzUtMS0xLTEtMA_4052e386-11dd-4a38-8798-a7595ea7a393">20,798</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzUtMy0xLTEtMA_0a793e95-4279-4a24-a2b9-9f2ca533c835">1,663</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzUtNS0xLTEtMA_a8d4c8f8-b456-4104-9f21-e93a2bbedafc">44,327</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzUtNy0xLTEtMA_1a96693d-ae97-4270-a20b-0066779bb0ba">5,383</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzctMS0xLTEtMA_0af18095-747a-4545-bf1e-8978357d092b">46,218</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzctMy0xLTEtMA_80abe055-11c1-4463-bd4d-a93a198782c3">40,984</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzctNS0xLTEtMA_3a143af4-f00d-424a-851d-c57b70560754">143,902</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzctNy0xLTEtMA_0d255c1e-4ac2-4fd6-90af-addd5efcbf70">108,246</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzgtMS0xLTEtMA_685ad280-f4c1-48c8-ab0a-bf3282606dcf">9,584</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzgtMy0xLTEtMA_91220371-0ec6-4c73-bf64-e991bef78281">8,403</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzgtNS0xLTEtMA_905836b1-259c-4511-88b0-dfd692811bda">29,953</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzgtNy0xLTEtMA_9a173afd-b5f3-4030-95c2-b4a0130bb6a0">24,249</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzktMS0xLTEtMA_e93f21ab-57f1-436a-935c-4e9f5a83ee01">55,802</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzktMy0xLTEtMA_f1070e43-0887-48fd-972b-cfe4d08ba52c">49,387</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzktNS0xLTEtMA_b474c5cd-d320-4032-958a-8b0c5896d1c8">173,855</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzktNy0xLTEtMA_d47a67c0-5b36-440f-9d1b-5f192006fd02">132,495</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEwLTEtMS0xLTA_552bc115-8576-42df-acf5-c63b0e8183dc">35,004</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEwLTMtMS0xLTA_4f92a168-274b-4e13-8203-d6ea15e657c0">47,724</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEwLTUtMS0xLTA_7fd0bf93-2e90-4750-bebc-50da4e1ae575">129,528</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEwLTctMS0xLTA_8a44e2b9-279b-4b7d-851a-371b6dafeb06">127,112</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzExLTEtMS0xLTA_bc3a236a-f467-447c-835a-5778020c9f2b">975</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzExLTMtMS0xLTA_3476098a-7c18-4f16-be6b-16954f4c1762">681</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzExLTUtMS0xLTA_0c44de19-9447-4e02-975e-b355f51bf226">2,719</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzExLTctMS0xLTA_6f38ef8b-2521-4bfd-ac12-6f87c73193c2">1,759</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEyLTEtMS0xLTA_25f29189-de39-43d4-98a3-563404caa052">34,029</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEyLTMtMS0xLTA_0b0cae66-e19b-4377-9f95-35f474ea5f09">47,043</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEyLTUtMS0xLTA_6cc02ada-7edf-4242-b02a-ed33b520ba05">126,809</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEyLTctMS0xLTA_3fb0ec44-b72c-42ee-b9df-90582333ba60">125,353</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss:&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain (loss) on investments&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE0LTEtMS0xLTA_af011db1-156d-448a-8d51-181a57c22259">18</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE0LTMtMS0xLTA_abe8e2cf-d27a-4fc6-9965-1b9514ad878f">56</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE0LTUtMS0xLTA_ddca6e13-0de3-476c-82eb-332d9da1a496">61</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE0LTctMS0xLTA_e9e3bf05-2322-42ef-9833-39494711bd50">55</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE1LTEtMS0xLTA_889bea93-c50a-4452-a30c-dba5855a9e55">34,047</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE1LTMtMS0xLTA_5b2fba60-d47c-4de9-ab7d-c529001cf402">46,987</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE1LTUtMS0xLTA_adb5a135-df8b-457e-b876-eab3969eca71">126,748</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE1LTctMS0xLTA_dbdfa9aa-d1e7-41d5-a131-4b6a04f3e04b">125,298</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE5LTEtMS0xLTA_56c8fb33-443d-4ac3-bc1a-b531607a97a1">0.81</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE5LTMtMS0xLTA_e9f95c1f-bb6b-4699-96d8-c73e02a3fc94">1.28</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE5LTUtMS0xLTA_648f972c-b8c8-4929-a066-e11d8384982d">3.13</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE5LTctMS0xLTA_48073963-ff0c-465f-9e6e-7215c2ec5f60">3.50</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted weighted average common shares outstanding&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzIxLTEtMS0xLTA_6e8b6223-f450-4055-b6ee-40de7d912da4">42,239,327</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzIxLTMtMS0xLTA_a65ac833-92d1-4f8a-b3e6-8e053d2cae2e">36,779,305</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzIxLTUtMS0xLTA_a285eb99-0eaa-48ca-ba68-48be409bd68e">40,462,658</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzIxLTctMS0xLTA_828ac9d9-aca3-40ef-89a5-c634067f76bf">35,847,449</ix:nonFraction>&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">See accompanying notes.</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_116"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:67.603524%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.831131%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.831131%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:22pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:22pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzMtMS0xLTEtMA_a6f51422-ec2a-4d01-b41b-0ae990b25b1c">126,809</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzMtMy0xLTEtMA_16dff779-ac91-457c-9c93-17b89fcc92c6">125,353</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzUtMS0xLTEtMA_be77cb27-0fd3-4b6e-9e46-f68807604d02">5,268</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzUtMy0xLTEtMA_675806b5-e813-4312-9a22-28ff160f61ec">5,886</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzYtMS0xLTEtMA_a557bb80-879b-448c-8a6f-ec72e71d07b4">12,168</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzYtMy0xLTEtMA_5bf473c7-9d29-4590-aa97-a6dd780c8ddd">11,064</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzgtMS0xLTEtMA_433c32d2-5373-49bc-9400-7e8b6c547b51">7,328</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzgtMy0xLTEtMA_5bafca07-25c0-4fd8-8e75-a05473084c02">570</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzktMS0xLTEtMA_8fe4ea31-fc35-4dc8-915a-f5ae8d56496f">1,164</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzktMy0xLTEtMA_4b9cb0f5-bfa0-4bae-8014-9f8df3dab75d">222</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEwLTEtMS0xLTA_fe14d147-1e27-4772-bb85-e50988c474c3">9,293</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEwLTMtMS0xLTA_a123a822-a000-43ba-a51d-c95f121bfc78">168</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and other liabilities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzExLTEtMS0xLTA_bc773a80-8547-47bd-a400-21d7dea5ceef">1,465</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzExLTMtMS0xLTA_d8e80c93-b02f-4790-9c3a-686c067cdd6f">2,138</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEyLTEtMS0xLTA_efcb7ef6-ea3d-4d32-8ad9-0e472f9593f7">9,460</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEyLTMtMS0xLTA_7f6807b1-f1cd-4ed7-bb6d-bd7f25ea7990">9,501</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease exit liability&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInRestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEzLTEtMS0xLTA_06ffaa38-90c7-46be-a13e-b83e1695b197">298</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInRestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEzLTMtMS0xLTA_b3661e6e-9908-49dd-bb73-2a722cd0f11f">1,176</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE0LTEtMS0xLTA_e0aa1a88-c8d0-4c50-81bf-61dfac57dc7c">5,807</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE0LTMtMS0xLTA_07dd61f6-e4e5-42e8-ba71-1fa298b3c9ea">2,666</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE1LTEtMS0xLTA_e4767ca3-44fe-40e3-98c4-c1f804769c7a">738</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE1LTMtMS0xLTA_cc5799c9-132e-46d8-8e95-5796030eb450">6,482</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE2LTEtMS0xLTA_de51f8c6-f5f9-4034-9a58-4ecdb79aac8e">126,006</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE2LTMtMS0xLTA_9e0c9262-5de2-4618-a3f8-5a303fad4a4c">97,440</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE4LTEtMS0xLTA_29980300-c1ea-4ec0-945a-56d5c85307eb">120,039</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE4LTMtMS0xLTA_5094ab42-4e2c-4535-9275-18e88720a124">89,124</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale and maturities of marketable securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE5LTEtMS0xLTA_f05fdb4a-cdfb-4151-8f9c-eb0bad5baf86">155,848</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE5LTMtMS0xLTA_cc9d4ece-aea1-41de-a76d-84fa0487717e">177,006</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIwLTEtMS0xLTA_6d06e949-1077-42e0-a802-e1880570d936">24,239</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIwLTMtMS0xLTA_ddec8e7b-0cf3-4f8d-811b-5696e0038b03">18,645</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by investing activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIxLTEtMS0xLTA_594282a4-100e-4f11-897f-2c1cab94a64b">11,570</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIxLTMtMS0xLTA_3d660e02-c672-4c34-93d4-0af19ecf066e">69,237</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock, net of offering costs&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIzLTEtMS0xLTA_c24ee5db-5ea2-4f36-a57b-b0c6d59c190d">103,259</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIzLTMtMS0xLTA_e1c3cc9d-15d9-4622-ab6c-3f58673310ef">34,294</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from stock option exercises and ESPP purchases&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI0LTEtMS0xLTA_cc3dbeeb-5dd9-4abf-b06d-6a1b6cc42f25">1,257</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI0LTMtMS0xLTA_4a7a4d1f-9f2b-4582-ab1f-5aa0da3a0e10">695</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI1LTEtMS0xLTA_1c00c850-390e-4b41-845c-5ee83ffccc96">104,516</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI1LTMtMS0xLTA_4319e828-1d94-4365-956e-837ecdb0d26c">34,989</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash and cash equivalents&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI2LTEtMS0xLTA_ff94fe7b-daac-41aa-be52-292dc57966e1">9,920</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI2LTMtMS0xLTA_30b40b5b-9559-4068-ad65-5b5edd352a0c">6,786</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI3LTEtMS0xLTA_fd1bf7e5-1b7d-4556-b8c5-938f3cca50d2">211,727</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i20a775ac09b1433ab3a29927f84e27f2_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI3LTMtMS0xLTA_961cbac6-a290-4c64-9194-92a0f29a45d8">84,098</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI4LTEtMS0xLTA_5dcf204d-79b8-424e-b982-6618e44b3498">201,807</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f061d896ab34adea1ec90f8ea217749_I20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI4LTMtMS0xLTA_b00d9e91-fbe7-46fa-b5e0-454e54b15c6d">90,884</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash operating and investing activities:&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of warrants received, including change in value&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzMwLTEtMS0xLTA_46115dfe-9aa7-4397-8dfe-a66f6b5d2925">6,130</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:zerodash" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzMwLTMtMS0xLTA_543194e3-fb61-4167-a235-96dbd3649f34">&#8212;</ix:nonFraction>&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">See accompanying notes.</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_129"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="i_0_142"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY5MDE_16100cd4-d7af-4f1c-bb2f-785e2eb68aba" continuedAt="i5bb9290232c247b5b19ed9e61924ab9e" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i5bb9290232c247b5b19ed9e61924ab9e" continuedAt="i012e44631b4f4bb58873e52b24f3e6be"><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY4OTY_4ad49fde-f39c-4b67-9412-c78d906a5421" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2017 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2018.</span></div></ix:nonNumeric><div style="margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="text-indent:18pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">With the exception of the adoption of Accounting Standards Update (ASU) No. 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> and all related amendments (collectively ASC 606) during the nine months ended September 30, 2018, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017.</span></div><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY4OTc_881265af-c16e-4420-ba30-b39eee40634b" continuedAt="ifbaf4c14e83f4fbeb724c55dc61523b3" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Effective January 1, 2018, the Company adopted ASC 606 using the modified retrospective transition method. Under this method, results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">accounting standards in effect for the period presented</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The Company applied the modified retrospective transition method only to contracts that were not completed as of January 1, 2018, the effective date of adoption for ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company also enters into manufacturing service agreements.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i012e44631b4f4bb58873e52b24f3e6be" continuedAt="i00ba3ca3cd9a4168bd77a117bf8bd0c9"><ix:continuation id="ifbaf4c14e83f4fbeb724c55dc61523b3" continuedAt="i97abe241f27d45cbb0793148d15ae4f4"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Licenses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Research, Development and/or Manufacturing Services. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Customer Options. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement, and the potential payments that the Company is eligible to receive upon exercise of the options are excluded from the transaction price. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Milestone Payments. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div></ix:continuation></ix:continuation><div style="text-indent:36pt;margin-bottom:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i00ba3ca3cd9a4168bd77a117bf8bd0c9" continuedAt="icf976baa9adf411eb14cc3db41767dbf"><ix:continuation id="i97abe241f27d45cbb0793148d15ae4f4"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Royalties. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 5, Collaboration and Other Agreements.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Accounting Pronouncements</span></div><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY5MDA_db22a2db-f8ee-4c08-b72e-d1277bc0728b" continuedAt="iad062b9180784439a7cf251548f579fd" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">Recently Adopted Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2014, the Financial Accounting Standards Board (FASB) issued ASC 606. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts that were not completed as of January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with available practical expedients.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Comparative prior period information continues to be reported under the accounting standards in effect for the period presented. </span></div><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY4OTg_ff5e61e8-f9c0-4984-af54-5d570e6de58d" continuedAt="i56dc0a8c13ac4357aab9bd81fdae22f3" escape="true"><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:52.465593%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.641288%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.641288%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.678477%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.641288%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Pre-Adoption</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">ASC 606 Adjustment</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Post-Adoption</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, current</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if800a2edba02435c841fd5ce6f7aada7_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzEtMS0xLTEtMA_e1303155-9dd9-4165-97ad-5b1528e357be">7,202</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb6469bec1ea4f8ca65fdad40040b929_I20180101" decimals="-3" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzEtMy0xLTEtMA_0ff616ce-7b26-422a-b689-97c6736dc352">540</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6bab00c844a44b45bc42e1f5791cae02_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzEtNS0xLTEtMA_60eee4a2-f050-488e-b841-316adb633766">7,742</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, net of current portion</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if800a2edba02435c841fd5ce6f7aada7_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzItMS0xLTEtMA_b23acd0f-886f-4da8-9c60-a18f50434559">13,637</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb6469bec1ea4f8ca65fdad40040b929_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzItMy0xLTEtMA_bff5b623-9f60-4e32-bda0-0ad28203346f">5,939</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6bab00c844a44b45bc42e1f5791cae02_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzItNS0xLTEtMA_2c53ed68-829b-4304-83fa-61432f25d711">19,576</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accumulated deficit</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if800a2edba02435c841fd5ce6f7aada7_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzMtMS0xLTEtMA_f8ad88b5-b9ce-4071-9eef-e64d6ca9bcda">312,340</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibb6469bec1ea4f8ca65fdad40040b929_I20180101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzMtMy0xLTEtMA_772b567f-49c9-4303-9354-2b2ef7328224">6,479</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6bab00c844a44b45bc42e1f5791cae02_I20180101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzMtNS0xLTEtMA_7acf6a7a-e608-480d-8b39-de0e89b14446">318,819</ix:nonFraction>)</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The transition adjustment resulted primarily from changes in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">the pattern of revenue recognition for upfront fees and the accounting for milestones.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:232%;">The following table shows the impact of adoption to our consolidated statement of income and balance sheet (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="icf976baa9adf411eb14cc3db41767dbf" continuedAt="ief721a67b174491b940ddc903b1cca5a"><ix:continuation id="iad062b9180784439a7cf251548f579fd" continuedAt="ie5f7d7989816439d98331d2e3bd2fa39"><div style="margin-bottom:6pt;"><ix:continuation id="i56dc0a8c13ac4357aab9bd81fdae22f3"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:42.199706%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.096916%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.942731%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.292217%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2018&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibdc22a390e884f349065805d8e43c679_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzItMS0xLTEtMA_f483b115-8c67-4592-952e-e1e09b557846">20,617</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d979866d3b64e8ba979cb9f915e748f_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzItMy0xLTEtMA_e3fa7d98-600f-48c8-a2ac-27b1e505b41b">20,482</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f5fdced0c8347e9aa3943f81e9837f6_D20180701-20180930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzItNS0xLTEtMA_36e37e06-7d3c-4fad-b90f-70eb5f8d22e4">135</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzMtMS0xLTEtMA_25f29189-de39-43d4-98a3-563404caa052">34,029</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i87517407dd334c3893ac19538b16fd3e_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzMtMy0xLTEtMA_eacf7c6c-a77d-4e98-b9bf-0ab98df15ed7">34,164</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bedc85266654eaab2882c9503e960e8_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzMtNS0xLTEtMA_f0f45a2d-9000-4c0b-917d-c98037f1226e">135</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i87517407dd334c3893ac19538b16fd3e_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzQtMy0xLTEtMA_aa59d8e9-81c7-4c2b-9205-edf76e80f25a">0.81</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bedc85266654eaab2882c9503e960e8_D20180701-20180930" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzQtNS0xLTEtMA_40a4a2db-9433-4e03-a1f2-4a6ad1063e55">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2018&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44dcd64c130143e7b61b89fe2646000c_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzgtMS0xLTEtMA_b87b305f-83f1-4fe8-acd0-477e4bbb7f0a">43,670</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b5ededd31534749ab8242be3126e5b2_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzgtMy0xLTEtMA_570efece-079e-4f45-9d99-7c909ea0f057">43,265</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib492f638d82e4414a041403e1eddbe3a_D20180101-20180930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzgtNS0xLTEtMA_e11548c5-4cd7-4664-bcd8-a4e0e372d2f4">405</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzktMS0xLTEtMA_6cc02ada-7edf-4242-b02a-ed33b520ba05">126,809</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if9d0da9b4cc14b75991174bfa7e7e7e0_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzktMy0xLTEtMA_69d0a567-12cf-496a-a87e-c07b7d424bcf">127,214</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2083d2f9a48048808e8f2445e7f65ceb_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzktNS0xLTEtMA_01e11b0b-170c-4c72-8b4a-4ba5ff7acb6e">405</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.13)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if9d0da9b4cc14b75991174bfa7e7e7e0_D20180101-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzEwLTMtMS0xLTA_ec2e2e36-3867-43ab-a9fe-7ab4cd69d9df">3.14</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2083d2f9a48048808e8f2445e7f65ceb_D20180101-20180930" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzEwLTUtMS0xLTA_f34dcf7e-78dd-451a-98a7-8ddf37988a4b">0.01</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, current&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE0LTEtMS0xLTA_fd7397f6-e2c5-47fd-bfbd-52172a6f0918">7,377</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c61aa06ff0442f384bef16716c9e006_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE0LTMtMS0xLTA_ccbd26c2-9688-47a4-8b6e-b772db836052">6,348</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8dd177baefb24c5da5f5d762ca97c05a_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE0LTUtMS0xLTA_99b45716-ec81-4716-85c8-a7d8efcb9581">1,029</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE1LTEtMS0xLTA_ffe14252-0b3e-4bae-a8d3-8a081558223c">14,134</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c61aa06ff0442f384bef16716c9e006_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE1LTMtMS0xLTA_46187e98-aae8-4931-b91a-e59b763cbc71">9,090</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8dd177baefb24c5da5f5d762ca97c05a_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE1LTUtMS0xLTA_55cd3c1d-cbb2-4316-a8c9-b3a6abe6a5b9">5,044</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE2LTEtMS0xLTA_fc10cf2c-196d-4f1e-9322-b3523dec3503">445,627</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5c61aa06ff0442f384bef16716c9e006_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE2LTMtMS0xLTA_741abb7b-8b62-41af-814d-5f052238ab8d">439,554</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8dd177baefb24c5da5f5d762ca97c05a_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE2LTUtMS0xLTA_e337870d-ab6f-40b2-80d3-efe3fb8d86ce">6,073</ix:nonFraction>)</span></td></tr></table></ix:continuation></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY4OTk_bf04abf3-1bfd-4fea-b053-5bc5e1c5b6e6" escape="true"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents changes in the Company&#8217;s contract liabilities during the nine months ended&#160;September&#160;30, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:41.024963%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.397944%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.572687%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.271659%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at Beginning of Period&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at End of Period&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160; Deferred revenue (current and non-current)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTo4OWRmOTQwMjI4ZDQ0Yzg1OTE2M2Y2YWQzNTY4MTFkNi90YWJsZXJhbmdlOjg5ZGY5NDAyMjhkNDRjODU5MTYzZjZhZDM1NjgxMWQ2XzEtMS0xLTEtMA_49d20922-7d36-4a25-a52c-5f6e1933e55a">27,318</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-5" name="mgnx:ContractWithCustomerLiabilityIncreasefromCashReceipts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTo4OWRmOTQwMjI4ZDQ0Yzg1OTE2M2Y2YWQzNTY4MTFkNi90YWJsZXJhbmdlOjg5ZGY5NDAyMjhkNDRjODU5MTYzZjZhZDM1NjgxMWQ2XzEtMy0xLTEtMA_17d8d350-7004-4ffc-b185-2c6426e59136">500</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTo4OWRmOTQwMjI4ZDQ0Yzg1OTE2M2Y2YWQzNTY4MTFkNi90YWJsZXJhbmdlOjg5ZGY5NDAyMjhkNDRjODU5MTYzZjZhZDM1NjgxMWQ2XzEtNS0xLTEtMA_a16afa38-da35-416b-b648-b0be3b4bdeff">6,307</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTo4OWRmOTQwMjI4ZDQ0Yzg1OTE2M2Y2YWQzNTY4MTFkNi90YWJsZXJhbmdlOjg5ZGY5NDAyMjhkNDRjODU5MTYzZjZhZDM1NjgxMWQ2XzEtNy0xLTEtMA_9635cf8f-6e57-45dc-ad21-973d8a453075">21,511</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the nine months ended&#160;September&#160;30, 2018, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzE1MDAw_9d9b1884-1742-4c09-b354-bbfd65429883">6.3</ix:nonFraction> million in revenue as a result of changes in the contract liability balance.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the FASB issued ASU 2017-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation &#8211; Stock Compensation (Topic 718): Scope Modification Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The new standard is intended to reduce the diversity in practice and cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard was effective beginning January 1, 2018. The adoption of this standard did not have a material impact on the Company&#8217;s financial position or results of operations upon adoption. </span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">Recently Issued Accounting Standards</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued&#160;ASU 2018-11,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases (Topic 842): Targeted Improvements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Codification Improvements to Topic 842, Leases,</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#8217;s fiscal year beginning January 1, 2019. Although early</span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div><ix:continuation id="ief721a67b174491b940ddc903b1cca5a" continuedAt="i9dad095609334bb8bf4cf6a314e40469"><ix:continuation id="ie5f7d7989816439d98331d2e3bd2fa39" continuedAt="ie3f19b5c812a46cda3bb32fbb879b6b1"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> adoption is permitted, the Company has not elected to do so.  The Company plans to</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:115%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> carryforward of the historical lease classification.</span></ix:continuation></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"><ix:continuation id="i9dad095609334bb8bf4cf6a314e40469"><ix:continuation id="ie3f19b5c812a46cda3bb32fbb879b6b1"> Based on its anticipated election of practical expedients, the Company anticipates the recognition of right of use assets and related lease liabilities on its consolidated balance sheets related to its leases.  The Company has engaged a professional services firm to assist in the implementation of ASC 842, and is completing its analysis of the impact of adopting ASC 842 on its consolidated statements of income and comprehensive income and consolidated balance sheets.</ix:continuation></ix:continuation> </span></div><div id="i_0_154"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzI3NDg3NzkwNzI2Njc_11d63d3e-75dc-42e9-bb45-063b581cce98" continuedAt="i52ac4b06a1a14ce0b80c2f2501450921" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i52ac4b06a1a14ce0b80c2f2501450921" continuedAt="i15285235d96f436886cf2be59138f588"><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued expenses and common stock warrants.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The carrying amount of accounts receivable, accounts payable&#160;and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzI3NDg3NzkwNzI2NjY_b9195884-b4a6-46db-b4bc-5952eeb527ac" continuedAt="i7ec49fcccb7f45928bc9b336ef36eda3" escape="true"><div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:28.633284%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.789396%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.789396%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.789396%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.789396%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at September 30, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i671934b6ca254466884554fbd72599a7_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzQtMS0xLTEtMA_aeb48ee7-a750-470d-8566-86eefcb2c7d5">99,808</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ec2c1d0e4f4f05bf9e358137601c56_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzQtMy0xLTEtMA_74eaa013-5e5c-42a5-874c-0fabd1dfb71b">99,808</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic80626a5f83c4f92b03a719528d899b3_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzQtNS0xLTEtMA_c3aab82f-d260-40f9-95a4-30c9e128b36c">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5643f6cec2de4538bc34d86d7a1d42ef_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzQtNy0xLTEtMA_e05aa072-fe75-411e-8c1d-8b41063c9a7f">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i588e913554c54d489854f5d7b18643f3_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzUtMS0xLTEtMA_bd314f2c-6a2e-43ab-a921-c97e20e080ac">3,996</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5e44fd3fe174432a63b857d20d62cb9_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzUtMy0xLTEtMA_5fc47543-415e-4d3e-b7a0-3edc24be5604">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5394f3e223d14c0f9d447b8dba062cc7_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzUtNS0xLTEtMA_3d44db94-c338-4dcd-9c2d-f970c88a8264">3,996</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a504713132440edac1e257a897cfc5e_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzUtNy0xLTEtMA_0b9a1bf0-7c7f-4b57-a270-3b20c75bb485">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01e4f28d5a2f4d8ba5410cb06f830efb_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzYtMS0xLTEtMA_dd6d049f-03f2-470a-8d82-6afc6f3d0ce4">5,477</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8dc0a6957b1049d1a7fd2aca4546de77_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzYtMy0xLTEtMA_f8b2d393-e5fe-41d3-82a6-7df7eda40bfe">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60a9918f2b454a02a9f52660bcfd9700_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzYtNS0xLTEtMA_1d1dee45-433e-4358-9516-df0bbb263adf">5,477</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i154046cc71f34152877eaec79ccfc61b_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzYtNy0xLTEtMA_bb61430e-96ed-42d1-a4cc-cb5f8b25d4b0">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14e72fa606524cb6811b76c6b57eb806_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzctMS0xLTEtMA_9bf174c1-d179-4838-bab3-2091f43756f9">48,863</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94648d0db7a94b95bcaa11b425cfe7af_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzctMy0xLTEtMA_5da9f803-d2b6-4bee-aa56-1d8ae38106bf">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3518f59ae82e4ef582788fe57cbcd3e0_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzctNS0xLTEtMA_0cafb812-edec-45ac-845e-7f6a181b56c1">48,863</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0e9852ab63b4061801c673b10dcb0cd_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzctNy0xLTEtMA_c84d2bdd-9420-4eb0-8559-090c0abf6b89">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39e27978db3d429bb2846824cbb065da_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzgtMS0xLTEtMA_3603a312-f805-4046-9b22-0a65257c6193">6,130</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice6b9ff22ede4845b89261faf1de4b00_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzgtMy0xLTEtMA_cee21f9e-503c-48f9-bcb2-00d83e3e012c">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0fa81042e394b329de76ce95f09cff5_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzgtNS0xLTEtMA_53b76532-6d78-4f2d-86cb-18a71f75033c">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice63152ef2424cc4a9579cbdc1d6240e_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzgtNy0xLTEtMA_1e79b0dc-14b0-4298-b2c9-31c993e8f5a6">6,130</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i723d050a26224f16a353738eb4442e04_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzktMS0xLTEtMA_cf1bbbe6-8889-4b13-9dba-4391de6dab5c">164,274</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9d77208352f4d25bf386d786bc798cd_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzktMy0xLTEtMA_11485743-0191-4456-be4f-ebbf2afd5744">99,808</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd4f120866b645c4bf3cce8586698473_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzktNS0xLTEtMA_1e0471ee-b780-44c2-8599-d0401c002c6a">58,336</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaadfc51e828143479b2403579738eaff_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzktNy0xLTEtMA_96e19dac-19f9-43ff-aeee-25ce07f35081">6,130</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i15285235d96f436886cf2be59138f588"><ix:continuation id="i7ec49fcccb7f45928bc9b336ef36eda3"><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:29.323529%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.617647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.617647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.617647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.617647%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60c4cc1bdf234cf987926cd8055b2734_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzQtMS0xLTEtMA_d80f100a-eb8a-4e33-a109-d23622504c60">61,512</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f0eeb462be349aea122b32abf38ffa1_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzQtMy0xLTEtMA_57ffcd40-91ec-4a70-a12b-5022f308f7be">61,512</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd2a21b952a4442dbd5213ed0c13c412_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzQtNS0xLTEtMA_d3e87bd3-f0fe-4059-8a0d-9df5ae313eaa">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ef68251110c449f86e8dd7547298305_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzQtNy0xLTEtMA_030c08cb-86bc-42b5-8614-0f78fc133290">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d1c05ab7cef41bda60ce9805aa4b8d6_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzUtMS0xLTEtMA_068c4af6-f295-4613-a96c-444896c61e22">3,990</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a7580bc237e44bba24dcaac666b17bd_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzUtMy0xLTEtMA_da7bb9df-045c-4812-8db4-f406ea22d5e9">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7c92391cb5f04624be95aa6135f9c5e0_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzUtNS0xLTEtMA_e525ccbf-1f6a-4e12-adf0-0459672e4589">3,990</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6626efe68b914e4aa0c4c00a038ca6fb_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzUtNy0xLTEtMA_fec6f73a-0a66-477e-9034-33ae8c33420e">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5b810da2b4434106be6a2f4868aa983b_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzYtMS0xLTEtMA_c0e60d7f-ca2a-4fba-b0c7-18b5c6307ef0">11,990</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i22f5d3be38314de693952411eb401367_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzYtMy0xLTEtMA_fc70dba0-f13b-4ce8-983b-3cdf155754c5">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8ab2c156a8d47f5b370a57673a58703_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzYtNS0xLTEtMA_9718927d-a171-4071-91ca-f3baa5c8d484">11,990</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i375187cfa8df4fac956142beb3307c5e_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzYtNy0xLTEtMA_d00f4ff7-c553-4fb9-823e-697b0972bc25">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadea8e8fa97d481495bfa26ed8bcb2e8_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzctMS0xLTEtMA_86d8e245-0f20-43f0-a382-c1e26ca2534b">78,418</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4e22d2b5dd8454fbebfa09f3feb0749_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzctMy0xLTEtMA_8007b457-bad1-4aca-be0d-854516dd2b02">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39b863145a6442bfa00fd78279e2e6d7_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzctNS0xLTEtMA_840ee07c-a0e1-4d3a-a25c-6ca86730b503">78,418</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2ec2edcab7e43d583877d5a7a390b74_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzctNy0xLTEtMA_de501253-6060-45af-abe0-6d096a415390">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">b</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i075636ae66df40faaee95c130bcf8ea4_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzgtMS0xLTEtMA_343ee78e-2c98-4d34-910c-d9ea67cbace9">155,910</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic4e13a785a984de8ab85335f4e573536_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzgtMy0xLTEtMA_36fc2ed9-eaf5-4608-b03c-c3ade46b2535">61,512</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if287162bc94548119144a45ef00144e0_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzgtNS0xLTEtMA_1a2c199c-68f6-413e-b995-d420b81c1c70">94,398</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1aa2e56fe0043f790bcc747ebd4cf13_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzgtNy0xLTEtMA_726599d9-6dad-4329-9688-02ac48c50714">&#8212;</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(a) Total assets measured at fair value at September&#160;30, 2018 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i723d050a26224f16a353738eb4442e04_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzcxNDY4MjU1ODQ2MjU_78b703b7-6898-484a-8a83-ecaf8055deff">99.8</ix:nonFraction> million reported in cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="i723d050a26224f16a353738eb4442e04_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzgyNDYzMzcyMTI0MTY_b35930df-afc5-4cbd-8fca-8c222be69a17">6.1</ix:nonFraction> million reported in other assets on the balance sheet.</span></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i075636ae66df40faaee95c130bcf8ea4_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzI2Nzc_eb7bbe8a-6eea-4792-88e7-dd436597d334">62.5</ix:nonFraction> million reported in cash and cash equivalents on the balance sheet.</span></div></ix:continuation><div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model.  There were no transfers between levels during the periods presented.</span></div></ix:continuation><div id="i_0_166"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90ZXh0cmVnaW9uOjllMzZlYzM4YTQxNjQ4Njc4YTAzNDE5NThhZjVjNjQzXzI3NDg3NzkwNjk5NDU_413c3cda-03a8-444a-8ed5-5620151158c3" continuedAt="i186cf99d816545958a54b53dfee86ade" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i186cf99d816545958a54b53dfee86ade"><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90ZXh0cmVnaW9uOjllMzZlYzM4YTQxNjQ4Njc4YTAzNDE5NThhZjVjNjQzXzI3NDg3NzkwNjk5NDQ_6c003c44-50a2-4126-8383-7256f7b035e9" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Available-for-sale marketable securities as of September&#160;30, 2018 and December&#160;31, 2017 were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:52.344624%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.898380%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.751105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.898380%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.898380%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4fac88e6145545bcab342e1996db0e66_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzItMS0xLTEtMA_526d6649-1bf8-476e-bac5-7bce639ec4ab">3,996</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4fac88e6145545bcab342e1996db0e66_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzItMy0xLTEtMA_6db28ef5-634d-4239-9a24-2dfc182531d1">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4fac88e6145545bcab342e1996db0e66_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzItNS0xLTEtMA_a5ba5df3-6d3f-4628-b467-30deceba153d">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4fac88e6145545bcab342e1996db0e66_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzItNy0xLTEtMA_b5c32937-fca9-4de2-82e5-a6319c4abf90">3,996</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03f6af7af270436ebef7bd53a4e07f80_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzMtMS0xLTEtMA_71a322f1-94b1-4c9c-b6f8-56d96d84c4d8">5,477</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03f6af7af270436ebef7bd53a4e07f80_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzMtMy0xLTEtMA_1c31b0d9-b843-4da8-b1e4-994bd38b9452">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03f6af7af270436ebef7bd53a4e07f80_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzMtNS0xLTEtMA_2ea7220d-0979-4389-8820-14e21a93793e">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03f6af7af270436ebef7bd53a4e07f80_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzMtNy0xLTEtMA_bd4d1302-6288-479a-ac01-c8dede254ff8">5,477</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if828ac34fb81419ca9d1984770c76254_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzQtMS0xLTEtMA_e198002e-9258-45fa-b317-7c93b4c25124">48,863</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if828ac34fb81419ca9d1984770c76254_I20180930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzQtMy0xLTEtMA_237b177c-a8e6-4f6c-9627-fb0790e5c2d4">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if828ac34fb81419ca9d1984770c76254_I20180930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzQtNS0xLTEtMA_c577ead9-c2d9-4674-8649-7f8ad6d331c9">2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if828ac34fb81419ca9d1984770c76254_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzQtNy0xLTEtMA_4861bfe7-5bfc-4c3d-8722-f718c1287884">48,863</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzUtMS0xLTEtMA_c4d2c92d-ed08-4e25-8a17-142dc85f39ed">58,336</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzUtMy0xLTEtMA_f92583b2-6c81-4628-a892-e7b122804f95">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzUtNS0xLTEtMA_8a3edde2-723e-436c-9193-0920cdc1d715">2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzUtNy0xLTEtMA_b94f5738-bd77-4a5b-b54a-cf7a9ae2483a">58,336</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:52.344624%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.898380%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.751105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.898380%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.898380%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a4af18da1684515ba77f3fadc4081d3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzItMS0xLTEtMA_1fe9daba-4caf-45a0-8bb3-6116d638a25e">3,995</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a4af18da1684515ba77f3fadc4081d3_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzItMy0xLTEtMA_297d87d4-5ef2-43c8-aa6f-3daceeb64acc">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2a4af18da1684515ba77f3fadc4081d3_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzItNS0xLTEtMA_affbdb60-ec1d-4dc6-9351-1dc3a31aaa28">6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a4af18da1684515ba77f3fadc4081d3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzItNy0xLTEtMA_0f6a07a8-321d-4999-83f0-e6d071c64caa">3,989</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i866096d237f54e4583f3e604e8c243ec_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzMtMS0xLTEtMA_54afe571-dc45-431f-8339-a3abbed6afc1">11,998</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i866096d237f54e4583f3e604e8c243ec_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzMtMy0xLTEtMA_8e40a87e-9975-479c-868c-1987cb09879f">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i866096d237f54e4583f3e604e8c243ec_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzMtNS0xLTEtMA_c0d26f27-fbe5-44b5-b6fc-cacaa08117d2">7</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i866096d237f54e4583f3e604e8c243ec_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzMtNy0xLTEtMA_63a68977-dab5-4339-91a1-f62318b8c335">11,991</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i026f26d0cf654febb2e1e5f3037d5afc_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzQtMS0xLTEtMA_e9d4b957-e36f-4967-aff4-787e7bf3a4e6">77,462</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i026f26d0cf654febb2e1e5f3037d5afc_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzQtMy0xLTEtMA_5da0c207-3663-45ca-8cec-00d8406480f3">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i026f26d0cf654febb2e1e5f3037d5afc_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzQtNS0xLTEtMA_9fe242f5-750c-449d-9e87-cbcd1841574a">50</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i026f26d0cf654febb2e1e5f3037d5afc_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzQtNy0xLTEtMA_33464c8e-07d4-40b3-bc9c-8f499dd623b5">77,414</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzUtMS0xLTEtMA_c09ba16a-33a0-4526-86e7-6837c710a73a">93,455</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzUtMy0xLTEtMA_a7b1e007-39ad-4e5b-8ec7-7cd09505abee">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzUtNS0xLTEtMA_331b853a-15e6-4482-b6c6-95d2ed53c050">63</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzUtNy0xLTEtMA_2ef9e308-5b95-495f-a595-73c531a858fa">93,394</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All available-for-sale marketable securities held as of September&#160;30, 2018 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable securities in an unrealized loss position as of September&#160;30, 2018 and December&#160;31, 2017 were in a loss position for less than twelve months.&#160; There were <ix:nonFraction unitRef="usd" contextRef="i5d0a400707884c2198f13e93d13ca5cf_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90ZXh0cmVnaW9uOjllMzZlYzM4YTQxNjQ4Njc4YTAzNDE5NThhZjVjNjQzXzQxMA_3ef4e28d-97e1-4b73-b6ea-5b20d3fd1dcf"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90ZXh0cmVnaW9uOjllMzZlYzM4YTQxNjQ4Njc4YTAzNDE5NThhZjVjNjQzXzQxMA_c49fdd79-5fcf-4182-b99b-2ecaafdcd477">no</ix:nonFraction></ix:nonFraction> unrealized losses at September&#160;30, 2018 or December&#160;31, 2017 that the Company determined to be other-than-temporary.</span></div></ix:continuation><div id="i_0_191"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">4.  <ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzI3NDg3NzkwNzEyMzE_6e7398ac-3517-436f-9851-d546f77c1edc" continuedAt="i06589b85b0084be385c50f77dc2f1a39" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i06589b85b0084be385c50f77dc2f1a39" continuedAt="i428ebf32502c41fea62f1df2dd69bb57">In April 2017, the Company entered into a definitive agreement with an institutional healthcare investor to purchase <ix:nonFraction unitRef="shares" contextRef="ib8b8d6b8d41d4fd494c10b56288a758f_D20170426-20170426" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzE1MQ_e0739cec-96c5-4364-9e54-9d849bec2d85">1,100,000</ix:nonFraction> shares of the Company's common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i187b1747b6ea4fe7bd1a794a51a3a8bf_I20170426" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzIwNA_544d58b3-0b02-4024-8dd9-fac2bf807699">21.50</ix:nonFraction> per share in a registered direct offering.</ix:continuation></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i428ebf32502c41fea62f1df2dd69bb57" continuedAt="ia231c303d8c9416aad27f98420f5e6ac"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Proceeds to the Company, before deducting estimated offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="ib8b8d6b8d41d4fd494c10b56288a758f_D20170426-20170426" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzMyNg_e3a1f3f2-7d92-4c66-8406-e6a01e1e6882">23.7</ix:nonFraction> million. The shares were offered pursuant to the Company&#8217;s effective shelf registration </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">on Form S-3 that was filed with the SEC on November 2, 2016</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i3ed9ef592d4e44dd88fcc594f7f2d847_D20170503-20170503" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzYzOQ_ea175021-eaa4-48d9-810a-940acd43343b">75.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended.  The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 2, 2016. During the year ended December&#160;31, 2017, the Company sold <ix:nonFraction unitRef="shares" contextRef="i273fc3440aa24332a0568edcf542e1aa_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzEwMTY_1a10a4fd-872a-49e9-a733-4f8aaa2b1720">599,284</ix:nonFraction> shares of common stock under the sales agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i273fc3440aa24332a0568edcf542e1aa_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzEwOTg_077eacbd-d8ff-4025-a3fc-3b91409303bf">10.8</ix:nonFraction> million related to the ATM Offering. <ix:nonFraction unitRef="shares" contextRef="i0c786749d1894dd6a9b452378513440b_D20180701-20180930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzExMzA_311287f5-5a52-4d18-9fbb-7238606633ce"><ix:nonFraction unitRef="shares" contextRef="icd9c327300a84aafaf0a8890a6378c39_D20180101-20180930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzExMzA_c0541cf9-c4fc-4bfe-af29-e630704dc7b5">No</ix:nonFraction></ix:nonFraction> shares of common stock were sold under the sales agreement during the&#160;nine months ended September 30, 2018. </span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="ia231c303d8c9416aad27f98420f5e6ac">On April 2, 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold <ix:nonFraction unitRef="shares" contextRef="id2d3c290311249a18501533c07d13527_D20180402-20180402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzEzMzU_e4badd88-21f5-4fe0-b9b4-4e5c6cbaab67">4,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9127f44e472a4031acb85a2e77e5c974_I20180402" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzEzNzk_19c0da2d-3135-4c1b-abe7-523e4a26ae19">21.25</ix:nonFraction> per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional <ix:nonFraction unitRef="shares" contextRef="i46f941ef8b4f48e482ec7ee2d06ebaa3_D20180402-20180402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzE1Mzc_237c0e71-a1a8-4c54-9bcc-0d8e8bab5a5c">675,000</ix:nonFraction> shares of the Company's common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e9cd335c9244d9fb051a1a01f207509_I20180402" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzE1OTE_ab38e3ef-8f68-4b00-b476-65a407281482">21.25</ix:nonFraction> per share.  Upon closing, the Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="id9e8c9eb9fa140f7bf495f250946e437_D20180402-20180402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzE2NzE_e49f9a4a-db35-423b-9ca1-5721f187bd0b">103.0</ix:nonFraction> million from this offering, net of underwriting discounts and commissions and other offering expenses.</ix:continuation>&#160;</span></div><div><span><br/></span></div><div id="i_0_216"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzkzNDU4NDg4NjkzMTg_84876755-5768-4707-9910-199e09c57d6b" continuedAt="i44fe1e4129fc48e2b8daee45ed60913d" escape="true">Collaboration and Other Agreements </ix:nonNumeric></span></div><ix:continuation id="i44fe1e4129fc48e2b8daee45ed60913d" continuedAt="i2477a300d98442d79e1fc233bd2c951a"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Incyte</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012 (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a $<ix:nonFraction unitRef="usd" contextRef="i2c2f267ad6954342818988358aaec05a_D20171001-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzU3Mg_40d580af-4666-4e4a-9160-a90f5ce2dd97">150.0</ix:nonFraction> million upfront payment from Incyte when the transaction closed in the fourth quarter of 2017.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="iaab2d3c47fcb482fb5016a56c6678a2f_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg2Mw_c6dc6c8c-50a6-4e25-9d1c-2dc057f60e94">420.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="iaab2d3c47fcb482fb5016a56c6678a2f_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzkxOA_e56bcc2c-776d-4012-9e11-7c60c7cfa54b">330.0</ix:nonFraction> million in commercial milestones. As of September 30, 2018, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="i583cbd7fe1f847cea4b7238b2bc9436a_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNTU0MjE_32099dae-9188-42b7-a61c-ec0aef8dadbf">10.0</ix:nonFraction> million in development milestones under this agreement.  If commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="ia06a043fda544306a7174163d4ba821a_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEwMjc_1ed510ca-8cbb-47f2-a43a-99bca1800445">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i85e4b6bf29674ed0bb853ac49b61574b_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEwMzM_74b897a4-e32e-4620-87ee-2f2f28ce961a">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study&#160;and will continue to fund certain related clinical activities.&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The Company evaluated the Incyte Agreement under the provisions of ASC 606 and identified the following <ix:nonFraction unitRef="performance_obligation" contextRef="iddfd5052e98f4ca28241b0916f60a7d1_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4Mjc_6026d43c-2f5e-417e-8424-69fb66293c20">two</ix:nonFraction> performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="iaab2d3c47fcb482fb5016a56c6678a2f_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzI1OTE_f7578527-f8cf-4d67-bd90-fe574d47d5f3">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">During the three months ended September 30, 2018, it became probable that a significant reversal of cumulative revenue would not occur for two development milestones totaling $<ix:nonFraction unitRef="usd" contextRef="ia03651a398b047e6ba26bc530ae802ba_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNDk5ODg_2858c2c3-a208-43a3-8f98-d0b77a88cfb1"><ix:nonFraction unitRef="usd" contextRef="i583cbd7fe1f847cea4b7238b2bc9436a_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNDk5ODY_32099dae-9188-42b7-a61c-ec0aef8dadbf">10.0</ix:nonFraction></ix:nonFraction> million related to MGA012 meeting certain clinical proof-of-concept criteria. During the three months ended</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i2477a300d98442d79e1fc233bd2c951a" continuedAt="i6862f74b85e7491aade705bef91757ad"><div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> September 30, 2018, the associated consideration was added to the estimated transaction price and was recognized as revenue and recorded as accounts receivable on the Company&#8217;s consolidated balance sheet.&#160;Subsequent to September 30, 2018, a third proof-of-concept milestone was achieved and an additional $5.0 million will be recognized in the fourth quarter of 2018.</span></div><div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="ibe8622ead245454683d6cd02732a930e_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzQwNTI_785123bb-03a6-4ca9-9ad8-2cc27bfd9d4c">150.0</ix:nonFraction> million allocated to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">license when it satisfied its performance obligation and transferred the license to Incyte in December 2017.  The $<ix:nonFraction unitRef="usd" contextRef="i8e9c20469d344180a7bdbf43ccc98126_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzQxODU_57276894-605e-433d-bae6-e3bd4765082b">4.0</ix:nonFraction> million allocated to the clinical activities is being recognized over the period from the effective date of the agreement until such time as the clinical activities are transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs.  These clinical activities were substantially completed as of June 30, 2018, although certain minimal work is ongoing.  Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i7afec6a50d3e4c49b2fceac1c053cee8_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzQ3NDk_851724e5-662d-47ea-a9c5-b843e818bce9">10.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i03336d63cb2e4abf99d71150176d9e2a_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzQ3NTY_adbc7867-1b20-4b45-8736-649f9e3b1676">13.6</ix:nonFraction> million&#160; under the Incyte Agreement during the three and nine months ended September 30, 2018, respectively, including $<ix:nonFraction unitRef="usd" contextRef="i583cbd7fe1f847cea4b7238b2bc9436a_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNDk5MTg_86c11345-05ee-4604-9eeb-ad1cfaaef508">10.0</ix:nonFraction> million in development milestones and the remainder&#160;related to clinical activities.&#160;&#160;</span></div><div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company&#160;also has an agreement with&#160;Incyte under which the Company is to perform manufacturing services for Incyte&#8217;s&#160;clinical needs of MGA012.  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement - to perform services related to manufacturing the clinical supply of MGA012.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.   During the three and&#160;nine months ended September 30, 2018, the Company recognized revenue of&#160;$<ix:nonFraction unitRef="usd" contextRef="ifd05ad37dc5648948de2ec1ebeeb9880_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNDk5NjI_105bbfb9-188c-4fe4-b8cc-e3323152b0e1">6.1</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="icd5dfaa7121c4b398f87a4bf82fe6818_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzU1ODM_2e7fd7fb-593d-4fe1-a324-5b4e3c5b3860">16.0</ix:nonFraction> million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Roche</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In December 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets  (Roche Agreement).  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate.  Roche would then further develop and commercialize any such product candidate.  Each company will be responsible for their own expenses during the research period. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i304e6e07763f45adac1a934bb867bb1b_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzY1MTk_6629eb41-cd30-42f6-9814-0aea0f3404c3">10.0</ix:nonFraction> million which was received in January 2018. The Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="iadb65054ca38420abd5f2059371dcff6_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzY2MDk_85b9b4e0-6436-46f0-9159-2ab6aa74385f">370.0</ix:nonFraction> million in potential milestone payments and royalties on future sales.&#160;As of September 30, 2018, the Company has not recognized any milestone revenue under this agreement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period.  The Company determined that the license is capable of being distinct, but is not distinct in the context of the contract because it has limited value to Roche without the research activities required to be performed by the Company.  Therefore, the Company concluded that there is <ix:nonFraction unitRef="performance_obligation" contextRef="iadb65054ca38420abd5f2059371dcff6_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzcyNzE_87760e7d-148e-4862-9a19-5628a9947cd8">one</ix:nonFraction> performance obligation under the agreement.  The Company determined that the transaction price of the Roche Agreement was $<ix:nonFraction unitRef="usd" contextRef="iadb65054ca38420abd5f2059371dcff6_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzczOTY_e65059c7-66c0-4c17-af47-10ba4c1f94f5">10.0</ix:nonFraction> million.  The potential milestone payments are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and have been excluded from the transaction price.  Any consideration related to sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore have also been excluded from the transaction price. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The $<ix:nonFraction unitRef="usd" contextRef="iadb65054ca38420abd5f2059371dcff6_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzc3NTk_871808f6-086a-45f3-a406-e1f1744d971a">10.0</ix:nonFraction> million transaction price is being recognized over the expected research period, which is <ix:nonNumeric contextRef="ibd2cfd87b18c4510b689cf0331b1d471_D20171201-20171231" format="ixt-sec:durmonth" name="mgnx:UpfrontPaymentRecognitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzc4NDM_22afb355-cedb-43f4-b37a-7cbbda744a3d">30</ix:nonNumeric> months, using a cost-based input method to measure performance.   Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606. The Company recognized revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="i2076bfb4648e47319c3d79dc8b4f052f_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzgxMTU_cbc225eb-1fe3-42fa-8541-457aea34bc7f">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i09bb778c2423410098bdc0c426490d87_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzgxMjI_027b40b0-d2ff-4f6f-8d65-902a771dff96">3.0</ix:nonFraction> million during the three and nine months ended September 30, 2018, respectively.  At September&#160;30, 2018, $<ix:nonFraction unitRef="usd" contextRef="i58ae03eea2c343388670589c0cc8cee6_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzgxNzI_17847b87-fda8-452f-b958-34e5283a52cd">7.0</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i58ae03eea2c343388670589c0cc8cee6_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzgyMjE_28180391-35d1-451a-88d8-c86595aa0ae1">4.0</ix:nonFraction> million of which was current.&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Les Laboratoires Servier </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In September 2012, the Company entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) and granted it exclusive options to obtain <ix:nonFraction unitRef="exclusive_license" contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfExclusiveOptionsToLicense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg0NjU_923ae772-f6e5-4144-bf33-3f0daf5e1b8b">three</ix:nonFraction> separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). During 2014, Servier exercised its exclusive option to develop and</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i6862f74b85e7491aade705bef91757ad" continuedAt="i9e41314b4037479a816b0b1d6f4f564e"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> commercialize flotetuzumab, and during 2016 Servier notified the Company that it did not intend to exercise the option for the third DART molecule.  Servier retains the option to obtain a license for MGD007.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon execution of the agreement, Servier made a nonrefundable payment of $<ix:nonFraction unitRef="usd" contextRef="ia6e0829991f74feeaba02806ccb252be_D20120901-20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzkxNDQ_8ca6d9c9-60f4-4cf4-8c35-a31e908c1e80">20.0</ix:nonFraction> million to the Company. In addition, if Servier exercises the remaining available options and successfully develops, obtains regulatory approval for, and commercializes a product under each license, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialLicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzkzODQ_5a970050-b1bd-4cb5-9a0e-f79441f0bdad">25.0</ix:nonFraction> million in license grant fees, $<ix:nonFraction unitRef="usd" contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialClinicalMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzk0MTA_8879dd12-aed1-4e28-8c42-c04b667a12e2">53.0</ix:nonFraction> million in clinical milestone payments, $<ix:nonFraction unitRef="usd" contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzk0NDU_3b84b31a-a43b-4b83-8e17-53cfb6a221fc">188.0</ix:nonFraction> million in regulatory milestone payments (excluding the $<ix:nonFraction unitRef="usd" contextRef="i9a2d8a380170427b92101d51e25a734b_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNTU0Mjk_26de73e4-7e9b-4c89-8fcc-2cebd1533c2f">10.0</ix:nonFraction> million for the flotetuzumab and MGD007 INDs noted below) and $<ix:nonFraction unitRef="usd" contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialSalesMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzk0ODU_f068d714-5be5-4384-a5be-6bf08d046cfe">420.0</ix:nonFraction> million in sales milestone payments. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the <ix:nonFraction unitRef="performance_obligation" contextRef="i061c41caf2584f488de00de72d70d359_I20120930" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfExclusiveOptionsToLicense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzk5MzE_13f144db-f418-4799-b2c5-1df3d2aa3741">three</ix:nonFraction> options.  The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package.  The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights.  As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of <ix:nonFraction unitRef="performance_obligation" contextRef="i061c41caf2584f488de00de72d70d359_I20120930" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExMDIz_e7e5ef7c-e626-4498-b717-a49a1bf0e2d7">three</ix:nonFraction> performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExMTYw_e65292f3-3b02-4455-b142-2eab1ecb56d0">20.0</ix:nonFraction> million</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the <ix:nonFraction unitRef="performance_obligation" contextRef="i061c41caf2584f488de00de72d70d359_I20120930" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExMzYy_e7e5ef7c-e626-4498-b717-a49a1bf0e2d7">three</ix:nonFraction> performance obligations based on their relative standalone selling price. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;<ix:nonFraction unitRef="milestone" contextRef="i88a4efe1362c4a3db0196262405ad178_D20140101-20141231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfMilestonesAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExNjcy_a4e476a2-0416-42d7-80a4-af67701d7fc3">Two</ix:nonFraction> milestones were achieved in 2014 when the INDs for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA).  Upon achievement of each milestone, the constraint related to the $<ix:nonFraction unitRef="usd" contextRef="i88a4efe1362c4a3db0196262405ad178_D20140101-20141231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:MilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExODcz_4bca87ff-ba1f-4114-bbaa-83aeba2d4113">5.0</ix:nonFraction> million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenue associated with each performance obligation is being recognized as the research and development services are provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.  The full transaction price allocated to flotetuzumab and the third DART molecule was recognized as revenue prior to the adoption of ASC 606 on January 1, 2018 as the option periods had ended. The development period for MGD007 was estimated to be <ix:nonNumeric contextRef="ifb7ae82b7fd94218adec5b37c3baf521_D20120901-20120930" format="ixt-sec:durmonth" name="mgnx:OptionExerciseFeeRecognitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEyNzQx_f95ce42c-6422-49df-944c-25a5b5e0db15">75</ix:nonNumeric> months, ending in December 2018, therefore the transaction price allocated to MGD007 is being recognized through that date.  Upon the adoption of ASC 606 on January 1, 2018, the pattern of revenue recognition for the upfront fee and the accounting for the milestones received in 2014 changed, but there was no material impact to revenue recognized during the three and nine months ended September 30, 2018.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i0bdd4ce1abcb4d84918166baa0aab54f_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEzMTUy_cee53fc1-c566-4fd2-ae33-a888a32537bd">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib593ee5aff884b09b56907f69f0517e1_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEzMTU5_9d719ce8-d988-48be-8ef6-61523c5f2fa9">1.4</ix:nonFraction> million during the three and nine months ended September 30, 2018, respectively, related to the MGD007 option.  At September&#160;30, 2018, $<ix:nonFraction unitRef="usd" contextRef="i166c43c2262341ea91348516a28bcbd9_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEzMjM5_5e00369f-8dd7-4897-a5e6-bf9d6ff6007c">0.5</ix:nonFraction> million of revenue related to the MGD007 option was deferred, all of which was current. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $<ix:nonFraction unitRef="usd" contextRef="idd6a295ad13346be87c34a41d8a59a09_I20141231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEzNDg2_a0f89076-8524-4005-82e8-2d455d1570bc">15.0</ix:nonFraction> million license grant fee.  Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808.  The arrangement consists of <ix:nonFraction unitRef="component" contextRef="ia231899505ea4e26b8ae99393f58f9f8_I20141231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfComponentsInLicenseAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE0MjM4_17c1729c-8682-4b87-a348-71a0206b5079">two</ix:nonFraction> components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan.  </span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license.  The Company evaluated its performance obligation to provide Servier with an exclusive license to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">develop and commercialize flotetuzumab and determined that its transaction price is equal to the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="idd6a295ad13346be87c34a41d8a59a09_I20141231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE0NzUx_a0f89076-8524-4005-82e8-2d455d1570bc">15.0</ix:nonFraction> million and Servier consumes the benefits of the license over time as the research and development activities are performed.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i9e41314b4037479a816b0b1d6f4f564e" continuedAt="i88254166b8994458b6e7584754b1959d"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Therefore, the Company will recognize the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The additional potential clinical, regulatory and sales milestones are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and have been excluded from the transaction price.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company will follow its policy to record expense incurred as research and development expense and reimbursements received from Servier will be recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period.  During the three and nine months ended September 30, 2018, the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i9f54d23042ce45e3b0f7b1f3527e965c_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1NzE4_ee216309-0551-4d39-aa90-3646d522b243">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9a2d8a380170427b92101d51e25a734b_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1NzI1_c55d9b94-f519-4ff4-9452-51c038e04908">4.9</ix:nonFraction> million, respectively, as an offset to research and development expense under this collaborative arrangement.</span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i42d44f7b71fc4200940cf6d3d09f2c3b_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1ODY4_eb9f3ce0-cb27-4222-aaf1-7fe62a021789">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i53b4e8d5c2cc41a7abc24c33b0b6b4e0_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1ODc1_59db20c6-75ad-4c1e-8a9e-763d7842b66b">0.9</ix:nonFraction> million, respectively, during the three and nine months ended September 30, 2018 related to the flotetuzumab option exercise.  At September&#160;30, 2018, $<ix:nonFraction unitRef="usd" contextRef="i1a09839b03404373938e8002919f2856_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1OTcw_d7701586-4955-4ca1-8c67-e25fddfc58d3">12.9</ix:nonFraction> million of revenue related to the flotetuzumab option exercise was deferred, $<ix:nonFraction unitRef="usd" contextRef="i1a09839b03404373938e8002919f2856_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE2MDQy_ace0ac51-9e3b-4237-9d68-9752d645711e">2.2</ix:nonFraction> million of which was current.  The deferred revenue balance related to the flotetuzumab option exercise as of December 31, 2017, prior to the adoption of ASC 606, was $<ix:nonFraction unitRef="usd" contextRef="i660cb75a1c0d41c983132bc62bb7d5cd_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE2MjA0_8c549e0e-bd11-42ae-9be7-bc7838b52364">7.4</ix:nonFraction> million. The adoption of ASC 606 increased that balance by approximately $<ix:nonFraction unitRef="usd" contextRef="i52bce1b6baef4facb924a318ed17002f_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE2Mjcy_ae58aacd-9fde-4cb3-9ae1-7178db5c8c25">6.4</ix:nonFraction> million. The adoption of ASC 606 did not have a material impact on revenue recognized during the three and nine months ended September 30, 2018, however it will increase the revenue to be recognized in the future as the pattern of revenue recognition has changed.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provention</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2018, the Company entered into a License Agreement with Provention Bio, Inc. (Provention), pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications.  As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i23557f80a0a245a690a3b1b11c018cc8_D20180531-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE3MDI4_f3ed3596-9724-4682-ab6c-c57c0d3d0ad8">2.50</ix:nonFraction> per share. The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i1b5de7b28e2d4befab1ed1cec48844f6_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE3MjI0_2a0ca3e0-7945-46b9-a358-8dc30daf3381">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i1b5de7b28e2d4befab1ed1cec48844f6_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE3Mjc4_b3e19d6b-669c-49c8-a884-00338f1c4bda">225.0</ix:nonFraction> million in commercial milestones. &#160;As of September 30, 2018, the Company has not recognized any milestone revenue under this agreement.&#160; If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;Also in May 2018, the Company entered into an Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement).  As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i829603c6236e41f2951a9087431df091_D20180531-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4MjIx_51546fca-b6c0-4ad0-a41b-8d5db0ed0b1a">2.50</ix:nonFraction> per share.  The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i77e14b4fd8a549c99d5b94473df0cbdb_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4NDE3_6f3ea8b5-f33f-4686-9d8b-15bbe3fc9757">170.0</ix:nonFraction> million in regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i77e14b4fd8a549c99d5b94473df0cbdb_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4NDU1_004095a8-74b1-47a0-8fbc-b3f33915d271">225.0</ix:nonFraction> million in commercial milestones.  If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i77e14b4fd8a549c99d5b94473df0cbdb_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4ODIy_8d7411ee-7667-4f87-bdcb-b7f3368bb101">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified <ix:nonFraction unitRef="performance_obligation" contextRef="ia27a68ad905842ba80b4de3e9d1b929e_I20180531" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE5NDAz_4ab95f11-c7e0-4faf-b761-e7d92cdd0b13">two</ix:nonFraction> performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="ia27a68ad905842ba80b4de3e9d1b929e_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE5NTk2_b752a7a6-7e96-4d3a-847e-43eff14cc83a">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ia27a68ad905842ba80b4de3e9d1b929e_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE5NjY1_09bb5992-3f64-414f-9020-37da1064ea77">2,432,688</ix:nonFraction> shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:8pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i88254166b8994458b6e7584754b1959d" continuedAt="ib6836f1cec7e472c8e69584f6e8e1832"><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i83423a11889045c1bcdec405be3fa546_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIwNjA3_3a91bf83-9607-4a3c-9553-5ff684b37741">6.1</ix:nonFraction> million when it satisfied its performance obligations and transferred the MGD010 license and teplizumab assets to Provention during May 2018.  The warrants are reported in other assets on the balance sheet at September&#160;30, 2018, and there was no material change in the valuation of the warrants from May 2018 through that date.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NIAID Contract</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIxMTQ0_2ea53746-eb02-4747-8224-7d0f0cb4772f">two</ix:nonFraction> DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="ib6836f1cec7e472c8e69584f6e8e1832">This contract includes a base period of up to $<ix:nonFraction unitRef="usd" contextRef="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915" decimals="-5" format="ixt:numdotdecimal" name="mgnx:FundedValueOfBasePeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIxNjg0_4a25384a-e74c-45d8-a3fd-e45bb946c657">7.5</ix:nonFraction> million to support development of MGD014 through IND application submission with the FDA, as well as up to $<ix:nonFraction unitRef="usd" contextRef="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIxNzg2_b7e0ae76-76ee-4935-9f6b-a22f082470f6">17.0</ix:nonFraction> million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $<ix:nonFraction unitRef="usd" contextRef="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:TotalPotentialValueUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIxOTM0_b096605d-9bb4-4d33-8904-6bdeb00be481">24.5</ix:nonFraction> million. The total potential period of performance under the award is from September&#160;15, 2015 through September&#160;14, 2022. In 2017, NIAID exercised the first option in the amount of up to $<ix:nonFraction unitRef="usd" contextRef="i452ee1a0ab714c34ababb41227155f6d_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMDg0_17d1dc99-a1be-47a8-8d6b-4740c07f6cee">10.8</ix:nonFraction> million.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i6da7c74defea4d8fb09ed95435cc7a03_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMTEy_c7600575-79fd-43c7-8d97-14fe10dd585c">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ife8821603bb64976be6518e29c1c250d_D20170701-20170930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMTE5_7a9a7547-1e64-4924-857a-31692f57d311">0.4</ix:nonFraction> million in revenue under this contract during the three months ended September 30, 2018 and 2017, respectively.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i28991436c91f443c8ede9c7a2c47f606_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMjEz_2797b3aa-1064-4844-a5bf-624911a1a0b3">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i54aa98e1360041ea8a6f19ceeab7a123_D20170101-20170930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMjIw_9c5ef98e-12a5-4336-ab01-c404609487ce">1.5</ix:nonFraction> million in revenue under this contract during the nine months ended September 30, 2018 and 2017, respectively.</ix:continuation>&#160;</span></div><div id="i_0_228"></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI3NDg3NzkwNzM2NDU_aaa0a28a-d655-4796-b7e2-0fb30b689aa9" continuedAt="i2bb98e54fa794cfab2fb9301d5380f6d" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i2bb98e54fa794cfab2fb9301d5380f6d" continuedAt="i1dd81a4914b04738a7123227b47dc8fc"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved <ix:nonFraction unitRef="shares" contextRef="ie758ea00f3b045d8aaf61ff77aa1bd5b_I20170531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzQyMg_c47246ec-3ea7-42cd-9803-2f6f7b2f10fd">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="ie3e9f6ff05ac42748139386a1f145650_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzYyMQ_d26d1b67-b82c-4cd8-bf82-b544db190b75">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="ie3e9f6ff05ac42748139386a1f145650_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzg2OA_512fe42a-abb4-40fa-a99d-056f67e7820a">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2018, <ix:nonFraction unitRef="shares" contextRef="ib21a72497c3f4f4586fc6f1f696f8ee0_D20180101-20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzk5OA_87d85442-5aa2-4b2d-8c50-d7cac12a4d4a">20,231</ix:nonFraction> shares of common stock were purchased under the 2016 ESPP for net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="ib21a72497c3f4f4586fc6f1f696f8ee0_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzExMDg_3fba691c-a7ba-48a6-9ee1-07608df69d99">0.5</ix:nonFraction> million. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Option Plans</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of <ix:nonFraction unitRef="shares" contextRef="idf2e982e7c3a42d487a756a32a510ac0_I20030228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzEzOTQ_7e273e2a-b5db-4f18-9625-7456920537a1">2,051,644</ix:nonFraction> shares of the Company's common stock. Between 2006 and 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="ib58f57547e3d4bb8a8a5328327afc915_I20121231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzE1Nzk_8cede787-625e-4797-aacf-db7488b611b0">4,336,730</ix:nonFraction>. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the Company's 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2018 there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i706d5cef31cd430e8365f6915ddcb64f_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzIyNTk_50eaf191-88d2-4b88-ac3c-e681b2280130">826,333</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i706d5cef31cd430e8365f6915ddcb64f_I20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzIzMzc_7003bce2-b024-47fc-9d7d-06df10b50365">1.93</ix:nonFraction> per share under the 2003 Plan.</span></div><div style="text-indent:39pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the provisions of the 2013 Plan, the number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="i53ec44ff783b431cb9ed2678498d5f97_I20180930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI2MDU_fa52dd5a-c013-46c0-a7b0-8989271443e6">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="i596e64c58833410299f5dd5853dd7260_D20180101-20180930" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI2MjA_d85d3f3c-1077-47cb-8207-641489dec643">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the nine months ended September&#160;30, 2018, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="i53ec44ff783b431cb9ed2678498d5f97_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI5NjI_a29e7995-8aae-4fed-be75-7e085a489391">8,244,131</ix:nonFraction>.&#160;&#160; As of September&#160;30, 2018, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i53ec44ff783b431cb9ed2678498d5f97_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzMwMjU_2204a171-c525-47b4-aa4f-b1a9100a9012">4,521,942</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i53ec44ff783b431cb9ed2678498d5f97_I20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzMxMDM_833a879b-2eba-4fd8-a20d-82b6a4a748cf">25.61</ix:nonFraction> per share under the 2013 Plan.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i1dd81a4914b04738a7123227b47dc8fc"><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI3NDg3NzkwNzM2NDQ_72b6c950-50db-4a34-a42b-6bf981a39b0f" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table shows stock-based compensation expense for stock options, RSUs and ESPP (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:32.117647%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.794118%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.029412%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.441176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.411765%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7042cd13db6549e7871f168d9d646e10_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzItMS0xLTEtMA_1294a4ed-3c06-4910-822d-aeedd1ca737e">2,440</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01e7fa001b0a43809cae26254818dd0a_D20170701-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzItMy0xLTEtMA_4a454dff-dae7-4ff5-a031-9cb3eb892b2c">2,006</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i331b887054c54310ba485d67cc56fd98_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzItNS0xLTEtMA_90cda303-719f-4034-a587-0f9a9e8bc048">6,347</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1169246d2ee645d2b41f43608d9c7971_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzItNy0xLTEtMA_823a210a-c2f7-4139-a6a9-1ce29c9e0411">5,512</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie67728928c2f4b7c926568160fbfbb42_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzMtMS0xLTEtMA_42d062bc-f330-458f-9364-780345fa591f">2,133</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c2c78af9f724b04b7f633e772d609d4_D20170701-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzMtMy0xLTEtMA_3989a18a-1cc5-4c0a-bda1-dbb640b7ca8d">1,995</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee7edc452a8d41b8a7136478d6aca726_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzMtNS0xLTEtMA_d0289a2c-a4a1-482c-b8cc-39c36515a6ff">5,821</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i47470559910c4104a2b667fa430274d6_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzMtNy0xLTEtMA_b4602f2b-a54d-4652-855f-569f07790812">5,552</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzQtMS0xLTEtMA_8d9d2e51-a335-4f7d-8b83-ace26a578e34">4,573</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzQtMy0xLTEtMA_682eb956-5886-4431-a115-badd7b186e92">4,001</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzQtNS0xLTEtMA_3c469b9a-b362-44c1-97e0-635170d8f547">12,168</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzQtNy0xLTEtMA_8ef51768-a9df-4227-97cd-f99051301a50">11,064</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI3NDg3NzkwNzM2NDM_327c179a-13f0-436f-80f4-5470990c6535" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:63.491924%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.767988%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.005874%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTphYTMxNTg3MzVjODM0ZjY3YTQ5Mzg4ZDhkNGZkMTY1Ni90YWJsZXJhbmdlOmFhMzE1ODczNWM4MzRmNjdhNDkzODhkOGQ0ZmQxNjU2XzItMS0xLTEtMA_38436363-18db-4080-ac07-cc330233dd11">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTphYTMxNTg3MzVjODM0ZjY3YTQ5Mzg4ZDhkNGZkMTY1Ni90YWJsZXJhbmdlOmFhMzE1ODczNWM4MzRmNjdhNDkzODhkOGQ0ZmQxNjU2XzItMy0xLTEtMA_d0bd279b-5ba5-4922-9da7-a540155c7498">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">67.8% - 72.2%&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">66.7% - 68.3%&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4% - 3.1%&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% - 2.3%&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTphYTMxNTg3MzVjODM0ZjY3YTQ5Mzg4ZDhkNGZkMTY1Ni90YWJsZXJhbmdlOmFhMzE1ODczNWM4MzRmNjdhNDkzODhkOGQ0ZmQxNjU2XzUtMS0xLTEtMA_472a1947-088f-41e6-9488-37ef5cc671f4">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTphYTMxNTg3MzVjODM0ZjY3YTQ5Mzg4ZDhkNGZkMTY1Ni90YWJsZXJhbmdlOmFhMzE1ODczNWM4MzRmNjdhNDkzODhkOGQ0ZmQxNjU2XzUtMy0xLTEtMA_d5b6f496-8241-49fd-a13a-78685a43d633">6.25</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI3NDg3NzkwNzM2NDI_03564c3c-ad94-40a2-a1c1-294df3983af9" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes stock option and restricted stock unit (RSU) activity during the nine months ended September&#160;30, 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:26.970588%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.205882%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.205882%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.205882%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.205882%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise Price&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value<br/> (in thousands)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzEtMS0xLTEtMA_fbf76825-fafb-4e7c-97c1-9891fec799c5">4,504,642</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzEtMy0xLTEtMA_b5baa816-ece1-46b7-a199-d33f1df224e9">19.79</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i5d0a400707884c2198f13e93d13ca5cf_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzEtNS0xLTEtMA_50c177b3-d430-475a-be10-a1df985198ee">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzItMS0xLTEtMA_186d88f4-c90b-460b-9324-197b4ca4bc53">1,230,244</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzItMy0xLTEtMA_2bce10a8-0190-4c9f-a912-a32cff3a444e">27.43</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzMtMS0xLTEtMA_9708c810-e3b9-4785-887f-35218f168eca">205,902</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzMtMy0xLTEtMA_2d78c540-55ad-4e24-a741-2c1d2c09625d">5.47</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzQtMS0xLTEtMA_7768d376-be8d-4689-89f9-79c3703e6813">180,709</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzQtMy0xLTEtMA_1cbdd7e9-2dd6-434e-b4b9-f3fbec32d461">24.25</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, September 30, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzUtMS0xLTEtMA_c27a5c10-1c46-4a78-b4eb-78d52140a593">5,348,275</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzUtMy0xLTEtMA_276e82e5-8a4e-410b-999e-34b0bbbfaec9">21.95</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzUtNS0xLTEtMA_f3eaa0b4-7eea-4e4a-a24d-100504fb82c9">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzUtNy0xLTEtMA_63828017-9a74-4cdc-9f2d-a55b5ad2a09d">19,762</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2018:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzctMS0xLTEtMA_f2352631-87dc-4094-b4bc-e431e75cc8bc">3,365,982</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzctMy0xLTEtMA_2728063b-3714-4cd8-962a-af167d8f3477">19.70</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzctNS0xLTEtMA_b5df469a-cedc-4ed7-a136-c67d6c2a9bf0">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzctNy0xLTEtMA_f55bce31-d37c-4c9f-b62a-44d2283a94b7">18,892</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzgtMS0xLTEtMA_633318f8-cedb-4042-8619-3965611a5bb4">5,138,801</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzgtMy0xLTEtMA_8fb6d962-3ef9-4692-81f7-30bcd136a57a">21.79</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzgtNS0xLTEtMA_7fddaa67-3ff0-4913-8e51-c6599788319c">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzgtNy0xLTEtMA_5d8c702e-0f55-4936-9ebc-42d6ddffcca9">19,671</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzM2NzU_15a2d13d-b96b-4312-9fff-6f314579be3d">18.07</ix:nonFraction>. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2018 was approximately $<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzM3NzQ_2108f1c5-9e4a-4056-a866-7852ed9b39b3">4.0</ix:nonFraction> million, and the total cash received for options exercised was approximately $<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzM4NDY_76069493-7e94-44ce-9986-90fc826486e2">0.9</ix:nonFraction> million. The total fair value of shares vested in the nine months ended September&#160;30, 2018 was approximately $<ix:nonFraction unitRef="usd" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzM5MzI_c4a1218b-9850-44bc-976d-7d802551b516">11.9</ix:nonFraction> million. As of September&#160;30, 2018, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was approximately $<ix:nonFraction unitRef="usd" contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzQwODI_3bfe7bc0-3b57-45a8-b59f-7b72e8d7d6b7">28.0</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzQxNzM_bcfc3db7-0d41-4a54-818b-21b3338a7258">2.65</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_253"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;"> 7. <ix:nonNumeric contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzI3NDg3NzkwNzA0NDU_e35d6b6b-a37f-4488-8f40-dfc28f74ad46" continuedAt="ia906bc173cf24d6d86ec83437b2e4446" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="ia906bc173cf24d6d86ec83437b2e4446">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants. <ix:nonFraction unitRef="shares" contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzUzNw_0266b72f-7377-4331-8e8f-d6461e07f3d3"><ix:nonFraction unitRef="shares" contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzUzNw_f1db0d81-235b-4eb8-961c-35a18183ea06">5,348,275</ix:nonFraction></ix:nonFraction> stock options (common stock equivalents) were excluded from the calculation of diluted loss per share for the three and nine months ended September&#160;30, 2018 because their inclusion would have been anti-dilutive. <ix:nonFraction unitRef="shares" contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzcyNA_4ba4e4c3-10ae-494e-aefd-807831b0713c"><ix:nonFraction unitRef="shares" contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzcyNA_b6dbee0d-0dde-447f-9324-13a3ce37d256">4,533,794</ix:nonFraction></ix:nonFraction> stock options were excluded from the calculation of diluted loss per share for the three and nine months ended September&#160;30, 2017 because their inclusion would have been anti-dilutive.</ix:continuation></span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div id="i_0_279"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:6.187135%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.812865%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 2.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS&#160;</span></td></tr></table></div><div style="text-indent:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with GAAP, for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2017.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:45pt;"><span><br/></span></div><div id="i_0_291"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics to modulate the human immune response for the treatment of cancer.  We currently have a pipeline of product candidates in human clinical testing that have been created primarily using our proprietary technology platforms, which also have broad applicability across other therapeutic domains.  We believe our programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="text-indent:31pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160; Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our existing cash, cash equivalents and marketable securities as of September&#160;30, 2018, as well as collaboration payments we anticipate receiving, should enable us to fund our operations into mid-2020, assuming our programs and collaborations advance as currently contemplated.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have incurred significant losses since our inception and we have an accumulated deficit of approximately $445.6 million as of September&#160;30, 2018. We expect to continue to incur losses for the foreseeable future and we expect that over the next several years our deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials for our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_303"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Strategic Collaborations</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We pursue a balanced approach between developing product candidates ourselves and developing other product candidates with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Currently, our most significant strategic collaborations include the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Incyte. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012 (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while we retain the right to develop our pipeline assets in combination with MGA012. The transaction closed in the fourth quarter of 2017 and we received a $150.0 million upfront payment from Incyte upon the closing.</span></div><div style="padding-left:54pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the collaboration, Incyte will lead global development of MGA012. Assuming successful development and commercialization by Incyte, we could receive up to approximately $420.0 million in development and regulatory milestones&#160;(including $10.0 million in development milestones recognized during the three&#160;months ended September 30, 2018), and up to $330.0 million in commercial milestones. If commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote with Incyte.  We retain the right to develop our pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and MacroGenics commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform manufacturing</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="padding-left:54pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> services for Incyte&#8217;s clinical needs of MGA012.&#160;In addition, we retain the right to manufacture a portion of both companies' global commercial supply needs of MGA012 subject to a separate commercial supply agreement.&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Servier. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In September 2012, we entered into an agreement with Les Laboratoires Servier and Institut de Recherches Servier (Servier) to develop and commercialize three DART&#174; molecules in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20.0 million upfront option fee. In addition, we will be eligible to receive up to approximately $700.0 million in additional license fees and clinical, development, regulatory and sales milestone payments if Servier exercises its remaining options and successfully develops, obtains regulatory approval for, and commercializes a product under each license. Additionally, assuming exercise of its options, Servier may share Phase 2 and Phase 3 development costs and would be obligated to pay us low double-digit to mid-teen royalties on product sales in its territories.</span></div><div style="padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In February 2014, Servier exercised its option to develop and commercialize flotetuzumab, for which we received a $15.0 million license option fee.&#160;&#160;We also received two $5.0 million milestone payments from Servier in 2014 in connection with the IND applications for flotetuzumab and MGD007 clearing the 30-day review period by the U.S. Food and Drug Administration (FDA). As of September 30, 2018, Servier still retains an option to obtain a license for MGD007, but Servier has notified us that they have terminated their rights to license the third DART molecule.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In addition, we have sought to complement our internal expertise and capabilities with collaborators that may help us advance our programs. For example, in December 2017, we entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively, Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets. During the research term, both companies will leverage their respective platforms, including our DART platform and Roche's CrossMAb and DutaFab technologies, to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_315"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:39pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. A summary of our critical accounting policies is presented in Part II, Item&#160;7, of our Annual Report on Form 10-K for the year ended December&#160;31, 2017. Except as described in Note 1 to our accompanying consolidated financial statements with respect to changes in our revenue recognition policy related to our adoption of the requirements of ASC 606, there have been no significant changes to our critical accounting policies and estimates during the nine months ended September 30, 2018. </span></div><div style="text-indent:39pt;"><span><br/></span></div><div id="i_0_327"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following represents a comparison of our revenue for the three and nine months ended September&#160;30, 2018 and 2017:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:45.368421%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative and other agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from government agreements&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(69)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:45.368421%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative and other agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">40.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1174&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from government agreements&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(70)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">44.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">38.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Collaboration revenue increased by $19.5 million and $40.3 million for the three and nine months ended September&#160;30, 2018 compared to the three and nine months ended September&#160;30, 2017, respectively, primarily due to revenue recognized under the Incyte MGA012 collaboration, the Roche agreement and the Provention agreement, all of which were initiated after September 30, 2017.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenue from government agreements decreased by $0.4 million and $1.4 million for the three and nine months ended September&#160;30, 2018 compared to the three and nine months ended September&#160;30, 2017, respectively, primarily due to less costs incurred under the NIAID cost plus fixed fee contract. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expense</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following represents a comparison of our research and development expense for the three and nine months ended September&#160;30, 2018 and 2017:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:39.812865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.228070%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.812865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.842105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.964912%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Margetuximab&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.2)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(23)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Enoblituzumab&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.9&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(55)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Flotetuzumab&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGA012&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8.1&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.7&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD013&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Orlotamab (formerly MGD009)&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGC018&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD007&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical immune checkpoint programs&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(43)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other preclinical and clinical programs, collectively&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">46.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">41.0&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our research and development expense for the three months ended September 30, 2018&#160;increased by $5.2 million compared to the three months ended September 30, 2017&#160;primarily due to:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    increased expenses related to the initiation of&#160;two&#160;combination studies of MGA012 during the three months ended September 30, 2018, partially offset by decreased costs related to the MGA012 monotherapy study which was transferred to Incyte during the period;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    increased development/manufacturing costs related to MGA012 (which are partially offset by revenue recognized under the Incyte clinical supply agreement);</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    increased expenses related to the continued enrollment in our&#160;two margetuximab studies and our flotetuzumab clinical trial;&#160;</span></div><div style="text-indent:18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    incurred costs related to the Phase 1 study of MGD013 which was initiated in the third quarter of 2017;</span></div><div style="text-indent:18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    decreased expenses related to the timing of manufacturing costs of margetuximab;</span></div><div style="text-indent:18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    decreased expenses from&#160;two&#160;enoblituzumab clinical trials;</span></div><div style="text-indent:18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    and increased headcount to support manufacturing and development activities.</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:33.964912%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Margetuximab&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">51.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35.0&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">16.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Enoblituzumab&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12.0&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15.9&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.9)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(25)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Flotetuzumab&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGA012&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9.2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9.9&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD013&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Orlotamab (formerly MGD009)&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGC018&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(27)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD007&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical immune checkpoint programs&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.8)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(47)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other preclinical and clinical programs, collectively&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">17.0&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13.4&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.6&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">143.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">108.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:15pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Our research and development expense for the nine months ended September 30, 2018 increased by $35.7 million compared to the nine months ended September 30, 2017, primarily due to:</span></div><div style="text-indent:18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    the continued enrollment in our two margetuximab studies and our flotetuzumab clinical trial;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    increased development/manufacturing costs related to MGA012&#160;(which are partially offset by revenue recognized under the Incyte clinical supply agreement);</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    increased expenses related to the initiation of two combination studies of MGA012 during the nine months ended September 30, 2018, partially offset by decreased costs related to the MGA012 monotherapy study which was transferred to Incyte during the period;</span></div><div style="text-indent:18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    incurred costs related to the Phase 1 study of MGD013 which was initiated in the third quarter of 2017;</span></div><div style="text-indent:18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    decreased expenses from two enoblituzumab clinical trials;</span></div><div style="text-indent:18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">-    and increased headcount to support manufacturing and development activities.</span></div><div style="margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expense</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following represents a comparison of our general and administrative expense for the three and nine months ended September&#160;30, 2018 and 2017:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:36.596491%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.374269%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.812865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:36.304094%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.374269%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.374269%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.035088%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.865497%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">30.0&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">General and administrative expense increased for the three and nine months ended September 30, 2018 compared to the three and nine months ended September 30, 2017&#160;primarily due to increased patent-related&#160;expenses and consulting and other costs incurred related to the implementation of our new enterprise resource planning (ERP) system.&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Other income increased by $0.3 million and $0.9 million for the three and nine months ended September 30, 2018 compared to the three and nine months ended September 30, 2017, respectively, due to an increase in interest income earned on investments.&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_339"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have historically financed our operations primarily through public and private offerings of equity, upfront fees, milestone payments and license option fees from collaborators and reimbursement through government grants and contracts.&#160;&#160;&#160; As of September&#160;30, 2018, we had $260.1 million in cash, cash equivalents and marketable securities. In addition to our existing cash, cash equivalents and marketable securities, we are eligible to receive additional reimbursement from our collaborators, including under various government grants or contracts, for certain research and development services rendered, additional milestone payments and opt-in payments. However, our ability to receive these milestone payments is dependent upon our ability to successfully complete specified research and development activities and is therefore uncertain at this time.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Funding Requirements</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval of and commercialize one or more of our product candidates. As we are currently in the clinical trial stage of development, it will be some time before we expect to achieve this and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as well as additional clinical trials and preclinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our existing cash, cash equivalents and marketable securities as of September&#160;30, 2018, as well as collaboration payments we anticipate receiving, should enable us to fund our operations into mid-2020, assuming our programs and collaborations advance as currently contemplated.</span></div><div style="margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table represents a summary of our cash flows for the nine months ended September&#160;30, 2018 and 2017:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:64.079295%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.593245%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.593245%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(126.0)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(97.4)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">69.2&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">104.5&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35.0&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash and cash equivalents&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.9)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Operating Activities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and preclinical activities. The increase in net cash used in operating activities during the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017 was primarily due to increased clinical trial activities, purchases of materials for our new manufacturing suite and increased headcount to support manufacturing and development activities.  These increases in expenses were partially offset by the receipt of the $10.0 million upfront payment from Roche during the nine months ended September 30, 2018.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Investing Activities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Net cash provided by investing activities during the nine months ended September 30, 2018 is primarily due to maturities of marketable securities partially offset by purchases of marketable securities and making significant leasehold improvements to our facilities, including the build-out of our manufacturing suite at our headquarters location.&#160;  Net cash provided by investing activities during the nine months ended September 30, 2017 is primarily due to maturities of marketable securities partially offset by purchases of marketable securities.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Financing Activities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Net cash provided by financing activities for the nine months ended September 30, 2018 is primarily due to the cash proceeds from our underwritten public offering which closed in April 2018.   Net cash provided by financing activities for the nine months ended September 30, 2017 is primarily due to the cash proceeds from our registered direct offering and at the market offering.  For all periods presented, financing activities also include proceeds from stock option exercises and our employee stock purchase plan. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_351"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission.</span></div><div id="i_0_363"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.567251%;"><tr><td style="width:1.0%;"></td><td style="width:6.750000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.250000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 3.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;&#160;As of September&#160;30, 2018, we had cash, cash equivalents and marketable securities of $260.1 million.&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;&#160;Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div id="i_0_376"></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.567251%;"><tr><td style="width:1.0%;"></td><td style="width:6.750000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.250000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 4.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">CONTROLS AND PROCEDURES&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Disclosure Controls and Procedures</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of September&#160;30, 2018. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of September&#160;30, 2018, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control</span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">We are engaged in a phased implementation of a new ERP system, which will replace or enhance certain internal financial, operating and other systems that are critical to our business operations.  Effective January 1, 2018 we completed the implementation of certain functional areas of the ERP implementation project that affect the processes that constitute our internal control over financial reporting and this initial deployment will require testing for effectiveness throughout 2018. The second phase of the implementation was completed in July 2018.  Management has taken steps to ensure that appropriate controls are designed and implemented as each functional area of the new ERP system is enacted.  </span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">With the exception of the ERP implementation described above, there were no changes in the Company's internal control over financial reporting that occurred during the nine months ended September 30, 2018 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.</span></div><div id="i_0_388"></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div id="i_0_400"></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.713450%;"><tr><td style="width:1.0%;"></td><td style="width:6.892356%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.107644%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1A.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk Factors&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our material risk factors are disclosed in Item&#160;1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2017. There have been no material changes from the risk factors previously disclosed in our Annual Report for the year ended December&#160;31, 2017&#160;</span></div><div id="i_0_412"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.251462%;"><tr><td style="width:1.0%;"></td><td style="width:5.448494%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.551506%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6.&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibits&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.116959%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-1q32018.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-2q32018.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-1q32018.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-2q32018.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Schema Document&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Calculation Linkbase Document&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Definition Linkbase Document&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Labels Linkbase Document&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Presentation Linkbase Document&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div id="i_0_426"></div><div style="text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:18pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SIGNATURES</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:46.973607%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.692082%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.334311%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MACROGENICS, INC.&#160;</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">BY:&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Scott Koenig&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Scott Koenig, M.D., Ph.D.&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">BY:&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ James Karrels&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">James Karrels&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Senior Vice President and Chief Financial Officer&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated: November 7, 2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_439"></div><div style="text-align:center;margin-bottom:9pt;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:18pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT INDEX</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:19.491228%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:76.508772%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Exhibit&#160;Page&#160;Number</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-1q32018.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-2q32018.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-1q32018.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-2q32018.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">101.INS</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">XBRL Instance Document</span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">101.SCH</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">XBRL Schema Document</span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">101.CAL</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">XBRL Calculation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">101.DEF</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">XBRL Definition Linkbase Document</span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">101.LAB</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">XBRL Labels Linkbase Document</span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">101.PRE</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">XBRL Presentation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">25</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31-1q32018.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2018 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:63pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT 31.1</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, Scott Koenig, certify that&#58;</font></div><div><font><br></font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I have reviewed this Quarterly Report on Form 10-Q for the period ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">September&#160;30, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of MacroGenics, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">3.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">4.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">c.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">d.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">5.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">President and Chief Executive Officer</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(Principal Executive Officer)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Dated&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">November&#160;7, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:63pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31-2q32018.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2018 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:63pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT 31.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, James Karrels, certify that&#58;</font></div><div><font><br></font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> have reviewed this Quarterly Report on Form 10-Q for the period ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">September&#160;30, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of MacroGenics, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">3.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">4.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">c.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">d.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">5.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">James Karrels</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Senior Vice President and Chief Financial Officer</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(Principal Financial Officer)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Dated&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">November&#160;7, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:63pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32-1q32018.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2018 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT 32.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Certification of Principal Executive Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Pursuant to 18 U.S.C. 1350</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Section 906 of the Sarbanes-Oxley Act of 2002</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">)</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">September&#160;30, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="text-indent:-22pt;padding-left:22pt;"><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Date&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">November&#160;7, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="padding-left:252pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32-2q32018.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2018 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT 32.2</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Certification of Principal Financial Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Pursuant to 18 U.S.C. 1350</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">September&#160;30, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2.    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Name&#58; James Karrels</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Date&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">November&#160;7, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mgnx-20180930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:b7316434-03a0-4e88-aa3b-e89ba2bd1bc0,g:5bed0e04-ab87-46dd-8d59-93be05bc483c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:mgnx="http://macrogenics.com/20180930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20180930">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <xs:element id="mgnx_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_LesLaboratoiresServierMGD007Member" abstract="true" name="LesLaboratoiresServierMGD007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_PublicOfferingandOverAllotmentOptionMember" abstract="true" name="PublicOfferingandOverAllotmentOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ServierDARTMember" abstract="true" name="ServierDARTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_OptionExerciseFee" abstract="false" name="OptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionBioInc.Member" abstract="true" name="ProventionBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts" abstract="false" name="ContractWithCustomerLiabilityIncreasefromCashReceipts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialLicenseFee" abstract="false" name="PotentialLicenseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" abstract="true" name="F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementServicesMember" abstract="true" name="IncyteMGA012AgreementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="AdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfMilestonesAchieved" abstract="false" name="NumberOfMilestonesAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_FairValueOfWarrantsReceived" abstract="false" name="FairValueOfWarrantsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementClinicalActivitiesMember" abstract="true" name="IncyteMGA012AgreementClinicalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_UpfrontPaymentRecognitionPeriod" abstract="false" name="UpfrontPaymentRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" abstract="false" name="PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" abstract="false" name="CollaborationArrangementOffsetToResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndOtherAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ServierMember" abstract="true" name="ServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" abstract="false" name="PotentialClinicalMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2003StockIncentivePlanMember" abstract="true" name="A2003StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_FundedValueOfBasePeriod" abstract="false" name="FundedValueOfBasePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_OptionExerciseFeeRecognitionPeriod" abstract="false" name="OptionExerciseFeeRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfExclusiveOptionsToLicense" abstract="false" name="NumberOfExclusiveOptionsToLicense" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialSalesMilestonePaymentsUnderAgreement" abstract="false" name="PotentialSalesMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfComponentsInLicenseAgreement" abstract="false" name="NumberOfComponentsInLicenseAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20180930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20180930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20180930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20180930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://macrogenics.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesTables" roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesDetails" roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments">
        <link:definition>2105102 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2306302 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsDetails" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails">
        <link:definition>2407402 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2108103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2309303 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2410403 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2111104 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2412404 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements">
        <link:definition>2113105 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails">
        <link:definition>2414405 - Disclosure - Collaboration and Other Agreements - Incyte (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsRocheDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails">
        <link:definition>2415406 - Disclosure - Collaboration and Other Agreements - Roche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsLesLaboratoiresServierDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails">
        <link:definition>2416407 - Disclosure - Collaboration and Other Agreements - Les Laboratoires Servier (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails">
        <link:definition>2417408 - Disclosure - Collaboration and Other Agreements Collaboration and Other Agreements - Provention (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2418409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>2119106 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>2320304 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2421410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2422411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2423412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://macrogenics.com/role/NetLossPerShare">
        <link:definition>2124107 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareNarrativeDetails" roleURI="http://macrogenics.com/role/NetLossPerShareNarrativeDetails">
        <link:definition>2425413 - Disclosure - Net Loss Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mgnx-20180930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:b7316434-03a0-4e88-aa3b-e89ba2bd1bc0,g:5bed0e04-ab87-46dd-8d59-93be05bc483c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="mgnx-20180930.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ab3bac85-c20c-4b54-9c1d-92fd507fd547" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_40b43535-1238-4fb9-b2bb-f9f8d0b8fcae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ab3bac85-c20c-4b54-9c1d-92fd507fd547" xlink:to="loc_us-gaap_AccountsPayableCurrent_40b43535-1238-4fb9-b2bb-f9f8d0b8fcae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_13653889-e1ae-4996-a406-e7e64ef2d0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ab3bac85-c20c-4b54-9c1d-92fd507fd547" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_13653889-e1ae-4996-a406-e7e64ef2d0d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_d9e64027-eced-44d1-ae3f-b665089bf901" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ab3bac85-c20c-4b54-9c1d-92fd507fd547" xlink:to="loc_us-gaap_DeferredRevenueCurrent_d9e64027-eced-44d1-ae3f-b665089bf901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_f90663e6-6b40-430b-9cc2-85994cc4ee90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ab3bac85-c20c-4b54-9c1d-92fd507fd547" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_f90663e6-6b40-430b-9cc2-85994cc4ee90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_cc613122-5267-42ac-a051-342660031bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ab3bac85-c20c-4b54-9c1d-92fd507fd547" xlink:to="loc_us-gaap_RestructuringReserveCurrent_cc613122-5267-42ac-a051-342660031bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_41b3d579-2984-427d-a095-b6b6d4a7be5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ab3bac85-c20c-4b54-9c1d-92fd507fd547" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_41b3d579-2984-427d-a095-b6b6d4a7be5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_67809294-e0c6-491d-a091-e001ea46f5da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6e3c9b05-26cb-47b5-b088-b0513a60be6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_67809294-e0c6-491d-a091-e001ea46f5da" xlink:to="loc_us-gaap_Liabilities_6e3c9b05-26cb-47b5-b088-b0513a60be6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_15ae3676-6208-4a30-b030-e21806a0a42b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_67809294-e0c6-491d-a091-e001ea46f5da" xlink:to="loc_us-gaap_StockholdersEquity_15ae3676-6208-4a30-b030-e21806a0a42b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa01d71c-db08-4207-b882-ac2401e67b99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4650602f-4389-4c8a-a2a5-cd13215bcfc2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa01d71c-db08-4207-b882-ac2401e67b99" xlink:to="loc_us-gaap_CommonStockValue_4650602f-4389-4c8a-a2a5-cd13215bcfc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9ab05924-dc94-49ad-a494-5bd86479d162" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa01d71c-db08-4207-b882-ac2401e67b99" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9ab05924-dc94-49ad-a494-5bd86479d162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a16739dd-3d17-4a21-a34e-b77c592457df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa01d71c-db08-4207-b882-ac2401e67b99" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a16739dd-3d17-4a21-a34e-b77c592457df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_45171b35-35fb-430d-bdc9-dfd4bb51eace" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa01d71c-db08-4207-b882-ac2401e67b99" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_45171b35-35fb-430d-bdc9-dfd4bb51eace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8d78cc36-41a0-48b1-aa87-643061301b73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9f68e93f-a9d3-4f3c-b655-3af749fdfc34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8d78cc36-41a0-48b1-aa87-643061301b73" xlink:to="loc_us-gaap_LiabilitiesCurrent_9f68e93f-a9d3-4f3c-b655-3af749fdfc34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_9030017a-f088-4a80-b1b8-9f83649b587e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8d78cc36-41a0-48b1-aa87-643061301b73" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_9030017a-f088-4a80-b1b8-9f83649b587e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_32559788-601f-4728-8a1f-8347ac222e8e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8d78cc36-41a0-48b1-aa87-643061301b73" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_32559788-601f-4728-8a1f-8347ac222e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c7e6447c-5c17-478b-ada1-61345cfc1265" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a0d4f16d-08a0-4466-ba93-7e75220f768b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7e6447c-5c17-478b-ada1-61345cfc1265" xlink:to="loc_us-gaap_AssetsCurrent_a0d4f16d-08a0-4466-ba93-7e75220f768b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ecf14be1-b4e2-4348-9cc5-07f779ba6837" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7e6447c-5c17-478b-ada1-61345cfc1265" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ecf14be1-b4e2-4348-9cc5-07f779ba6837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b231bc65-7272-4fd7-8eaa-61b8411233a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7e6447c-5c17-478b-ada1-61345cfc1265" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b231bc65-7272-4fd7-8eaa-61b8411233a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_179eba75-0036-4ba7-8f0d-61598999f660" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d34dfeb8-8180-43da-aca6-3a5fce2b9478" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_179eba75-0036-4ba7-8f0d-61598999f660" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d34dfeb8-8180-43da-aca6-3a5fce2b9478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_519513a7-42c5-4a74-85ee-a4f68dacdc38" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_179eba75-0036-4ba7-8f0d-61598999f660" xlink:to="loc_us-gaap_Investments_519513a7-42c5-4a74-85ee-a4f68dacdc38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d0a564f3-5fd9-4927-a17d-8ff4b53178f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_179eba75-0036-4ba7-8f0d-61598999f660" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d0a564f3-5fd9-4927-a17d-8ff4b53178f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_105c5cfd-8cf1-47f5-88a5-fa2d1e578888" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_179eba75-0036-4ba7-8f0d-61598999f660" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_105c5cfd-8cf1-47f5-88a5-fa2d1e578888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_ed0f4ca5-3007-4fbe-a33e-b6d3e1cd21f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_179eba75-0036-4ba7-8f0d-61598999f660" xlink:to="loc_us-gaap_OtherAssets_ed0f4ca5-3007-4fbe-a33e-b6d3e1cd21f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bdf38cca-bece-46b0-8991-0c7520117829" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77426186-5a8f-4b8b-aee6-af83a026a10b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bdf38cca-bece-46b0-8991-0c7520117829" xlink:to="loc_us-gaap_NetIncomeLoss_77426186-5a8f-4b8b-aee6-af83a026a10b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6d253a47-fa64-4037-991b-1a88f3bb45ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bdf38cca-bece-46b0-8991-0c7520117829" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6d253a47-fa64-4037-991b-1a88f3bb45ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a25b950e-9b32-4919-963f-6d2873aece4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8d82a302-08cb-4d66-aeaa-b3fab4475e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a25b950e-9b32-4919-963f-6d2873aece4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8d82a302-08cb-4d66-aeaa-b3fab4475e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ed9cf4f6-ae76-4174-9529-a227c1661731" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a25b950e-9b32-4919-963f-6d2873aece4e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ed9cf4f6-ae76-4174-9529-a227c1661731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8bb3f5b-d77f-43c6-93ab-de80f550949f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_423fc4a8-2627-4ae7-b8a3-18f53eab292b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c8bb3f5b-d77f-43c6-93ab-de80f550949f" xlink:to="loc_us-gaap_OperatingIncomeLoss_423fc4a8-2627-4ae7-b8a3-18f53eab292b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2582a065-6a09-4cde-bb1d-a70a82a76eab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c8bb3f5b-d77f-43c6-93ab-de80f550949f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2582a065-6a09-4cde-bb1d-a70a82a76eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_226a7ec3-df33-491c-985b-e0874b7fbbbd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7472ca36-2fa0-469a-a730-cebcd1382b30" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_226a7ec3-df33-491c-985b-e0874b7fbbbd" xlink:to="loc_us-gaap_Revenues_7472ca36-2fa0-469a-a730-cebcd1382b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_480cd64a-9932-4517-a3aa-1c82806886c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_226a7ec3-df33-491c-985b-e0874b7fbbbd" xlink:to="loc_us-gaap_CostsAndExpenses_480cd64a-9932-4517-a3aa-1c82806886c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_73c6e043-00b5-4147-9c27-825a8d950ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_NetIncomeLoss_73c6e043-00b5-4147-9c27-825a8d950ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ce75254e-9682-4c8e-89b5-a75949017727" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ce75254e-9682-4c8e-89b5-a75949017727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_df76a7d3-53bc-4801-8efc-2a9ad648bd22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_ShareBasedCompensation_df76a7d3-53bc-4801-8efc-2a9ad648bd22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ad9b800-d320-4046-8d2f-a16945947c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ad9b800-d320-4046-8d2f-a16945947c6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_52a69dbb-0a26-4194-871d-484300fc3197" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_52a69dbb-0a26-4194-871d-484300fc3197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a04dc6cf-187a-449f-a151-c743ebf660e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a04dc6cf-187a-449f-a151-c743ebf660e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_d6c92ddb-ee41-4a89-beed-8e3b522ccc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_d6c92ddb-ee41-4a89-beed-8e3b522ccc6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_22d94992-9928-4963-90ea-c46441c372b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_22d94992-9928-4963-90ea-c46441c372b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_e0ca14f8-bf4e-4dec-aac9-8fa2625bbcc4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_e0ca14f8-bf4e-4dec-aac9-8fa2625bbcc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_a161d6af-2b98-47c9-9d7e-403958bc918a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_a161d6af-2b98-47c9-9d7e-403958bc918a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_1a540852-2afe-499d-8ab5-19bc6c450a9f" xlink:href="mgnx-20180930.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_155b08bb-bf6b-4d41-98b7-8788a343fa2b" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_1a540852-2afe-499d-8ab5-19bc6c450a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_977b3a8f-1bb8-464e-b711-5e7156d22304" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_32c88490-27be-4d6b-b97e-32773568ccd3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_977b3a8f-1bb8-464e-b711-5e7156d22304" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_32c88490-27be-4d6b-b97e-32773568ccd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_adbdeae2-e47e-4b02-9faa-093f298b6a23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_977b3a8f-1bb8-464e-b711-5e7156d22304" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_adbdeae2-e47e-4b02-9faa-093f298b6a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_89b67d8f-4fde-4334-9040-6b0232166c44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_977b3a8f-1bb8-464e-b711-5e7156d22304" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_89b67d8f-4fde-4334-9040-6b0232166c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_5fbd2fb9-53ff-417c-9b37-25c076ff0c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d83f6f56-6888-456d-9f87-600d73394df1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_5fbd2fb9-53ff-417c-9b37-25c076ff0c4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d83f6f56-6888-456d-9f87-600d73394df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_b9c24a65-eac9-4f54-9edd-26e8bc7ef2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_5fbd2fb9-53ff-417c-9b37-25c076ff0c4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_b9c24a65-eac9-4f54-9edd-26e8bc7ef2c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_747c419e-7198-440e-a0e9-caf668ac3128" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_5fbd2fb9-53ff-417c-9b37-25c076ff0c4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_747c419e-7198-440e-a0e9-caf668ac3128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_53d2e5a7-4863-45a7-814b-cd7bf1c6fbeb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_01cd5342-530c-4e5e-9d17-a27d31e8fd72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_53d2e5a7-4863-45a7-814b-cd7bf1c6fbeb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_01cd5342-530c-4e5e-9d17-a27d31e8fd72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_bd4d4c6e-8111-4d5e-80ad-72b0f0113d28" xlink:href="mgnx-20180930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_53d2e5a7-4863-45a7-814b-cd7bf1c6fbeb" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_bd4d4c6e-8111-4d5e-80ad-72b0f0113d28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20180930.xsd#FairValueofFinancialInstruments"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a82fa812-85c9-4363-979e-91024a14acfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8249a043-eb25-44d7-85c1-c5bc832424f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a82fa812-85c9-4363-979e-91024a14acfb" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8249a043-eb25-44d7-85c1-c5bc832424f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_38990c39-325a-46a2-81d7-aff6d04d224e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a82fa812-85c9-4363-979e-91024a14acfb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_38990c39-325a-46a2-81d7-aff6d04d224e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20180930.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e5ed1a68-f86d-479a-9036-7ff573891a62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00542427-3966-4df9-a65c-7e01ac22e03c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e5ed1a68-f86d-479a-9036-7ff573891a62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00542427-3966-4df9-a65c-7e01ac22e03c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7e146838-366e-4773-8684-736751ebb1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e5ed1a68-f86d-479a-9036-7ff573891a62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7e146838-366e-4773-8684-736751ebb1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4988931-d401-4d76-9d6a-9d8650c6d941" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e5ed1a68-f86d-479a-9036-7ff573891a62" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4988931-d401-4d76-9d6a-9d8650c6d941" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreements"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsIncyteDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsLesLaboratoiresServierDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_92326d30-6714-48b3-8e8c-557881811470" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1cb1379f-cdb7-4678-87cd-f04712072d48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensation_92326d30-6714-48b3-8e8c-557881811470" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1cb1379f-cdb7-4678-87cd-f04712072d48" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="mgnx-20180930.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#NetLossPerShareNarrativeDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mgnx-20180930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:b7316434-03a0-4e88-aa3b-e89ba2bd1bc0,g:5bed0e04-ab87-46dd-8d59-93be05bc483c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="mgnx-20180930.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="extended" id="ie49584ecb5924f01904782d4ac0e34b2_107fa178-39b4-4ba4-98b4-40a1c22e9d90"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i3c46b2e3c1ae47e89a89fbff305b195f_a08eaa37-da1a-4c57-97c0-07cda6cb10b3"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ia3679d69941d4708ac82365a98c5cc16_da6b53df-7902-4f44-949d-734480c861ac"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="icdb1d23f49654793b33c9d89a2c04580_6066d6c9-8903-4f6e-ae29-46b2f0637fb7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a74ed189-c95d-44c0-9dd9-522c7fa1648e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:to="loc_us-gaap_StatementTable_a74ed189-c95d-44c0-9dd9-522c7fa1648e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c61b5102-ad56-4f92-b303-8bc75f499deb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a74ed189-c95d-44c0-9dd9-522c7fa1648e" xlink:to="loc_srt_ProductOrServiceAxis_c61b5102-ad56-4f92-b303-8bc75f499deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c61b5102-ad56-4f92-b303-8bc75f499deb" xlink:to="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c61b5102-ad56-4f92-b303-8bc75f499deb" xlink:to="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_bf46b978-c264-4969-8b65-950da21d8792" xlink:href="mgnx-20180930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_bf46b978-c264-4969-8b65-950da21d8792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_c56fc919-c737-4351-bba1-e4509f127789" xlink:href="mgnx-20180930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_c56fc919-c737-4351-bba1-e4509f127789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1d6b04cb-7db2-425f-9f30-84e733677d03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:to="loc_us-gaap_RevenuesAbstract_1d6b04cb-7db2-425f-9f30-84e733677d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_20e1b9ea-0daa-4ff6-9333-e2f32decbc28" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1d6b04cb-7db2-425f-9f30-84e733677d03" xlink:to="loc_us-gaap_Revenues_20e1b9ea-0daa-4ff6-9333-e2f32decbc28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b373504e-11c3-4da0-bb0a-28b9e24fe199" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b373504e-11c3-4da0-bb0a-28b9e24fe199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9eb0be8b-ced8-43a6-9c71-51017c2eac2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9eb0be8b-ced8-43a6-9c71-51017c2eac2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9f817f67-2626-4687-a3a7-ed4f5950b07c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_CostsAndExpenses_9f817f67-2626-4687-a3a7-ed4f5950b07c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c272380d-8709-4e31-833c-69977f23702c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_OperatingIncomeLoss_c272380d-8709-4e31-833c-69977f23702c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ac28b338-ee80-4522-aee8-b9dc7b5178de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ac28b338-ee80-4522-aee8-b9dc7b5178de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e8b7a056-8090-4a9e-8c1b-036b39f81c41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_NetIncomeLoss_e8b7a056-8090-4a9e-8c1b-036b39f81c41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4dee1197-d481-451e-900c-024736c42754" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4dee1197-d481-451e-900c-024736c42754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_675307af-a26d-431a-86dd-b5d5ad3d7b17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_675307af-a26d-431a-86dd-b5d5ad3d7b17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_b03f40c4-d89e-4df4-b0c0-c9d01ad0709d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_b03f40c4-d89e-4df4-b0c0-c9d01ad0709d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_bf2142fa-58ea-46e6-bd5f-6e3b2d1f3d67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_bf2142fa-58ea-46e6-bd5f-6e3b2d1f3d67" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ifab97522680e426a9151e26749230fc3_34d536d7-3769-4bb1-bb60-90320df898b6"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended" id="i343c54fca68548189e048b899607432d_9b63428c-e75b-433b-948e-0f971c7a4225"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ieaa6f8bd95224feb9eb01026d20ff880_31898d77-14a9-4352-8ca5-051af128aafe"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended" id="ic9ce8aa589e441dfb0f81c36d304acc9_f95ed653-f76f-42eb-95d3-195354d566b1"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="extended" id="i79ed701279494360a041a5c98354acb3_df449d2e-271d-40e4-948f-9e3a1de08c4d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_232c5236-3b76-42c0-8db4-0c2c6cf48ffd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:to="loc_srt_ProductOrServiceAxis_232c5236-3b76-42c0-8db4-0c2c6cf48ffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ce91edc-6718-43a8-af67-bcd022329d6c_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_232c5236-3b76-42c0-8db4-0c2c6cf48ffd" xlink:to="loc_srt_ProductsAndServicesDomain_6ce91edc-6718-43a8-af67-bcd022329d6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ce91edc-6718-43a8-af67-bcd022329d6c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_232c5236-3b76-42c0-8db4-0c2c6cf48ffd" xlink:to="loc_srt_ProductsAndServicesDomain_6ce91edc-6718-43a8-af67-bcd022329d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_8b9cde99-03c9-4364-89f8-919400fca444" xlink:href="mgnx-20180930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ce91edc-6718-43a8-af67-bcd022329d6c" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_8b9cde99-03c9-4364-89f8-919400fca444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_04655218-82cf-4847-a724-60c747a1a84f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_04655218-82cf-4847-a724-60c747a1a84f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7ef46a62-8a46-40d4-b2ee-42cc326e1336_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_04655218-82cf-4847-a724-60c747a1a84f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7ef46a62-8a46-40d4-b2ee-42cc326e1336_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7ef46a62-8a46-40d4-b2ee-42cc326e1336" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_04655218-82cf-4847-a724-60c747a1a84f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7ef46a62-8a46-40d4-b2ee-42cc326e1336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_f954ed11-d592-4e6a-8165-9b0380498928" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7ef46a62-8a46-40d4-b2ee-42cc326e1336" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_f954ed11-d592-4e6a-8165-9b0380498928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_e1eaf175-819e-4883-9528-d9ca08c0e1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_e1eaf175-819e-4883-9528-d9ca08c0e1b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_e1eaf175-819e-4883-9528-d9ca08c0e1b1" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_e1eaf175-819e-4883-9528-d9ca08c0e1b1" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_d7ab55d1-8e21-4236-9bdf-ffc37ad5a575" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_d7ab55d1-8e21-4236-9bdf-ffc37ad5a575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_f79bc649-07b1-429e-811d-c8b7b7a614bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_f79bc649-07b1-429e-811d-c8b7b7a614bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_0960df38-e027-40e9-8d73-0bcce31acf3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_DeferredRevenueCurrent_0960df38-e027-40e9-8d73-0bcce31acf3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_82aa5aaf-687e-4064-9f48-65eecd0d0403" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_82aa5aaf-687e-4064-9f48-65eecd0d0403" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9728e1d-729c-4745-ae5c-0b005c3d4beb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9728e1d-729c-4745-ae5c-0b005c3d4beb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_158c7148-d29b-4bd6-a794-9a7eec5abf41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_Revenues_158c7148-d29b-4bd6-a794-9a7eec5abf41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_979eb436-3ee1-43cd-9dbf-d858a344afae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_NetIncomeLoss_979eb436-3ee1-43cd-9dbf-d858a344afae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4b7e9197-e8f8-40bb-aa9c-b05e765ff761" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_4b7e9197-e8f8-40bb-aa9c-b05e765ff761" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:href="mgnx-20180930.xsd#mgnx_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_bff0f816-6e16-46cf-b98b-137ec9d6ccc1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:to="loc_us-gaap_ContractWithCustomerLiability_bff0f816-6e16-46cf-b98b-137ec9d6ccc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts_684ec312-8aa9-475b-a42b-a75303ee0043" xlink:href="mgnx-20180930.xsd#mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:to="loc_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts_684ec312-8aa9-475b-a42b-a75303ee0043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d3e524a-12f1-44e4-82d6-a889959ae965" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d3e524a-12f1-44e4-82d6-a889959ae965" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_de198c9c-994d-4a03-a4f4-73fdf53c8b27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20180930.xsd#FairValueofFinancialInstruments"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended" id="i0c3a37d2cdfd44fe81f2bf237193c4d0_8116f3c7-488c-4edb-ac75-10e6d340e3f7"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended" id="i42288f73b53449cfac832a31b9c2a83d_bc9b46fc-febc-447e-aa6c-6b51286bc316"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended" id="ia8d2308cf6c941438cc700e63bfa02d9_ac870915-d8eb-4437-981d-299a7b81b7ba">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99c1346f-29f5-41c6-80c4-eb701c592a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99c1346f-29f5-41c6-80c4-eb701c592a8c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7666722d-3b8d-4b78-9531-344e3d1d0b45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7666722d-3b8d-4b78-9531-344e3d1d0b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a808e5e0-285f-4e6a-80da-9922ee8d7465_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7666722d-3b8d-4b78-9531-344e3d1d0b45" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a808e5e0-285f-4e6a-80da-9922ee8d7465_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a808e5e0-285f-4e6a-80da-9922ee8d7465" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7666722d-3b8d-4b78-9531-344e3d1d0b45" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a808e5e0-285f-4e6a-80da-9922ee8d7465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_61ddeb5c-925f-4e08-8634-0e0434c01ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a808e5e0-285f-4e6a-80da-9922ee8d7465" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_61ddeb5c-925f-4e08-8634-0e0434c01ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d504efa5-9f7f-4304-a6d4-3dfbfc5293cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d504efa5-9f7f-4304-a6d4-3dfbfc5293cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d504efa5-9f7f-4304-a6d4-3dfbfc5293cf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d504efa5-9f7f-4304-a6d4-3dfbfc5293cf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_fbf46f04-2cbc-4361-802d-ce5d21134e92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_MoneyMarketFundsMember_fbf46f04-2cbc-4361-802d-ce5d21134e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_30668632-7f08-42f2-8807-c5709e0d497e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_30668632-7f08-42f2-8807-c5709e0d497e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ca24ebf4-f525-47be-a5b2-59029df3adc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ca24ebf4-f525-47be-a5b2-59029df3adc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0c8d8482-3d63-4a8d-b41e-01b29e211a49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0c8d8482-3d63-4a8d-b41e-01b29e211a49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_470457bc-d6cd-43a9-93b3-f44c55b16a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_WarrantMember_470457bc-d6cd-43a9-93b3-f44c55b16a7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652925e4-5542-48a1-9c8c-99bd42978a34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652925e4-5542-48a1-9c8c-99bd42978a34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652925e4-5542-48a1-9c8c-99bd42978a34" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652925e4-5542-48a1-9c8c-99bd42978a34" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_25c6cc4b-f5f1-4d36-aada-638cf810d2ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_25c6cc4b-f5f1-4d36-aada-638cf810d2ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_05700786-bc28-450e-b697-06a96fe8eec0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_05700786-bc28-450e-b697-06a96fe8eec0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f7a22b36-1e61-4974-968f-7f91b91c2d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f7a22b36-1e61-4974-968f-7f91b91c2d5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99c1346f-29f5-41c6-80c4-eb701c592a8c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fe1894a1-5dbe-4de9-9b7a-b4c0d7da2a41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fe1894a1-5dbe-4de9-9b7a-b4c0d7da2a41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e31732e9-4785-4782-a047-7f28b9b36fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e31732e9-4785-4782-a047-7f28b9b36fa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8c893fd5-3466-40ff-90ae-e86c48247b17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8c893fd5-3466-40ff-90ae-e86c48247b17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_316389ff-45f6-442f-9334-d79ad6fca29f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_316389ff-45f6-442f-9334-d79ad6fca29f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20180930.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended" id="i8ed6ebc8ad294d0c89fe255f475614a1_9c9be74b-0f54-4306-a9f4-54bc582d40f7"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended" id="i70c96c8cc7194e58be072dc44eae069d_14eabca1-05b9-4156-bab1-1dfc8c26a27e"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i6ee470b1bef34238b7500654fb6de8ee_5d77e99b-5d76-4019-865c-90a1dc2536f5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_e9cca573-e89b-4e19-a5c4-69eee270fb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_e9cca573-e89b-4e19-a5c4-69eee270fb3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_832615f0-9b7a-49f4-8a39-8050ee3f5dea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_e9cca573-e89b-4e19-a5c4-69eee270fb3c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_832615f0-9b7a-49f4-8a39-8050ee3f5dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_832615f0-9b7a-49f4-8a39-8050ee3f5dea" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_832615f0-9b7a-49f4-8a39-8050ee3f5dea" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0738d04c-77a0-4866-9896-7ba65f686d74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0738d04c-77a0-4866-9896-7ba65f686d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3b460356-1a72-4fa4-9d52-cae5acc310f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3b460356-1a72-4fa4-9d52-cae5acc310f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c4771208-9eeb-4507-878b-c060e0469d58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c4771208-9eeb-4507-878b-c060e0469d58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1d5cc21b-ca2e-422f-9dc9-b89c4993e1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1d5cc21b-ca2e-422f-9dc9-b89c4993e1ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a99e1096-3c54-4e81-9e88-7e878964e87a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a99e1096-3c54-4e81-9e88-7e878964e87a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ccf50140-11b9-4802-bc58-2bb7171d606e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ccf50140-11b9-4802-bc58-2bb7171d606e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_427901e4-c333-40b6-af9b-0f2b327ab614" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_427901e4-c333-40b6-af9b-0f2b327ab614" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_5b893db9-9d4a-4516-8a81-0b335ac447f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_5b893db9-9d4a-4516-8a81-0b335ac447f8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended" id="i45a87fed1522472f85c9e8bcc1d8701a_735a77b6-f0b6-41d1-b2b9-40f7596a3e0d"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="i40cac3c5736b410288578f8e09fb87e6_069e1f90-9a0f-49e3-a7cc-f3ed43fc66b5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0af92432-d5f3-4748-af74-cb5823323084" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0af92432-d5f3-4748-af74-cb5823323084" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6060a641-a087-4137-93bd-f2ae86f5684e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0af92432-d5f3-4748-af74-cb5823323084" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6060a641-a087-4137-93bd-f2ae86f5684e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6060a641-a087-4137-93bd-f2ae86f5684e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6060a641-a087-4137-93bd-f2ae86f5684e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RegisteredDirectOfferingMember_945d73cd-cb28-49a5-9081-af8a8247c56e" xlink:href="mgnx-20180930.xsd#mgnx_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_mgnx_RegisteredDirectOfferingMember_945d73cd-cb28-49a5-9081-af8a8247c56e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_ba19e03b-b6f7-49f3-8cdd-abef4ee67045" xlink:href="mgnx-20180930.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_mgnx_AtTheMarketOfferingMember_ba19e03b-b6f7-49f3-8cdd-abef4ee67045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PublicOfferingMember_cc2486dd-7643-43d8-b1f2-c4b04363ffcf" xlink:href="mgnx-20180930.xsd#mgnx_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_mgnx_PublicOfferingMember_cc2486dd-7643-43d8-b1f2-c4b04363ffcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_d546b68b-bce8-4a64-a0d3-28520ccb3d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_us-gaap_OverAllotmentOptionMember_d546b68b-bce8-4a64-a0d3-28520ccb3d7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PublicOfferingandOverAllotmentOptionMember_d2f36ad2-72d2-4b97-9b90-93b288bbeb3d" xlink:href="mgnx-20180930.xsd#mgnx_PublicOfferingandOverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_mgnx_PublicOfferingandOverAllotmentOptionMember_d2f36ad2-72d2-4b97-9b90-93b288bbeb3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f1bc763-2580-4fbe-9b85-735b3bcfbfe7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f1bc763-2580-4fbe-9b85-735b3bcfbfe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_380240a8-01b8-4511-ba02-0757de669330" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_380240a8-01b8-4511-ba02-0757de669330" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4546acc3-fe8f-44da-b01e-7aa2f447c271" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4546acc3-fe8f-44da-b01e-7aa2f447c271" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_6cee2714-96bd-4ed2-b7a0-ac25b7a85b72" xlink:href="mgnx-20180930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_6cee2714-96bd-4ed2-b7a0-ac25b7a85b72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b57a9100-f5dc-4287-b5bf-393f73b59106" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b57a9100-f5dc-4287-b5bf-393f73b59106" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreements"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended" id="if6995f69a1f4429dbc492581cb2d4aa0_3feaac8d-9ba6-464a-b880-918c4e9b89a5"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsIncyteDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="extended" id="i6dfa042a3cec4c21a67049a69a694c44_57ef58ef-b9ed-4449-8d8a-d4019efc1c83">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c11f0553-c0f7-4be2-a9e4-f67a9d3a85a0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:to="loc_srt_ProductOrServiceAxis_c11f0553-c0f7-4be2-a9e4-f67a9d3a85a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_828d351b-76e3-48d7-b098-d11cef6a243c_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c11f0553-c0f7-4be2-a9e4-f67a9d3a85a0" xlink:to="loc_srt_ProductsAndServicesDomain_828d351b-76e3-48d7-b098-d11cef6a243c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_828d351b-76e3-48d7-b098-d11cef6a243c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c11f0553-c0f7-4be2-a9e4-f67a9d3a85a0" xlink:to="loc_srt_ProductsAndServicesDomain_828d351b-76e3-48d7-b098-d11cef6a243c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_52bf5008-1405-4b45-821e-3f1b259c6dca" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_828d351b-76e3-48d7-b098-d11cef6a243c" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_52bf5008-1405-4b45-821e-3f1b259c6dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_70c16311-5317-4508-8bf2-230ad1d273c3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:to="loc_srt_RangeAxis_70c16311-5317-4508-8bf2-230ad1d273c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_70c16311-5317-4508-8bf2-230ad1d273c3" xlink:to="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_70c16311-5317-4508-8bf2-230ad1d273c3" xlink:to="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e84701f7-c202-4e88-a88e-621d795b5670" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828" xlink:to="loc_srt_MaximumMember_e84701f7-c202-4e88-a88e-621d795b5670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07d1bbf6-479c-4011-90a9-32b5c368669e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828" xlink:to="loc_srt_MinimumMember_07d1bbf6-479c-4011-90a9-32b5c368669e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_84289786-0964-43dd-a511-d7ea2a804529" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:to="loc_srt_CounterpartyNameAxis_84289786-0964-43dd-a511-d7ea2a804529" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc0f0e22-8bb4-43c1-af7d-0922ca13f42c_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_84289786-0964-43dd-a511-d7ea2a804529" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc0f0e22-8bb4-43c1-af7d-0922ca13f42c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc0f0e22-8bb4-43c1-af7d-0922ca13f42c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_84289786-0964-43dd-a511-d7ea2a804529" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc0f0e22-8bb4-43c1-af7d-0922ca13f42c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_ca6dac3c-c887-4b4f-8ab4-865a3fbdc086" xlink:href="mgnx-20180930.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc0f0e22-8bb4-43c1-af7d-0922ca13f42c" xlink:to="loc_mgnx_IncyteCorporationMember_ca6dac3c-c887-4b4f-8ab4-865a3fbdc086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0a55807b-f4d1-47e7-b807-68bd4707d8a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0a55807b-f4d1-47e7-b807-68bd4707d8a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3ca500ef-caf3-4371-9a60-92dac138a2a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0a55807b-f4d1-47e7-b807-68bd4707d8a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3ca500ef-caf3-4371-9a60-92dac138a2a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3ca500ef-caf3-4371-9a60-92dac138a2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0a55807b-f4d1-47e7-b807-68bd4707d8a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3ca500ef-caf3-4371-9a60-92dac138a2a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_4a902ab9-6455-44fc-ad0a-1eef0d9cba9e" xlink:href="mgnx-20180930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3ca500ef-caf3-4371-9a60-92dac138a2a4" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_4a902ab9-6455-44fc-ad0a-1eef0d9cba9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_10163198-1c0f-4ebd-9f6f-cb96306e2a19" xlink:href="mgnx-20180930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_4a902ab9-6455-44fc-ad0a-1eef0d9cba9e" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_10163198-1c0f-4ebd-9f6f-cb96306e2a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementServicesMember_959c78ab-c73e-445f-a081-168f55afb2d8" xlink:href="mgnx-20180930.xsd#mgnx_IncyteMGA012AgreementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_4a902ab9-6455-44fc-ad0a-1eef0d9cba9e" xlink:to="loc_mgnx_IncyteMGA012AgreementServicesMember_959c78ab-c73e-445f-a081-168f55afb2d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_b6aba003-bfd2-4007-b80b-e5095d9b7e02" xlink:href="mgnx-20180930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_NonRefundableUpfrontFees_b6aba003-bfd2-4007-b80b-e5095d9b7e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_3bfdc539-96bb-4ee4-a297-f9ddedf67e93" xlink:href="mgnx-20180930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_3bfdc539-96bb-4ee4-a297-f9ddedf67e93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_af4bb863-012f-4298-9c4d-332e8670a5ac" xlink:href="mgnx-20180930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_af4bb863-012f-4298-9c4d-332e8670a5ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_847108e0-6f54-4c75-bf3c-2fccd46adf20" xlink:href="mgnx-20180930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_847108e0-6f54-4c75-bf3c-2fccd46adf20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_20c81d72-fd43-4b60-b1b4-b32d551f4460" xlink:href="mgnx-20180930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_20c81d72-fd43-4b60-b1b4-b32d551f4460" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_eebae09f-9735-410a-b665-984bf2583bd2" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_NumberOfPerformanceObligations_eebae09f-9735-410a-b665-984bf2583bd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_42ddaf56-56e1-4325-8f37-d68940430e62" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_42ddaf56-56e1-4325-8f37-d68940430e62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_3942dc98-3a06-4726-82c0-075d299aaea4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_3942dc98-3a06-4726-82c0-075d299aaea4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_661fb3e9-9fba-4df8-8161-6bb06f62ad89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_us-gaap_Revenues_661fb3e9-9fba-4df8-8161-6bb06f62ad89" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended" id="ib8bb5c76b4cb4b359f3c36f761f0d382_d9bc9868-aaae-443a-a964-d09e8a731e07">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924014dc-17cd-48d2-bfe1-2e51ad5c7441" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924014dc-17cd-48d2-bfe1-2e51ad5c7441" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5a15bc1-f15d-40ba-a580-fe13c875bcf9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924014dc-17cd-48d2-bfe1-2e51ad5c7441" xlink:to="loc_srt_ProductOrServiceAxis_e5a15bc1-f15d-40ba-a580-fe13c875bcf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25ff8497-f453-42dc-a028-406d51855481_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e5a15bc1-f15d-40ba-a580-fe13c875bcf9" xlink:to="loc_srt_ProductsAndServicesDomain_25ff8497-f453-42dc-a028-406d51855481_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25ff8497-f453-42dc-a028-406d51855481" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e5a15bc1-f15d-40ba-a580-fe13c875bcf9" xlink:to="loc_srt_ProductsAndServicesDomain_25ff8497-f453-42dc-a028-406d51855481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_4a75eb42-012c-4837-a9c7-5055a1bb2811" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_25ff8497-f453-42dc-a028-406d51855481" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_4a75eb42-012c-4837-a9c7-5055a1bb2811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0fa3025e-35aa-4010-a855-e9933cdacad9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924014dc-17cd-48d2-bfe1-2e51ad5c7441" xlink:to="loc_srt_CounterpartyNameAxis_0fa3025e-35aa-4010-a855-e9933cdacad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bbaa110-06af-40ad-918e-dfafeac07097_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0fa3025e-35aa-4010-a855-e9933cdacad9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bbaa110-06af-40ad-918e-dfafeac07097_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bbaa110-06af-40ad-918e-dfafeac07097" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0fa3025e-35aa-4010-a855-e9933cdacad9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bbaa110-06af-40ad-918e-dfafeac07097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_413011e2-3fcd-488d-b29a-39b7a07ce96e" xlink:href="mgnx-20180930.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bbaa110-06af-40ad-918e-dfafeac07097" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_413011e2-3fcd-488d-b29a-39b7a07ce96e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_95a8018e-4be7-4672-969c-b77279b4bce2" xlink:href="mgnx-20180930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_NonRefundableUpfrontFees_95a8018e-4be7-4672-969c-b77279b4bce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_56953c0d-a275-457d-9f70-f23f89da4e19" xlink:href="mgnx-20180930.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_56953c0d-a275-457d-9f70-f23f89da4e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_3c413a61-2ca4-43f9-91fd-aee35cba2164" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_NumberOfPerformanceObligations_3c413a61-2ca4-43f9-91fd-aee35cba2164" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_ed85412e-69a8-4b01-aca8-09d2f2ff096b" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_ed85412e-69a8-4b01-aca8-09d2f2ff096b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_9c774d67-f402-40f3-a99d-4e59965d9b45" xlink:href="mgnx-20180930.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_9c774d67-f402-40f3-a99d-4e59965d9b45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7a75ac3a-c735-4eb2-aa38-626938acd5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_us-gaap_Revenues_7a75ac3a-c735-4eb2-aa38-626938acd5ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_29b27864-13e3-4bd7-b551-3659274b24c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_us-gaap_DeferredRevenue_29b27864-13e3-4bd7-b551-3659274b24c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_79caf4c9-6b9b-4e98-907f-4662383056b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_us-gaap_DeferredRevenueCurrent_79caf4c9-6b9b-4e98-907f-4662383056b9" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsLesLaboratoiresServierDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="extended" id="i03b93892e0df4fab8a3d942543e1cc34_4811b693-93be-4d10-8109-f1368d13fff8">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_199861b3-0e9f-44f0-b67e-ac8f1fbd88a9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_srt_ProductOrServiceAxis_199861b3-0e9f-44f0-b67e-ac8f1fbd88a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5631fd3-27d4-43f1-af50-a8200f76be55_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_199861b3-0e9f-44f0-b67e-ac8f1fbd88a9" xlink:to="loc_srt_ProductsAndServicesDomain_d5631fd3-27d4-43f1-af50-a8200f76be55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5631fd3-27d4-43f1-af50-a8200f76be55" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_199861b3-0e9f-44f0-b67e-ac8f1fbd88a9" xlink:to="loc_srt_ProductsAndServicesDomain_d5631fd3-27d4-43f1-af50-a8200f76be55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_22f16eb1-432c-4d0c-9b47-4af1472676f2" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d5631fd3-27d4-43f1-af50-a8200f76be55" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_22f16eb1-432c-4d0c-9b47-4af1472676f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_78d4d43c-d1ed-4bd2-a9a8-db030c920782" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_78d4d43c-d1ed-4bd2-a9a8-db030c920782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c481422f-c747-46b5-b8ab-bf4a8488d8e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_78d4d43c-d1ed-4bd2-a9a8-db030c920782" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c481422f-c747-46b5-b8ab-bf4a8488d8e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c481422f-c747-46b5-b8ab-bf4a8488d8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_78d4d43c-d1ed-4bd2-a9a8-db030c920782" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c481422f-c747-46b5-b8ab-bf4a8488d8e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_7d0bd742-e652-4279-9956-13bce1e407da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_c481422f-c747-46b5-b8ab-bf4a8488d8e7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_7d0bd742-e652-4279-9956-13bce1e407da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_ee844f5a-545b-4adb-954f-32c316cbda85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_ee844f5a-545b-4adb-954f-32c316cbda85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_ee844f5a-545b-4adb-954f-32c316cbda85" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_ee844f5a-545b-4adb-954f-32c316cbda85" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_7e1fc224-5815-47d4-a4ee-036a4f171756" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_7e1fc224-5815-47d4-a4ee-036a4f171756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33200cf1-633e-4b51-ae87-6efaa62d9353" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33200cf1-633e-4b51-ae87-6efaa62d9353" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_56048410-7e7a-4891-9ee0-e43eb602f04d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_56048410-7e7a-4891-9ee0-e43eb602f04d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6b9a3d5-b642-43f5-ace2-6be56341e01d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_56048410-7e7a-4891-9ee0-e43eb602f04d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6b9a3d5-b642-43f5-ace2-6be56341e01d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6b9a3d5-b642-43f5-ace2-6be56341e01d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_56048410-7e7a-4891-9ee0-e43eb602f04d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6b9a3d5-b642-43f5-ace2-6be56341e01d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierMGD007Member_a0abecc4-2d7b-4d9b-937b-230b8bd91283" xlink:href="mgnx-20180930.xsd#mgnx_LesLaboratoiresServierMGD007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6b9a3d5-b642-43f5-ace2-6be56341e01d" xlink:to="loc_mgnx_LesLaboratoiresServierMGD007Member_a0abecc4-2d7b-4d9b-937b-230b8bd91283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a652222c-4225-4c2b-861a-f083f96f1365" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_srt_CounterpartyNameAxis_a652222c-4225-4c2b-861a-f083f96f1365" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f8c283-a4f2-4b66-a22f-7d818da1a7c4_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a652222c-4225-4c2b-861a-f083f96f1365" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f8c283-a4f2-4b66-a22f-7d818da1a7c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f8c283-a4f2-4b66-a22f-7d818da1a7c4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a652222c-4225-4c2b-861a-f083f96f1365" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f8c283-a4f2-4b66-a22f-7d818da1a7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember_40432a7e-d0b8-4bb5-bb73-2de5a073a2ed" xlink:href="mgnx-20180930.xsd#mgnx_ServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f8c283-a4f2-4b66-a22f-7d818da1a7c4" xlink:to="loc_mgnx_ServierMember_40432a7e-d0b8-4bb5-bb73-2de5a073a2ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ea99ae1e-b01c-4a3a-9f95-cbe975d6251e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ea99ae1e-b01c-4a3a-9f95-cbe975d6251e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c00e-ff85-458f-9b08-9936fdb6d80b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ea99ae1e-b01c-4a3a-9f95-cbe975d6251e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c00e-ff85-458f-9b08-9936fdb6d80b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c00e-ff85-458f-9b08-9936fdb6d80b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ea99ae1e-b01c-4a3a-9f95-cbe975d6251e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c00e-ff85-458f-9b08-9936fdb6d80b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember_62061e4a-0b83-41c7-8bab-bb05075017fc" xlink:href="mgnx-20180930.xsd#mgnx_ServierDARTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c00e-ff85-458f-9b08-9936fdb6d80b" xlink:to="loc_mgnx_ServierDARTMember_62061e4a-0b83-41c7-8bab-bb05075017fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6242021-258d-4c30-b0e3-38d429003d5a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_srt_RangeAxis_e6242021-258d-4c30-b0e3-38d429003d5a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8880ae3-c5d8-4075-a0ea-8ac635da6819_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e6242021-258d-4c30-b0e3-38d429003d5a" xlink:to="loc_srt_RangeMember_f8880ae3-c5d8-4075-a0ea-8ac635da6819_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8880ae3-c5d8-4075-a0ea-8ac635da6819" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e6242021-258d-4c30-b0e3-38d429003d5a" xlink:to="loc_srt_RangeMember_f8880ae3-c5d8-4075-a0ea-8ac635da6819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cdd8fed1-d875-4d57-9844-fd3eeb473643" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f8880ae3-c5d8-4075-a0ea-8ac635da6819" xlink:to="loc_srt_MaximumMember_cdd8fed1-d875-4d57-9844-fd3eeb473643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_702c8302-eea7-4ce6-8390-a4c1cf633623" xlink:href="mgnx-20180930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_702c8302-eea7-4ce6-8390-a4c1cf633623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_9989bb9c-11a1-4529-abc9-270406655df6" xlink:href="mgnx-20180930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NonRefundableUpfrontFees_9989bb9c-11a1-4529-abc9-270406655df6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialLicenseFee_af212398-4b5f-4697-ab9e-c39b0843feec" xlink:href="mgnx-20180930.xsd#mgnx_PotentialLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_PotentialLicenseFee_af212398-4b5f-4697-ab9e-c39b0843feec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_d5d7ec4e-e837-488d-927e-2eaed532d1b2" xlink:href="mgnx-20180930.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_d5d7ec4e-e837-488d-927e-2eaed532d1b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_d17e6072-3fec-48e8-ad6e-59edb813c4df" xlink:href="mgnx-20180930.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_d17e6072-3fec-48e8-ad6e-59edb813c4df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_1fa301dc-14fc-4ab1-beee-b0af12df6d9a" xlink:href="mgnx-20180930.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_1fa301dc-14fc-4ab1-beee-b0af12df6d9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_c4271680-769d-4bf9-b0a2-3b8621454c18" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_c4271680-769d-4bf9-b0a2-3b8621454c18" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfExclusiveOptionsToLicense_189f6b5a-63a7-425b-9d29-6c036b2246c4" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfExclusiveOptionsToLicense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NumberOfExclusiveOptionsToLicense_189f6b5a-63a7-425b-9d29-6c036b2246c4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_6e3d3e0a-4828-4ade-af23-c961aa4b1e66" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NumberOfPerformanceObligations_6e3d3e0a-4828-4ade-af23-c961aa4b1e66" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMilestonesAchieved_76925ce5-a43e-4031-9d01-bda6243ccaec" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NumberOfMilestonesAchieved_76925ce5-a43e-4031-9d01-bda6243ccaec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment_c0126828-30c9-4d35-a9e9-8301a55fd08c" xlink:href="mgnx-20180930.xsd#mgnx_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_MilestonePayment_c0126828-30c9-4d35-a9e9-8301a55fd08c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_4a181b8a-bec8-4091-a4fe-a88065e4f675" xlink:href="mgnx-20180930.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_4a181b8a-bec8-4091-a4fe-a88065e4f675" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee_00764dd6-f58d-447e-a970-3296e5d56ac2" xlink:href="mgnx-20180930.xsd#mgnx_OptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_OptionExerciseFee_00764dd6-f58d-447e-a970-3296e5d56ac2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfComponentsInLicenseAgreement_d2c06b45-9881-4719-ad0d-5a1bccca521c" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfComponentsInLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NumberOfComponentsInLicenseAgreement_d2c06b45-9881-4719-ad0d-5a1bccca521c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_d8bda530-3545-4b35-85c6-d09c0a330793" xlink:href="mgnx-20180930.xsd#mgnx_OptionExerciseFeeRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_OptionExerciseFeeRecognitionPeriod_d8bda530-3545-4b35-85c6-d09c0a330793" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_4a7fbae7-2320-4a9b-a449-96616c7f87fe" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_4a7fbae7-2320-4a9b-a449-96616c7f87fe" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_06b055cb-f47a-4577-9d3a-54df0cf9c94e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_us-gaap_Revenues_06b055cb-f47a-4577-9d3a-54df0cf9c94e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_5dfe2ad1-9135-4c16-9edb-416579de4a14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_us-gaap_DeferredRevenue_5dfe2ad1-9135-4c16-9edb-416579de4a14" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2b1f7cb1-90bb-4e6d-a65c-bc5687599028" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2b1f7cb1-90bb-4e6d-a65c-bc5687599028" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails" xlink:type="extended" id="i2c429336a03345b0a482d8276ed2f60f_1d3e28c8-03fe-472d-8bd6-e75ae8f24117">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_257f10ae-5c67-4d20-890f-d7685897c7c3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:to="loc_srt_ProductOrServiceAxis_257f10ae-5c67-4d20-890f-d7685897c7c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_659d6747-9e1a-4bc2-bc37-94c244ad1bc8_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_257f10ae-5c67-4d20-890f-d7685897c7c3" xlink:to="loc_srt_ProductsAndServicesDomain_659d6747-9e1a-4bc2-bc37-94c244ad1bc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_659d6747-9e1a-4bc2-bc37-94c244ad1bc8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_257f10ae-5c67-4d20-890f-d7685897c7c3" xlink:to="loc_srt_ProductsAndServicesDomain_659d6747-9e1a-4bc2-bc37-94c244ad1bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_50b73760-57a5-4920-be2e-4a50625fff39" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_659d6747-9e1a-4bc2-bc37-94c244ad1bc8" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_50b73760-57a5-4920-be2e-4a50625fff39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e272a37d-2715-46c6-a2d5-f6f739a28db1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e272a37d-2715-46c6-a2d5-f6f739a28db1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e272a37d-2715-46c6-a2d5-f6f739a28db1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e272a37d-2715-46c6-a2d5-f6f739a28db1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_04ae8a85-2dc0-4288-b6b0-006f2465164e" xlink:href="mgnx-20180930.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_04ae8a85-2dc0-4288-b6b0-006f2465164e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_f023f928-6abd-4d18-8d18-de3ee71ce17b" xlink:href="mgnx-20180930.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_f023f928-6abd-4d18-8d18-de3ee71ce17b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8007f4dd-4e68-4c70-9427-d62ad331bd99" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:to="loc_srt_CounterpartyNameAxis_8007f4dd-4e68-4c70-9427-d62ad331bd99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67cb897-0690-482c-a8cf-5751a01ca015_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8007f4dd-4e68-4c70-9427-d62ad331bd99" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67cb897-0690-482c-a8cf-5751a01ca015_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67cb897-0690-482c-a8cf-5751a01ca015" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8007f4dd-4e68-4c70-9427-d62ad331bd99" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67cb897-0690-482c-a8cf-5751a01ca015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioInc.Member_0dbae4cc-1807-4189-a414-44fbd1db0771" xlink:href="mgnx-20180930.xsd#mgnx_ProventionBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67cb897-0690-482c-a8cf-5751a01ca015" xlink:to="loc_mgnx_ProventionBioInc.Member_0dbae4cc-1807-4189-a414-44fbd1db0771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_121fd418-ff1b-4caf-a85d-8819ea10f543" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_121fd418-ff1b-4caf-a85d-8819ea10f543" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_121fd418-ff1b-4caf-a85d-8819ea10f543" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_121fd418-ff1b-4caf-a85d-8819ea10f543" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_bca184cf-d108-45a2-bad2-767420ce885b" xlink:href="mgnx-20180930.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab" xlink:to="loc_mgnx_ProventionPRV3279Member_bca184cf-d108-45a2-bad2-767420ce885b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_b2cbd266-ea6e-4115-9a65-4e8bef20c379" xlink:href="mgnx-20180930.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab" xlink:to="loc_mgnx_ProventionPRV031Member_b2cbd266-ea6e-4115-9a65-4e8bef20c379" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_7c085737-b3e1-432e-b4ad-46b130e00797" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_7c085737-b3e1-432e-b4ad-46b130e00797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_0d20305f-73ed-46ae-a787-7c7480dcc49c" xlink:href="mgnx-20180930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_0d20305f-73ed-46ae-a787-7c7480dcc49c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_0794d3e3-90ba-4d27-875d-eba8ead7c17b" xlink:href="mgnx-20180930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_0794d3e3-90ba-4d27-875d-eba8ead7c17b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_7a7065b6-fa25-4613-a4e8-506ae80978c3" xlink:href="mgnx-20180930.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_7a7065b6-fa25-4613-a4e8-506ae80978c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_9dba4d4d-03ca-4af7-babc-38499516728a" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_NumberOfPerformanceObligations_9dba4d4d-03ca-4af7-babc-38499516728a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a7e90f19-df47-4f03-b34d-010a9d9d6996" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a7e90f19-df47-4f03-b34d-010a9d9d6996" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_7a162e40-2b29-442f-abf5-98d0b926f06c" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_7a162e40-2b29-442f-abf5-98d0b926f06c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ac2701a9-4211-4de1-ade3-cf02d9d18581" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_us-gaap_Revenues_ac2701a9-4211-4de1-ade3-cf02d9d18581" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="i061fe9dc95154ba7800d2af1998f8082_0232a124-5348-483d-a006-d50cb2e6d380">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d2987519-17f8-4618-99e3-2cf0120f4ff9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:to="loc_srt_ProductOrServiceAxis_d2987519-17f8-4618-99e3-2cf0120f4ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91b39b23-81b3-4351-a1f1-762087332ddd_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d2987519-17f8-4618-99e3-2cf0120f4ff9" xlink:to="loc_srt_ProductsAndServicesDomain_91b39b23-81b3-4351-a1f1-762087332ddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91b39b23-81b3-4351-a1f1-762087332ddd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d2987519-17f8-4618-99e3-2cf0120f4ff9" xlink:to="loc_srt_ProductsAndServicesDomain_91b39b23-81b3-4351-a1f1-762087332ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_968589a2-d567-47e8-9145-09906ac0e722" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_91b39b23-81b3-4351-a1f1-762087332ddd" xlink:to="loc_mgnx_RevenuesFromGrantsMember_968589a2-d567-47e8-9145-09906ac0e722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cbcf7882-3ffb-4a66-938b-dbc7e7533bcd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:to="loc_srt_CounterpartyNameAxis_cbcf7882-3ffb-4a66-938b-dbc7e7533bcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f999f577-32ac-4a0b-bd3d-02a6ce3e1398_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cbcf7882-3ffb-4a66-938b-dbc7e7533bcd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f999f577-32ac-4a0b-bd3d-02a6ce3e1398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f999f577-32ac-4a0b-bd3d-02a6ce3e1398" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cbcf7882-3ffb-4a66-938b-dbc7e7533bcd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f999f577-32ac-4a0b-bd3d-02a6ce3e1398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_3ad00ad9-9fec-44cd-ae67-f28151b0395e" xlink:href="mgnx-20180930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f999f577-32ac-4a0b-bd3d-02a6ce3e1398" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_3ad00ad9-9fec-44cd-ae67-f28151b0395e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4da93df8-04f4-47c4-b815-d6a398509012" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:to="loc_srt_RangeAxis_4da93df8-04f4-47c4-b815-d6a398509012" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c00e8f7-e461-4030-ab0b-87b9f223f290_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4da93df8-04f4-47c4-b815-d6a398509012" xlink:to="loc_srt_RangeMember_7c00e8f7-e461-4030-ab0b-87b9f223f290_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c00e8f7-e461-4030-ab0b-87b9f223f290" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4da93df8-04f4-47c4-b815-d6a398509012" xlink:to="loc_srt_RangeMember_7c00e8f7-e461-4030-ab0b-87b9f223f290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4eb8b295-e991-48ba-9690-ba196e541b4d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c00e8f7-e461-4030-ab0b-87b9f223f290" xlink:to="loc_srt_MaximumMember_4eb8b295-e991-48ba-9690-ba196e541b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_fdd3bcba-16bc-4b59-8844-9457d516c61b" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_fdd3bcba-16bc-4b59-8844-9457d516c61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_5a84b3d2-3162-4a32-8074-450cfb4bd423" xlink:href="mgnx-20180930.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_FundedValueOfBasePeriod_5a84b3d2-3162-4a32-8074-450cfb4bd423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_3d72565e-1485-4507-9692-f79123a32b28" xlink:href="mgnx-20180930.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_3d72565e-1485-4507-9692-f79123a32b28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_f60af8b2-11f0-4bf7-a179-b787db787344" xlink:href="mgnx-20180930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_f60af8b2-11f0-4bf7-a179-b787db787344" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_1093da58-0de8-4a25-a598-6296911ca9c8" xlink:href="mgnx-20180930.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_1093da58-0de8-4a25-a598-6296911ca9c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b9bde993-1690-4469-8dc6-d9ba23a2e71e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_us-gaap_Revenues_b9bde993-1690-4469-8dc6-d9ba23a2e71e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended" id="i4753b7e73ece49beb54d262dd1bc18b7_f2de6eec-7522-44e4-9420-69cf5cc64c50"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended" id="i37ef40530b6f492da53935cf3b3d18b4_e1b06eed-1404-47e5-b797-76a29b18e076"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="ie7260c2f3f234096b8c30f5bd80405ee_763a7726-d812-4631-ac75-fe8761220957">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5613942d-fdba-4411-9631-59d756d141d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5613942d-fdba-4411-9631-59d756d141d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_986483d3-3c51-4fc4-a283-e3e0bf4657a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5613942d-fdba-4411-9631-59d756d141d5" xlink:to="loc_us-gaap_PlanNameAxis_986483d3-3c51-4fc4-a283-e3e0bf4657a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_986483d3-3c51-4fc4-a283-e3e0bf4657a8" xlink:to="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_986483d3-3c51-4fc4-a283-e3e0bf4657a8" xlink:to="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b0215809-a2d1-4eef-8a26-b1f2f7793904" xlink:href="mgnx-20180930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b0215809-a2d1-4eef-8a26-b1f2f7793904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_9871175a-e9b2-4020-a4f9-83cf86e09486" xlink:href="mgnx-20180930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_9871175a-e9b2-4020-a4f9-83cf86e09486" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_4d2287af-56da-4951-a955-2489cf7bc800" xlink:href="mgnx-20180930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:to="loc_mgnx_StockIncentivePlan2013Member_4d2287af-56da-4951-a955-2489cf7bc800" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5c4a6087-0bf9-4359-9604-3c7b5a9d07ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5c4a6087-0bf9-4359-9604-3c7b5a9d07ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_d2d55589-a591-44d6-bf47-5f21e0188324" xlink:href="mgnx-20180930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_d2d55589-a591-44d6-bf47-5f21e0188324" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1b6789ca-3e6b-4859-a5bf-8e6f82359ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1b6789ca-3e6b-4859-a5bf-8e6f82359ae2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2946050e-f23c-42c8-ba86-3f77ed773ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2946050e-f23c-42c8-ba86-3f77ed773ec7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_e736b485-c6a0-42ec-81a1-7f19c3fab276" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ProceedsFromStockPlans_e736b485-c6a0-42ec-81a1-7f19c3fab276" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e846f00a-2213-49c2-bea7-303f22b2dd6e" xlink:href="mgnx-20180930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e846f00a-2213-49c2-bea7-303f22b2dd6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_fa7d7fcf-7c08-4e2f-8d4d-0b164203792d" xlink:href="mgnx-20180930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_fa7d7fcf-7c08-4e2f-8d4d-0b164203792d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c7e6f56-6d0f-46d1-a773-4c8cd8bc5343" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c7e6f56-6d0f-46d1-a773-4c8cd8bc5343" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b6a785c-8d8f-4ad5-a89d-15bd7a2ca19f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b6a785c-8d8f-4ad5-a89d-15bd7a2ca19f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37c17eed-3563-4bfa-a4ed-179f0ef71462" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a1285d68-b03e-489a-8c6b-3f9a81f07159" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37c17eed-3563-4bfa-a4ed-179f0ef71462" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a1285d68-b03e-489a-8c6b-3f9a81f07159" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d1e3c396-7e71-4a0d-8f38-7884853e08be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a1285d68-b03e-489a-8c6b-3f9a81f07159" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d1e3c396-7e71-4a0d-8f38-7884853e08be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d1e3c396-7e71-4a0d-8f38-7884853e08be" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d1e3c396-7e71-4a0d-8f38-7884853e08be" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_15ce5c19-e244-4cda-9d0f-f5a109641911" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_15ce5c19-e244-4cda-9d0f-f5a109641911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72bed09c-3e8e-4b21-a8a1-97d5d478f5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72bed09c-3e8e-4b21-a8a1-97d5d478f5c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_abac070b-ad4e-4093-adb2-f93364cd2c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37c17eed-3563-4bfa-a4ed-179f0ef71462" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_abac070b-ad4e-4093-adb2-f93364cd2c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_27620bc9-3a26-4a21-97fc-500c7b22ce83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37c17eed-3563-4bfa-a4ed-179f0ef71462" xlink:to="loc_us-gaap_ShareBasedCompensation_27620bc9-3a26-4a21-97fc-500c7b22ce83" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="i8652c7b306fe4d24a4c36a539c83ecdf_cf290490-13e4-417f-80bd-2f26d14adceb">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00506a22-594a-420c-8799-ab0556f5f07c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00506a22-594a-420c-8799-ab0556f5f07c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_326dc7ed-e2e2-464f-8e33-3ae06ef3f262" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00506a22-594a-420c-8799-ab0556f5f07c" xlink:to="loc_srt_RangeAxis_326dc7ed-e2e2-464f-8e33-3ae06ef3f262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_326dc7ed-e2e2-464f-8e33-3ae06ef3f262" xlink:to="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_326dc7ed-e2e2-464f-8e33-3ae06ef3f262" xlink:to="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4836837e-f70a-4c8b-a539-e1e9333aaa3b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927" xlink:to="loc_srt_MinimumMember_4836837e-f70a-4c8b-a539-e1e9333aaa3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_323eb10d-195f-41b7-b3d7-6ff8af83093e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927" xlink:to="loc_srt_MaximumMember_323eb10d-195f-41b7-b3d7-6ff8af83093e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13647743-baac-4264-85e3-9c32a28dd7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13647743-baac-4264-85e3-9c32a28dd7ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40712fac-6364-4ca6-8ac9-30a9bea57f50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40712fac-6364-4ca6-8ac9-30a9bea57f50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cac509c0-eb20-488f-8cac-5e8ad8c41ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cac509c0-eb20-488f-8cac-5e8ad8c41ab3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b9e6ad96-1b8d-425a-b96e-5002d35f8880" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b9e6ad96-1b8d-425a-b96e-5002d35f8880" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="if8ae610f2570425ea8c447ab90575d2b_f671b4dc-43b9-48d7-b44f-87d66eb46db6"/>
  <link:roleRef roleURI="http://macrogenics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="mgnx-20180930.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/NetLossPerShare" xlink:type="extended" id="icc77b0b8c92442a793d962c7bdc71ea4_457b8858-d3c8-4652-9f19-ad21f22d0bf7"/>
  <link:roleRef roleURI="http://macrogenics.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#NetLossPerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended" id="i64586a0f1df74fc59b4f91a4942b10f8_ad35fefe-4768-4000-9a75-d4899451c5fc"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mgnx-20180930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:b7316434-03a0-4e88-aa3b-e89ba2bd1bc0,g:5bed0e04-ab87-46dd-8d59-93be05bc483c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_9e66218a-33e9-4682-9075-fb36ac0d4d22_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0430d39c-bc79-4bd5-942d-399ca6b18c92_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_8c2f099a-1a0c-4624-af27-4e604ec7f479_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease exit liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:to="lab_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_a4fdeb6f-90a2-4625-b317-585f99f68939_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent of the fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f8434bca-a756-41dc-b3f9-6fa60e6787de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c1dd15a4-104d-4b23-bab6-9756e7ba16cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_5b3b6ee0-41da-464a-b31f-815c80a16836_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_a216e5ef-5c53-4ecf-9d2a-9786f41fa0fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary unrealized losses</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8eff998c-09b1-4128-83ba-6778b3c0633f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_b6b9b167-c5ee-499c-804a-6cf929747d8a_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIncentivePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20180930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c0b61100-b479-49af-8843-d2eaaaf95634_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4dd8b30e-b12f-42bf-b002-abdd98b85db6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_69b7e46f-44c0-42cb-bce9-c028ba7803e2_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant to purchase shares of common stock, exercise price (in dollars per share)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac57309b-2151-434d-bdf9-5da439129ecc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ad6829c1-8ab1-4227-a88f-35714758f1f3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfComponentsInLicenseAgreement_05c46c5d-986f-49d3-8f1f-37feeab38edf_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfComponentsInLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of components in license agreement</link:label>
    <link:label id="lab_mgnx_NumberOfComponentsInLicenseAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfComponentsInLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfComponentsInLicenseAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfComponentsInLicenseAgreement" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfComponentsInLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfComponentsInLicenseAgreement" xlink:to="lab_mgnx_NumberOfComponentsInLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9b8bb591-54ce-41ca-8cee-7a5094814659_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_a475a2d5-0aa2-4b2b-acf7-3225f71e50d0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration recognized</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7b677c3b-1597-4249-8d7e-709824d5b060_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7c826d9-0c71-4ffe-95b4-12ef8ac9a0d4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c65e33d-4d52-4f37-a2da-3b5240c1f860_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_522d97e6-3f82-4a71-9f18-764d4de922d6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierDARTMember_c9a65345-28d2-4b0f-96d0-745c03ee64f3_terseLabel_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier DART</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_label_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ServierDARTMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember" xlink:href="mgnx-20180930.xsd#mgnx_ServierDARTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierDARTMember" xlink:to="lab_mgnx_ServierDARTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_135bffd5-460b-480e-892e-a22d2cfa75f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_de5ef9f7-b8d6-485a-8b1f-8d2465009995_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_137bf8a1-75d6-4eb1-a61f-d4dfeff25bb2_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments to third parties</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_e147e741-5afa-41cb-9929-ba31aa3b6661_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfPerformanceObligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementServicesMember_ee1db217-bcf3-4c35-95a4-c306854b468f_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementServicesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementServicesMember" xlink:href="mgnx-20180930.xsd#mgnx_IncyteMGA012AgreementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementServicesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_03ebfe3a-f1e3-4fd7-a2c5-6209a07941dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f030fbab-92c3-4fb6-b329-1fd6b9a5ff36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9c4c13a2-8d18-4014-8070-6ac2cb448b7e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d31f785-febe-46df-9858-5afa7cf25ee1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_01311855-f563-4445-8dc9-c76db3be6b79_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6eabcc7c-a332-4e74-8767-7a0957d7a590_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a0417e25-4961-412c-819d-3e30f23c6711_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d5303416-8773-422f-a8d1-e6092fc2390b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_91e24be4-092d-4c7b-b3da-f3b7cd64f5ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_35eb31e0-e806-456f-b51e-709e8826a7d5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_4b9a5c40-87d3-498b-8f29-37d19cd5f646_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromCollaborativeAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20180930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7248bd5c-9f61-4668-9d0b-d42eccecdd6b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_aa0a04b7-f0d7-49f3-aaa1-54be7862dcd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioInc.Member_299ec733-2cff-484d-8716-28ff5e2fce58_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention</link:label>
    <link:label id="lab_mgnx_ProventionBioInc.Member_label_en-US" xlink:label="lab_mgnx_ProventionBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionBioInc.Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioInc.Member" xlink:href="mgnx-20180930.xsd#mgnx_ProventionBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioInc.Member" xlink:to="lab_mgnx_ProventionBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f3ca2e8a-53f8-4a14-b813-f8a29e0b879a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e3450f9a-3ed7-4405-87d9-6bef4c0b78fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_69673fe6-395f-4e74-9a96-fbed240010e6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_54f47477-fc03-4d41-a97f-fd29afb41e89_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0592f8f2-2254-45d9-a0f9-d8a05896936c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_86aa523c-31c2-48c6-b17c-9d6992fe46b2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_52ee2ff2-996a-4b63-bbcb-78130b4a3a58_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_f48bde8f-68a8-444c-8154-c44457b80e5d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_fb28ed15-ca2f-4cbb-9401-678297315ba7_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20180930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_17d566a9-a8c7-4beb-a4ec-9c619ab77a48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_045041a6-c055-46b2-ae95-dddf7f0d81b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd6661c9-946a-4c6c-b5bf-3021dbada70c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99fc1c35-8056-495c-b34b-b80c43c9da31_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_80d68a30-2cc2-46b4-bd03-2c0c998abdfe_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV-3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionPRV3279Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20180930.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_07139f3a-27c6-47a2-8a3e-44367d4cbcc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ba407eb1-6627-47ed-bc4a-aaf45757b6a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_102c3970-f6d8-467f-bce0-80630dac5cfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of New Accounting Pronouncement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef20685c-7b2b-4590-babd-8dc805b126f2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_18e09e1d-4130-4273-b5b5-97c2110355a7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_349d69dd-0c0f-425d-b969-54640a3461dd_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_19a2d849-1d55-4ded-9d84-bd543035f422_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_18d597f6-2edf-4093-99ff-95531c15e15a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptionExerciseFee_91a716d0-956b-4db5-bcc3-ebcb3e58441e_terseLabel_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_label_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OptionExerciseFee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee" xlink:href="mgnx-20180930.xsd#mgnx_OptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionExerciseFee" xlink:to="lab_mgnx_OptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MilestonePayment_6774e3f2-8174-4e07-9fcb-c1350ebf9b41_terseLabel_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_mgnx_MilestonePayment_label_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilestonePayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment" xlink:href="mgnx-20180930.xsd#mgnx_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MilestonePayment" xlink:to="lab_mgnx_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_377ca797-1523-4668-9fa4-a63e328bfd57_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromGovernmentAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20180930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_916e3d9c-1674-4cfb-b916-9e1c812f6023_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating and investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8e64539d-8520-447e-80d2-6811f3757d7b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d43bfc11-8def-4d3a-b4b8-b8aba15f02f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26b49699-d447-4e5c-b950-ab281f1b7e4e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_072fac62-f6e0-46c0-bbf2-48c6b0ba83aa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_b7cbba2d-b9b4-4f12-b6e1-e3457c0c8b4c_terseLabel_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.</link:label>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_label_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:href="mgnx-20180930.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:to="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialLicenseFee_35c94e39-56db-4341-9571-74590faeeab9_verboseLabel_en-US" xlink:label="lab_mgnx_PotentialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential license fee</link:label>
    <link:label id="lab_mgnx_PotentialLicenseFee_label_en-US" xlink:label="lab_mgnx_PotentialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialLicenseFee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialLicenseFee" xlink:href="mgnx-20180930.xsd#mgnx_PotentialLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialLicenseFee" xlink:to="lab_mgnx_PotentialLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_07ab3009-7b07-477a-9d3d-bf8331a5d589_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_97c21a25-b4b1-4e7c-a1fd-e2ac6476c74c_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d734106a-79b2-4e5d-80b8-fb7af5332cd1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_3da9f8b4-51bd-4782-8ab5-d37604f3de1c_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20180930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_4b38d80d-b721-42d4-bcbb-cb1caeb7d513_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c897efe5-0ca0-4ebc-927d-1cfc6658df73_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7e4e6764-7be4-4631-8152-282a39a01121_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ChangeInContractWithCustomerLiabilityRollForward_e42fdf89-0152-47ae-b944-d3b392673f74_terseLabel_en-US" xlink:label="lab_mgnx_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward] [Roll Forward]</link:label>
    <link:label id="lab_mgnx_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_mgnx_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_mgnx_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_mgnx_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="mgnx-20180930.xsd#mgnx_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_mgnx_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_667ade87-f56e-474b-9d4a-24c58f3bf26a_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonRefundableUpfrontFees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20180930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_cb93c356-382f-4ce5-ad13-a28097e5dfa7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_ed68005f-9cda-441d-8f2a-6417268f5ad1_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdditionalDevelopmentFundingOptionsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3d86197f-52ae-47f0-8263-fcb85053227b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_e9522a51-23a9-4d0b-a705-9e056737a80c_terseLabel_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base period</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_label_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FundedValueOfBasePeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod" xlink:href="mgnx-20180930.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FundedValueOfBasePeriod" xlink:to="lab_mgnx_FundedValueOfBasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_a47d702f-37aa-4973-82ab-51eb1448d63c_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionLicenseAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20180930.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_87b5dc8e-3cec-4eba-957e-4e787e0ff193_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInDeferredRent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:href="mgnx-20180930.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:to="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_48966cfb-fda9-4afe-b3c0-5f818c1d95e9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_587bd526-3d34-473b-9902-58258a77f7c1_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementTransactionPrice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3feacbcc-a1b6-4ff7-9db7-556d8c37c4e9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_823d76b0-7de3-4d37-8ce0-70b02714ddc5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_6c9dbb0b-e5af-440b-ab3d-7d40bea00410_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_873359ba-eade-4452-840c-60d26b1311b3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e123607b-10ef-41fd-b496-663a3aa87864_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_d9f81576-0211-4b62-8395-0d6286b77931_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f353b864-3445-494d-a435-5148af52e1ae_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e45a3bf7-f7e2-4856-ab7b-08a98a660793_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d25237fa-c844-4d51-92ff-e6eb0d29536b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_557ea05b-4325-4303-bba9-5c79ca2e604b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_3f839d72-1b83-460f-958e-2f8827c1f85d_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization of molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dfefb482-c75e-4580-a8be-bc69c8e7b257_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_5e68c312-5416-42e4-8125-c1cb9d393434_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3300d654-dfb0-49e1-9e6e-5403f1ecd98a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_25408d51-ec8c-4314-81f5-c1af56aaaa10_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PublicOfferingMember_c6465f6e-82a9-440a-8636-e8ffec5bd877_terseLabel_en-US" xlink:label="lab_mgnx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_mgnx_PublicOfferingMember_label_en-US" xlink:label="lab_mgnx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PublicOfferingMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PublicOfferingMember" xlink:href="mgnx-20180930.xsd#mgnx_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PublicOfferingMember" xlink:to="lab_mgnx_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_040eaa20-20d7-4a1c-b02b-e3627889305b_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_2ba809a9-0a44-4663-8c40-28fd72c976f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4ab2e7a1-8847-4bb8-b17d-03a88f4e8f0b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 42,248,075 and 36,859,077 shares outstanding at September 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_21a06f84-c753-445d-ae75-82b59772ee43_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0828e0c7-1f38-4ce5-be51-0abe04a07c04_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_6042fefc-96e3-49d2-b33d-cc52f38a839b_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssetPurchaseAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20180930.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e03828c1-a2bb-43c1-9054-99013e05def3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_648e2e87-8758-4cf2-bc22-c59e640440dc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_ae908a2a-c5b3-4c26-8ac8-c9561d57f8b5_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockMaximumAmountAvailableForIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20180930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_877d1815-40de-4628-b72c-3be6b77ddfae_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6351eadb-537e-44b7-8b24-aab05139eaeb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_151c9b24-a24e-450a-8ef5-479e6f188203_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RegisteredDirectOfferingMember_750adcc9-2f51-402e-b297-945dd569d170_terseLabel_en-US" xlink:label="lab_mgnx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_mgnx_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_mgnx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RegisteredDirectOfferingMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RegisteredDirectOfferingMember" xlink:href="mgnx-20180930.xsd#mgnx_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RegisteredDirectOfferingMember" xlink:to="lab_mgnx_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_293c2e34-d344-4ead-aa8d-09640662cb42_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_20d00699-6b91-4f21-89b9-13016686d18c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_76e88f3a-2204-4512-881f-13bdb8fad302_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_38feb185-755d-4b1f-8554-ba6061bb84a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_050415c7-8f9c-41d6-b1ef-4c1722aaa139_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfExclusiveOptionsToLicense_260682c7-20c9-49a2-a472-1293f9145630_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfExclusiveOptionsToLicense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of exclusive options to license</link:label>
    <link:label id="lab_mgnx_NumberOfExclusiveOptionsToLicense_label_en-US" xlink:label="lab_mgnx_NumberOfExclusiveOptionsToLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfExclusiveOptionsToLicense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfExclusiveOptionsToLicense" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfExclusiveOptionsToLicense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfExclusiveOptionsToLicense" xlink:to="lab_mgnx_NumberOfExclusiveOptionsToLicense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1110596b-f822-4c07-a3fd-c7370d0b57f4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_529ae366-0011-4adb-87b2-4359d74fd50b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f4697dc7-0400-4ec2-bcb8-b45db24ecdc7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_2ba9ca23-2ccf-40ba-8b00-f53bfea341b0_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AtTheMarketOfferingMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20180930.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6a6d5d3c-c7b8-4abf-af3e-3705aef58938_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c846cc54-607d-44d3-9364-9430e0ccba0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33dfdc92-51bc-4986-a36e-d33078a91438_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_f6fd8579-fa9f-413e-892d-c4e999210f75_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_36503bf5-a23c-4a48-8b37-1db2e635cee7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e6c0a107-fadf-484c-b96d-dd21d04be19f_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSixteenEmployeeStockPurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20180930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_601729d1-104d-4057-8ffc-36d03c7d0117_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_c52d5984-6a2f-46f5-be78-7c9a1284ef83_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteCorporationMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20180930.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_161abf29-03c3-4d2a-bd02-dd4aa3402aff_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deduction discount</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20180930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5922358a-a26c-4638-a95c-39201eeb1471_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7bd8d049-5f20-4e3b-a988-1ae2f227a5b3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9d4944bc-fd12-4c0a-bbf7-b8d901d3e7e4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b6bc2d07-384c-4a39-a506-ad18227e5fb0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_c9191f55-5485-4e60-9140-b9b51ad34087_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_54356b51-06eb-4d12-8b0b-d805a096b6fb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_5ed793ce-6096-40e5-be1f-a34379e2b954_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c10ce99f-59c8-4cf0-bbf0-6ad456a6fcf2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_1589b486-b92a-43f3-a37c-71d7a147041e_terseLabel_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential clinical milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialClinicalMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_83fcb73d-2d47-42a9-b586-9a21e82e0dcf_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_63ce49b3-a628-46c1-8c2a-eb654176ac41_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_454f5e68-cb50-405e-ab88-7415a27a63dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ccdac4ed-736b-4330-a65e-4536bfbef60e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3edbfad1-f062-42ce-9654-532eff47c1c8_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92f9e43d-7dfb-4b5f-b1aa-ac729d4b7ddd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_52976014-b60b-481e-8fbd-8c8ca6da7cee_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5a8e144f-339a-469e-a478-8f1575134480_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_ce0cd300-dc77-436c-9109-7e723ef9bd2e_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_a448c5c4-2668-4f38-aed8-198653a9acc4_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Clinical activities</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementClinicalActivitiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:href="mgnx-20180930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9ac14a67-3871-4f38-a739-27be8848a9f9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cb65e5-e39d-4cbf-b440-3d59d4291c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8c2ca882-55f3-415e-bdc4-6bc689a579f9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6af7e958-20bc-4df5-9a61-c9cf79333a56_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offset to research and development costs under the collaboration agreement</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborationArrangementOffsetToResearchAndDevelopmentCosts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:to="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c445c124-78c3-48e0-ae47-f31dab4727ff_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e152930b-c39d-4e72-9fff-37d96c27016f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9ff2d326-d0bf-40d9-8083-1a33fc4b6b32_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b0a47f1-ac9a-4f46-bc72-d0f4e632e034_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptionExerciseFeeRecognitionPeriod_b80a1f4b-21d6-47c4-979b-14fe5ded30c8_terseLabel_en-US" xlink:label="lab_mgnx_OptionExerciseFeeRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee recognition period</link:label>
    <link:label id="lab_mgnx_OptionExerciseFeeRecognitionPeriod_label_en-US" xlink:label="lab_mgnx_OptionExerciseFeeRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OptionExerciseFeeRecognitionPeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod" xlink:href="mgnx-20180930.xsd#mgnx_OptionExerciseFeeRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionExerciseFeeRecognitionPeriod" xlink:to="lab_mgnx_OptionExerciseFeeRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b5d71d5f-2497-4684-a7cd-7e7761dea42f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_3c4cedbc-cd06-41b5-a800-b90f01663e9a_terseLabel_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_d2ea2841-59aa-424f-8577-d7745ea5b5d7_terseLabel_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialRegulatoryMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3ebcbb34-64a6-46a8-93a6-bb1b05a7f141_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_cc99962d-0f2c-4590-a419-36da34c54799_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2c116335-13e2-4393-a280-f237c979cee2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7587a85c-987b-4c2e-bc85-f2c388fa9066_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_614ba882-81cb-4b16-8a31-f1f399de5cfa_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease exit liability</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent" xlink:to="lab_us-gaap_RestructuringReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_42361e5f-71e8-4949-88c3-3e53b2be581f_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalties (percent)</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromRoyaltiesPercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20180930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4c1c6f9c-1a3a-418b-adc7-4ebfa56efd4d_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialCommercialMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_177efe88-df6b-4d32-8f74-2eaa68d447f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_effeb69f-211c-4416-a7c2-d4e74a5aa96d_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ccb7a05b-540e-4f87-be18-bee704a062b7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierMember_ce51b14e-f793-4cd6-9a63-967899a0cb34_terseLabel_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_mgnx_ServierMember_label_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ServierMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember" xlink:href="mgnx-20180930.xsd#mgnx_ServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierMember" xlink:to="lab_mgnx_ServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_e8b450c4-09db-4731-95af-de05871d8de9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_846b4100-0b2c-4eee-92a7-4c6f256e7780_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_883af4d2-1dc7-4a2a-b017-33b4072cec74_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_131e6a89-6f35-4eea-9c25-990aa336dfcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55253a1d-9993-478d-aeb8-37f4cbbce265_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7a6fe159-2945-4e8f-b8d6-de1063bc1c25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price of stock options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c55dc5c-3bbe-49f9-9fa9-3f0f76af886f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fb2587b4-1480-48f6-b57d-a474b9aaa177_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PublicOfferingandOverAllotmentOptionMember_a3dd76e3-a574-43c5-9594-f3ed6b2386b6_terseLabel_en-US" xlink:label="lab_mgnx_PublicOfferingandOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering and over-allotment option</link:label>
    <link:label id="lab_mgnx_PublicOfferingandOverAllotmentOptionMember_label_en-US" xlink:label="lab_mgnx_PublicOfferingandOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PublicOfferingandOverAllotmentOptionMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PublicOfferingandOverAllotmentOptionMember" xlink:href="mgnx-20180930.xsd#mgnx_PublicOfferingandOverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PublicOfferingandOverAllotmentOptionMember" xlink:to="lab_mgnx_PublicOfferingandOverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_71e8b817-f3ec-4335-afa2-75227a6b03f3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_2bf8f8b4-1f74-44e1-aa1b-086307b563cc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1e6e2ed4-fb8a-4f17-98be-664e5833d27a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8d70728a-ed0b-486c-b491-c9dfcc71c9ac_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_737bf953-91cf-47db-9bc7-4184ca83cdd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_406565c0-468b-4a28-91eb-609a938a039a_totalLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_e6d3619b-6ed6-4128-b1de-fd1312b7d2aa_terseLabel_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Stock Incentive Plan</link:label>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_label_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2003StockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember" xlink:href="mgnx-20180930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2003StockIncentivePlanMember" xlink:to="lab_mgnx_A2003StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e7b64d22-e9de-41dc-986b-69209d91d3c8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_fad4dcde-8c50-4fca-8d32-a8eeed20e5d9_terseLabel_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential sales milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialSalesMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f9c8951-67e5-48bf-ac8d-4f65614549fd_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_882ea4c5-f786-48d8-b54f-fa0bc5c584a6_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_09dda277-ba66-43ce-b5a4-ba03453473ab_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2bbcd5db-11d3-4454-8b33-9e760f3c73ad_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_21c81ac9-87d4-4fe1-be22-4cf228195ed2_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available under warrants (in shares)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMilestonesAchieved_dad3d78f-239e-45ec-8896-fe81d64c7441_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones achieved</link:label>
    <link:label id="lab_mgnx_NumberOfMilestonesAchieved_label_en-US" xlink:label="lab_mgnx_NumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMilestonesAchieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMilestonesAchieved" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMilestonesAchieved" xlink:to="lab_mgnx_NumberOfMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_973dc37b-9354-4d63-a1e2-fd56534e4b0f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d3e914f9-867e-4202-9b8d-5359a84b833c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_45f86b5f-9fdf-4b00-850e-8b32dd29acab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_687cc069-ca00-498a-aba7-04d146a43e44_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromLicenseAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f4eebe78-b650-4310-a389-90212148da53_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_a1ae5c7a-28bd-44ab-9258-2b8ff0b75ad2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_16e65e4e-0b55-4158-a5b7-25faece2708c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_013a8294-c935-4559-9800-749dcd60249b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a8d627aa-d7cc-42e3-92cc-3b632d9e4d48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ad0efbcb-3562-4ef9-80e3-97f6e19f48f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_da0af36f-7df4-498d-b8e8-65b87f42708c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts_031cfd99-49fa-414e-9215-af3a97137b28_terseLabel_en-US" xlink:label="lab_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts_label_en-US" xlink:label="lab_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ContractWithCustomerLiabilityIncreasefromCashReceipts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts" xlink:href="mgnx-20180930.xsd#mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts" xlink:to="lab_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b10cdcce-8094-4cbe-b892-269360ff6599_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_294a667d-2156-4187-8143-bd91a8e7be66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_aac8a6f1-eed1-4afa-9543-62bf746afdb9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a762547d-1a51-445f-892a-5cc5db51bd60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_dd5744ee-1a5d-47b8-8676-bd048b73f15a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_93175bdc-2b89-400c-955d-d3f6614a1a37_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9903bc0a-ad1d-4e24-b43f-2716fb265c65_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_79e5b4f9-757b-4df6-8ee4-5444f7ad8587_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ba375d0d-8028-4175-9c9d-a246cc4af279_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_58c759c1-0a8a-449c-b187-118db21fba1e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_32e48bcb-6b75-46eb-af37-462f15740674_terseLabel_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants received, including change in value</link:label>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_label_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FairValueOfWarrantsReceived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FairValueOfWarrantsReceived" xlink:href="mgnx-20180930.xsd#mgnx_FairValueOfWarrantsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FairValueOfWarrantsReceived" xlink:to="lab_mgnx_FairValueOfWarrantsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_bdefdca9-60cc-434e-8bab-581dd13524a3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_34ac5450-688a-4bdb-8e95-9cc6a6b80cb5_terseLabel_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606</link:label>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_label_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:to="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1200a6df-b13c-4a12-83ae-0f0f5f5f98d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3fef6f5e-a603-4aec-874c-23111ba12578_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_6a76ca00-835e-4e3c-8eba-51015b7a7cd4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_cabf8e2a-2758-4e9e-88a9-1338fd728482_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment recognition period</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_label_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UpfrontPaymentRecognitionPeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod" xlink:href="mgnx-20180930.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPaymentRecognitionPeriod" xlink:to="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_b1d3041b-81d1-449b-b5bf-d74e2ff8e1e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_04ce8ac6-803a-4166-aaae-782b4d8b6019_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57ea9d9d-6153-4749-b6e7-4659b3ebbbcf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8fcd97c1-a653-4b25-b768-703c5425878e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_b7674078-bda4-4054-857f-98d696725e2c_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20180930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_f21524d9-ed45-46de-9ff2-7bf9a3969706_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-allotment option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0e5d85ca-0ab9-41bd-88a8-57d1c6f0f627_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4044f083-f6ab-4193-bdee-90bdba75ac9c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c5f63973-2c57-446d-867f-8ebcb1c0de30_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41b9c2a-2544-40f9-8193-3ebda80afd41_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_ccc6d983-8649-4253-97b4-4b8bb7f843f3_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV-031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionPRV031Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20180930.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_32c73645-9b30-475c-a84d-e98101e707c6_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_49968887-fa89-496f-84ae-e2100f33e2aa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_6cec6987-c373-47ba-ac78-48ae8d0487b1_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7120ae5c-b6c5-4ddd-b82d-187c65bef505_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_489dfc32-6c14-4aa7-ab5d-bc1cba247c1a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a15f4ac3-53bf-40ee-9165-45528c4bb8b1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3679751b-208f-4f3a-bc1c-5da3ea2ce062_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca70f7da-e30d-4b49-9991-e33cea564c7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ce428567-aa64-4b59-be26-0c57c3e38888_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a02fd8cd-1e6f-4259-815b-394a9dfc65d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_29338b1d-2c70-493d-8fd0-30768c3b018f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f8c92313-ff28-411e-97ca-ee9f643ebdcd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2e395dba-99d1-4ce1-a654-8a1e89e58ff9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_1895874b-7f8b-4ea3-bb0b-ee0f2ba8703b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5a2b918a-b531-4db8-8958-292813bb512b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_da48f979-bb8e-4f15-9bd1-7ef5d82eee30_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_083e95d5-1e28-4b31-aa08-afdb571fcff7_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option and Restricted Stock Unit Activity</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="mgnx-20180930.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LesLaboratoiresServierMGD007Member_d8eba151-b13d-41a2-8b94-305941b2f3c2_terseLabel_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierMGD007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier MGD007</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierMGD007Member_label_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierMGD007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LesLaboratoiresServierMGD007Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierMGD007Member" xlink:href="mgnx-20180930.xsd#mgnx_LesLaboratoiresServierMGD007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LesLaboratoiresServierMGD007Member" xlink:to="lab_mgnx_LesLaboratoiresServierMGD007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1ccc8a4f-8cbb-489e-8375-2c348f292c87_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_4ca7faf8-9a24-49e1-a259-435abbd42b3b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_8c9313d4-d372-419c-a463-155b9d9da6d8_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NationalInstituteOfAllergyAndInfectiousDiseasesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20180930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_18b6e025-8cb5-416b-a659-1cadce948e88_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f29a8e69-8e96-4e1f-b15d-7b63b5f069cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_4a55dc71-3f93-4f5b-9bea-aba677dc654f_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on future sales under agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_d17f8b60-225a-4cf7-9484-bce76fd84cad_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_176367a2-84af-43c5-a517-573556c93f95_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From Grants</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_d5150aef-404b-4ed7-a836-eb718d2f3508_verboseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromStockOptionsExercisedAndESPPPurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20180930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5a655e07-c5c4-4784-9575-a17754163716_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_05a504ae-58cd-4b0b-9dbb-bf2722746d86_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_f9a45fde-958c-4cac-b802-6493230ba671_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20180930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_334af574-3421-4360-b286-a7f4eeb80b88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d91ab160-a64f-4328-a316-2e59267b3784_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_924545ad-6a0f-41e6-8249-c7042e132d4a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_mgnx_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_mgnx_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_mgnx_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DocumentAndEntityInformationAbstract" xlink:href="mgnx-20180930.xsd#mgnx_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract" xlink:to="lab_mgnx_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5e38d77e-fd41-401a-9313-94506abf1fe4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fa12aa20-d332-4701-a937-9832052d2d8d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a198615c-0fd9-4fe2-a272-dcdb654977b3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_c65df4c6-47c7-4335-9772-138108d23c50_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalPotentialValueUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20180930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6c83780b-69ea-452f-8327-ff75f202adf5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d6ad6d0b-f3ae-4698-9eed-5298c674fde1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_636e8448-4526-465b-88aa-39ee5ba1e50a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5750723b-5b8e-4ffc-9a5e-9223b3273f76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mgnx-20180930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:b7316434-03a0-4e88-aa3b-e89ba2bd1bc0,g:5bed0e04-ab87-46dd-8d59-93be05bc483c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="mgnx-20180930.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:href="mgnx-20180930.xsd#mgnx_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6f0d7861-a98c-4785-9801-890b6098f686" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_DocumentType_6f0d7861-a98c-4785-9801-890b6098f686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4a2f967b-ebf7-4948-943b-ff066013d902" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_AmendmentFlag_4a2f967b-ebf7-4948-943b-ff066013d902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_aaffd8b9-e3e1-44f7-a097-feddc24e4951" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_DocumentPeriodEndDate_aaffd8b9-e3e1-44f7-a097-feddc24e4951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4b579aa6-9ef9-4a98-bd8e-5766b164410f" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_DocumentFiscalYearFocus_4b579aa6-9ef9-4a98-bd8e-5766b164410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_30f923f9-1204-4197-9907-e2ac67deef75" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_DocumentFiscalPeriodFocus_30f923f9-1204-4197-9907-e2ac67deef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_028464fb-2eb2-4bd4-8c73-b53155d8efe4" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_EntityRegistrantName_028464fb-2eb2-4bd4-8c73-b53155d8efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0936a5a9-b107-41e5-b0a0-3895f139c1a2" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_EntityCentralIndexKey_0936a5a9-b107-41e5-b0a0-3895f139c1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_13c9f004-a405-4cce-bb0c-1f6561287a0b" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_CurrentFiscalYearEndDate_13c9f004-a405-4cce-bb0c-1f6561287a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c91acc09-1eb1-4152-9cd6-3c0e5671dc88" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_EntityFilerCategory_c91acc09-1eb1-4152-9cd6-3c0e5671dc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3a768f0e-4ec2-45dc-8b06-577547413103" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_EntityEmergingGrowthCompany_3a768f0e-4ec2-45dc-8b06-577547413103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_200cd3a9-bc8a-4f59-bc1b-9edbeb77c1e3" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_EntitySmallBusiness_200cd3a9-bc8a-4f59-bc1b-9edbeb77c1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_99b49bf6-b1cb-4ba5-8221-490652952f8c" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_b3213cc7-f7b9-4f7a-8fc0-1a060f735e83" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_99b49bf6-b1cb-4ba5-8221-490652952f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d96a08b2-ca2b-4723-b9b1-62ff7bb9a54e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_06a5ec51-9000-40c9-bedf-e0ff729eb2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d96a08b2-ca2b-4723-b9b1-62ff7bb9a54e" xlink:to="loc_us-gaap_AssetsAbstract_06a5ec51-9000-40c9-bedf-e0ff729eb2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8de09e62-b7b3-40ba-9e23-03fee659adf8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a5ec51-9000-40c9-bedf-e0ff729eb2c7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8de09e62-b7b3-40ba-9e23-03fee659adf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6331b91b-4883-4d4b-bab5-08ad5004bcb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8de09e62-b7b3-40ba-9e23-03fee659adf8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6331b91b-4883-4d4b-bab5-08ad5004bcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_6461506b-64e3-47c3-a84f-b8034198c615" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8de09e62-b7b3-40ba-9e23-03fee659adf8" xlink:to="loc_us-gaap_Investments_6461506b-64e3-47c3-a84f-b8034198c615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_45e3aec8-1546-4eb8-a961-0e657332ed78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8de09e62-b7b3-40ba-9e23-03fee659adf8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_45e3aec8-1546-4eb8-a961-0e657332ed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_6fbcbb53-0571-4e71-9168-3cb9e6f88244" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8de09e62-b7b3-40ba-9e23-03fee659adf8" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_6fbcbb53-0571-4e71-9168-3cb9e6f88244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_db247f62-ccd1-4473-82b2-1062c7195270" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8de09e62-b7b3-40ba-9e23-03fee659adf8" xlink:to="loc_us-gaap_OtherAssets_db247f62-ccd1-4473-82b2-1062c7195270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_297a85c6-5739-46fa-9ef0-b8c37c397071" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8de09e62-b7b3-40ba-9e23-03fee659adf8" xlink:to="loc_us-gaap_AssetsCurrent_297a85c6-5739-46fa-9ef0-b8c37c397071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c6256366-b428-420b-b2a9-a11d83798d86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a5ec51-9000-40c9-bedf-e0ff729eb2c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c6256366-b428-420b-b2a9-a11d83798d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cec10ef5-96ef-4a5f-9e6f-272182974a98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a5ec51-9000-40c9-bedf-e0ff729eb2c7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cec10ef5-96ef-4a5f-9e6f-272182974a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b48390ae-08ff-48a6-8ee5-38ab583b74b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06a5ec51-9000-40c9-bedf-e0ff729eb2c7" xlink:to="loc_us-gaap_Assets_b48390ae-08ff-48a6-8ee5-38ab583b74b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23bcd8b6-939e-4580-a2e8-e705be2cefb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d96a08b2-ca2b-4723-b9b1-62ff7bb9a54e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23bcd8b6-939e-4580-a2e8-e705be2cefb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f9c480f3-411b-4443-84e6-a678d0ee344a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23bcd8b6-939e-4580-a2e8-e705be2cefb1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f9c480f3-411b-4443-84e6-a678d0ee344a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f23fc6b0-d827-4d8d-aa53-f1424c8438ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f9c480f3-411b-4443-84e6-a678d0ee344a" xlink:to="loc_us-gaap_AccountsPayableCurrent_f23fc6b0-d827-4d8d-aa53-f1424c8438ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_856424c8-412b-457d-9425-2477afb5143d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f9c480f3-411b-4443-84e6-a678d0ee344a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_856424c8-412b-457d-9425-2477afb5143d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_b933468f-12b1-4ec8-a38d-78d5946b7a24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f9c480f3-411b-4443-84e6-a678d0ee344a" xlink:to="loc_us-gaap_DeferredRevenueCurrent_b933468f-12b1-4ec8-a38d-78d5946b7a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_88ec5578-bc05-4846-b3d3-86bd0de3d557" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f9c480f3-411b-4443-84e6-a678d0ee344a" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_88ec5578-bc05-4846-b3d3-86bd0de3d557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_3cdbd2f0-38bd-4235-8b0c-fdb308dbd901" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f9c480f3-411b-4443-84e6-a678d0ee344a" xlink:to="loc_us-gaap_RestructuringReserveCurrent_3cdbd2f0-38bd-4235-8b0c-fdb308dbd901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6aa7ff88-d3bd-4092-8870-dfa13feec3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f9c480f3-411b-4443-84e6-a678d0ee344a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6aa7ff88-d3bd-4092-8870-dfa13feec3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_76a176c6-0a0e-4558-b1d1-9b1b6a36a5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f9c480f3-411b-4443-84e6-a678d0ee344a" xlink:to="loc_us-gaap_LiabilitiesCurrent_76a176c6-0a0e-4558-b1d1-9b1b6a36a5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_6b7a6ec5-60d8-4f66-8b19-1680a99ee78b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23bcd8b6-939e-4580-a2e8-e705be2cefb1" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_6b7a6ec5-60d8-4f66-8b19-1680a99ee78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_b74f5ced-7b5b-4b56-8ce6-724611344220" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23bcd8b6-939e-4580-a2e8-e705be2cefb1" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_b74f5ced-7b5b-4b56-8ce6-724611344220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cfd65ecc-19cb-463e-95b6-0cad1cebd599" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23bcd8b6-939e-4580-a2e8-e705be2cefb1" xlink:to="loc_us-gaap_Liabilities_cfd65ecc-19cb-463e-95b6-0cad1cebd599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_36473757-eb02-4c87-810b-f1d1c3990943" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23bcd8b6-939e-4580-a2e8-e705be2cefb1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_36473757-eb02-4c87-810b-f1d1c3990943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1f01b247-c768-4428-b1ee-26e7b9819f81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36473757-eb02-4c87-810b-f1d1c3990943" xlink:to="loc_us-gaap_CommonStockValue_1f01b247-c768-4428-b1ee-26e7b9819f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2a2002c8-12c9-4608-ad22-3bb467266f97" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36473757-eb02-4c87-810b-f1d1c3990943" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2a2002c8-12c9-4608-ad22-3bb467266f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2789b4b-3e98-4bce-8f9c-ba4813c82227" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36473757-eb02-4c87-810b-f1d1c3990943" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2789b4b-3e98-4bce-8f9c-ba4813c82227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_631fcdb8-d922-46f9-8731-3a9ba2676b17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36473757-eb02-4c87-810b-f1d1c3990943" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_631fcdb8-d922-46f9-8731-3a9ba2676b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8fe936ca-4e5e-4c78-b276-3df097f4a836" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36473757-eb02-4c87-810b-f1d1c3990943" xlink:to="loc_us-gaap_StockholdersEquity_8fe936ca-4e5e-4c78-b276-3df097f4a836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e006591c-5b04-4af3-9acd-b0c6f164ad54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23bcd8b6-939e-4580-a2e8-e705be2cefb1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e006591c-5b04-4af3-9acd-b0c6f164ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0a7104d0-7fdd-4a36-a152-fa2b071cded6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b64d52af-39c4-4cf2-ad6f-4de2d0c283de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0a7104d0-7fdd-4a36-a152-fa2b071cded6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b64d52af-39c4-4cf2-ad6f-4de2d0c283de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_edc0c06b-d737-4428-a00c-3cbac010e0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b64d52af-39c4-4cf2-ad6f-4de2d0c283de" xlink:to="loc_us-gaap_StockholdersEquityAbstract_edc0c06b-d737-4428-a00c-3cbac010e0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4360ff07-bc41-4211-ae86-5487cfc2a11d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edc0c06b-d737-4428-a00c-3cbac010e0ad" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4360ff07-bc41-4211-ae86-5487cfc2a11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_78615b44-3d1d-49b2-8264-c8abe7bb90df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edc0c06b-d737-4428-a00c-3cbac010e0ad" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_78615b44-3d1d-49b2-8264-c8abe7bb90df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_944564e0-3f8d-4337-ae4a-c00eb5ca53e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edc0c06b-d737-4428-a00c-3cbac010e0ad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_944564e0-3f8d-4337-ae4a-c00eb5ca53e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3a471ee9-9139-42d3-9ed0-3666affa803f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a74ed189-c95d-44c0-9dd9-522c7fa1648e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a471ee9-9139-42d3-9ed0-3666affa803f" xlink:to="loc_us-gaap_StatementTable_a74ed189-c95d-44c0-9dd9-522c7fa1648e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c61b5102-ad56-4f92-b303-8bc75f499deb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a74ed189-c95d-44c0-9dd9-522c7fa1648e" xlink:to="loc_srt_ProductOrServiceAxis_c61b5102-ad56-4f92-b303-8bc75f499deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c61b5102-ad56-4f92-b303-8bc75f499deb" xlink:to="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_bf46b978-c264-4969-8b65-950da21d8792" xlink:href="mgnx-20180930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_bf46b978-c264-4969-8b65-950da21d8792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_c56fc919-c737-4351-bba1-e4509f127789" xlink:href="mgnx-20180930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7042fe1c-72ff-4d14-ac9b-6f2ef6989da3" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_c56fc919-c737-4351-bba1-e4509f127789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a74ed189-c95d-44c0-9dd9-522c7fa1648e" xlink:to="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1d6b04cb-7db2-425f-9f30-84e733677d03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:to="loc_us-gaap_RevenuesAbstract_1d6b04cb-7db2-425f-9f30-84e733677d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_20e1b9ea-0daa-4ff6-9333-e2f32decbc28" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1d6b04cb-7db2-425f-9f30-84e733677d03" xlink:to="loc_us-gaap_Revenues_20e1b9ea-0daa-4ff6-9333-e2f32decbc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b373504e-11c3-4da0-bb0a-28b9e24fe199" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b373504e-11c3-4da0-bb0a-28b9e24fe199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9eb0be8b-ced8-43a6-9c71-51017c2eac2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9eb0be8b-ced8-43a6-9c71-51017c2eac2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9f817f67-2626-4687-a3a7-ed4f5950b07c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_CostsAndExpenses_9f817f67-2626-4687-a3a7-ed4f5950b07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c272380d-8709-4e31-833c-69977f23702c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_OperatingIncomeLoss_c272380d-8709-4e31-833c-69977f23702c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ac28b338-ee80-4522-aee8-b9dc7b5178de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ac28b338-ee80-4522-aee8-b9dc7b5178de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e8b7a056-8090-4a9e-8c1b-036b39f81c41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9ee0a705-3c22-4ef5-a272-83200aa99b7c" xlink:to="loc_us-gaap_NetIncomeLoss_e8b7a056-8090-4a9e-8c1b-036b39f81c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cd1f7586-974d-4c57-8016-d32e04fd579c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4dee1197-d481-451e-900c-024736c42754" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4dee1197-d481-451e-900c-024736c42754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_675307af-a26d-431a-86dd-b5d5ad3d7b17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_675307af-a26d-431a-86dd-b5d5ad3d7b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_b03f40c4-d89e-4df4-b0c0-c9d01ad0709d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_b03f40c4-d89e-4df4-b0c0-c9d01ad0709d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_bf2142fa-58ea-46e6-bd5f-6e3b2d1f3d67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f7930ad1-225e-4506-bbaa-43f306686e90" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_bf2142fa-58ea-46e6-bd5f-6e3b2d1f3d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8a2cb407-bad2-4018-83a9-82c1b9cbdd11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6219152-4fda-4d5c-910a-a0d4a311da7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a2cb407-bad2-4018-83a9-82c1b9cbdd11" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6219152-4fda-4d5c-910a-a0d4a311da7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e85960e6-8257-42a4-9019-a51d89330719" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6219152-4fda-4d5c-910a-a0d4a311da7a" xlink:to="loc_us-gaap_NetIncomeLoss_e85960e6-8257-42a4-9019-a51d89330719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfff582f-ea5b-4526-9943-d63772c377dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6219152-4fda-4d5c-910a-a0d4a311da7a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfff582f-ea5b-4526-9943-d63772c377dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0e779869-53f0-4176-ab83-5de4d13d2d72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfff582f-ea5b-4526-9943-d63772c377dd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0e779869-53f0-4176-ab83-5de4d13d2d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6c371282-ecaa-4adc-a386-a4cc7d22610a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfff582f-ea5b-4526-9943-d63772c377dd" xlink:to="loc_us-gaap_ShareBasedCompensation_6c371282-ecaa-4adc-a386-a4cc7d22610a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfff582f-ea5b-4526-9943-d63772c377dd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbae455b-b496-43a2-94f4-ae4727f1179f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbae455b-b496-43a2-94f4-ae4727f1179f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d11646da-2d13-4a17-8ee0-4b4d7be64c92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d11646da-2d13-4a17-8ee0-4b4d7be64c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9e996d68-e09b-490f-9291-f485539f2061" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9e996d68-e09b-490f-9291-f485539f2061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_374b6977-e8de-4274-9b40-e9ac05b9a2fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_374b6977-e8de-4274-9b40-e9ac05b9a2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eba3ee7e-439f-4b70-ab83-8a9e3f81ec93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eba3ee7e-439f-4b70-ab83-8a9e3f81ec93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_5f2b7c31-cd06-40c0-a571-ac5817c15eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_5f2b7c31-cd06-40c0-a571-ac5817c15eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5661065a-e9af-4000-b279-6a27f6c97055" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5661065a-e9af-4000-b279-6a27f6c97055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_06a5c56b-5d87-421e-87bf-c6bd043ce324" xlink:href="mgnx-20180930.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08b62583-56bd-486f-a773-4ae4a447f31b" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_06a5c56b-5d87-421e-87bf-c6bd043ce324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d99cee83-9336-4a1a-a95d-9484416fe892" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6219152-4fda-4d5c-910a-a0d4a311da7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d99cee83-9336-4a1a-a95d-9484416fe892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_64391da2-6bf8-471e-8b16-16b9de303334" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a2cb407-bad2-4018-83a9-82c1b9cbdd11" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_64391da2-6bf8-471e-8b16-16b9de303334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_94a1382b-ee37-4137-9595-9a15010ff385" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_64391da2-6bf8-471e-8b16-16b9de303334" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_94a1382b-ee37-4137-9595-9a15010ff385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_43c74bcd-601d-47f2-a7ba-03bf12c37171" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_64391da2-6bf8-471e-8b16-16b9de303334" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_43c74bcd-601d-47f2-a7ba-03bf12c37171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_80f9f366-29aa-4db8-b027-4992cf0837d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_64391da2-6bf8-471e-8b16-16b9de303334" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_80f9f366-29aa-4db8-b027-4992cf0837d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_fa61ca39-e112-41c5-9b28-40b5ad72387b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_64391da2-6bf8-471e-8b16-16b9de303334" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_fa61ca39-e112-41c5-9b28-40b5ad72387b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_322edf0e-fc21-45e9-a6f4-db4060d6abbd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a2cb407-bad2-4018-83a9-82c1b9cbdd11" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_322edf0e-fc21-45e9-a6f4-db4060d6abbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_70262fec-1203-4995-bc21-22a176fc4363" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_322edf0e-fc21-45e9-a6f4-db4060d6abbd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_70262fec-1203-4995-bc21-22a176fc4363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_2fcfd9e2-2772-4bd8-ab2f-31795da7cd28" xlink:href="mgnx-20180930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_322edf0e-fc21-45e9-a6f4-db4060d6abbd" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_2fcfd9e2-2772-4bd8-ab2f-31795da7cd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_7547e95c-7d21-4fc1-9a70-f3011c5aabc9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_322edf0e-fc21-45e9-a6f4-db4060d6abbd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_7547e95c-7d21-4fc1-9a70-f3011c5aabc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6e4de251-1dbe-4f2e-8038-5ce3d9f655dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a2cb407-bad2-4018-83a9-82c1b9cbdd11" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6e4de251-1dbe-4f2e-8038-5ce3d9f655dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_008a2885-4db4-431c-a75b-42cdca2e47c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a2cb407-bad2-4018-83a9-82c1b9cbdd11" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_008a2885-4db4-431c-a75b-42cdca2e47c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1b7adff-7180-4d0b-bd04-90ff2f9944ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a2cb407-bad2-4018-83a9-82c1b9cbdd11" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1b7adff-7180-4d0b-bd04-90ff2f9944ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8d79d6ee-a96a-44cf-95a1-c6c702473ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a2cb407-bad2-4018-83a9-82c1b9cbdd11" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8d79d6ee-a96a-44cf-95a1-c6c702473ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FairValueOfWarrantsReceived_350a3e55-6c7b-41db-a0e2-8c5b535bab07" xlink:href="mgnx-20180930.xsd#mgnx_FairValueOfWarrantsReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8d79d6ee-a96a-44cf-95a1-c6c702473ab6" xlink:to="loc_mgnx_FairValueOfWarrantsReceived_350a3e55-6c7b-41db-a0e2-8c5b535bab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28390bb6-1125-4e0b-bd4e-355e9e569eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_736db707-7173-413b-8a7b-2d13bc9e8e10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28390bb6-1125-4e0b-bd4e-355e9e569eb0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_736db707-7173-413b-8a7b-2d13bc9e8e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ab53e8a-7251-4d05-a9f7-98e2eb35d8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4cb189b4-db3d-46ac-9da2-d65bb4f66a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ab53e8a-7251-4d05-a9f7-98e2eb35d8f5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4cb189b4-db3d-46ac-9da2-d65bb4f66a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2b60aecb-3bce-47c4-96d6-120d03cbc1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ab53e8a-7251-4d05-a9f7-98e2eb35d8f5" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2b60aecb-3bce-47c4-96d6-120d03cbc1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_686bc7a9-a761-4b6d-be30-5191f55147f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ab53e8a-7251-4d05-a9f7-98e2eb35d8f5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_686bc7a9-a761-4b6d-be30-5191f55147f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b0d65d79-42d3-4232-9c1d-c6e97c3ee52f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b9655e21-3c29-4bfd-ae8e-6c65aa61970e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b0d65d79-42d3-4232-9c1d-c6e97c3ee52f" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b9655e21-3c29-4bfd-ae8e-6c65aa61970e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7cecbd13-ebd9-4cc4-95c4-ec79f0a2b56f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b0d65d79-42d3-4232-9c1d-c6e97c3ee52f" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7cecbd13-ebd9-4cc4-95c4-ec79f0a2b56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#BasisofPresentationandSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f7e7db3-438e-401c-a5e6-cb82aaf1dd45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f7e7db3-438e-401c-a5e6-cb82aaf1dd45" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_232c5236-3b76-42c0-8db4-0c2c6cf48ffd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:to="loc_srt_ProductOrServiceAxis_232c5236-3b76-42c0-8db4-0c2c6cf48ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ce91edc-6718-43a8-af67-bcd022329d6c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_232c5236-3b76-42c0-8db4-0c2c6cf48ffd" xlink:to="loc_srt_ProductsAndServicesDomain_6ce91edc-6718-43a8-af67-bcd022329d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_8b9cde99-03c9-4364-89f8-919400fca444" xlink:href="mgnx-20180930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ce91edc-6718-43a8-af67-bcd022329d6c" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_8b9cde99-03c9-4364-89f8-919400fca444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_04655218-82cf-4847-a724-60c747a1a84f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_04655218-82cf-4847-a724-60c747a1a84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7ef46a62-8a46-40d4-b2ee-42cc326e1336" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_04655218-82cf-4847-a724-60c747a1a84f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7ef46a62-8a46-40d4-b2ee-42cc326e1336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_f954ed11-d592-4e6a-8165-9b0380498928" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7ef46a62-8a46-40d4-b2ee-42cc326e1336" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_f954ed11-d592-4e6a-8165-9b0380498928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_e1eaf175-819e-4883-9528-d9ca08c0e1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_e1eaf175-819e-4883-9528-d9ca08c0e1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_e1eaf175-819e-4883-9528-d9ca08c0e1b1" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_d7ab55d1-8e21-4236-9bdf-ffc37ad5a575" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_d7ab55d1-8e21-4236-9bdf-ffc37ad5a575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_f79bc649-07b1-429e-811d-c8b7b7a614bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_cce5f331-7615-4293-9bfa-3556b4ab88f6" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_f79bc649-07b1-429e-811d-c8b7b7a614bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_9942eb4f-13f7-492e-8e3e-5216c3bb65d5" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_0960df38-e027-40e9-8d73-0bcce31acf3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_DeferredRevenueCurrent_0960df38-e027-40e9-8d73-0bcce31acf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_82aa5aaf-687e-4064-9f48-65eecd0d0403" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_82aa5aaf-687e-4064-9f48-65eecd0d0403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9728e1d-729c-4745-ae5c-0b005c3d4beb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9728e1d-729c-4745-ae5c-0b005c3d4beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_158c7148-d29b-4bd6-a794-9a7eec5abf41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_Revenues_158c7148-d29b-4bd6-a794-9a7eec5abf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_979eb436-3ee1-43cd-9dbf-d858a344afae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_NetIncomeLoss_979eb436-3ee1-43cd-9dbf-d858a344afae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4b7e9197-e8f8-40bb-aa9c-b05e765ff761" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_4b7e9197-e8f8-40bb-aa9c-b05e765ff761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:href="mgnx-20180930.xsd#mgnx_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_af9c6409-5788-4ec3-b1d1-5d9ede4ed576" xlink:to="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_bff0f816-6e16-46cf-b98b-137ec9d6ccc1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:to="loc_us-gaap_ContractWithCustomerLiability_bff0f816-6e16-46cf-b98b-137ec9d6ccc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts_684ec312-8aa9-475b-a42b-a75303ee0043" xlink:href="mgnx-20180930.xsd#mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:to="loc_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts_684ec312-8aa9-475b-a42b-a75303ee0043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d3e524a-12f1-44e4-82d6-a889959ae965" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d3e524a-12f1-44e4-82d6-a889959ae965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_de198c9c-994d-4a03-a4f4-73fdf53c8b27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ChangeInContractWithCustomerLiabilityRollForward_1ec7574e-45c5-421d-8cbe-05b6ab619d63" xlink:to="loc_us-gaap_ContractWithCustomerLiability_de198c9c-994d-4a03-a4f4-73fdf53c8b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20180930.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_db1b5f39-707d-4051-a99f-f4df81ac5ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2f68550b-6b42-418a-a22e-8e8663f1b9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_db1b5f39-707d-4051-a99f-f4df81ac5ed2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2f68550b-6b42-418a-a22e-8e8663f1b9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dbb3dd42-fceb-429e-b9c4-fe533ca611c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1fff01e1-43dd-4d53-a472-d90972ede8ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbb3dd42-fceb-429e-b9c4-fe533ca611c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1fff01e1-43dd-4d53-a472-d90972ede8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc8165ff-e316-4186-879e-461855d27f78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc8165ff-e316-4186-879e-461855d27f78" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7666722d-3b8d-4b78-9531-344e3d1d0b45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7666722d-3b8d-4b78-9531-344e3d1d0b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a808e5e0-285f-4e6a-80da-9922ee8d7465" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7666722d-3b8d-4b78-9531-344e3d1d0b45" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a808e5e0-285f-4e6a-80da-9922ee8d7465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_61ddeb5c-925f-4e08-8634-0e0434c01ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a808e5e0-285f-4e6a-80da-9922ee8d7465" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_61ddeb5c-925f-4e08-8634-0e0434c01ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d504efa5-9f7f-4304-a6d4-3dfbfc5293cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d504efa5-9f7f-4304-a6d4-3dfbfc5293cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d504efa5-9f7f-4304-a6d4-3dfbfc5293cf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_fbf46f04-2cbc-4361-802d-ce5d21134e92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_MoneyMarketFundsMember_fbf46f04-2cbc-4361-802d-ce5d21134e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_30668632-7f08-42f2-8807-c5709e0d497e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_30668632-7f08-42f2-8807-c5709e0d497e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ca24ebf4-f525-47be-a5b2-59029df3adc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ca24ebf4-f525-47be-a5b2-59029df3adc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0c8d8482-3d63-4a8d-b41e-01b29e211a49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0c8d8482-3d63-4a8d-b41e-01b29e211a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_470457bc-d6cd-43a9-93b3-f44c55b16a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d1a77fc-0add-42c0-9dfa-df6234fd2f79" xlink:to="loc_us-gaap_WarrantMember_470457bc-d6cd-43a9-93b3-f44c55b16a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652925e4-5542-48a1-9c8c-99bd42978a34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652925e4-5542-48a1-9c8c-99bd42978a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652925e4-5542-48a1-9c8c-99bd42978a34" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_25c6cc4b-f5f1-4d36-aada-638cf810d2ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_25c6cc4b-f5f1-4d36-aada-638cf810d2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_05700786-bc28-450e-b697-06a96fe8eec0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_05700786-bc28-450e-b697-06a96fe8eec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f7a22b36-1e61-4974-968f-7f91b91c2d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5014426c-83c1-461b-b9d8-23cb3968e1e3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f7a22b36-1e61-4974-968f-7f91b91c2d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99c1346f-29f5-41c6-80c4-eb701c592a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01fae2ac-9607-4de3-a5e6-93d0327141e1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99c1346f-29f5-41c6-80c4-eb701c592a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99c1346f-29f5-41c6-80c4-eb701c592a8c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fe1894a1-5dbe-4de9-9b7a-b4c0d7da2a41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fe1894a1-5dbe-4de9-9b7a-b4c0d7da2a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e31732e9-4785-4782-a047-7f28b9b36fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e31732e9-4785-4782-a047-7f28b9b36fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8c893fd5-3466-40ff-90ae-e86c48247b17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8c893fd5-3466-40ff-90ae-e86c48247b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_316389ff-45f6-442f-9334-d79ad6fca29f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ece79153-e774-46bb-ad68-4225bd24eeae" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_316389ff-45f6-442f-9334-d79ad6fca29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20180930.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3b1bb6df-0f8a-4111-a212-691980e4c8c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ac498143-e872-47b8-b78c-6d655c15ef8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3b1bb6df-0f8a-4111-a212-691980e4c8c5" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ac498143-e872-47b8-b78c-6d655c15ef8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_045662d1-fa39-4fad-a6ee-50eb3b1042b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_32feb162-ded2-4ce2-bc69-ba86ae966b89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_045662d1-fa39-4fad-a6ee-50eb3b1042b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_32feb162-ded2-4ce2-bc69-ba86ae966b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9edc23af-3db8-42b1-b9c0-60e7db774935" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_e9cca573-e89b-4e19-a5c4-69eee270fb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9edc23af-3db8-42b1-b9c0-60e7db774935" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_e9cca573-e89b-4e19-a5c4-69eee270fb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_832615f0-9b7a-49f4-8a39-8050ee3f5dea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_e9cca573-e89b-4e19-a5c4-69eee270fb3c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_832615f0-9b7a-49f4-8a39-8050ee3f5dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_832615f0-9b7a-49f4-8a39-8050ee3f5dea" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0738d04c-77a0-4866-9896-7ba65f686d74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0738d04c-77a0-4866-9896-7ba65f686d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3b460356-1a72-4fa4-9d52-cae5acc310f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3b460356-1a72-4fa4-9d52-cae5acc310f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c4771208-9eeb-4507-878b-c060e0469d58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fb86bfc-31af-4b2c-b8e8-60b7db2879db" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c4771208-9eeb-4507-878b-c060e0469d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_e9cca573-e89b-4e19-a5c4-69eee270fb3c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1d5cc21b-ca2e-422f-9dc9-b89c4993e1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1d5cc21b-ca2e-422f-9dc9-b89c4993e1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a99e1096-3c54-4e81-9e88-7e878964e87a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a99e1096-3c54-4e81-9e88-7e878964e87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ccf50140-11b9-4802-bc58-2bb7171d606e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ccf50140-11b9-4802-bc58-2bb7171d606e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_427901e4-c333-40b6-af9b-0f2b327ab614" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_427901e4-c333-40b6-af9b-0f2b327ab614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_5b893db9-9d4a-4516-8a81-0b335ac447f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03eca0ad-3640-4a97-a2aa-ee13264f76d5" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_5b893db9-9d4a-4516-8a81-0b335ac447f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fbe43ebc-afe3-4a56-bfa1-75186d01240e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e7bc6481-dd8d-40a0-a426-be07d9f46960" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fbe43ebc-afe3-4a56-bfa1-75186d01240e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e7bc6481-dd8d-40a0-a426-be07d9f46960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c37a69a1-d84a-48c4-b8e0-39c59042fdb2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0af92432-d5f3-4748-af74-cb5823323084" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c37a69a1-d84a-48c4-b8e0-39c59042fdb2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0af92432-d5f3-4748-af74-cb5823323084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6060a641-a087-4137-93bd-f2ae86f5684e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0af92432-d5f3-4748-af74-cb5823323084" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6060a641-a087-4137-93bd-f2ae86f5684e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6060a641-a087-4137-93bd-f2ae86f5684e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RegisteredDirectOfferingMember_945d73cd-cb28-49a5-9081-af8a8247c56e" xlink:href="mgnx-20180930.xsd#mgnx_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_mgnx_RegisteredDirectOfferingMember_945d73cd-cb28-49a5-9081-af8a8247c56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_ba19e03b-b6f7-49f3-8cdd-abef4ee67045" xlink:href="mgnx-20180930.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_mgnx_AtTheMarketOfferingMember_ba19e03b-b6f7-49f3-8cdd-abef4ee67045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PublicOfferingMember_cc2486dd-7643-43d8-b1f2-c4b04363ffcf" xlink:href="mgnx-20180930.xsd#mgnx_PublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_mgnx_PublicOfferingMember_cc2486dd-7643-43d8-b1f2-c4b04363ffcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_d546b68b-bce8-4a64-a0d3-28520ccb3d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_us-gaap_OverAllotmentOptionMember_d546b68b-bce8-4a64-a0d3-28520ccb3d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PublicOfferingandOverAllotmentOptionMember_d2f36ad2-72d2-4b97-9b90-93b288bbeb3d" xlink:href="mgnx-20180930.xsd#mgnx_PublicOfferingandOverAllotmentOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7458a668-524a-42ef-80c2-342608f5ef3d" xlink:to="loc_mgnx_PublicOfferingandOverAllotmentOptionMember_d2f36ad2-72d2-4b97-9b90-93b288bbeb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0af92432-d5f3-4748-af74-cb5823323084" xlink:to="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f1bc763-2580-4fbe-9b85-735b3bcfbfe7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f1bc763-2580-4fbe-9b85-735b3bcfbfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_380240a8-01b8-4511-ba02-0757de669330" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_380240a8-01b8-4511-ba02-0757de669330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4546acc3-fe8f-44da-b01e-7aa2f447c271" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4546acc3-fe8f-44da-b01e-7aa2f447c271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_6cee2714-96bd-4ed2-b7a0-ac25b7a85b72" xlink:href="mgnx-20180930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_6cee2714-96bd-4ed2-b7a0-ac25b7a85b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b57a9100-f5dc-4287-b5bf-393f73b59106" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_90d0b2d1-5e79-4b83-90c1-46f2e591539a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b57a9100-f5dc-4287-b5bf-393f73b59106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreements"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_114c04d7-81f5-491e-8373-1138e91c05cd" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_376b2f19-e7e7-4420-97de-05e4846b8dc8" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_114c04d7-81f5-491e-8373-1138e91c05cd" xlink:to="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_376b2f19-e7e7-4420-97de-05e4846b8dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsIncyteDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_dc5de7b5-efc0-4f34-8066-e838d0106a13" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_dc5de7b5-efc0-4f34-8066-e838d0106a13" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c11f0553-c0f7-4be2-a9e4-f67a9d3a85a0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:to="loc_srt_ProductOrServiceAxis_c11f0553-c0f7-4be2-a9e4-f67a9d3a85a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_828d351b-76e3-48d7-b098-d11cef6a243c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c11f0553-c0f7-4be2-a9e4-f67a9d3a85a0" xlink:to="loc_srt_ProductsAndServicesDomain_828d351b-76e3-48d7-b098-d11cef6a243c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_52bf5008-1405-4b45-821e-3f1b259c6dca" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_828d351b-76e3-48d7-b098-d11cef6a243c" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_52bf5008-1405-4b45-821e-3f1b259c6dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_70c16311-5317-4508-8bf2-230ad1d273c3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:to="loc_srt_RangeAxis_70c16311-5317-4508-8bf2-230ad1d273c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_70c16311-5317-4508-8bf2-230ad1d273c3" xlink:to="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e84701f7-c202-4e88-a88e-621d795b5670" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828" xlink:to="loc_srt_MaximumMember_e84701f7-c202-4e88-a88e-621d795b5670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07d1bbf6-479c-4011-90a9-32b5c368669e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75bd4e40-3ff8-49d4-8cee-e1b12a187828" xlink:to="loc_srt_MinimumMember_07d1bbf6-479c-4011-90a9-32b5c368669e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_84289786-0964-43dd-a511-d7ea2a804529" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:to="loc_srt_CounterpartyNameAxis_84289786-0964-43dd-a511-d7ea2a804529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc0f0e22-8bb4-43c1-af7d-0922ca13f42c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_84289786-0964-43dd-a511-d7ea2a804529" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc0f0e22-8bb4-43c1-af7d-0922ca13f42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_ca6dac3c-c887-4b4f-8ab4-865a3fbdc086" xlink:href="mgnx-20180930.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc0f0e22-8bb4-43c1-af7d-0922ca13f42c" xlink:to="loc_mgnx_IncyteCorporationMember_ca6dac3c-c887-4b4f-8ab4-865a3fbdc086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0a55807b-f4d1-47e7-b807-68bd4707d8a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0a55807b-f4d1-47e7-b807-68bd4707d8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3ca500ef-caf3-4371-9a60-92dac138a2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0a55807b-f4d1-47e7-b807-68bd4707d8a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3ca500ef-caf3-4371-9a60-92dac138a2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_4a902ab9-6455-44fc-ad0a-1eef0d9cba9e" xlink:href="mgnx-20180930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3ca500ef-caf3-4371-9a60-92dac138a2a4" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_4a902ab9-6455-44fc-ad0a-1eef0d9cba9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_10163198-1c0f-4ebd-9f6f-cb96306e2a19" xlink:href="mgnx-20180930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_4a902ab9-6455-44fc-ad0a-1eef0d9cba9e" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_10163198-1c0f-4ebd-9f6f-cb96306e2a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementServicesMember_959c78ab-c73e-445f-a081-168f55afb2d8" xlink:href="mgnx-20180930.xsd#mgnx_IncyteMGA012AgreementServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_4a902ab9-6455-44fc-ad0a-1eef0d9cba9e" xlink:to="loc_mgnx_IncyteMGA012AgreementServicesMember_959c78ab-c73e-445f-a081-168f55afb2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7be33b5e-b243-4a96-8ffd-011843be15a2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_b6aba003-bfd2-4007-b80b-e5095d9b7e02" xlink:href="mgnx-20180930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_NonRefundableUpfrontFees_b6aba003-bfd2-4007-b80b-e5095d9b7e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_3bfdc539-96bb-4ee4-a297-f9ddedf67e93" xlink:href="mgnx-20180930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_3bfdc539-96bb-4ee4-a297-f9ddedf67e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_af4bb863-012f-4298-9c4d-332e8670a5ac" xlink:href="mgnx-20180930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_af4bb863-012f-4298-9c4d-332e8670a5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_847108e0-6f54-4c75-bf3c-2fccd46adf20" xlink:href="mgnx-20180930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_847108e0-6f54-4c75-bf3c-2fccd46adf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_20c81d72-fd43-4b60-b1b4-b32d551f4460" xlink:href="mgnx-20180930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_20c81d72-fd43-4b60-b1b4-b32d551f4460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_eebae09f-9735-410a-b665-984bf2583bd2" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_NumberOfPerformanceObligations_eebae09f-9735-410a-b665-984bf2583bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_42ddaf56-56e1-4325-8f37-d68940430e62" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_42ddaf56-56e1-4325-8f37-d68940430e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_3942dc98-3a06-4726-82c0-075d299aaea4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_3942dc98-3a06-4726-82c0-075d299aaea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_661fb3e9-9fba-4df8-8161-6bb06f62ad89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ca9a832-ab55-4982-adb7-0734c3d5a0d9" xlink:to="loc_us-gaap_Revenues_661fb3e9-9fba-4df8-8161-6bb06f62ad89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_df38ee14-446b-4127-91d5-724b606c5e52" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924014dc-17cd-48d2-bfe1-2e51ad5c7441" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_df38ee14-446b-4127-91d5-724b606c5e52" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924014dc-17cd-48d2-bfe1-2e51ad5c7441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5a15bc1-f15d-40ba-a580-fe13c875bcf9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924014dc-17cd-48d2-bfe1-2e51ad5c7441" xlink:to="loc_srt_ProductOrServiceAxis_e5a15bc1-f15d-40ba-a580-fe13c875bcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25ff8497-f453-42dc-a028-406d51855481" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e5a15bc1-f15d-40ba-a580-fe13c875bcf9" xlink:to="loc_srt_ProductsAndServicesDomain_25ff8497-f453-42dc-a028-406d51855481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_4a75eb42-012c-4837-a9c7-5055a1bb2811" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_25ff8497-f453-42dc-a028-406d51855481" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_4a75eb42-012c-4837-a9c7-5055a1bb2811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0fa3025e-35aa-4010-a855-e9933cdacad9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924014dc-17cd-48d2-bfe1-2e51ad5c7441" xlink:to="loc_srt_CounterpartyNameAxis_0fa3025e-35aa-4010-a855-e9933cdacad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bbaa110-06af-40ad-918e-dfafeac07097" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0fa3025e-35aa-4010-a855-e9933cdacad9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bbaa110-06af-40ad-918e-dfafeac07097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_413011e2-3fcd-488d-b29a-39b7a07ce96e" xlink:href="mgnx-20180930.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bbaa110-06af-40ad-918e-dfafeac07097" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_413011e2-3fcd-488d-b29a-39b7a07ce96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924014dc-17cd-48d2-bfe1-2e51ad5c7441" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_95a8018e-4be7-4672-969c-b77279b4bce2" xlink:href="mgnx-20180930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_NonRefundableUpfrontFees_95a8018e-4be7-4672-969c-b77279b4bce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_56953c0d-a275-457d-9f70-f23f89da4e19" xlink:href="mgnx-20180930.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_56953c0d-a275-457d-9f70-f23f89da4e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_3c413a61-2ca4-43f9-91fd-aee35cba2164" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_NumberOfPerformanceObligations_3c413a61-2ca4-43f9-91fd-aee35cba2164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_ed85412e-69a8-4b01-aca8-09d2f2ff096b" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_ed85412e-69a8-4b01-aca8-09d2f2ff096b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_9c774d67-f402-40f3-a99d-4e59965d9b45" xlink:href="mgnx-20180930.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_9c774d67-f402-40f3-a99d-4e59965d9b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7a75ac3a-c735-4eb2-aa38-626938acd5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_us-gaap_Revenues_7a75ac3a-c735-4eb2-aa38-626938acd5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_29b27864-13e3-4bd7-b551-3659274b24c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_us-gaap_DeferredRevenue_29b27864-13e3-4bd7-b551-3659274b24c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_79caf4c9-6b9b-4e98-907f-4662383056b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_331696f7-13f7-4cf6-bf94-a1d095906d72" xlink:to="loc_us-gaap_DeferredRevenueCurrent_79caf4c9-6b9b-4e98-907f-4662383056b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsLesLaboratoiresServierDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_2801f1e1-fd17-418c-ae69-a69e7704f1e8" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_2801f1e1-fd17-418c-ae69-a69e7704f1e8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_199861b3-0e9f-44f0-b67e-ac8f1fbd88a9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_srt_ProductOrServiceAxis_199861b3-0e9f-44f0-b67e-ac8f1fbd88a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5631fd3-27d4-43f1-af50-a8200f76be55" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_199861b3-0e9f-44f0-b67e-ac8f1fbd88a9" xlink:to="loc_srt_ProductsAndServicesDomain_d5631fd3-27d4-43f1-af50-a8200f76be55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_22f16eb1-432c-4d0c-9b47-4af1472676f2" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d5631fd3-27d4-43f1-af50-a8200f76be55" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_22f16eb1-432c-4d0c-9b47-4af1472676f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_78d4d43c-d1ed-4bd2-a9a8-db030c920782" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_78d4d43c-d1ed-4bd2-a9a8-db030c920782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c481422f-c747-46b5-b8ab-bf4a8488d8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_78d4d43c-d1ed-4bd2-a9a8-db030c920782" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c481422f-c747-46b5-b8ab-bf4a8488d8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_7d0bd742-e652-4279-9956-13bce1e407da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_c481422f-c747-46b5-b8ab-bf4a8488d8e7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_7d0bd742-e652-4279-9956-13bce1e407da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_ee844f5a-545b-4adb-954f-32c316cbda85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_ee844f5a-545b-4adb-954f-32c316cbda85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_ee844f5a-545b-4adb-954f-32c316cbda85" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_7e1fc224-5815-47d4-a4ee-036a4f171756" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_7e1fc224-5815-47d4-a4ee-036a4f171756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33200cf1-633e-4b51-ae87-6efaa62d9353" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73c1fc42-6aa1-4e99-98a3-78ca2a926faa" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33200cf1-633e-4b51-ae87-6efaa62d9353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_56048410-7e7a-4891-9ee0-e43eb602f04d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_56048410-7e7a-4891-9ee0-e43eb602f04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6b9a3d5-b642-43f5-ace2-6be56341e01d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_56048410-7e7a-4891-9ee0-e43eb602f04d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6b9a3d5-b642-43f5-ace2-6be56341e01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierMGD007Member_a0abecc4-2d7b-4d9b-937b-230b8bd91283" xlink:href="mgnx-20180930.xsd#mgnx_LesLaboratoiresServierMGD007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6b9a3d5-b642-43f5-ace2-6be56341e01d" xlink:to="loc_mgnx_LesLaboratoiresServierMGD007Member_a0abecc4-2d7b-4d9b-937b-230b8bd91283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a652222c-4225-4c2b-861a-f083f96f1365" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_srt_CounterpartyNameAxis_a652222c-4225-4c2b-861a-f083f96f1365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f8c283-a4f2-4b66-a22f-7d818da1a7c4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a652222c-4225-4c2b-861a-f083f96f1365" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f8c283-a4f2-4b66-a22f-7d818da1a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember_40432a7e-d0b8-4bb5-bb73-2de5a073a2ed" xlink:href="mgnx-20180930.xsd#mgnx_ServierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f8c283-a4f2-4b66-a22f-7d818da1a7c4" xlink:to="loc_mgnx_ServierMember_40432a7e-d0b8-4bb5-bb73-2de5a073a2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ea99ae1e-b01c-4a3a-9f95-cbe975d6251e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ea99ae1e-b01c-4a3a-9f95-cbe975d6251e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c00e-ff85-458f-9b08-9936fdb6d80b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ea99ae1e-b01c-4a3a-9f95-cbe975d6251e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c00e-ff85-458f-9b08-9936fdb6d80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember_62061e4a-0b83-41c7-8bab-bb05075017fc" xlink:href="mgnx-20180930.xsd#mgnx_ServierDARTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c00e-ff85-458f-9b08-9936fdb6d80b" xlink:to="loc_mgnx_ServierDARTMember_62061e4a-0b83-41c7-8bab-bb05075017fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6242021-258d-4c30-b0e3-38d429003d5a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_srt_RangeAxis_e6242021-258d-4c30-b0e3-38d429003d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8880ae3-c5d8-4075-a0ea-8ac635da6819" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e6242021-258d-4c30-b0e3-38d429003d5a" xlink:to="loc_srt_RangeMember_f8880ae3-c5d8-4075-a0ea-8ac635da6819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cdd8fed1-d875-4d57-9844-fd3eeb473643" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f8880ae3-c5d8-4075-a0ea-8ac635da6819" xlink:to="loc_srt_MaximumMember_cdd8fed1-d875-4d57-9844-fd3eeb473643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4de00e0e-d4a9-4d92-ab52-c2618c3eb81f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_702c8302-eea7-4ce6-8390-a4c1cf633623" xlink:href="mgnx-20180930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_702c8302-eea7-4ce6-8390-a4c1cf633623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_9989bb9c-11a1-4529-abc9-270406655df6" xlink:href="mgnx-20180930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NonRefundableUpfrontFees_9989bb9c-11a1-4529-abc9-270406655df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialLicenseFee_af212398-4b5f-4697-ab9e-c39b0843feec" xlink:href="mgnx-20180930.xsd#mgnx_PotentialLicenseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_PotentialLicenseFee_af212398-4b5f-4697-ab9e-c39b0843feec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_d5d7ec4e-e837-488d-927e-2eaed532d1b2" xlink:href="mgnx-20180930.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_d5d7ec4e-e837-488d-927e-2eaed532d1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_d17e6072-3fec-48e8-ad6e-59edb813c4df" xlink:href="mgnx-20180930.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_d17e6072-3fec-48e8-ad6e-59edb813c4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_1fa301dc-14fc-4ab1-beee-b0af12df6d9a" xlink:href="mgnx-20180930.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_1fa301dc-14fc-4ab1-beee-b0af12df6d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_c4271680-769d-4bf9-b0a2-3b8621454c18" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_c4271680-769d-4bf9-b0a2-3b8621454c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfExclusiveOptionsToLicense_189f6b5a-63a7-425b-9d29-6c036b2246c4" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfExclusiveOptionsToLicense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NumberOfExclusiveOptionsToLicense_189f6b5a-63a7-425b-9d29-6c036b2246c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_6e3d3e0a-4828-4ade-af23-c961aa4b1e66" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NumberOfPerformanceObligations_6e3d3e0a-4828-4ade-af23-c961aa4b1e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMilestonesAchieved_76925ce5-a43e-4031-9d01-bda6243ccaec" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfMilestonesAchieved"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NumberOfMilestonesAchieved_76925ce5-a43e-4031-9d01-bda6243ccaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment_c0126828-30c9-4d35-a9e9-8301a55fd08c" xlink:href="mgnx-20180930.xsd#mgnx_MilestonePayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_MilestonePayment_c0126828-30c9-4d35-a9e9-8301a55fd08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_4a181b8a-bec8-4091-a4fe-a88065e4f675" xlink:href="mgnx-20180930.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_4a181b8a-bec8-4091-a4fe-a88065e4f675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee_00764dd6-f58d-447e-a970-3296e5d56ac2" xlink:href="mgnx-20180930.xsd#mgnx_OptionExerciseFee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_OptionExerciseFee_00764dd6-f58d-447e-a970-3296e5d56ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfComponentsInLicenseAgreement_d2c06b45-9881-4719-ad0d-5a1bccca521c" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfComponentsInLicenseAgreement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_NumberOfComponentsInLicenseAgreement_d2c06b45-9881-4719-ad0d-5a1bccca521c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_d8bda530-3545-4b35-85c6-d09c0a330793" xlink:href="mgnx-20180930.xsd#mgnx_OptionExerciseFeeRecognitionPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_OptionExerciseFeeRecognitionPeriod_d8bda530-3545-4b35-85c6-d09c0a330793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_4a7fbae7-2320-4a9b-a449-96616c7f87fe" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_4a7fbae7-2320-4a9b-a449-96616c7f87fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_06b055cb-f47a-4577-9d3a-54df0cf9c94e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_us-gaap_Revenues_06b055cb-f47a-4577-9d3a-54df0cf9c94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_5dfe2ad1-9135-4c16-9edb-416579de4a14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_us-gaap_DeferredRevenue_5dfe2ad1-9135-4c16-9edb-416579de4a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2b1f7cb1-90bb-4e6d-a65c-bc5687599028" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3100b890-0832-4e75-a825-cd91e9c2cdfe" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2b1f7cb1-90bb-4e6d-a65c-bc5687599028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d203120a-485f-4818-b6c7-c3458cb6acd8" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d203120a-485f-4818-b6c7-c3458cb6acd8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_257f10ae-5c67-4d20-890f-d7685897c7c3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:to="loc_srt_ProductOrServiceAxis_257f10ae-5c67-4d20-890f-d7685897c7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_659d6747-9e1a-4bc2-bc37-94c244ad1bc8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_257f10ae-5c67-4d20-890f-d7685897c7c3" xlink:to="loc_srt_ProductsAndServicesDomain_659d6747-9e1a-4bc2-bc37-94c244ad1bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_50b73760-57a5-4920-be2e-4a50625fff39" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_659d6747-9e1a-4bc2-bc37-94c244ad1bc8" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_50b73760-57a5-4920-be2e-4a50625fff39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e272a37d-2715-46c6-a2d5-f6f739a28db1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e272a37d-2715-46c6-a2d5-f6f739a28db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e272a37d-2715-46c6-a2d5-f6f739a28db1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_04ae8a85-2dc0-4288-b6b0-006f2465164e" xlink:href="mgnx-20180930.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_04ae8a85-2dc0-4288-b6b0-006f2465164e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_f023f928-6abd-4d18-8d18-de3ee71ce17b" xlink:href="mgnx-20180930.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bd0470-5fc0-427e-b67b-ebce31e9523d" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_f023f928-6abd-4d18-8d18-de3ee71ce17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8007f4dd-4e68-4c70-9427-d62ad331bd99" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:to="loc_srt_CounterpartyNameAxis_8007f4dd-4e68-4c70-9427-d62ad331bd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67cb897-0690-482c-a8cf-5751a01ca015" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8007f4dd-4e68-4c70-9427-d62ad331bd99" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67cb897-0690-482c-a8cf-5751a01ca015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioInc.Member_0dbae4cc-1807-4189-a414-44fbd1db0771" xlink:href="mgnx-20180930.xsd#mgnx_ProventionBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67cb897-0690-482c-a8cf-5751a01ca015" xlink:to="loc_mgnx_ProventionBioInc.Member_0dbae4cc-1807-4189-a414-44fbd1db0771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_121fd418-ff1b-4caf-a85d-8819ea10f543" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_121fd418-ff1b-4caf-a85d-8819ea10f543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_121fd418-ff1b-4caf-a85d-8819ea10f543" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_bca184cf-d108-45a2-bad2-767420ce885b" xlink:href="mgnx-20180930.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab" xlink:to="loc_mgnx_ProventionPRV3279Member_bca184cf-d108-45a2-bad2-767420ce885b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_b2cbd266-ea6e-4115-9a65-4e8bef20c379" xlink:href="mgnx-20180930.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_33eb8ae8-998d-425b-aee3-eec782144fab" xlink:to="loc_mgnx_ProventionPRV031Member_b2cbd266-ea6e-4115-9a65-4e8bef20c379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5b97cdb-fb92-460c-be80-0db2fe78926b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_7c085737-b3e1-432e-b4ad-46b130e00797" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_7c085737-b3e1-432e-b4ad-46b130e00797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_0d20305f-73ed-46ae-a787-7c7480dcc49c" xlink:href="mgnx-20180930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_0d20305f-73ed-46ae-a787-7c7480dcc49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_0794d3e3-90ba-4d27-875d-eba8ead7c17b" xlink:href="mgnx-20180930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_0794d3e3-90ba-4d27-875d-eba8ead7c17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_7a7065b6-fa25-4613-a4e8-506ae80978c3" xlink:href="mgnx-20180930.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_7a7065b6-fa25-4613-a4e8-506ae80978c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_9dba4d4d-03ca-4af7-babc-38499516728a" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_NumberOfPerformanceObligations_9dba4d4d-03ca-4af7-babc-38499516728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a7e90f19-df47-4f03-b34d-010a9d9d6996" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a7e90f19-df47-4f03-b34d-010a9d9d6996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_7a162e40-2b29-442f-abf5-98d0b926f06c" xlink:href="mgnx-20180930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_7a162e40-2b29-442f-abf5-98d0b926f06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ac2701a9-4211-4de1-ade3-cf02d9d18581" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4d30fcb-2067-48a5-b4c8-28d6595e8c97" xlink:to="loc_us-gaap_Revenues_ac2701a9-4211-4de1-ade3-cf02d9d18581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_c9c83830-cbb5-40b8-95e0-b4f7edf95fb7" xlink:href="mgnx-20180930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_c9c83830-cbb5-40b8-95e0-b4f7edf95fb7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d2987519-17f8-4618-99e3-2cf0120f4ff9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:to="loc_srt_ProductOrServiceAxis_d2987519-17f8-4618-99e3-2cf0120f4ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91b39b23-81b3-4351-a1f1-762087332ddd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d2987519-17f8-4618-99e3-2cf0120f4ff9" xlink:to="loc_srt_ProductsAndServicesDomain_91b39b23-81b3-4351-a1f1-762087332ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_968589a2-d567-47e8-9145-09906ac0e722" xlink:href="mgnx-20180930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_91b39b23-81b3-4351-a1f1-762087332ddd" xlink:to="loc_mgnx_RevenuesFromGrantsMember_968589a2-d567-47e8-9145-09906ac0e722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cbcf7882-3ffb-4a66-938b-dbc7e7533bcd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:to="loc_srt_CounterpartyNameAxis_cbcf7882-3ffb-4a66-938b-dbc7e7533bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f999f577-32ac-4a0b-bd3d-02a6ce3e1398" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cbcf7882-3ffb-4a66-938b-dbc7e7533bcd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f999f577-32ac-4a0b-bd3d-02a6ce3e1398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_3ad00ad9-9fec-44cd-ae67-f28151b0395e" xlink:href="mgnx-20180930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f999f577-32ac-4a0b-bd3d-02a6ce3e1398" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_3ad00ad9-9fec-44cd-ae67-f28151b0395e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4da93df8-04f4-47c4-b815-d6a398509012" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:to="loc_srt_RangeAxis_4da93df8-04f4-47c4-b815-d6a398509012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c00e8f7-e461-4030-ab0b-87b9f223f290" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4da93df8-04f4-47c4-b815-d6a398509012" xlink:to="loc_srt_RangeMember_7c00e8f7-e461-4030-ab0b-87b9f223f290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4eb8b295-e991-48ba-9690-ba196e541b4d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c00e8f7-e461-4030-ab0b-87b9f223f290" xlink:to="loc_srt_MaximumMember_4eb8b295-e991-48ba-9690-ba196e541b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7aa8e144-c35c-4707-8c43-ae8e2753f368" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_fdd3bcba-16bc-4b59-8844-9457d516c61b" xlink:href="mgnx-20180930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_fdd3bcba-16bc-4b59-8844-9457d516c61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_5a84b3d2-3162-4a32-8074-450cfb4bd423" xlink:href="mgnx-20180930.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_FundedValueOfBasePeriod_5a84b3d2-3162-4a32-8074-450cfb4bd423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_3d72565e-1485-4507-9692-f79123a32b28" xlink:href="mgnx-20180930.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_3d72565e-1485-4507-9692-f79123a32b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_f60af8b2-11f0-4bf7-a179-b787db787344" xlink:href="mgnx-20180930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_f60af8b2-11f0-4bf7-a179-b787db787344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_1093da58-0de8-4a25-a598-6296911ca9c8" xlink:href="mgnx-20180930.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_1093da58-0de8-4a25-a598-6296911ca9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b9bde993-1690-4469-8dc6-d9ba23a2e71e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3ddea399-d7cc-4c3d-9140-5b7b4aa7d17f" xlink:to="loc_us-gaap_Revenues_b9bde993-1690-4469-8dc6-d9ba23a2e71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66e78e43-ac41-43fd-a4ef-796e3e586e78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a348f941-b90f-4e26-9460-e9b2bf6a60b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66e78e43-ac41-43fd-a4ef-796e3e586e78" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a348f941-b90f-4e26-9460-e9b2bf6a60b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a52163b0-2056-413d-ba16-b3c1b959b506" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02f5ff9d-2a68-4c42-8cc0-b20ae8b48a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a52163b0-2056-413d-ba16-b3c1b959b506" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02f5ff9d-2a68-4c42-8cc0-b20ae8b48a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_79140179-d92a-4f99-9cab-3ee6362eed2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a52163b0-2056-413d-ba16-b3c1b959b506" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_79140179-d92a-4f99-9cab-3ee6362eed2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_7ae629ef-3167-4c11-aaf5-342eb26a28bf" xlink:href="mgnx-20180930.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a52163b0-2056-413d-ba16-b3c1b959b506" xlink:to="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_7ae629ef-3167-4c11-aaf5-342eb26a28bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13a3ce89-963d-4b76-9b35-96201410398f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5613942d-fdba-4411-9631-59d756d141d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13a3ce89-963d-4b76-9b35-96201410398f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5613942d-fdba-4411-9631-59d756d141d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_986483d3-3c51-4fc4-a283-e3e0bf4657a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5613942d-fdba-4411-9631-59d756d141d5" xlink:to="loc_us-gaap_PlanNameAxis_986483d3-3c51-4fc4-a283-e3e0bf4657a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_986483d3-3c51-4fc4-a283-e3e0bf4657a8" xlink:to="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b0215809-a2d1-4eef-8a26-b1f2f7793904" xlink:href="mgnx-20180930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b0215809-a2d1-4eef-8a26-b1f2f7793904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_9871175a-e9b2-4020-a4f9-83cf86e09486" xlink:href="mgnx-20180930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_9871175a-e9b2-4020-a4f9-83cf86e09486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_4d2287af-56da-4951-a955-2489cf7bc800" xlink:href="mgnx-20180930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_91a9d4df-b95a-4ab9-8ae5-ec27a6a822d5" xlink:to="loc_mgnx_StockIncentivePlan2013Member_4d2287af-56da-4951-a955-2489cf7bc800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5613942d-fdba-4411-9631-59d756d141d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5c4a6087-0bf9-4359-9604-3c7b5a9d07ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5c4a6087-0bf9-4359-9604-3c7b5a9d07ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_d2d55589-a591-44d6-bf47-5f21e0188324" xlink:href="mgnx-20180930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_d2d55589-a591-44d6-bf47-5f21e0188324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1b6789ca-3e6b-4859-a5bf-8e6f82359ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1b6789ca-3e6b-4859-a5bf-8e6f82359ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2946050e-f23c-42c8-ba86-3f77ed773ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2946050e-f23c-42c8-ba86-3f77ed773ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_e736b485-c6a0-42ec-81a1-7f19c3fab276" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ProceedsFromStockPlans_e736b485-c6a0-42ec-81a1-7f19c3fab276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e846f00a-2213-49c2-bea7-303f22b2dd6e" xlink:href="mgnx-20180930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e846f00a-2213-49c2-bea7-303f22b2dd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_fa7d7fcf-7c08-4e2f-8d4d-0b164203792d" xlink:href="mgnx-20180930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_fa7d7fcf-7c08-4e2f-8d4d-0b164203792d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c7e6f56-6d0f-46d1-a773-4c8cd8bc5343" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c7e6f56-6d0f-46d1-a773-4c8cd8bc5343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b6a785c-8d8f-4ad5-a89d-15bd7a2ca19f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ab0a751-ab97-4623-87af-5fe888cb6ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b6a785c-8d8f-4ad5-a89d-15bd7a2ca19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a1285d68-b03e-489a-8c6b-3f9a81f07159" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13a3ce89-963d-4b76-9b35-96201410398f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a1285d68-b03e-489a-8c6b-3f9a81f07159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d1e3c396-7e71-4a0d-8f38-7884853e08be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a1285d68-b03e-489a-8c6b-3f9a81f07159" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d1e3c396-7e71-4a0d-8f38-7884853e08be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d1e3c396-7e71-4a0d-8f38-7884853e08be" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_15ce5c19-e244-4cda-9d0f-f5a109641911" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_15ce5c19-e244-4cda-9d0f-f5a109641911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72bed09c-3e8e-4b21-a8a1-97d5d478f5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9e047aec-a4f9-475c-96a6-22f0656e23fe" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72bed09c-3e8e-4b21-a8a1-97d5d478f5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37c17eed-3563-4bfa-a4ed-179f0ef71462" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a1285d68-b03e-489a-8c6b-3f9a81f07159" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37c17eed-3563-4bfa-a4ed-179f0ef71462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_abac070b-ad4e-4093-adb2-f93364cd2c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37c17eed-3563-4bfa-a4ed-179f0ef71462" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_abac070b-ad4e-4093-adb2-f93364cd2c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_27620bc9-3a26-4a21-97fc-500c7b22ce83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37c17eed-3563-4bfa-a4ed-179f0ef71462" xlink:to="loc_us-gaap_ShareBasedCompensation_27620bc9-3a26-4a21-97fc-500c7b22ce83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c751c25-f08e-430b-a330-f48c71288e96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00506a22-594a-420c-8799-ab0556f5f07c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c751c25-f08e-430b-a330-f48c71288e96" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00506a22-594a-420c-8799-ab0556f5f07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_326dc7ed-e2e2-464f-8e33-3ae06ef3f262" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00506a22-594a-420c-8799-ab0556f5f07c" xlink:to="loc_srt_RangeAxis_326dc7ed-e2e2-464f-8e33-3ae06ef3f262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_326dc7ed-e2e2-464f-8e33-3ae06ef3f262" xlink:to="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4836837e-f70a-4c8b-a539-e1e9333aaa3b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927" xlink:to="loc_srt_MinimumMember_4836837e-f70a-4c8b-a539-e1e9333aaa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_323eb10d-195f-41b7-b3d7-6ff8af83093e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13a80f0a-6fc9-4074-91c6-22dd0ba83927" xlink:to="loc_srt_MaximumMember_323eb10d-195f-41b7-b3d7-6ff8af83093e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00506a22-594a-420c-8799-ab0556f5f07c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13647743-baac-4264-85e3-9c32a28dd7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13647743-baac-4264-85e3-9c32a28dd7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40712fac-6364-4ca6-8ac9-30a9bea57f50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40712fac-6364-4ca6-8ac9-30a9bea57f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cac509c0-eb20-488f-8cac-5e8ad8c41ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cac509c0-eb20-488f-8cac-5e8ad8c41ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b9e6ad96-1b8d-425a-b96e-5002d35f8880" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b4dc0e-ec25-4a67-9276-e1de12aee8e6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b9e6ad96-1b8d-425a-b96e-5002d35f8880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e57f27dd-3765-463b-91bb-546545b8b5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e57f27dd-3765-463b-91bb-546545b8b5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ece0d998-3835-4b37-8a25-be3e2afaf7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e57f27dd-3765-463b-91bb-546545b8b5b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ece0d998-3835-4b37-8a25-be3e2afaf7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_66ff37f4-aff2-43c1-b0a0-ba7607c8763a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e57f27dd-3765-463b-91bb-546545b8b5b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_66ff37f4-aff2-43c1-b0a0-ba7607c8763a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de35f914-ce17-452a-8791-95a24eafb7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e57f27dd-3765-463b-91bb-546545b8b5b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de35f914-ce17-452a-8791-95a24eafb7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3a6813b-324f-4f41-aa22-62e64aeeb1df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e57f27dd-3765-463b-91bb-546545b8b5b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3a6813b-324f-4f41-aa22-62e64aeeb1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_793d67b1-bd1d-4250-bb95-73052a794e75" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e57f27dd-3765-463b-91bb-546545b8b5b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_793d67b1-bd1d-4250-bb95-73052a794e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c4e1a61a-4577-47bf-a84e-7b54bbd37169" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e57f27dd-3765-463b-91bb-546545b8b5b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c4e1a61a-4577-47bf-a84e-7b54bbd37169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_82616262-0e94-462a-a76a-1973833a5be0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e57f27dd-3765-463b-91bb-546545b8b5b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_82616262-0e94-462a-a76a-1973833a5be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_878c3f5a-7577-46d8-bf13-fdff8863dc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_878c3f5a-7577-46d8-bf13-fdff8863dc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_05c7d845-7372-42c9-bd95-1dcf37586649" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_878c3f5a-7577-46d8-bf13-fdff8863dc6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_05c7d845-7372-42c9-bd95-1dcf37586649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_056a499f-9491-4a38-9266-d12f2a464390" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_878c3f5a-7577-46d8-bf13-fdff8863dc6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_056a499f-9491-4a38-9266-d12f2a464390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7ad2af04-14c0-4f9d-984a-6d9b0df2ebc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_878c3f5a-7577-46d8-bf13-fdff8863dc6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7ad2af04-14c0-4f9d-984a-6d9b0df2ebc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7035269c-64e2-41d3-9eeb-2251e7618b10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_878c3f5a-7577-46d8-bf13-fdff8863dc6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7035269c-64e2-41d3-9eeb-2251e7618b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_175f4ddf-3ec6-4a6c-b78a-43e55121e942" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_878c3f5a-7577-46d8-bf13-fdff8863dc6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_175f4ddf-3ec6-4a6c-b78a-43e55121e942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7ed8c778-0897-4c76-a0ec-17bb51cbd3fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_878c3f5a-7577-46d8-bf13-fdff8863dc6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7ed8c778-0897-4c76-a0ec-17bb51cbd3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1681282a-bead-45ec-9edc-77051c9451e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_878c3f5a-7577-46d8-bf13-fdff8863dc6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1681282a-bead-45ec-9edc-77051c9451e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_edad9544-9c4c-4ae4-a11f-e5384f900efd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_edad9544-9c4c-4ae4-a11f-e5384f900efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8ccec360-997f-4f02-8acf-7ba1173e30e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_edad9544-9c4c-4ae4-a11f-e5384f900efd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8ccec360-997f-4f02-8acf-7ba1173e30e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_604c3e65-ea69-4421-930d-a39355e2fdae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_edad9544-9c4c-4ae4-a11f-e5384f900efd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_604c3e65-ea69-4421-930d-a39355e2fdae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2e31e872-5b7c-4d33-8fbf-6f1b0b9109b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_edad9544-9c4c-4ae4-a11f-e5384f900efd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2e31e872-5b7c-4d33-8fbf-6f1b0b9109b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_04c50959-f2ce-4cc7-81d5-09ac4797dc12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_edad9544-9c4c-4ae4-a11f-e5384f900efd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_04c50959-f2ce-4cc7-81d5-09ac4797dc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28a4ec27-b5f3-4981-86e4-32518df44ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_edad9544-9c4c-4ae4-a11f-e5384f900efd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28a4ec27-b5f3-4981-86e4-32518df44ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3f33bba8-dd5a-48f0-94d2-1353892a0558" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_edad9544-9c4c-4ae4-a11f-e5384f900efd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3f33bba8-dd5a-48f0-94d2-1353892a0558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38681db7-47b6-4cea-896d-157ccc06b70b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38681db7-47b6-4cea-896d-157ccc06b70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2a6786f-2439-4db6-a22a-b153e6e3e21e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2a6786f-2439-4db6-a22a-b153e6e3e21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_38835ad7-4436-40fe-a1fc-2704f82c7fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_38835ad7-4436-40fe-a1fc-2704f82c7fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2236ccab-e618-4885-8d16-5cc97c65e48f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2236ccab-e618-4885-8d16-5cc97c65e48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_34dd70a1-9adb-40a5-9af2-62bbb7be2574" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_34dd70a1-9adb-40a5-9af2-62bbb7be2574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_205d2910-ffd9-4cc0-8eb1-2b9747690766" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29e652ac-9126-4884-9a2c-e8e4719a8f22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_205d2910-ffd9-4cc0-8eb1-2b9747690766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="mgnx-20180930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_386554e4-e274-4a93-a4d3-1e62f9acf121" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_17f53f9e-f3e9-4d06-b0b3-cb3e272f7829" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_386554e4-e274-4a93-a4d3-1e62f9acf121" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_17f53f9e-f3e9-4d06-b0b3-cb3e272f7829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20180930.xsd#NetLossPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_68f9a09a-23f0-41cc-a6b5-e5cf5f596241" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01828430-01d5-48f8-822f-9a6a69a9ac90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_68f9a09a-23f0-41cc-a6b5-e5cf5f596241" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01828430-01d5-48f8-822f-9a6a69a9ac90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>mgnx-20180930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20180930"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20180930.xsd" xlink:type="simple"/>
    <context id="i2148cf3272754e1f879d4823913b518d_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i44dcd64c130143e7b61b89fe2646000c_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia06a043fda544306a7174163d4ba821a_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i85e4b6bf29674ed0bb853ac49b61574b_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="iddfd5052e98f4ca28241b0916f60a7d1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia03651a398b047e6ba26bc530ae802ba_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ibe8622ead245454683d6cd02732a930e_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i8e9c20469d344180a7bdbf43ccc98126_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i7afec6a50d3e4c49b2fceac1c053cee8_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i03336d63cb2e4abf99d71150176d9e2a_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ifd05ad37dc5648948de2ec1ebeeb9880_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="icf7551c75d6a4793b8ba11659882c30b_D20170101-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="icd5dfaa7121c4b398f87a4bf82fe6818_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i304e6e07763f45adac1a934bb867bb1b_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="iadb65054ca38420abd5f2059371dcff6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ibd2cfd87b18c4510b689cf0331b1d471_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i2076bfb4648e47319c3d79dc8b4f052f_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i09bb778c2423410098bdc0c426490d87_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i58ae03eea2c343388670589c0cc8cee6_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-09-30</instant>
        </period>
    </context>
    <context id="ia6e0829991f74feeaba02806ccb252be_D20120901-20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-09-01</startDate>
            <endDate>2012-09-30</endDate>
        </period>
    </context>
    <context id="i39a267842ce243189b28090dcf3b6338_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i9a2d8a380170427b92101d51e25a734b_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i061c41caf2584f488de00de72d70d359_I20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-09-30</instant>
        </period>
    </context>
    <context id="i88a4efe1362c4a3db0196262405ad178_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="ifb7ae82b7fd94218adec5b37c3baf521_D20120901-20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-09-01</startDate>
            <endDate>2012-09-30</endDate>
        </period>
    </context>
    <context id="i0bdd4ce1abcb4d84918166baa0aab54f_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ib593ee5aff884b09b56907f69f0517e1_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i166c43c2262341ea91348516a28bcbd9_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="idd6a295ad13346be87c34a41d8a59a09_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i1ccb567960f5405fb383ac91138849ca_D20170701-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ia231899505ea4e26b8ae99393f58f9f8_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i9f54d23042ce45e3b0f7b1f3527e965c_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i42d44f7b71fc4200940cf6d3d09f2c3b_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i53b4e8d5c2cc41a7abc24c33b0b6b4e0_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i1a09839b03404373938e8002919f2856_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i660cb75a1c0d41c983132bc62bb7d5cd_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i52bce1b6baef4facb924a318ed17002f_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i23557f80a0a245a690a3b1b11c018cc8_D20180531-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i1b5de7b28e2d4befab1ed1cec48844f6_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i829603c6236e41f2951a9087431df091_D20180531-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i8497085013f24f54a1464c82acde208c_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i77e14b4fd8a549c99d5b94473df0cbdb_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ia27a68ad905842ba80b4de3e9d1b929e_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i83423a11889045c1bcdec405be3fa546_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="i452ee1a0ab714c34ababb41227155f6d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i6da7c74defea4d8fb09ed95435cc7a03_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ife8821603bb64976be6518e29c1c250d_D20170701-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i28991436c91f443c8ede9c7a2c47f606_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i54aa98e1360041ea8a6f19ceeab7a123_D20170101-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i1ca90c5a445d4c77b930deb2ab301751_D20170101-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ie758ea00f3b045d8aaf61ff77aa1bd5b_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ie3e9f6ff05ac42748139386a1f145650_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ib21a72497c3f4f4586fc6f1f696f8ee0_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="idf2e982e7c3a42d487a756a32a510ac0_I20030228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2003-02-28</instant>
        </period>
    </context>
    <context id="ib58f57547e3d4bb8a8a5328327afc915_I20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="i706d5cef31cd430e8365f6915ddcb64f_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i53ec44ff783b431cb9ed2678498d5f97_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i596e64c58833410299f5dd5853dd7260_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i7042cd13db6549e7871f168d9d646e10_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i01e7fa001b0a43809cae26254818dd0a_D20170701-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i331b887054c54310ba485d67cc56fd98_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i1169246d2ee645d2b41f43608d9c7971_D20170101-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ie67728928c2f4b7c926568160fbfbb42_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i4c2c78af9f724b04b7f633e772d609d4_D20170701-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="iee7edc452a8d41b8a7136478d6aca726_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i47470559910c4104a2b667fa430274d6_D20170101-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i6d547ea0cc684d02aaf167a81f92222e_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i52b5b8baf4a04bc0a8515a755c75a5c6_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie82d67a794864a96916fa3f3a87b1009_D20170101-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i922b4063c16e435394fae5cdc427b832_D20170101-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i2c071206cf7f4239b167641403572000_D20170701-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i20a775ac09b1433ab3a29927f84e27f2_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i5f061d896ab34adea1ec90f8ea217749_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="if800a2edba02435c841fd5ce6f7aada7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ibb6469bec1ea4f8ca65fdad40040b929_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i6bab00c844a44b45bc42e1f5791cae02_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i6d979866d3b64e8ba979cb9f915e748f_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i2f5fdced0c8347e9aa3943f81e9837f6_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i87517407dd334c3893ac19538b16fd3e_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i8bedc85266654eaab2882c9503e960e8_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i2b5ededd31534749ab8242be3126e5b2_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ib492f638d82e4414a041403e1eddbe3a_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i663eb470436c44d0b0424c19e8eab05c_I20181102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-11-02</instant>
        </period>
    </context>
    <context id="if9d0da9b4cc14b75991174bfa7e7e7e0_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i2083d2f9a48048808e8f2445e7f65ceb_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i5c61aa06ff0442f384bef16716c9e006_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i8dd177baefb24c5da5f5d762ca97c05a_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i671934b6ca254466884554fbd72599a7_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i50ec2c1d0e4f4f05bf9e358137601c56_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ic80626a5f83c4f92b03a719528d899b3_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i5643f6cec2de4538bc34d86d7a1d42ef_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i588e913554c54d489854f5d7b18643f3_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ic5e44fd3fe174432a63b857d20d62cb9_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i5394f3e223d14c0f9d447b8dba062cc7_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i3a504713132440edac1e257a897cfc5e_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i01e4f28d5a2f4d8ba5410cb06f830efb_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i8dc0a6957b1049d1a7fd2aca4546de77_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i60a9918f2b454a02a9f52660bcfd9700_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i154046cc71f34152877eaec79ccfc61b_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i14e72fa606524cb6811b76c6b57eb806_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i94648d0db7a94b95bcaa11b425cfe7af_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i3518f59ae82e4ef582788fe57cbcd3e0_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="id0e9852ab63b4061801c673b10dcb0cd_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i160748b7708d470795cebd2e08cb1b72_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i39e27978db3d429bb2846824cbb065da_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ice6b9ff22ede4845b89261faf1de4b00_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="id0fa81042e394b329de76ce95f09cff5_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ice63152ef2424cc4a9579cbdc1d6240e_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i723d050a26224f16a353738eb4442e04_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="if9d77208352f4d25bf386d786bc798cd_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="icd4f120866b645c4bf3cce8586698473_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="iaadfc51e828143479b2403579738eaff_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i60c4cc1bdf234cf987926cd8055b2734_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2f0eeb462be349aea122b32abf38ffa1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ibd438d154f414b74a7d87ac6e9098fa3_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="idd2a21b952a4442dbd5213ed0c13c412_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9ef68251110c449f86e8dd7547298305_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0d1c05ab7cef41bda60ce9805aa4b8d6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9a7580bc237e44bba24dcaac666b17bd_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7c92391cb5f04624be95aa6135f9c5e0_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6626efe68b914e4aa0c4c00a038ca6fb_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5b810da2b4434106be6a2f4868aa983b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i22f5d3be38314de693952411eb401367_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie8ab2c156a8d47f5b370a57673a58703_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i375187cfa8df4fac956142beb3307c5e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iadea8e8fa97d481495bfa26ed8bcb2e8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie4e22d2b5dd8454fbebfa09f3feb0749_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i39b863145a6442bfa00fd78279e2e6d7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id2ec2edcab7e43d583877d5a7a390b74_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i075636ae66df40faaee95c130bcf8ea4_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic4e13a785a984de8ab85335f4e573536_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if287162bc94548119144a45ef00144e0_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if1aa2e56fe0043f790bcc747ebd4cf13_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4fac88e6145545bcab342e1996db0e66_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i03f6af7af270436ebef7bd53a4e07f80_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ibdc22a390e884f349065805d8e43c679_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="if828ac34fb81419ca9d1984770c76254_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i2a4af18da1684515ba77f3fadc4081d3_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i866096d237f54e4583f3e604e8c243ec_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i026f26d0cf654febb2e1e5f3037d5afc_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5d0a400707884c2198f13e93d13ca5cf_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib8b8d6b8d41d4fd494c10b56288a758f_D20170426-20170426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-26</startDate>
            <endDate>2017-04-26</endDate>
        </period>
    </context>
    <context id="i187b1747b6ea4fe7bd1a794a51a3a8bf_I20170426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-26</instant>
        </period>
    </context>
    <context id="i3ed9ef592d4e44dd88fcc594f7f2d847_D20170503-20170503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-03</startDate>
            <endDate>2017-05-03</endDate>
        </period>
    </context>
    <context id="i273fc3440aa24332a0568edcf542e1aa_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0c786749d1894dd6a9b452378513440b_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i44bef5523be840cea494b1c6a9b364fe_D20170701-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="icd9c327300a84aafaf0a8890a6378c39_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="id2d3c290311249a18501533c07d13527_D20180402-20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="i9127f44e472a4031acb85a2e77e5c974_I20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-02</instant>
        </period>
    </context>
    <context id="i46f941ef8b4f48e482ec7ee2d06ebaa3_D20180402-20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="i9e9cd335c9244d9fb051a1a01f207509_I20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-02</instant>
        </period>
    </context>
    <context id="id9e8c9eb9fa140f7bf495f250946e437_D20180402-20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:PublicOfferingandOverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="i2c2f267ad6954342818988358aaec05a_D20171001-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iaab2d3c47fcb482fb5016a56c6678a2f_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i583cbd7fe1f847cea4b7238b2bc9436a_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <unit id="performance_obligation">
        <measure>mgnx:performance_obligation</measure>
    </unit>
    <unit id="exclusive_license">
        <measure>mgnx:exclusive_license</measure>
    </unit>
    <unit id="milestone">
        <measure>mgnx:milestone</measure>
    </unit>
    <unit id="component">
        <measure>mgnx:component</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfNC0xLTEtMS0w_9c3377a5-2377-4ee7-bdc4-1d50adc34b34">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfNS0xLTEtMS0w_e2fbccb0-bf75-4da5-85e2-8fc2aa2ff46f">2018-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfNi0xLTEtMS0w_febdfbb4-25b7-4970-b865-97b883eb15fb">2018</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfNy0xLTEtMS0w_42032e07-ba2e-4615-a013-76b0083bb74f">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityFilerCategory
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfMTQtMS0xLTEtMA_609ba57e-c11f-4055-8af3-e4dd9432e79a">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfMTQtMS0xLTEtODcz_474b2569-5890-4c20-ac91-872171fb7511">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RhYmxlOmIwMzY2NjZkZmRmYzQwNTliNTU5MDRiZjI2Mzc0YTkxL3RhYmxlcmFuZ2U6YjAzNjY2NmRmZGZjNDA1OWI1NTkwNGJmMjYzNzRhOTFfMTUtMS0xLTEtODc1_87c16290-4959-40c5-b554-92cf7f9d24b8">false</dei:EntitySmallBusiness>
    <dei:EntityRegistrantName
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RleHRyZWdpb246MTQ3MWIyMjcxYTAxNDZkNTllMjU4NTBmMzAzOTg2ODRfNzE0NjgyNTU4MDY5Mg_362cf4ec-f5cf-4e21-ac7d-9d0512a45b9a">MACROGENICS INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RleHRyZWdpb246MTQ3MWIyMjcxYTAxNDZkNTllMjU4NTBmMzAzOTg2ODRfMjc0ODc3OTA2OTQ5MQ_86e1294e-4904-48a7-9947-0d55c34e2499">0001125345</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMy9mcmFnOjE0NzFiMjI3MWEwMTQ2ZDU5ZTI1ODUwZjMwMzk4Njg0L3RleHRyZWdpb246MTQ3MWIyMjcxYTAxNDZkNTllMjU4NTBmMzAzOTg2ODRfMjc0ODc3OTA2OTU0Mw_942057ec-6717-486e-ace7-483721cd680d">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfMi0xLTEtMS0w_23dcdd2a-5f00-4bb6-915c-a84ad788e63d"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfMi0zLTEtMS0w_393c0b9a-379c-4de8-8240-76d323d4701e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfMy0xLTEtMS0w_f541d0af-06e7-45c9-9303-1cbf8b046d37"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfMy0zLTEtMS0w_45c13a89-4086-47b7-9196-3281eca36c6e"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfNC0xLTEtMS0w_61470536-8b9f-48b6-9258-3d5dc2477536"
      unitRef="shares">42248075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF85MC9mcmFnOjQwOTc0ODBjZDNmMTQ3ZWY5MjBmYmNiMmI5NTE2OGE5L3RhYmxlOjE1NTQyNTkyMjAyZTQ1NzFiN2E1OTZlYzZiNTg1ZTQ3L3RhYmxlcmFuZ2U6MTU1NDI1OTIyMDJlNDU3MWI3YTU5NmVjNmI1ODVlNDdfNC0zLTEtMS0w_935ed1dd-81d2-4f70-b38c-f3dd24bd9255"
      unitRef="shares">36859077</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6d547ea0cc684d02aaf167a81f92222e_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzMtMS0xLTEtMA_d5ed95a9-21cd-4c85-aac1-0c2883784cab"
      unitRef="number">0.678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i52b5b8baf4a04bc0a8515a755c75a5c6_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzMtMy0xLTEtMA_02e461a7-710a-4897-ab15-63b79b0722de"
      unitRef="number">0.722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie82d67a794864a96916fa3f3a87b1009_D20170101-20170930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzMtNC0xLTEtMA_da304e26-fd93-4fec-a63f-a9ba826d36fd"
      unitRef="number">0.667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i922b4063c16e435394fae5cdc427b832_D20170101-20170930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzMtNi0xLTEtMA_d7774ac0-179a-4523-ae3c-fb11586adfac"
      unitRef="number">0.683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6d547ea0cc684d02aaf167a81f92222e_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzQtMS0xLTEtMA_4d7b573a-a0ee-43a6-93d6-ad832575e3ee"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i52b5b8baf4a04bc0a8515a755c75a5c6_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzQtMy0xLTEtMA_876cf79e-8f4f-475e-98f2-ced5cb1741a7"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie82d67a794864a96916fa3f3a87b1009_D20170101-20170930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzQtNC0xLTEtMA_74dc8fa0-36da-473d-96cf-642502101459"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i922b4063c16e435394fae5cdc427b832_D20170101-20170930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNDAvZnJhZzo5OWExODExODRkMmM0ZmY5YjU4ODcxMzI1NDRjOTc2MC90YWJsZTphNWRlYWE0YTk1YTQ0MmQ2OGY0ODZhNmYwMGE5NjI2Ny90YWJsZXJhbmdlOmE1ZGVhYTRhOTVhNDQyZDY4ZjQ4NmE2ZjAwYTk2MjY3XzQtNi0xLTEtMA_f2467f92-5105-4822-b46d-564ac8f16be1"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <dei:DocumentType
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xL2ZyYWc6ZjZiZDE4MzhkMTNkNGIxNGI2MjI3YjMwMjVkNDliNzgvdGV4dHJlZ2lvbjpmNmJkMTgzOGQxM2Q0YjE0YjYyMjdiMzAyNWQ0OWI3OF81NDk3NTU4MTU4MjA_db3b3318-a8fe-43fd-9c5b-8b823422137c">10-Q</dei:DocumentType>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i663eb470436c44d0b0424c19e8eab05c_I20181102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xL2ZyYWc6ZjZiZDE4MzhkMTNkNGIxNGI2MjI3YjMwMjVkNDliNzgvdGV4dHJlZ2lvbjpmNmJkMTgzOGQxM2Q0YjE0YjYyMjdiMzAyNWQ0OWI3OF8xOTA3_903c9f43-35c5-4313-ae35-10bf280212e2"
      unitRef="shares">42259080</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNC0xLTEtMS0w_01a5a890-2f57-42e3-a20d-48de6d902b18"
      unitRef="usd">201807000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNC0zLTEtMS0w_b43fd99f-a1db-4392-bad5-5d77bbb342b0"
      unitRef="usd">211727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNS0xLTEtMS0w_119ab845-2a1a-49d0-9dbb-cc194f664185"
      unitRef="usd">58336000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNS0zLTEtMS0w_c5352ddb-ef29-48ce-9300-bf584e9cd022"
      unitRef="usd">93394000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNi0xLTEtMS0w_0ac79038-4248-46dd-bcf7-4678d06fc05d"
      unitRef="usd">20970000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNi0zLTEtMS0w_631e4194-fd2a-40c0-a95e-e85e6aa6f81b"
      unitRef="usd">13643000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNy0xLTEtMS0w_7b72df1c-a32f-4b77-aef6-5670b8ab9076"
      unitRef="usd">4315000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfNy0zLTEtMS0w_efc9b429-eec8-4f84-98f8-ed0cde6098ba"
      unitRef="usd">3151000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssets
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfOC0xLTEtMS0w_256fd5bf-0326-491c-892f-baf04e8373b7"
      unitRef="usd">214000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfOC0zLTEtMS0w_ccac1129-d2f3-4bd9-9eaa-ac59fc46b0ec"
      unitRef="usd">383000</us-gaap:OtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfOS0xLTEtMS0w_8c378dfd-1087-4e6b-a8d3-eea8a6497d78"
      unitRef="usd">285642000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfOS0zLTEtMS0w_49b920c8-94dc-422b-83d3-10e61bb4a6d1"
      unitRef="usd">322298000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTAtMS0xLTEtMA_226f753c-6516-4b1f-9c88-6dc552035114"
      unitRef="usd">58649000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTAtMy0xLTEtMA_d1cf40c6-0fe1-4084-a70c-5f5c7fe0d7af"
      unitRef="usd">49983000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTItMS0xLTEtMA_0d4c5ec8-2439-44e5-9701-ba2cbd2f2494"
      unitRef="usd">11065000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTItMy0xLTEtMA_14c95eec-d98f-47ce-a39a-d46c9591a09a"
      unitRef="usd">1602000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTMtMS0xLTEtMA_8ed1d431-4699-43ff-994b-c6274ce59264"
      unitRef="usd">355356000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTMtMy0xLTEtMA_02bd552b-6bc8-4c3e-9a63-375b46fb12c5"
      unitRef="usd">373883000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTctMS0xLTEtMA_74df915a-cbda-4c51-8f4c-0647937d9648"
      unitRef="usd">986000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTctMy0xLTEtMA_4d256f77-3d3a-4322-b596-5514bbe00283"
      unitRef="usd">2451000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTgtMS0xLTEtMA_b76f2040-b963-46e5-9d83-a6691b23666c"
      unitRef="usd">38477000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTgtMy0xLTEtMA_ddc14542-0b7c-4000-83b9-7932b7c07c0b"
      unitRef="usd">38581000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTktMS0xLTEtMA_d126fd16-d01c-4f3b-a21e-2892d75fd093"
      unitRef="usd">7377000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMTktMy0xLTEtMA_ba56c708-4430-4126-bf04-34ed6794bd8c"
      unitRef="usd">7202000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjAtMS0xLTEtMA_ff581faa-6ba9-4986-abeb-40a47284405c"
      unitRef="usd">1010000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjAtMy0xLTEtMA_173611e3-c70e-4f92-ba0f-36e69a027041"
      unitRef="usd">1048000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjEtMS0xLTEtMA_044b7e7d-d1d1-45ee-9180-949cf5af146a"
      unitRef="usd">0</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjEtMy0xLTEtMA_21945281-c7b3-4560-9932-0b16611a19a3"
      unitRef="usd">298000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjItMS0xLTEtMA_1c47b099-b762-4a13-be12-32dfc816b713"
      unitRef="usd">175000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjItMy0xLTEtMA_10ea059b-867f-43bf-bda6-61efe49ac653"
      unitRef="usd">175000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjMtMS0xLTEtMA_6ad57b66-e52d-49fc-839c-59f8b63df8f4"
      unitRef="usd">48025000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjMtMy0xLTEtMA_9dbfc26e-e51f-4649-b598-54ffc2b800ef"
      unitRef="usd">49755000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjQtMS0xLTEtMA_9fa4cc9e-d32b-4036-98eb-8e2e7a1e19fc"
      unitRef="usd">14134000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjQtMy0xLTEtMA_050a213e-7a91-4ff2-9633-fd24933d7d90"
      unitRef="usd">13637000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjUtMS0xLTEtMA_1dd74b7b-11fe-44c8-9c65-ac05583b2d64"
      unitRef="usd">10553000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjUtMy0xLTEtMA_822bd73f-f030-42d0-9dd1-edb2993e8927"
      unitRef="usd">11253000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjctMS0xLTEtMA_b9a26fab-e1a2-4e2d-8a19-bc0b97b4390b"
      unitRef="usd">72712000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjctMy0xLTEtMA_d715f962-cc30-44cd-95aa-50314f830332"
      unitRef="usd">74645000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjktMS0xLTEtMA_f7be2d78-cd87-406b-aa7e-d69a829a50d8"
      unitRef="usd">422000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMjktMy0xLTEtMA_e4d01dc5-4c78-4b11-a8bb-01e55d4cfcc1"
      unitRef="usd">369000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzAtMS0xLTEtMA_04e93210-f951-433c-b88c-aaa2dbd4c17b"
      unitRef="usd">727849000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzAtMy0xLTEtMA_42579f69-4cc1-4327-aa65-f82974057e87"
      unitRef="usd">611270000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzEtMS0xLTEtMA_fc10cf2c-196d-4f1e-9322-b3523dec3503"
      unitRef="usd">-445627000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzEtMy0xLTEtMA_cf8b23cf-7dc0-450c-8251-ff648b26e9e5"
      unitRef="usd">-312340000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzItMS0xLTEtMA_72e8c292-bb13-4c3b-b863-b2e0e9aa23f0"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzItMy0xLTEtMA_0b70a78e-f20f-43ef-badf-707b2debbf90"
      unitRef="usd">-61000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzMtMS0xLTEtMA_2ebb9777-827c-42cb-aceb-2ccb8cfae39e"
      unitRef="usd">282644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzMtMy0xLTEtMA_c4e041d1-a9bd-447b-bc3e-b89e7db8f293"
      unitRef="usd">299238000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzQtMS0xLTEtMA_6cea2ab6-81d0-4e6b-8dbc-2c9b29bd9ba1"
      unitRef="usd">355356000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF83OC9mcmFnOmJkZjk4OGIyZTQ0ZjRiZTdiY2UzZjU0ZjNkYzFjOTM2L3RhYmxlOjU0Y2ViMjYyNDYyZjRhNTg5NmY1YTNhOTVkMzg4MzgyL3RhYmxlcmFuZ2U6NTRjZWIyNjI0NjJmNGE1ODk2ZjVhM2E5NWQzODgzODJfMzQtMy0xLTEtMA_1e2f7294-6eb5-4c8c-a280-5a6748349b76"
      unitRef="usd">373883000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ibdc22a390e884f349065805d8e43c679_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzMtMS0xLTEtMA_f483b115-8c67-4592-952e-e1e09b557846"
      unitRef="usd">20617000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44bef5523be840cea494b1c6a9b364fe_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzMtMy0xLTEtMA_80d7bed7-6661-44c1-b955-07a8a061aad2"
      unitRef="usd">1076000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44dcd64c130143e7b61b89fe2646000c_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzMtNS0xLTEtMA_b87b305f-83f1-4fe8-acd0-477e4bbb7f0a"
      unitRef="usd">43670000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf7551c75d6a4793b8ba11659882c30b_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzMtNy0xLTEtMA_2cab91ff-1e42-4ed9-b3ed-f8a48ab25d35"
      unitRef="usd">3435000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39a267842ce243189b28090dcf3b6338_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzQtMS0xLTEtMA_5bbe088a-3171-4993-8775-4003b946b082"
      unitRef="usd">181000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ccb567960f5405fb383ac91138849ca_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzQtMy0xLTEtMA_a51a4968-c25c-4da0-b4e5-0bbd0b03490a"
      unitRef="usd">587000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8497085013f24f54a1464c82acde208c_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzQtNS0xLTEtMA_269d8e84-10de-4811-80cb-c78040aebd22"
      unitRef="usd">657000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ca90c5a445d4c77b930deb2ab301751_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzQtNy0xLTEtMA_0d333e4f-8a0f-4494-b844-5b7d46874fa0"
      unitRef="usd">1948000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzUtMS0xLTEtMA_4052e386-11dd-4a38-8798-a7595ea7a393"
      unitRef="usd">20798000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzUtMy0xLTEtMA_0a793e95-4279-4a24-a2b9-9f2ca533c835"
      unitRef="usd">1663000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzUtNS0xLTEtMA_a8d4c8f8-b456-4104-9f21-e93a2bbedafc"
      unitRef="usd">44327000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzUtNy0xLTEtMA_1a96693d-ae97-4270-a20b-0066779bb0ba"
      unitRef="usd">5383000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzctMS0xLTEtMA_0af18095-747a-4545-bf1e-8978357d092b"
      unitRef="usd">46218000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzctMy0xLTEtMA_80abe055-11c1-4463-bd4d-a93a198782c3"
      unitRef="usd">40984000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzctNS0xLTEtMA_3a143af4-f00d-424a-851d-c57b70560754"
      unitRef="usd">143902000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzctNy0xLTEtMA_0d255c1e-4ac2-4fd6-90af-addd5efcbf70"
      unitRef="usd">108246000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzgtMS0xLTEtMA_685ad280-f4c1-48c8-ab0a-bf3282606dcf"
      unitRef="usd">9584000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzgtMy0xLTEtMA_91220371-0ec6-4c73-bf64-e991bef78281"
      unitRef="usd">8403000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzgtNS0xLTEtMA_905836b1-259c-4511-88b0-dfd692811bda"
      unitRef="usd">29953000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzgtNy0xLTEtMA_9a173afd-b5f3-4030-95c2-b4a0130bb6a0"
      unitRef="usd">24249000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzktMS0xLTEtMA_e93f21ab-57f1-436a-935c-4e9f5a83ee01"
      unitRef="usd">55802000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzktMy0xLTEtMA_f1070e43-0887-48fd-972b-cfe4d08ba52c"
      unitRef="usd">49387000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzktNS0xLTEtMA_b474c5cd-d320-4032-958a-8b0c5896d1c8"
      unitRef="usd">173855000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzktNy0xLTEtMA_d47a67c0-5b36-440f-9d1b-5f192006fd02"
      unitRef="usd">132495000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEwLTEtMS0xLTA_552bc115-8576-42df-acf5-c63b0e8183dc"
      unitRef="usd">-35004000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEwLTMtMS0xLTA_4f92a168-274b-4e13-8203-d6ea15e657c0"
      unitRef="usd">-47724000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEwLTUtMS0xLTA_7fd0bf93-2e90-4750-bebc-50da4e1ae575"
      unitRef="usd">-129528000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEwLTctMS0xLTA_8a44e2b9-279b-4b7d-851a-371b6dafeb06"
      unitRef="usd">-127112000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzExLTEtMS0xLTA_bc3a236a-f467-447c-835a-5778020c9f2b"
      unitRef="usd">975000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzExLTMtMS0xLTA_3476098a-7c18-4f16-be6b-16954f4c1762"
      unitRef="usd">681000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzExLTUtMS0xLTA_0c44de19-9447-4e02-975e-b355f51bf226"
      unitRef="usd">2719000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzExLTctMS0xLTA_6f38ef8b-2521-4bfd-ac12-6f87c73193c2"
      unitRef="usd">1759000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEyLTEtMS0xLTA_25f29189-de39-43d4-98a3-563404caa052"
      unitRef="usd">-34029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEyLTMtMS0xLTA_0b0cae66-e19b-4377-9f95-35f474ea5f09"
      unitRef="usd">-47043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEyLTUtMS0xLTA_6cc02ada-7edf-4242-b02a-ed33b520ba05"
      unitRef="usd">-126809000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzEyLTctMS0xLTA_3fb0ec44-b72c-42ee-b9df-90582333ba60"
      unitRef="usd">-125353000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE0LTEtMS0xLTA_af011db1-156d-448a-8d51-181a57c22259"
      unitRef="usd">-18000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE0LTMtMS0xLTA_abe8e2cf-d27a-4fc6-9965-1b9514ad878f"
      unitRef="usd">56000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE0LTUtMS0xLTA_ddca6e13-0de3-476c-82eb-332d9da1a496"
      unitRef="usd">61000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE0LTctMS0xLTA_e9e3bf05-2322-42ef-9833-39494711bd50"
      unitRef="usd">55000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE1LTEtMS0xLTA_889bea93-c50a-4452-a30c-dba5855a9e55"
      unitRef="usd">-34047000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE1LTMtMS0xLTA_5b2fba60-d47c-4de9-ab7d-c529001cf402"
      unitRef="usd">-46987000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE1LTUtMS0xLTA_adb5a135-df8b-457e-b876-eab3969eca71"
      unitRef="usd">-126748000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE1LTctMS0xLTA_dbdfa9aa-d1e7-41d5-a131-4b6a04f3e04b"
      unitRef="usd">-125298000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE5LTEtMS0xLTA_56c8fb33-443d-4ac3-bc1a-b531607a97a1"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE5LTMtMS0xLTA_e9f95c1f-bb6b-4699-96d8-c73e02a3fc94"
      unitRef="usdPerShare">-1.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE5LTUtMS0xLTA_648f972c-b8c8-4929-a066-e11d8384982d"
      unitRef="usdPerShare">-3.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzE5LTctMS0xLTA_48073963-ff0c-465f-9e6e-7215c2ec5f60"
      unitRef="usdPerShare">-3.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzIxLTEtMS0xLTA_6e8b6223-f450-4055-b6ee-40de7d912da4"
      unitRef="shares">42239327</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzIxLTMtMS0xLTA_a65ac833-92d1-4f8a-b3e6-8e053d2cae2e"
      unitRef="shares">36779305</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzIxLTUtMS0xLTA_a285eb99-0eaa-48ca-ba68-48be409bd68e"
      unitRef="shares">40462658</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMDQvZnJhZzpkMjAzOGNjMWIxNWE0MjYwYTBmNmE4YzNiZjY3NmZiMC90YWJsZToxZmZlYTNjYzAyNGE0ZDFiOGU1YThhMmM4NDQ1ZWU0Ny90YWJsZXJhbmdlOjFmZmVhM2NjMDI0YTRkMWI4ZTVhOGEyYzg0NDVlZTQ3XzIxLTctMS0xLTA_828ac9d9-aca3-40ef-89a5-c634067f76bf"
      unitRef="shares">35847449</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzMtMS0xLTEtMA_a6f51422-ec2a-4d01-b41b-0ae990b25b1c"
      unitRef="usd">-126809000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzMtMy0xLTEtMA_16dff779-ac91-457c-9c93-17b89fcc92c6"
      unitRef="usd">-125353000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzUtMS0xLTEtMA_be77cb27-0fd3-4b6e-9e46-f68807604d02"
      unitRef="usd">5268000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzUtMy0xLTEtMA_675806b5-e813-4312-9a22-28ff160f61ec"
      unitRef="usd">5886000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzYtMS0xLTEtMA_a557bb80-879b-448c-8a6f-ec72e71d07b4"
      unitRef="usd">12168000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzYtMy0xLTEtMA_5bf473c7-9d29-4590-aa97-a6dd780c8ddd"
      unitRef="usd">11064000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzgtMS0xLTEtMA_433c32d2-5373-49bc-9400-7e8b6c547b51"
      unitRef="usd">7328000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzgtMy0xLTEtMA_5bafca07-25c0-4fd8-8e75-a05473084c02"
      unitRef="usd">-570000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzktMS0xLTEtMA_8fe4ea31-fc35-4dc8-915a-f5ae8d56496f"
      unitRef="usd">1164000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzktMy0xLTEtMA_4b9cb0f5-bfa0-4bae-8014-9f8df3dab75d"
      unitRef="usd">-222000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEwLTEtMS0xLTA_fe14d147-1e27-4772-bb85-e50988c474c3"
      unitRef="usd">9293000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEwLTMtMS0xLTA_a123a822-a000-43ba-a51d-c95f121bfc78"
      unitRef="usd">-168000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzExLTEtMS0xLTA_bc773a80-8547-47bd-a400-21d7dea5ceef"
      unitRef="usd">-1465000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzExLTMtMS0xLTA_d8e80c93-b02f-4790-9c3a-686c067cdd6f"
      unitRef="usd">-2138000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEyLTEtMS0xLTA_efcb7ef6-ea3d-4d32-8ad9-0e472f9593f7"
      unitRef="usd">9460000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEyLTMtMS0xLTA_7f6807b1-f1cd-4ed7-bb6d-bd7f25ea7990"
      unitRef="usd">9501000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInRestructuringReserve
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEzLTEtMS0xLTA_06ffaa38-90c7-46be-a13e-b83e1695b197"
      unitRef="usd">-298000</us-gaap:IncreaseDecreaseInRestructuringReserve>
    <us-gaap:IncreaseDecreaseInRestructuringReserve
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzEzLTMtMS0xLTA_b3661e6e-9908-49dd-bb73-2a722cd0f11f"
      unitRef="usd">-1176000</us-gaap:IncreaseDecreaseInRestructuringReserve>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE0LTEtMS0xLTA_e0aa1a88-c8d0-4c50-81bf-61dfac57dc7c"
      unitRef="usd">-5807000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE0LTMtMS0xLTA_07dd61f6-e4e5-42e8-ba71-1fa298b3c9ea"
      unitRef="usd">-2666000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE1LTEtMS0xLTA_e4767ca3-44fe-40e3-98c4-c1f804769c7a"
      unitRef="usd">-738000</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE1LTMtMS0xLTA_cc5799c9-132e-46d8-8e95-5796030eb450"
      unitRef="usd">6482000</mgnx:IncreaseDecreaseInDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE2LTEtMS0xLTA_de51f8c6-f5f9-4034-9a58-4ecdb79aac8e"
      unitRef="usd">-126006000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE2LTMtMS0xLTA_9e0c9262-5de2-4618-a3f8-5a303fad4a4c"
      unitRef="usd">-97440000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE4LTEtMS0xLTA_29980300-c1ea-4ec0-945a-56d5c85307eb"
      unitRef="usd">120039000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE4LTMtMS0xLTA_5094ab42-4e2c-4535-9275-18e88720a124"
      unitRef="usd">89124000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE5LTEtMS0xLTA_f05fdb4a-cdfb-4151-8f9c-eb0bad5baf86"
      unitRef="usd">155848000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzE5LTMtMS0xLTA_cc9d4ece-aea1-41de-a76d-84fa0487717e"
      unitRef="usd">177006000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIwLTEtMS0xLTA_6d06e949-1077-42e0-a802-e1880570d936"
      unitRef="usd">24239000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIwLTMtMS0xLTA_ddec8e7b-0cf3-4f8d-811b-5696e0038b03"
      unitRef="usd">18645000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIxLTEtMS0xLTA_594282a4-100e-4f11-897f-2c1cab94a64b"
      unitRef="usd">11570000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIxLTMtMS0xLTA_3d660e02-c672-4c34-93d4-0af19ecf066e"
      unitRef="usd">69237000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIzLTEtMS0xLTA_c24ee5db-5ea2-4f36-a57b-b0c6d59c190d"
      unitRef="usd">103259000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzIzLTMtMS0xLTA_e1c3cc9d-15d9-4622-ab6c-3f58673310ef"
      unitRef="usd">34294000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI0LTEtMS0xLTA_cc3dbeeb-5dd9-4abf-b06d-6a1b6cc42f25"
      unitRef="usd">1257000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI0LTMtMS0xLTA_4a7a4d1f-9f2b-4582-ab1f-5aa0da3a0e10"
      unitRef="usd">695000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI1LTEtMS0xLTA_1c00c850-390e-4b41-845c-5ee83ffccc96"
      unitRef="usd">104516000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI1LTMtMS0xLTA_4319e828-1d94-4365-956e-837ecdb0d26c"
      unitRef="usd">34989000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI2LTEtMS0xLTA_ff94fe7b-daac-41aa-be52-292dc57966e1"
      unitRef="usd">-9920000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI2LTMtMS0xLTA_30b40b5b-9559-4068-ad65-5b5edd352a0c"
      unitRef="usd">6786000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI3LTEtMS0xLTA_fd1bf7e5-1b7d-4556-b8c5-938f3cca50d2"
      unitRef="usd">211727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i20a775ac09b1433ab3a29927f84e27f2_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI3LTMtMS0xLTA_961cbac6-a290-4c64-9194-92a0f29a45d8"
      unitRef="usd">84098000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI4LTEtMS0xLTA_5dcf204d-79b8-424e-b982-6618e44b3498"
      unitRef="usd">201807000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5f061d896ab34adea1ec90f8ea217749_I20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzI4LTMtMS0xLTA_b00d9e91-fbe7-46fa-b5e0-454e54b15c6d"
      unitRef="usd">90884000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzMwLTEtMS0xLTA_46115dfe-9aa7-4397-8dfe-a66f6b5d2925"
      unitRef="usd">6130000</mgnx:FairValueOfWarrantsReceived>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xMTYvZnJhZzo4ZTlkNDBlOTMzZGI0NzQ0OTc1YzE2ZmJkNGVhOGRhNS90YWJsZTpmZTQxZDY4MTQzMmQ0MTMyOThlMzdjMjEzZjM5NGVjYS90YWJsZXJhbmdlOmZlNDFkNjgxNDMyZDQxMzI5OGUzN2MyMTNmMzk0ZWNhXzMwLTMtMS0xLTA_543194e3-fb61-4167-a235-96dbd3649f34"
      unitRef="usd">0</mgnx:FairValueOfWarrantsReceived>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY5MDE_16100cd4-d7af-4f1c-bb2f-785e2eb68aba">Basis of Presentation and Significant Accounting Policies&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2017 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:5pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;With the exception of the adoption of Accounting Standards Update (ASU) No. 2014-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; and all related amendments (collectively ASC 606) during the nine months ended September 30, 2018, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Effective January 1, 2018, the Company adopted ASC 606 using the modified retrospective transition method. Under this method, results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;accounting standards in effect for the period presented&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. The Company applied the modified retrospective transition method only to contracts that were not completed as of January 1, 2018, the effective date of adoption for ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company also enters into manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Licenses. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Customer Options. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement, and the potential payments that the Company is eligible to receive upon exercise of the options are excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Royalties. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 5, Collaboration and Other Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2014, the Financial Accounting Standards Board (FASB) issued ASC 606. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts that were not completed as of January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with available practical expedients.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Comparative prior period information continues to be reported under the accounting standards in effect for the period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.465593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.678477%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Pre-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;ASC 606 Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Post-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(312,340)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,479)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(318,819)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The transition adjustment resulted primarily from changes in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;the pattern of revenue recognition for upfront fees and the accounting for milestones.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:232%;"&gt;The following table shows the impact of adoption to our consolidated statement of income and balance sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.199706%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096916%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.942731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.292217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances without adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from collaborative agreements&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,029)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances without adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from collaborative agreements&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(126,809)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(127,214)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(405)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances without adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, current&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, net of current portion&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(445,627)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(439,554)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,073)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table presents changes in the Company&#x2019;s contract liabilities during the nine months ended&#160;September&#160;30, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.024963%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.397944%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.572687%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.271659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at Beginning of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at End of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160; Deferred revenue (current and non-current)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,307)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;During the nine months ended&#160;September&#160;30, 2018, the Company recognized $6.3 million in revenue as a result of changes in the contract liability balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Compensation &#x2013; Stock Compensation (Topic 718): Scope Modification Accounting&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. The new standard is intended to reduce the diversity in practice and cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard was effective beginning January 1, 2018. The adoption of this standard did not have a material impact on the Company&#x2019;s financial position or results of operations upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued&#160;ASU 2018-11,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Leases (Topic 842): Targeted Improvements,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Codification Improvements to Topic 842, Leases,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#x2019;s fiscal year beginning January 1, 2019. Although early&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; adoption is permitted, the Company has not elected to do so.  The Company plans to&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:115%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; carryforward of the historical lease classification.&lt;/span&gt; Based on its anticipated election of practical expedients, the Company anticipates the recognition of right of use assets and related lease liabilities on its consolidated balance sheets related to its leases.  The Company has engaged a professional services firm to assist in the implementation of ASC 842, and is completing its analysis of the impact of adopting ASC 842 on its consolidated statements of income and comprehensive income and consolidated balance sheets.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY4OTY_4ad49fde-f39c-4b67-9412-c78d906a5421">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2017 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY4OTc_881265af-c16e-4420-ba30-b39eee40634b">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Effective January 1, 2018, the Company adopted ASC 606 using the modified retrospective transition method. Under this method, results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;accounting standards in effect for the period presented&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. The Company applied the modified retrospective transition method only to contracts that were not completed as of January 1, 2018, the effective date of adoption for ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company also enters into manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Licenses. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Customer Options. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement, and the potential payments that the Company is eligible to receive upon exercise of the options are excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Royalties. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY5MDA_db22a2db-f8ee-4c08-b72e-d1277bc0728b">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2014, the Financial Accounting Standards Board (FASB) issued ASC 606. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts that were not completed as of January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with available practical expedients.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Comparative prior period information continues to be reported under the accounting standards in effect for the period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.465593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.678477%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Pre-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;ASC 606 Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Post-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(312,340)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,479)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(318,819)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The transition adjustment resulted primarily from changes in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;the pattern of revenue recognition for upfront fees and the accounting for milestones.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:232%;"&gt;The following table shows the impact of adoption to our consolidated statement of income and balance sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.199706%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096916%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.942731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.292217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances without adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from collaborative agreements&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,029)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances without adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from collaborative agreements&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(126,809)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(127,214)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(405)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances without adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, current&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, net of current portion&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(445,627)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(439,554)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,073)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table presents changes in the Company&#x2019;s contract liabilities during the nine months ended&#160;September&#160;30, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.024963%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.397944%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.572687%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.271659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at Beginning of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at End of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160; Deferred revenue (current and non-current)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,307)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;During the nine months ended&#160;September&#160;30, 2018, the Company recognized $6.3 million in revenue as a result of changes in the contract liability balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Compensation &#x2013; Stock Compensation (Topic 718): Scope Modification Accounting&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. The new standard is intended to reduce the diversity in practice and cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard was effective beginning January 1, 2018. The adoption of this standard did not have a material impact on the Company&#x2019;s financial position or results of operations upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued&#160;ASU 2018-11,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Leases (Topic 842): Targeted Improvements,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Codification Improvements to Topic 842, Leases,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#x2019;s fiscal year beginning January 1, 2019. Although early&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; adoption is permitted, the Company has not elected to do so.  The Company plans to&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:115%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; carryforward of the historical lease classification.&lt;/span&gt; Based on its anticipated election of practical expedients, the Company anticipates the recognition of right of use assets and related lease liabilities on its consolidated balance sheets related to its leases.  The Company has engaged a professional services firm to assist in the implementation of ASC 842, and is completing its analysis of the impact of adopting ASC 842 on its consolidated statements of income and comprehensive income and consolidated balance sheets.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY4OTg_ff5e61e8-f9c0-4984-af54-5d570e6de58d">&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.465593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.678477%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Pre-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;ASC 606 Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Post-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(312,340)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,479)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(318,819)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The transition adjustment resulted primarily from changes in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;the pattern of revenue recognition for upfront fees and the accounting for milestones.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:232%;"&gt;The following table shows the impact of adoption to our consolidated statement of income and balance sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.199706%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096916%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.942731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.292217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances without adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from collaborative agreements&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,029)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances without adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from collaborative agreements&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(126,809)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(127,214)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(405)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances without adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, current&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, net of current portion&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(445,627)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(439,554)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,073)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:DeferredRevenueCurrent
      contextRef="if800a2edba02435c841fd5ce6f7aada7_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzEtMS0xLTEtMA_e1303155-9dd9-4165-97ad-5b1528e357be"
      unitRef="usd">7202000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ibb6469bec1ea4f8ca65fdad40040b929_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzEtMy0xLTEtMA_0ff616ce-7b26-422a-b689-97c6736dc352"
      unitRef="usd">540000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i6bab00c844a44b45bc42e1f5791cae02_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzEtNS0xLTEtMA_60eee4a2-f050-488e-b841-316adb633766"
      unitRef="usd">7742000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="if800a2edba02435c841fd5ce6f7aada7_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzItMS0xLTEtMA_b23acd0f-886f-4da8-9c60-a18f50434559"
      unitRef="usd">13637000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ibb6469bec1ea4f8ca65fdad40040b929_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzItMy0xLTEtMA_bff5b623-9f60-4e32-bda0-0ad28203346f"
      unitRef="usd">5939000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i6bab00c844a44b45bc42e1f5791cae02_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzItNS0xLTEtMA_2c53ed68-829b-4304-83fa-61432f25d711"
      unitRef="usd">19576000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if800a2edba02435c841fd5ce6f7aada7_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzMtMS0xLTEtMA_f8ad88b5-b9ce-4071-9eef-e64d6ca9bcda"
      unitRef="usd">-312340000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibb6469bec1ea4f8ca65fdad40040b929_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzMtMy0xLTEtMA_772b567f-49c9-4303-9354-2b2ef7328224"
      unitRef="usd">-6479000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6bab00c844a44b45bc42e1f5791cae02_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZToxMDBhMGEzMmUxM2U0M2RmYTM0ODJjMGY3MjlmMDVhMy90YWJsZXJhbmdlOjEwMGEwYTMyZTEzZTQzZGZhMzQ4MmMwZjcyOWYwNWEzXzMtNS0xLTEtMA_7acf6a7a-e608-480d-8b39-de0e89b14446"
      unitRef="usd">-318819000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Revenues
      contextRef="ibdc22a390e884f349065805d8e43c679_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzItMS0xLTEtMA_f483b115-8c67-4592-952e-e1e09b557846"
      unitRef="usd">20617000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d979866d3b64e8ba979cb9f915e748f_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzItMy0xLTEtMA_e3fa7d98-600f-48c8-a2ac-27b1e505b41b"
      unitRef="usd">20482000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f5fdced0c8347e9aa3943f81e9837f6_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzItNS0xLTEtMA_36e37e06-7d3c-4fad-b90f-70eb5f8d22e4"
      unitRef="usd">135000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzMtMS0xLTEtMA_25f29189-de39-43d4-98a3-563404caa052"
      unitRef="usd">-34029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i87517407dd334c3893ac19538b16fd3e_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzMtMy0xLTEtMA_eacf7c6c-a77d-4e98-b9bf-0ab98df15ed7"
      unitRef="usd">-34164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8bedc85266654eaab2882c9503e960e8_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzMtNS0xLTEtMA_f0f45a2d-9000-4c0b-917d-c98037f1226e"
      unitRef="usd">-135000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i87517407dd334c3893ac19538b16fd3e_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzQtMy0xLTEtMA_aa59d8e9-81c7-4c2b-9205-edf76e80f25a"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8bedc85266654eaab2882c9503e960e8_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzQtNS0xLTEtMA_40a4a2db-9433-4e03-a1f2-4a6ad1063e55"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:Revenues
      contextRef="i44dcd64c130143e7b61b89fe2646000c_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzgtMS0xLTEtMA_b87b305f-83f1-4fe8-acd0-477e4bbb7f0a"
      unitRef="usd">43670000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b5ededd31534749ab8242be3126e5b2_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzgtMy0xLTEtMA_570efece-079e-4f45-9d99-7c909ea0f057"
      unitRef="usd">43265000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib492f638d82e4414a041403e1eddbe3a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzgtNS0xLTEtMA_e11548c5-4cd7-4664-bcd8-a4e0e372d2f4"
      unitRef="usd">405000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzktMS0xLTEtMA_6cc02ada-7edf-4242-b02a-ed33b520ba05"
      unitRef="usd">-126809000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if9d0da9b4cc14b75991174bfa7e7e7e0_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzktMy0xLTEtMA_69d0a567-12cf-496a-a87e-c07b7d424bcf"
      unitRef="usd">-127214000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2083d2f9a48048808e8f2445e7f65ceb_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzktNS0xLTEtMA_01e11b0b-170c-4c72-8b4a-4ba5ff7acb6e"
      unitRef="usd">-405000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if9d0da9b4cc14b75991174bfa7e7e7e0_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzEwLTMtMS0xLTA_ec2e2e36-3867-43ab-a9fe-7ab4cd69d9df"
      unitRef="usdPerShare">-3.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i2083d2f9a48048808e8f2445e7f65ceb_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzEwLTUtMS0xLTA_f34dcf7e-78dd-451a-98a7-8ddf37988a4b"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE0LTEtMS0xLTA_fd7397f6-e2c5-47fd-bfbd-52172a6f0918"
      unitRef="usd">7377000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i5c61aa06ff0442f384bef16716c9e006_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE0LTMtMS0xLTA_ccbd26c2-9688-47a4-8b6e-b772db836052"
      unitRef="usd">6348000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i8dd177baefb24c5da5f5d762ca97c05a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE0LTUtMS0xLTA_99b45716-ec81-4716-85c8-a7d8efcb9581"
      unitRef="usd">1029000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE1LTEtMS0xLTA_ffe14252-0b3e-4bae-a8d3-8a081558223c"
      unitRef="usd">14134000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i5c61aa06ff0442f384bef16716c9e006_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE1LTMtMS0xLTA_46187e98-aae8-4931-b91a-e59b763cbc71"
      unitRef="usd">9090000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i8dd177baefb24c5da5f5d762ca97c05a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE1LTUtMS0xLTA_55cd3c1d-cbb2-4316-a8c9-b3a6abe6a5b9"
      unitRef="usd">5044000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE2LTEtMS0xLTA_fc10cf2c-196d-4f1e-9322-b3523dec3503"
      unitRef="usd">-445627000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5c61aa06ff0442f384bef16716c9e006_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE2LTMtMS0xLTA_741abb7b-8b62-41af-814d-5f052238ab8d"
      unitRef="usd">-439554000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8dd177baefb24c5da5f5d762ca97c05a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTowYWQ3OGMzZDFmYzU0ZjU2OTk2YjIyNWI2NjIyODMxZC90YWJsZXJhbmdlOjBhZDc4YzNkMWZjNTRmNTY5OTZiMjI1YjY2MjI4MzFkXzE2LTUtMS0xLTA_e337870d-ab6f-40b2-80d3-efe3fb8d86ce"
      unitRef="usd">6073000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzI3NDg3NzkwODY4OTk_bf04abf3-1bfd-4fea-b053-5bc5e1c5b6e6">&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table presents changes in the Company&#x2019;s contract liabilities during the nine months ended&#160;September&#160;30, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.024963%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.397944%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.572687%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.271659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at Beginning of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at End of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160; Deferred revenue (current and non-current)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,307)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTo4OWRmOTQwMjI4ZDQ0Yzg1OTE2M2Y2YWQzNTY4MTFkNi90YWJsZXJhbmdlOjg5ZGY5NDAyMjhkNDRjODU5MTYzZjZhZDM1NjgxMWQ2XzEtMS0xLTEtMA_49d20922-7d36-4a25-a52c-5f6e1933e55a"
      unitRef="usd">27318000</us-gaap:ContractWithCustomerLiability>
    <mgnx:ContractWithCustomerLiabilityIncreasefromCashReceipts
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTo4OWRmOTQwMjI4ZDQ0Yzg1OTE2M2Y2YWQzNTY4MTFkNi90YWJsZXJhbmdlOjg5ZGY5NDAyMjhkNDRjODU5MTYzZjZhZDM1NjgxMWQ2XzEtMy0xLTEtMA_17d8d350-7004-4ffc-b185-2c6426e59136"
      unitRef="usd">500000</mgnx:ContractWithCustomerLiabilityIncreasefromCashReceipts>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTo4OWRmOTQwMjI4ZDQ0Yzg1OTE2M2Y2YWQzNTY4MTFkNi90YWJsZXJhbmdlOjg5ZGY5NDAyMjhkNDRjODU5MTYzZjZhZDM1NjgxMWQ2XzEtNS0xLTEtMA_a16afa38-da35-416b-b648-b0be3b4bdeff"
      unitRef="usd">6307000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90YWJsZTo4OWRmOTQwMjI4ZDQ0Yzg1OTE2M2Y2YWQzNTY4MTFkNi90YWJsZXJhbmdlOjg5ZGY5NDAyMjhkNDRjODU5MTYzZjZhZDM1NjgxMWQ2XzEtNy0xLTEtMA_9635cf8f-6e57-45dc-ad21-973d8a453075"
      unitRef="usd">21511000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNDIvZnJhZzo4NDk1NmYwZmUxODU0ZjM4YWMyNTI2ZTI2Mzc0NDYxNy90ZXh0cmVnaW9uOjg0OTU2ZjBmZTE4NTRmMzhhYzI1MjZlMjYzNzQ0NjE3XzE1MDAw_9d9b1884-1742-4c09-b354-bbfd65429883"
      unitRef="usd">6300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzI3NDg3NzkwNzI2Njc_11d63d3e-75dc-42e9-bb45-063b581cce98">Fair Value of Financial Instruments&lt;div style="text-indent:36pt;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued expenses and common stock warrants.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The carrying amount of accounts receivable, accounts payable&#160;and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#x2022;    Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#x2022;    Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#x2022;    Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.633284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted Prices in Active Markets for Identical Assets&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Other Observable Inputs&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Unobservable Inputs&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.323529%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted Prices in Active Markets for Identical Assets&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Other Observable Inputs&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Unobservable Inputs&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(&lt;/sup&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;b&lt;/sup&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;(a) Total assets measured at fair value at September&#160;30, 2018 includes approximately $99.8 million reported in cash and cash equivalents and $6.1 million reported in other assets on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $62.5 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model.  There were no transfers between levels during the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzI3NDg3NzkwNzI2NjY_b9195884-b4a6-46db-b4bc-5952eeb527ac">&lt;div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.633284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted Prices in Active Markets for Identical Assets&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Other Observable Inputs&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Unobservable Inputs&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.323529%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted Prices in Active Markets for Identical Assets&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Other Observable Inputs&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Unobservable Inputs&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(&lt;/sup&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;b&lt;/sup&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;(a) Total assets measured at fair value at September&#160;30, 2018 includes approximately $99.8 million reported in cash and cash equivalents and $6.1 million reported in other assets on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $62.5 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i671934b6ca254466884554fbd72599a7_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzQtMS0xLTEtMA_aeb48ee7-a750-470d-8566-86eefcb2c7d5"
      unitRef="usd">99808000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i50ec2c1d0e4f4f05bf9e358137601c56_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzQtMy0xLTEtMA_74eaa013-5e5c-42a5-874c-0fabd1dfb71b"
      unitRef="usd">99808000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic80626a5f83c4f92b03a719528d899b3_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzQtNS0xLTEtMA_c3aab82f-d260-40f9-95a4-30c9e128b36c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5643f6cec2de4538bc34d86d7a1d42ef_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzQtNy0xLTEtMA_e05aa072-fe75-411e-8c1d-8b41063c9a7f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i588e913554c54d489854f5d7b18643f3_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzUtMS0xLTEtMA_bd314f2c-6a2e-43ab-a921-c97e20e080ac"
      unitRef="usd">3996000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ic5e44fd3fe174432a63b857d20d62cb9_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzUtMy0xLTEtMA_5fc47543-415e-4d3e-b7a0-3edc24be5604"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i5394f3e223d14c0f9d447b8dba062cc7_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzUtNS0xLTEtMA_3d44db94-c338-4dcd-9c2d-f970c88a8264"
      unitRef="usd">3996000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i3a504713132440edac1e257a897cfc5e_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzUtNy0xLTEtMA_0b9a1bf0-7c7f-4b57-a270-3b20c75bb485"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i01e4f28d5a2f4d8ba5410cb06f830efb_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzYtMS0xLTEtMA_dd6d049f-03f2-470a-8d82-6afc6f3d0ce4"
      unitRef="usd">5477000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i8dc0a6957b1049d1a7fd2aca4546de77_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzYtMy0xLTEtMA_f8b2d393-e5fe-41d3-82a6-7df7eda40bfe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i60a9918f2b454a02a9f52660bcfd9700_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzYtNS0xLTEtMA_1d1dee45-433e-4358-9516-df0bbb263adf"
      unitRef="usd">5477000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i154046cc71f34152877eaec79ccfc61b_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzYtNy0xLTEtMA_bb61430e-96ed-42d1-a4cc-cb5f8b25d4b0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i14e72fa606524cb6811b76c6b57eb806_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzctMS0xLTEtMA_9bf174c1-d179-4838-bab3-2091f43756f9"
      unitRef="usd">48863000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i94648d0db7a94b95bcaa11b425cfe7af_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzctMy0xLTEtMA_5da9f803-d2b6-4bee-aa56-1d8ae38106bf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i3518f59ae82e4ef582788fe57cbcd3e0_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzctNS0xLTEtMA_0cafb812-edec-45ac-845e-7f6a181b56c1"
      unitRef="usd">48863000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="id0e9852ab63b4061801c673b10dcb0cd_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzctNy0xLTEtMA_c84d2bdd-9420-4eb0-8559-090c0abf6b89"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i39e27978db3d429bb2846824cbb065da_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzgtMS0xLTEtMA_3603a312-f805-4046-9b22-0a65257c6193"
      unitRef="usd">6130000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ice6b9ff22ede4845b89261faf1de4b00_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzgtMy0xLTEtMA_cee21f9e-503c-48f9-bcb2-00d83e3e012c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="id0fa81042e394b329de76ce95f09cff5_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzgtNS0xLTEtMA_53b76532-6d78-4f2d-86cb-18a71f75033c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ice63152ef2424cc4a9579cbdc1d6240e_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzgtNy0xLTEtMA_1e79b0dc-14b0-4298-b2c9-31c993e8f5a6"
      unitRef="usd">6130000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i723d050a26224f16a353738eb4442e04_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzktMS0xLTEtMA_cf1bbbe6-8889-4b13-9dba-4391de6dab5c"
      unitRef="usd">164274000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9d77208352f4d25bf386d786bc798cd_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzktMy0xLTEtMA_11485743-0191-4456-be4f-ebbf2afd5744"
      unitRef="usd">99808000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icd4f120866b645c4bf3cce8586698473_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzktNS0xLTEtMA_1e0471ee-b780-44c2-8599-d0401c002c6a"
      unitRef="usd">58336000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaadfc51e828143479b2403579738eaff_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZToxZWE2YjM5MWQ5M2I0ZGIwYmY5ZTJlODY4NzdmYTI3NS90YWJsZXJhbmdlOjFlYTZiMzkxZDkzYjRkYjBiZjllMmU4Njg3N2ZhMjc1XzktNy0xLTEtMA_96e19dac-19f9-43ff-aeee-25ce07f35081"
      unitRef="usd">6130000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i60c4cc1bdf234cf987926cd8055b2734_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzQtMS0xLTEtMA_d80f100a-eb8a-4e33-a109-d23622504c60"
      unitRef="usd">61512000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f0eeb462be349aea122b32abf38ffa1_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzQtMy0xLTEtMA_57ffcd40-91ec-4a70-a12b-5022f308f7be"
      unitRef="usd">61512000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idd2a21b952a4442dbd5213ed0c13c412_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzQtNS0xLTEtMA_d3e87bd3-f0fe-4059-8a0d-9df5ae313eaa"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9ef68251110c449f86e8dd7547298305_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzQtNy0xLTEtMA_030c08cb-86bc-42b5-8614-0f78fc133290"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i0d1c05ab7cef41bda60ce9805aa4b8d6_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzUtMS0xLTEtMA_068c4af6-f295-4613-a96c-444896c61e22"
      unitRef="usd">3990000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i9a7580bc237e44bba24dcaac666b17bd_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzUtMy0xLTEtMA_da7bb9df-045c-4812-8db4-f406ea22d5e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i7c92391cb5f04624be95aa6135f9c5e0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzUtNS0xLTEtMA_e525ccbf-1f6a-4e12-adf0-0459672e4589"
      unitRef="usd">3990000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i6626efe68b914e4aa0c4c00a038ca6fb_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzUtNy0xLTEtMA_fec6f73a-0a66-477e-9034-33ae8c33420e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i5b810da2b4434106be6a2f4868aa983b_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzYtMS0xLTEtMA_c0e60d7f-ca2a-4fba-b0c7-18b5c6307ef0"
      unitRef="usd">11990000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i22f5d3be38314de693952411eb401367_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzYtMy0xLTEtMA_fc70dba0-f13b-4ce8-983b-3cdf155754c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ie8ab2c156a8d47f5b370a57673a58703_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzYtNS0xLTEtMA_9718927d-a171-4071-91ca-f3baa5c8d484"
      unitRef="usd">11990000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i375187cfa8df4fac956142beb3307c5e_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzYtNy0xLTEtMA_d00f4ff7-c553-4fb9-823e-697b0972bc25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="iadea8e8fa97d481495bfa26ed8bcb2e8_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzctMS0xLTEtMA_86d8e245-0f20-43f0-a382-c1e26ca2534b"
      unitRef="usd">78418000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ie4e22d2b5dd8454fbebfa09f3feb0749_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzctMy0xLTEtMA_8007b457-bad1-4aca-be0d-854516dd2b02"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i39b863145a6442bfa00fd78279e2e6d7_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzctNS0xLTEtMA_840ee07c-a0e1-4d3a-a25c-6ca86730b503"
      unitRef="usd">78418000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="id2ec2edcab7e43d583877d5a7a390b74_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzctNy0xLTEtMA_de501253-6060-45af-abe0-6d096a415390"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i075636ae66df40faaee95c130bcf8ea4_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzgtMS0xLTEtMA_343ee78e-2c98-4d34-910c-d9ea67cbace9"
      unitRef="usd">155910000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic4e13a785a984de8ab85335f4e573536_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzgtMy0xLTEtMA_36fc2ed9-eaf5-4608-b03c-c3ade46b2535"
      unitRef="usd">61512000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if287162bc94548119144a45ef00144e0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzgtNS0xLTEtMA_1a2c199c-68f6-413e-b995-d420b81c1c70"
      unitRef="usd">94398000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1aa2e56fe0043f790bcc747ebd4cf13_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90YWJsZTplNjQ0ZmJhMjk4NDg0ZmI3OWJhYjkxMDYyZTJiZDdiNC90YWJsZXJhbmdlOmU2NDRmYmEyOTg0ODRmYjc5YmFiOTEwNjJlMmJkN2I0XzgtNy0xLTEtMA_726599d9-6dad-4329-9688-02ac48c50714"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i723d050a26224f16a353738eb4442e04_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzcxNDY4MjU1ODQ2MjU_78b703b7-6898-484a-8a83-ecaf8055deff"
      unitRef="usd">99800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i723d050a26224f16a353738eb4442e04_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzgyNDYzMzcyMTI0MTY_b35930df-afc5-4cbd-8fca-8c222be69a17"
      unitRef="usd">6100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i075636ae66df40faaee95c130bcf8ea4_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNTQvZnJhZzpiNGJmOTViZTYzNzk0M2U3OGU1YjY2MjZhZWJmYWQzMy90ZXh0cmVnaW9uOmI0YmY5NWJlNjM3OTQzZTc4ZTViNjYyNmFlYmZhZDMzXzI2Nzc_eb7bbe8a-6eea-4792-88e7-dd436597d334"
      unitRef="usd">62500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90ZXh0cmVnaW9uOjllMzZlYzM4YTQxNjQ4Njc4YTAzNDE5NThhZjVjNjQzXzI3NDg3NzkwNjk5NDU_413c3cda-03a8-444a-8ed5-5620151158c3">Marketable Securities&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Available-for-sale marketable securities as of September&#160;30, 2018 and December&#160;31, 2017 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.344624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.751105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.344624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.751105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;All available-for-sale marketable securities held as of September&#160;30, 2018 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable securities in an unrealized loss position as of September&#160;30, 2018 and December&#160;31, 2017 were in a loss position for less than twelve months.&#160; There were no unrealized losses at September&#160;30, 2018 or December&#160;31, 2017 that the Company determined to be other-than-temporary.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90ZXh0cmVnaW9uOjllMzZlYzM4YTQxNjQ4Njc4YTAzNDE5NThhZjVjNjQzXzI3NDg3NzkwNjk5NDQ_6c003c44-50a2-4126-8383-7256f7b035e9">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Available-for-sale marketable securities as of September&#160;30, 2018 and December&#160;31, 2017 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.344624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.751105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.344624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.751105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4fac88e6145545bcab342e1996db0e66_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzItMS0xLTEtMA_526d6649-1bf8-476e-bac5-7bce639ec4ab"
      unitRef="usd">3996000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4fac88e6145545bcab342e1996db0e66_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzItMy0xLTEtMA_6db28ef5-634d-4239-9a24-2dfc182531d1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4fac88e6145545bcab342e1996db0e66_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzItNS0xLTEtMA_a5ba5df3-6d3f-4628-b467-30deceba153d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4fac88e6145545bcab342e1996db0e66_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzItNy0xLTEtMA_b5c32937-fca9-4de2-82e5-a6319c4abf90"
      unitRef="usd">3996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i03f6af7af270436ebef7bd53a4e07f80_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzMtMS0xLTEtMA_71a322f1-94b1-4c9c-b6f8-56d96d84c4d8"
      unitRef="usd">5477000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i03f6af7af270436ebef7bd53a4e07f80_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzMtMy0xLTEtMA_1c31b0d9-b843-4da8-b1e4-994bd38b9452"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i03f6af7af270436ebef7bd53a4e07f80_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzMtNS0xLTEtMA_2ea7220d-0979-4389-8820-14e21a93793e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i03f6af7af270436ebef7bd53a4e07f80_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzMtNy0xLTEtMA_bd4d1302-6288-479a-ac01-c8dede254ff8"
      unitRef="usd">5477000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if828ac34fb81419ca9d1984770c76254_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzQtMS0xLTEtMA_e198002e-9258-45fa-b317-7c93b4c25124"
      unitRef="usd">48863000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if828ac34fb81419ca9d1984770c76254_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzQtMy0xLTEtMA_237b177c-a8e6-4f6c-9627-fb0790e5c2d4"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if828ac34fb81419ca9d1984770c76254_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzQtNS0xLTEtMA_c577ead9-c2d9-4674-8649-7f8ad6d331c9"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if828ac34fb81419ca9d1984770c76254_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzQtNy0xLTEtMA_4861bfe7-5bfc-4c3d-8722-f718c1287884"
      unitRef="usd">48863000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzUtMS0xLTEtMA_c4d2c92d-ed08-4e25-8a17-142dc85f39ed"
      unitRef="usd">58336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzUtMy0xLTEtMA_f92583b2-6c81-4628-a892-e7b122804f95"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzUtNS0xLTEtMA_8a3edde2-723e-436c-9193-0920cdc1d715"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo4NDVmYWRhN2I5NTM0M2VkYmRjNGI5Nzc2YTNiYTBmYy90YWJsZXJhbmdlOjg0NWZhZGE3Yjk1MzQzZWRiZGM0Yjk3NzZhM2JhMGZjXzUtNy0xLTEtMA_b94f5738-bd77-4a5b-b54a-cf7a9ae2483a"
      unitRef="usd">58336000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2a4af18da1684515ba77f3fadc4081d3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzItMS0xLTEtMA_1fe9daba-4caf-45a0-8bb3-6116d638a25e"
      unitRef="usd">3995000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2a4af18da1684515ba77f3fadc4081d3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzItMy0xLTEtMA_297d87d4-5ef2-43c8-aa6f-3daceeb64acc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2a4af18da1684515ba77f3fadc4081d3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzItNS0xLTEtMA_affbdb60-ec1d-4dc6-9351-1dc3a31aaa28"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a4af18da1684515ba77f3fadc4081d3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzItNy0xLTEtMA_0f6a07a8-321d-4999-83f0-e6d071c64caa"
      unitRef="usd">3989000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i866096d237f54e4583f3e604e8c243ec_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzMtMS0xLTEtMA_54afe571-dc45-431f-8339-a3abbed6afc1"
      unitRef="usd">11998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i866096d237f54e4583f3e604e8c243ec_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzMtMy0xLTEtMA_8e40a87e-9975-479c-868c-1987cb09879f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i866096d237f54e4583f3e604e8c243ec_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzMtNS0xLTEtMA_c0d26f27-fbe5-44b5-b6fc-cacaa08117d2"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i866096d237f54e4583f3e604e8c243ec_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzMtNy0xLTEtMA_63a68977-dab5-4339-91a1-f62318b8c335"
      unitRef="usd">11991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i026f26d0cf654febb2e1e5f3037d5afc_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzQtMS0xLTEtMA_e9d4b957-e36f-4967-aff4-787e7bf3a4e6"
      unitRef="usd">77462000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i026f26d0cf654febb2e1e5f3037d5afc_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzQtMy0xLTEtMA_5da0c207-3663-45ca-8cec-00d8406480f3"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i026f26d0cf654febb2e1e5f3037d5afc_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzQtNS0xLTEtMA_9fe242f5-750c-449d-9e87-cbcd1841574a"
      unitRef="usd">50000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i026f26d0cf654febb2e1e5f3037d5afc_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzQtNy0xLTEtMA_33464c8e-07d4-40b3-bc9c-8f499dd623b5"
      unitRef="usd">77414000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzUtMS0xLTEtMA_c09ba16a-33a0-4526-86e7-6837c710a73a"
      unitRef="usd">93455000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzUtMy0xLTEtMA_a7b1e007-39ad-4e5b-8ec7-7cd09505abee"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzUtNS0xLTEtMA_331b853a-15e6-4482-b6c6-95d2ed53c050"
      unitRef="usd">63000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90YWJsZTo3YzEzY2Q5OGFhYTc0NjNmODk0OTc1NTAxYTJiOWE4OS90YWJsZXJhbmdlOjdjMTNjZDk4YWFhNzQ2M2Y4OTQ5NzU1MDFhMmI5YTg5XzUtNy0xLTEtMA_2ef9e308-5b95-495f-a595-73c531a858fa"
      unitRef="usd">93394000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="i5d0a400707884c2198f13e93d13ca5cf_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90ZXh0cmVnaW9uOjllMzZlYzM4YTQxNjQ4Njc4YTAzNDE5NThhZjVjNjQzXzQxMA_3ef4e28d-97e1-4b73-b6ea-5b20d3fd1dcf"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xNjYvZnJhZzo5ZTM2ZWMzOGE0MTY0ODY3OGEwMzQxOTU4YWY1YzY0My90ZXh0cmVnaW9uOjllMzZlYzM4YTQxNjQ4Njc4YTAzNDE5NThhZjVjNjQzXzQxMA_c49fdd79-5fcf-4182-b99b-2ecaafdcd477"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzI3NDg3NzkwNzEyMzE_6e7398ac-3517-436f-9851-d546f77c1edc">Stockholders' EquityIn April 2017, the Company entered into a definitive agreement with an institutional healthcare investor to purchase 1,100,000 shares of the Company's common stock at a purchase price of $21.50 per share in a registered direct offering.&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; Proceeds to the Company, before deducting estimated offering expenses, were $23.7 million. The shares were offered pursuant to the Company&#x2019;s effective shelf registration &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;on Form S-3 that was filed with the SEC on November 2, 2016&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2017, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $75.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended.  The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 2, 2016. During the year ended December&#160;31, 2017, the Company sold 599,284 shares of common stock under the sales agreement, resulting in net proceeds of $10.8 million related to the ATM Offering. No shares of common stock were sold under the sales agreement during the&#160;nine months ended September 30, 2018. &lt;/span&gt;&lt;/div&gt;On April 2, 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold 4,500,000 shares of its common stock at a price of $21.25 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 675,000 shares of the Company's common stock at a price of $21.25 per share.  Upon closing, the Company received net proceeds of approximately $103.0 million from this offering, net of underwriting discounts and commissions and other offering expenses.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib8b8d6b8d41d4fd494c10b56288a758f_D20170426-20170426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzE1MQ_e0739cec-96c5-4364-9e54-9d849bec2d85"
      unitRef="shares">1100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i187b1747b6ea4fe7bd1a794a51a3a8bf_I20170426"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzIwNA_544d58b3-0b02-4024-8dd9-fac2bf807699"
      unitRef="usdPerShare">21.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib8b8d6b8d41d4fd494c10b56288a758f_D20170426-20170426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzMyNg_e3a1f3f2-7d92-4c66-8406-e6a01e1e6882"
      unitRef="usd">23700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i3ed9ef592d4e44dd88fcc594f7f2d847_D20170503-20170503"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzYzOQ_ea175021-eaa4-48d9-810a-940acd43343b"
      unitRef="usd">75000000.0</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i273fc3440aa24332a0568edcf542e1aa_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzEwMTY_1a10a4fd-872a-49e9-a733-4f8aaa2b1720"
      unitRef="shares">599284</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i273fc3440aa24332a0568edcf542e1aa_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzEwOTg_077eacbd-d8ff-4025-a3fc-3b91409303bf"
      unitRef="usd">10800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0c786749d1894dd6a9b452378513440b_D20180701-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzExMzA_311287f5-5a52-4d18-9fbb-7238606633ce"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icd9c327300a84aafaf0a8890a6378c39_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzExMzA_c0541cf9-c4fc-4bfe-af29-e630704dc7b5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id2d3c290311249a18501533c07d13527_D20180402-20180402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzEzMzU_e4badd88-21f5-4fe0-b9b4-4e5c6cbaab67"
      unitRef="shares">4500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i9127f44e472a4031acb85a2e77e5c974_I20180402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzEzNzk_19c0da2d-3135-4c1b-abe7-523e4a26ae19"
      unitRef="usdPerShare">21.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i46f941ef8b4f48e482ec7ee2d06ebaa3_D20180402-20180402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzE1Mzc_237c0e71-a1a8-4c54-9bcc-0d8e8bab5a5c"
      unitRef="shares">675000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i9e9cd335c9244d9fb051a1a01f207509_I20180402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzE1OTE_ab38e3ef-8f68-4b00-b476-65a407281482"
      unitRef="usdPerShare">21.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id9e8c9eb9fa140f7bf495f250946e437_D20180402-20180402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8xOTEvZnJhZzoyMTA1NGM2ZDhhNzQ0ZDhhYjdmOTAyNTcxYjBjNWE0My90ZXh0cmVnaW9uOjIxMDU0YzZkOGE3NDRkOGFiN2Y5MDI1NzFiMGM1YTQzXzE2NzE_e49f9a4a-db35-423b-9ca1-5721f187bd0b"
      unitRef="usd">103000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzkzNDU4NDg4NjkzMTg_84876755-5768-4707-9910-199e09c57d6b">Collaboration and Other Agreements &lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Incyte&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012 (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a $150.0 million upfront payment from Incyte when the transaction closed in the fourth quarter of 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. As of September 30, 2018, the Company has recognized $10.0 million in development milestones under this agreement.  If commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study&#160;and will continue to fund certain related clinical activities.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;The Company evaluated the Incyte Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;During the three months ended September 30, 2018, it became probable that a significant reversal of cumulative revenue would not occur for two development milestones totaling $10.0 million related to MGA012 meeting certain clinical proof-of-concept criteria. During the three months ended&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; September 30, 2018, the associated consideration was added to the estimated transaction price and was recognized as revenue and recorded as accounts receivable on the Company&#x2019;s consolidated balance sheet.&#160;Subsequent to September 30, 2018, a third proof-of-concept milestone was achieved and an additional $5.0 million will be recognized in the fourth quarter of 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company recognized the $150.0 million allocated to the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;license when it satisfied its performance obligation and transferred the license to Incyte in December 2017.  The $4.0 million allocated to the clinical activities is being recognized over the period from the effective date of the agreement until such time as the clinical activities are transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs.  These clinical activities were substantially completed as of June 30, 2018, although certain minimal work is ongoing.  Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606.  The Company recognized revenue of $10.5 million and $13.6 million&#160; under the Incyte Agreement during the three and nine months ended September 30, 2018, respectively, including $10.0 million in development milestones and the remainder&#160;related to clinical activities.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company&#160;also has an agreement with&#160;Incyte under which the Company is to perform manufacturing services for Incyte&#x2019;s&#160;clinical needs of MGA012.  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement - to perform services related to manufacturing the clinical supply of MGA012.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.   During the three and&#160;nine months ended September 30, 2018, the Company recognized revenue of&#160;$6.1 million&#160;and $16.0 million, respectively, for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Roche&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In December 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets  (Roche Agreement).  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate.  Roche would then further develop and commercialize any such product candidate.  Each company will be responsible for their own expenses during the research period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#x2019;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $10.0 million which was received in January 2018. The Company will also be eligible to receive up to $370.0 million in potential milestone payments and royalties on future sales.&#160;As of September 30, 2018, the Company has not recognized any milestone revenue under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period.  The Company determined that the license is capable of being distinct, but is not distinct in the context of the contract because it has limited value to Roche without the research activities required to be performed by the Company.  Therefore, the Company concluded that there is one performance obligation under the agreement.  The Company determined that the transaction price of the Roche Agreement was $10.0 million.  The potential milestone payments are &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;fully constrained &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;and have been excluded from the transaction price.  Any consideration related to sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore have also been excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The $10.0 million transaction price is being recognized over the expected research period, which is 30 months, using a cost-based input method to measure performance.   Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606. The Company recognized revenue under this agreement of $1.0 million and $3.0 million during the three and nine months ended September 30, 2018, respectively.  At September&#160;30, 2018, $7.0 million of revenue was deferred under this agreement, $4.0 million of which was current.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Les Laboratoires Servier &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In September 2012, the Company entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). During 2014, Servier exercised its exclusive option to develop and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; commercialize flotetuzumab, and during 2016 Servier notified the Company that it did not intend to exercise the option for the third DART molecule.  Servier retains the option to obtain a license for MGD007.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Upon execution of the agreement, Servier made a nonrefundable payment of $20.0 million to the Company. In addition, if Servier exercises the remaining available options and successfully develops, obtains regulatory approval for, and commercializes a product under each license, the Company will be eligible to receive up to $25.0 million in license grant fees, $53.0 million in clinical milestone payments, $188.0 million in regulatory milestone payments (excluding the $10.0 million for the flotetuzumab and MGD007 INDs noted below) and $420.0 million in sales milestone payments. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options.  The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package.  The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights.  As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company determined that the $20.0 million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;Two milestones were achieved in 2014 when the INDs for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA).  Upon achievement of each milestone, the constraint related to the $5.0 million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Revenue associated with each performance obligation is being recognized as the research and development services are provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation.  The full transaction price allocated to flotetuzumab and the third DART molecule was recognized as revenue prior to the adoption of ASC 606 on January 1, 2018 as the option periods had ended. The development period for MGD007 was estimated to be 75 months, ending in December 2018, therefore the transaction price allocated to MGD007 is being recognized through that date.  Upon the adoption of ASC 606 on January 1, 2018, the pattern of revenue recognition for the upfront fee and the accounting for the milestones received in 2014 changed, but there was no material impact to revenue recognized during the three and nine months ended September 30, 2018.  The Company recognized revenue of $0.5 million and $1.4 million during the three and nine months ended September 30, 2018, respectively, related to the MGD007 option.  At September&#160;30, 2018, $0.5 million of revenue related to the MGD007 option was deferred, all of which was current. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $15.0 million license grant fee.  Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808.  The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license.  The Company evaluated its performance obligation to provide Servier with an exclusive license to &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;develop and commercialize flotetuzumab and determined that its transaction price is equal to the upfront payment of $15.0 million and Servier consumes the benefits of the license over time as the research and development activities are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; Therefore, the Company will recognize the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The additional potential clinical, regulatory and sales milestones are &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;fully constrained &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;and have been excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company will follow its policy to record expense incurred as research and development expense and reimbursements received from Servier will be recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period.  During the three and nine months ended September 30, 2018, the Company recorded approximately $2.1 million and $4.9 million, respectively, as an offset to research and development expense under this collaborative arrangement.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; The Company recognized revenue of $0.3 million and $0.9 million, respectively, during the three and nine months ended September 30, 2018 related to the flotetuzumab option exercise.  At September&#160;30, 2018, $12.9 million of revenue related to the flotetuzumab option exercise was deferred, $2.2 million of which was current.  The deferred revenue balance related to the flotetuzumab option exercise as of December 31, 2017, prior to the adoption of ASC 606, was $7.4 million. The adoption of ASC 606 increased that balance by approximately $6.4 million. The adoption of ASC 606 did not have a material impact on revenue recognized during the three and nine months ended September 30, 2018, however it will increase the revenue to be recognized in the future as the pattern of revenue recognition has changed.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Provention&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2018, the Company entered into a License Agreement with Provention Bio, Inc. (Provention), pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications.  As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. &#160;As of September 30, 2018, the Company has not recognized any milestone revenue under this agreement.&#160; If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;Also in May 2018, the Company entered into an Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement).  As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share.  The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones.  If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase 2,432,688 shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company recognized revenue of $6.1 million when it satisfied its performance obligations and transferred the MGD010 license and teplizumab assets to Provention during May 2018.  The warrants are reported in other assets on the balance sheet at September&#160;30, 2018, and there was no material change in the valuation of the warrants from May 2018 through that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.&lt;/span&gt;&lt;/div&gt;This contract includes a base period of up to $7.5 million to support development of MGD014 through IND application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September&#160;15, 2015 through September&#160;14, 2022. In 2017, NIAID exercised the first option in the amount of up to $10.8 million.  The Company recognized $0.2 million and $0.4 million in revenue under this contract during the three months ended September 30, 2018 and 2017, respectively.  The Company recognized $0.6 million and $1.5 million in revenue under this contract during the nine months ended September 30, 2018 and 2017, respectively.</mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i2c2f267ad6954342818988358aaec05a_D20171001-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzU3Mg_40d580af-4666-4e4a-9160-a90f5ce2dd97"
      unitRef="usd">150000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="iaab2d3c47fcb482fb5016a56c6678a2f_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg2Mw_c6dc6c8c-50a6-4e25-9d1c-2dc057f60e94"
      unitRef="usd">420000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="iaab2d3c47fcb482fb5016a56c6678a2f_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzkxOA_e56bcc2c-776d-4012-9e11-7c60c7cfa54b"
      unitRef="usd">330000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i583cbd7fe1f847cea4b7238b2bc9436a_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNTU0MjE_32099dae-9188-42b7-a61c-ec0aef8dadbf"
      unitRef="usd">10000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ia06a043fda544306a7174163d4ba821a_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEwMjc_1ed510ca-8cbb-47f2-a43a-99bca1800445"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i85e4b6bf29674ed0bb853ac49b61574b_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEwMzM_74b897a4-e32e-4620-87ee-2f2f28ce961a"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NumberOfPerformanceObligations
      contextRef="iddfd5052e98f4ca28241b0916f60a7d1_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4Mjc_6026d43c-2f5e-417e-8424-69fb66293c20"
      unitRef="performance_obligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="iaab2d3c47fcb482fb5016a56c6678a2f_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzI1OTE_f7578527-f8cf-4d67-bd90-fe574d47d5f3"
      unitRef="usd">154000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ia03651a398b047e6ba26bc530ae802ba_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNDk5ODg_2858c2c3-a208-43a3-8f98-d0b77a88cfb1"
      unitRef="usd">10000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i583cbd7fe1f847cea4b7238b2bc9436a_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNDk5ODY_32099dae-9188-42b7-a61c-ec0aef8dadbf"
      unitRef="usd">10000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="ibe8622ead245454683d6cd02732a930e_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzQwNTI_785123bb-03a6-4ca9-9ad8-2cc27bfd9d4c"
      unitRef="usd">150000000.0</us-gaap:Revenues>
    <us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i8e9c20469d344180a7bdbf43ccc98126_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzQxODU_57276894-605e-433d-bae6-e3bd4765082b"
      unitRef="usd">4000000.0</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="i7afec6a50d3e4c49b2fceac1c053cee8_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzQ3NDk_851724e5-662d-47ea-a9c5-b843e818bce9"
      unitRef="usd">10500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03336d63cb2e4abf99d71150176d9e2a_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzQ3NTY_adbc7867-1b20-4b45-8736-649f9e3b1676"
      unitRef="usd">13600000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i583cbd7fe1f847cea4b7238b2bc9436a_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNDk5MTg_86c11345-05ee-4604-9eeb-ad1cfaaef508"
      unitRef="usd">10000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="ifd05ad37dc5648948de2ec1ebeeb9880_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNDk5NjI_105bbfb9-188c-4fe4-b8cc-e3323152b0e1"
      unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd5dfaa7121c4b398f87a4bf82fe6818_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzU1ODM_2e7fd7fb-593d-4fe1-a324-5b4e3c5b3860"
      unitRef="usd">16000000.0</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i304e6e07763f45adac1a934bb867bb1b_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzY1MTk_6629eb41-cd30-42f6-9814-0aea0f3404c3"
      unitRef="usd">10000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement
      contextRef="iadb65054ca38420abd5f2059371dcff6_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzY2MDk_85b9b4e0-6436-46f0-9159-2ab6aa74385f"
      unitRef="usd">370000000.0</mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement>
    <mgnx:NumberOfPerformanceObligations
      contextRef="iadb65054ca38420abd5f2059371dcff6_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzcyNzE_87760e7d-148e-4862-9a19-5628a9947cd8"
      unitRef="performance_obligation">1</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="iadb65054ca38420abd5f2059371dcff6_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzczOTY_e65059c7-66c0-4c17-af47-10ba4c1f94f5"
      unitRef="usd">10000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="iadb65054ca38420abd5f2059371dcff6_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzc3NTk_871808f6-086a-45f3-a406-e1f1744d971a"
      unitRef="usd">10000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:UpfrontPaymentRecognitionPeriod
      contextRef="ibd2cfd87b18c4510b689cf0331b1d471_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzc4NDM_22afb355-cedb-43f4-b37a-7cbbda744a3d">P30M</mgnx:UpfrontPaymentRecognitionPeriod>
    <us-gaap:Revenues
      contextRef="i2076bfb4648e47319c3d79dc8b4f052f_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzgxMTU_cbc225eb-1fe3-42fa-8541-457aea34bc7f"
      unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09bb778c2423410098bdc0c426490d87_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzgxMjI_027b40b0-d2ff-4f6f-8d65-902a771dff96"
      unitRef="usd">3000000.0</us-gaap:Revenues>
    <us-gaap:DeferredRevenue
      contextRef="i58ae03eea2c343388670589c0cc8cee6_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzgxNzI_17847b87-fda8-452f-b958-34e5283a52cd"
      unitRef="usd">7000000.0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i58ae03eea2c343388670589c0cc8cee6_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzgyMjE_28180391-35d1-451a-88d8-c86595aa0ae1"
      unitRef="usd">4000000.0</us-gaap:DeferredRevenueCurrent>
    <mgnx:NumberOfExclusiveOptionsToLicense
      contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg0NjU_923ae772-f6e5-4144-bf33-3f0daf5e1b8b"
      unitRef="exclusive_license">3</mgnx:NumberOfExclusiveOptionsToLicense>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ia6e0829991f74feeaba02806ccb252be_D20120901-20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzkxNDQ_8ca6d9c9-60f4-4cf4-8c35-a31e908c1e80"
      unitRef="usd">20000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialLicenseFee
      contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzkzODQ_5a970050-b1bd-4cb5-9a0e-f79441f0bdad"
      unitRef="usd">25000000.0</mgnx:PotentialLicenseFee>
    <mgnx:PotentialClinicalMilestonePaymentsUnderAgreement
      contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzk0MTA_8879dd12-aed1-4e28-8c42-c04b667a12e2"
      unitRef="usd">53000000.0</mgnx:PotentialClinicalMilestonePaymentsUnderAgreement>
    <mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzk0NDU_3b84b31a-a43b-4b83-8e17-53cfb6a221fc"
      unitRef="usd">188000000.0</mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i9a2d8a380170427b92101d51e25a734b_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzg3OTYwOTMwNTU0Mjk_26de73e4-7e9b-4c89-8fcc-2cebd1533c2f"
      unitRef="usd">10000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:PotentialSalesMilestonePaymentsUnderAgreement
      contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzk0ODU_f068d714-5be5-4384-a5be-6bf08d046cfe"
      unitRef="usd">420000000.0</mgnx:PotentialSalesMilestonePaymentsUnderAgreement>
    <mgnx:NumberOfExclusiveOptionsToLicense
      contextRef="i061c41caf2584f488de00de72d70d359_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzk5MzE_13f144db-f418-4799-b2c5-1df3d2aa3741"
      unitRef="performance_obligation">3</mgnx:NumberOfExclusiveOptionsToLicense>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i061c41caf2584f488de00de72d70d359_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExMDIz_e7e5ef7c-e626-4498-b717-a49a1bf0e2d7"
      unitRef="performance_obligation">3</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i4758f7e2b6884b5183698bdca5ffa1bc_I20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExMTYw_e65292f3-3b02-4455-b142-2eab1ecb56d0"
      unitRef="usd">20000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i061c41caf2584f488de00de72d70d359_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExMzYy_e7e5ef7c-e626-4498-b717-a49a1bf0e2d7"
      unitRef="performance_obligation">3</mgnx:NumberOfPerformanceObligations>
    <mgnx:NumberOfMilestonesAchieved
      contextRef="i88a4efe1362c4a3db0196262405ad178_D20140101-20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExNjcy_a4e476a2-0416-42d7-80a4-af67701d7fc3"
      unitRef="milestone">2</mgnx:NumberOfMilestonesAchieved>
    <mgnx:MilestonePayment
      contextRef="i88a4efe1362c4a3db0196262405ad178_D20140101-20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzExODcz_4bca87ff-ba1f-4114-bbaa-83aeba2d4113"
      unitRef="usd">5000000.0</mgnx:MilestonePayment>
    <mgnx:OptionExerciseFeeRecognitionPeriod
      contextRef="ifb7ae82b7fd94218adec5b37c3baf521_D20120901-20120930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEyNzQx_f95ce42c-6422-49df-944c-25a5b5e0db15">P75M</mgnx:OptionExerciseFeeRecognitionPeriod>
    <us-gaap:Revenues
      contextRef="i0bdd4ce1abcb4d84918166baa0aab54f_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEzMTUy_cee53fc1-c566-4fd2-ae33-a888a32537bd"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib593ee5aff884b09b56907f69f0517e1_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEzMTU5_9d719ce8-d988-48be-8ef6-61523c5f2fa9"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i166c43c2262341ea91348516a28bcbd9_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEzMjM5_5e00369f-8dd7-4897-a5e6-bf9d6ff6007c"
      unitRef="usd">500000</us-gaap:DeferredRevenueCurrent>
    <mgnx:OptionExerciseFee
      contextRef="idd6a295ad13346be87c34a41d8a59a09_I20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzEzNDg2_a0f89076-8524-4005-82e8-2d455d1570bc"
      unitRef="usd">15000000.0</mgnx:OptionExerciseFee>
    <mgnx:NumberOfComponentsInLicenseAgreement
      contextRef="ia231899505ea4e26b8ae99393f58f9f8_I20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE0MjM4_17c1729c-8682-4b87-a348-71a0206b5079"
      unitRef="component">2</mgnx:NumberOfComponentsInLicenseAgreement>
    <mgnx:OptionExerciseFee
      contextRef="idd6a295ad13346be87c34a41d8a59a09_I20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE0NzUx_a0f89076-8524-4005-82e8-2d455d1570bc"
      unitRef="usd">15000000.0</mgnx:OptionExerciseFee>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="i9f54d23042ce45e3b0f7b1f3527e965c_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1NzE4_ee216309-0551-4d39-aa90-3646d522b243"
      unitRef="usd">2100000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="i9a2d8a380170427b92101d51e25a734b_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1NzI1_c55d9b94-f519-4ff4-9452-51c038e04908"
      unitRef="usd">4900000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <us-gaap:Revenues
      contextRef="i42d44f7b71fc4200940cf6d3d09f2c3b_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1ODY4_eb9f3ce0-cb27-4222-aaf1-7fe62a021789"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53b4e8d5c2cc41a7abc24c33b0b6b4e0_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1ODc1_59db20c6-75ad-4c1e-8a9e-763d7842b66b"
      unitRef="usd">900000</us-gaap:Revenues>
    <us-gaap:DeferredRevenue
      contextRef="i1a09839b03404373938e8002919f2856_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE1OTcw_d7701586-4955-4ca1-8c67-e25fddfc58d3"
      unitRef="usd">12900000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i1a09839b03404373938e8002919f2856_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE2MDQy_ace0ac51-9e3b-4237-9d68-9752d645711e"
      unitRef="usd">2200000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenue
      contextRef="i660cb75a1c0d41c983132bc62bb7d5cd_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE2MjA0_8c549e0e-bd11-42ae-9be7-bc7838b52364"
      unitRef="usd">7400000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="i52bce1b6baef4facb924a318ed17002f_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE2Mjcy_ae58aacd-9fde-4cb3-9ae1-7178db5c8c25"
      unitRef="usd">6400000</us-gaap:DeferredRevenue>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i23557f80a0a245a690a3b1b11c018cc8_D20180531-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE3MDI4_f3ed3596-9724-4682-ab6c-c57c0d3d0ad8"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i1b5de7b28e2d4befab1ed1cec48844f6_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE3MjI0_2a0ca3e0-7945-46b9-a358-8dc30daf3381"
      unitRef="usd">65000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i1b5de7b28e2d4befab1ed1cec48844f6_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE3Mjc4_b3e19d6b-669c-49c8-a884-00338f1c4bda"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i829603c6236e41f2951a9087431df091_D20180531-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4MjIx_51546fca-b6c0-4ad0-a41b-8d5db0ed0b1a"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i77e14b4fd8a549c99d5b94473df0cbdb_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4NDE3_6f3ea8b5-f33f-4686-9d8b-15bbe3fc9757"
      unitRef="usd">170000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i77e14b4fd8a549c99d5b94473df0cbdb_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4NDU1_004095a8-74b1-47a0-8fbc-b3f33915d271"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement
      contextRef="i77e14b4fd8a549c99d5b94473df0cbdb_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE4ODIy_8d7411ee-7667-4f87-bdcb-b7f3368bb101"
      unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:NumberOfPerformanceObligations
      contextRef="ia27a68ad905842ba80b4de3e9d1b929e_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE5NDAz_4ab95f11-c7e0-4faf-b761-e7d92cdd0b13"
      unitRef="performance_obligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="ia27a68ad905842ba80b4de3e9d1b929e_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE5NTk2_b752a7a6-7e96-4d3a-847e-43eff14cc83a"
      unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="ia27a68ad905842ba80b4de3e9d1b929e_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzE5NjY1_09bb5992-3f64-414f-9020-37da1064ea77"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues
      contextRef="i83423a11889045c1bcdec405be3fa546_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIwNjA3_3a91bf83-9607-4a3c-9553-5ff684b37741"
      unitRef="usd">6100000</us-gaap:Revenues>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIxMTQ0_2ea53746-eb02-4747-8224-7d0f0cb4772f"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:FundedValueOfBasePeriod
      contextRef="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIxNjg0_4a25384a-e74c-45d8-a3fd-e45bb946c657"
      unitRef="usd">7500000</mgnx:FundedValueOfBasePeriod>
    <mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIxNzg2_b7e0ae76-76ee-4935-9f6b-a22f082470f6"
      unitRef="usd">17000000.0</mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIxOTM0_b096605d-9bb4-4d33-8904-6bdeb00be481"
      unitRef="usd">24500000</mgnx:TotalPotentialValueUnderAgreement>
    <mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="i452ee1a0ab714c34ababb41227155f6d_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMDg0_17d1dc99-a1be-47a8-8d6b-4740c07f6cee"
      unitRef="usd">10800000</mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement>
    <us-gaap:Revenues
      contextRef="i6da7c74defea4d8fb09ed95435cc7a03_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMTEy_c7600575-79fd-43c7-8d97-14fe10dd585c"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife8821603bb64976be6518e29c1c250d_D20170701-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMTE5_7a9a7547-1e64-4924-857a-31692f57d311"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28991436c91f443c8ede9c7a2c47f606_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMjEz_2797b3aa-1064-4844-a5bf-624911a1a0b3"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54aa98e1360041ea8a6f19ceeab7a123_D20170101-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMTYvZnJhZzozODZkZjQ3NmZlMTk0YjFjOGY1MzE0YmIxYjMwMGE2ZS90ZXh0cmVnaW9uOjM4NmRmNDc2ZmUxOTRiMWM4ZjUzMTRiYjFiMzAwYTZlXzIyMjIw_9c5ef98e-12a5-4336-ab01-c404609487ce"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI3NDg3NzkwNzM2NDU_aaa0a28a-d655-4796-b7e2-0fb30b689aa9">Stock-Based Compensation&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2018, 20,231 shares of common stock were purchased under the 2016 ESPP for net proceeds to the Company of approximately $0.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Employee Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of 2,051,644 shares of the Company's common stock. Between 2006 and 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased to 4,336,730. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the Company's 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2018 there were options to purchase an aggregate of 826,333 shares of common stock outstanding at a weighted average exercise price of $1.93 per share under the 2003 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:39pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Under the provisions of the 2013 Plan, the number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the nine months ended September&#160;30, 2018, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 8,244,131.&#160;&#160; As of September&#160;30, 2018, there were options to purchase an aggregate of 4,521,942 shares of common stock outstanding at a weighted average exercise price of $25.61 per share under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table shows stock-based compensation expense for stock options, RSUs and ESPP (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.117647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.794118%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.029412%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.441176%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.411765%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.491924%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.767988%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.005874%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67.8% - 72.2%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.7% - 68.3%&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.4% - 3.1%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.9% - 2.3%&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes stock option and restricted stock unit (RSU) activity during the nine months ended September&#160;30, 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:26.970588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt; (in thousands)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,504,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,230,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(205,902)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited or expired&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(180,709)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,348,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,365,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,138,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2018 was $18.07. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2018 was approximately $4.0 million, and the total cash received for options exercised was approximately $0.9 million. The total fair value of shares vested in the nine months ended September&#160;30, 2018 was approximately $11.9 million. As of September&#160;30, 2018, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was approximately $28.0 million, which the Company expects to recognize over a weighted-average period of approximately 2.65 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie758ea00f3b045d8aaf61ff77aa1bd5b_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzQyMg_c47246ec-3ea7-42cd-9803-2f6f7b2f10fd"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ie3e9f6ff05ac42748139386a1f145650_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzYyMQ_d26d1b67-b82c-4cd8-bf82-b544db190b75"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ie3e9f6ff05ac42748139386a1f145650_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzg2OA_512fe42a-abb4-40fa-a99d-056f67e7820a"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ib21a72497c3f4f4586fc6f1f696f8ee0_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzk5OA_87d85442-5aa2-4b2d-8c50-d7cac12a4d4a"
      unitRef="shares">20231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ib21a72497c3f4f4586fc6f1f696f8ee0_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzExMDg_3fba691c-a7ba-48a6-9ee1-07608df69d99"
      unitRef="usd">500000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idf2e982e7c3a42d487a756a32a510ac0_I20030228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzEzOTQ_7e273e2a-b5db-4f18-9625-7456920537a1"
      unitRef="shares">2051644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib58f57547e3d4bb8a8a5328327afc915_I20121231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzE1Nzk_8cede787-625e-4797-aacf-db7488b611b0"
      unitRef="shares">4336730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i706d5cef31cd430e8365f6915ddcb64f_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzIyNTk_50eaf191-88d2-4b88-ac3c-e681b2280130"
      unitRef="shares">826333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i706d5cef31cd430e8365f6915ddcb64f_I20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzIzMzc_7003bce2-b024-47fc-9d7d-06df10b50365"
      unitRef="usdPerShare">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="i53ec44ff783b431cb9ed2678498d5f97_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI2MDU_fa52dd5a-c013-46c0-a7b0-8989271443e6"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="i596e64c58833410299f5dd5853dd7260_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI2MjA_d85d3f3c-1077-47cb-8207-641489dec643"
      unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i53ec44ff783b431cb9ed2678498d5f97_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI5NjI_a29e7995-8aae-4fed-be75-7e085a489391"
      unitRef="shares">8244131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i53ec44ff783b431cb9ed2678498d5f97_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzMwMjU_2204a171-c525-47b4-aa4f-b1a9100a9012"
      unitRef="shares">4521942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i53ec44ff783b431cb9ed2678498d5f97_I20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzMxMDM_833a879b-2eba-4fd8-a20d-82b6a4a748cf"
      unitRef="usdPerShare">25.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI3NDg3NzkwNzM2NDQ_72b6c950-50db-4a34-a42b-6bf981a39b0f">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table shows stock-based compensation expense for stock options, RSUs and ESPP (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.117647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.794118%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.029412%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.441176%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.411765%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7042cd13db6549e7871f168d9d646e10_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzItMS0xLTEtMA_1294a4ed-3c06-4910-822d-aeedd1ca737e"
      unitRef="usd">2440000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i01e7fa001b0a43809cae26254818dd0a_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzItMy0xLTEtMA_4a454dff-dae7-4ff5-a031-9cb3eb892b2c"
      unitRef="usd">2006000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i331b887054c54310ba485d67cc56fd98_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzItNS0xLTEtMA_90cda303-719f-4034-a587-0f9a9e8bc048"
      unitRef="usd">6347000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1169246d2ee645d2b41f43608d9c7971_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzItNy0xLTEtMA_823a210a-c2f7-4139-a6a9-1ce29c9e0411"
      unitRef="usd">5512000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie67728928c2f4b7c926568160fbfbb42_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzMtMS0xLTEtMA_42d062bc-f330-458f-9364-780345fa591f"
      unitRef="usd">2133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c2c78af9f724b04b7f633e772d609d4_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzMtMy0xLTEtMA_3989a18a-1cc5-4c0a-bda1-dbb640b7ca8d"
      unitRef="usd">1995000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee7edc452a8d41b8a7136478d6aca726_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzMtNS0xLTEtMA_d0289a2c-a4a1-482c-b8cc-39c36515a6ff"
      unitRef="usd">5821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i47470559910c4104a2b667fa430274d6_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzMtNy0xLTEtMA_b4602f2b-a54d-4652-855f-569f07790812"
      unitRef="usd">5552000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzQtMS0xLTEtMA_8d9d2e51-a335-4f7d-8b83-ace26a578e34"
      unitRef="usd">4573000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzQtMy0xLTEtMA_682eb956-5886-4431-a115-badd7b186e92"
      unitRef="usd">4001000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzQtNS0xLTEtMA_3c469b9a-b362-44c1-97e0-635170d8f547"
      unitRef="usd">12168000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTo5ODYxZTg4M2M2YmQ0ZjM1YmM4OTdkNzc2YmEzM2I2My90YWJsZXJhbmdlOjk4NjFlODgzYzZiZDRmMzViYzg5N2Q3NzZiYTMzYjYzXzQtNy0xLTEtMA_8ef51768-a9df-4227-97cd-f99051301a50"
      unitRef="usd">11064000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI3NDg3NzkwNzM2NDM_327c179a-13f0-436f-80f4-5470990c6535">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.491924%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.767988%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.005874%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67.8% - 72.2%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.7% - 68.3%&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.4% - 3.1%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.9% - 2.3%&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTphYTMxNTg3MzVjODM0ZjY3YTQ5Mzg4ZDhkNGZkMTY1Ni90YWJsZXJhbmdlOmFhMzE1ODczNWM4MzRmNjdhNDkzODhkOGQ0ZmQxNjU2XzItMS0xLTEtMA_38436363-18db-4080-ac07-cc330233dd11"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTphYTMxNTg3MzVjODM0ZjY3YTQ5Mzg4ZDhkNGZkMTY1Ni90YWJsZXJhbmdlOmFhMzE1ODczNWM4MzRmNjdhNDkzODhkOGQ0ZmQxNjU2XzItMy0xLTEtMA_d0bd279b-5ba5-4922-9da7-a540155c7498"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTphYTMxNTg3MzVjODM0ZjY3YTQ5Mzg4ZDhkNGZkMTY1Ni90YWJsZXJhbmdlOmFhMzE1ODczNWM4MzRmNjdhNDkzODhkOGQ0ZmQxNjU2XzUtMS0xLTEtMA_472a1947-088f-41e6-9488-37ef5cc671f4">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZTphYTMxNTg3MzVjODM0ZjY3YTQ5Mzg4ZDhkNGZkMTY1Ni90YWJsZXJhbmdlOmFhMzE1ODczNWM4MzRmNjdhNDkzODhkOGQ0ZmQxNjU2XzUtMy0xLTEtMA_d5b6f496-8241-49fd-a13a-78685a43d633">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzI3NDg3NzkwNzM2NDI_03564c3c-ad94-40a2-a1c1-294df3983af9">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes stock option and restricted stock unit (RSU) activity during the nine months ended September&#160;30, 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:26.970588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt; (in thousands)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,504,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,230,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(205,902)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited or expired&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(180,709)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,348,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,365,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,138,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzEtMS0xLTEtMA_fbf76825-fafb-4e7c-97c1-9891fec799c5"
      unitRef="shares">4504642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibd438d154f414b74a7d87ac6e9098fa3_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzEtMy0xLTEtMA_b5baa816-ece1-46b7-a199-d33f1df224e9"
      unitRef="usdPerShare">19.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5d0a400707884c2198f13e93d13ca5cf_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzEtNS0xLTEtMA_50c177b3-d430-475a-be10-a1df985198ee">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzItMS0xLTEtMA_186d88f4-c90b-460b-9324-197b4ca4bc53"
      unitRef="shares">1230244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzItMy0xLTEtMA_2bce10a8-0190-4c9f-a912-a32cff3a444e"
      unitRef="usdPerShare">27.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzMtMS0xLTEtMA_9708c810-e3b9-4785-887f-35218f168eca"
      unitRef="shares">205902</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzMtMy0xLTEtMA_2d78c540-55ad-4e24-a741-2c1d2c09625d"
      unitRef="usdPerShare">5.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzQtMS0xLTEtMA_7768d376-be8d-4689-89f9-79c3703e6813"
      unitRef="shares">180709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzQtMy0xLTEtMA_1cbdd7e9-2dd6-434e-b4b9-f3fbec32d461"
      unitRef="usdPerShare">24.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzUtMS0xLTEtMA_c27a5c10-1c46-4a78-b4eb-78d52140a593"
      unitRef="shares">5348275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzUtMy0xLTEtMA_276e82e5-8a4e-410b-999e-34b0bbbfaec9"
      unitRef="usdPerShare">21.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzUtNS0xLTEtMA_f3eaa0b4-7eea-4e4a-a24d-100504fb82c9">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzUtNy0xLTEtMA_63828017-9a74-4cdc-9f2d-a55b5ad2a09d"
      unitRef="usd">19762000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzctMS0xLTEtMA_f2352631-87dc-4094-b4bc-e431e75cc8bc"
      unitRef="shares">3365982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzctMy0xLTEtMA_2728063b-3714-4cd8-962a-af167d8f3477"
      unitRef="usdPerShare">19.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzctNS0xLTEtMA_b5df469a-cedc-4ed7-a136-c67d6c2a9bf0">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzctNy0xLTEtMA_f55bce31-d37c-4c9f-b62a-44d2283a94b7"
      unitRef="usd">18892000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzgtMS0xLTEtMA_633318f8-cedb-4042-8619-3965611a5bb4"
      unitRef="shares">5138801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzgtMy0xLTEtMA_8fb6d962-3ef9-4692-81f7-30bcd136a57a"
      unitRef="usdPerShare">21.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzgtNS0xLTEtMA_7fddaa67-3ff0-4913-8e51-c6599788319c">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90YWJsZToxMjc5NThiZDhhYTA0YzBmYTg4OWNmNjY0ODUyYjBkMC90YWJsZXJhbmdlOjEyNzk1OGJkOGFhMDRjMGZhODg5Y2Y2NjQ4NTJiMGQwXzgtNy0xLTEtMA_5d8c702e-0f55-4936-9ebc-42d6ddffcca9"
      unitRef="usd">19671000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzM2NzU_15a2d13d-b96b-4312-9fff-6f314579be3d"
      unitRef="usdPerShare">18.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzM3NzQ_2108f1c5-9e4a-4056-a866-7852ed9b39b3"
      unitRef="usd">4000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzM4NDY_76069493-7e94-44ce-9986-90fc826486e2"
      unitRef="usd">900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzM5MzI_c4a1218b-9850-44bc-976d-7d802551b516"
      unitRef="usd">11900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i160748b7708d470795cebd2e08cb1b72_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzQwODI_3bfe7bc0-3b57-45a8-b59f-7b72e8d7d6b7"
      unitRef="usd">28000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yMjgvZnJhZzo3ZDQwOGFiYjc1ZjQ0MTRhOGEwNzk2YzZjMWFmMmUyMS90ZXh0cmVnaW9uOjdkNDA4YWJiNzVmNDQxNGE4YTA3OTZjNmMxYWYyZTIxXzQxNzM_bcfc3db7-0d41-4a54-818b-21b3338a7258">P2Y7M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzI3NDg3NzkwNzA0NDU_e35d6b6b-a37f-4488-8f40-dfc28f74ad46">Net Loss Per ShareBasic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants. 5,348,275 stock options (common stock equivalents) were excluded from the calculation of diluted loss per share for the three and nine months ended September&#160;30, 2018 because their inclusion would have been anti-dilutive. 4,533,794 stock options were excluded from the calculation of diluted loss per share for the three and nine months ended September&#160;30, 2017 because their inclusion would have been anti-dilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2148cf3272754e1f879d4823913b518d_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzUzNw_0266b72f-7377-4331-8e8f-d6461e07f3d3"
      unitRef="shares">5348275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzUzNw_f1db0d81-235b-4eb8-961c-35a18183ea06"
      unitRef="shares">5348275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c071206cf7f4239b167641403572000_D20170701-20170930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzcyNA_4ba4e4c3-10ae-494e-aefd-807831b0713c"
      unitRef="shares">4533794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1fde2a049a54b829b2f5a29d4215cac_D20170101-20170930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVkNzI2ODc5OGVlMDRlMDdiYmQxZWQ0NmIzZTdkYWI4L3NlYzo1ZDcyNjg3OThlZTA0ZTA3YmJkMWVkNDZiM2U3ZGFiOF8yNTMvZnJhZzowOWU3ZTdiNzMyMjU0YTFkYWJjMmM3MDYzOGQyNTU0Ni90ZXh0cmVnaW9uOjA5ZTdlN2I3MzIyNTRhMWRhYmMyYzcwNjM4ZDI1NTQ2XzcyNA_b6dbee0d-0dde-447f-9324-13a3ce37d256"
      unitRef="shares">4533794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750170400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Nov. 02, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,259,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750602960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 201,807<span></span>
</td>
<td class="nump">$ 211,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">58,336<span></span>
</td>
<td class="nump">93,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">20,970<span></span>
</td>
<td class="nump">13,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,315<span></span>
</td>
<td class="nump">3,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other current assets</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">285,642<span></span>
</td>
<td class="nump">322,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">58,649<span></span>
</td>
<td class="nump">49,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">11,065<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">355,356<span></span>
</td>
<td class="nump">373,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">2,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">38,477<span></span>
</td>
<td class="nump">38,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">7,377<span></span>
</td>
<td class="nump">7,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Lease exit liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,025<span></span>
</td>
<td class="nump">49,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">14,134<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">10,553<span></span>
</td>
<td class="nump">11,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">72,712<span></span>
</td>
<td class="nump">74,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 42,248,075 and 36,859,077 shares outstanding at September 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">727,849<span></span>
</td>
<td class="nump">611,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(445,627)<span></span>
</td>
<td class="num">(312,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">282,644<span></span>
</td>
<td class="nump">299,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 355,356<span></span>
</td>
<td class="nump">$ 373,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated unrealized gain (loss), after tax, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6903545616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,248,075<span></span>
</td>
<td class="nump">36,859,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750938560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 44,327<span></span>
</td>
<td class="nump">$ 5,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">46,218<span></span>
</td>
<td class="nump">40,984<span></span>
</td>
<td class="nump">143,902<span></span>
</td>
<td class="nump">108,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,584<span></span>
</td>
<td class="nump">8,403<span></span>
</td>
<td class="nump">29,953<span></span>
</td>
<td class="nump">24,249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">55,802<span></span>
</td>
<td class="nump">49,387<span></span>
</td>
<td class="nump">173,855<span></span>
</td>
<td class="nump">132,495<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(35,004)<span></span>
</td>
<td class="num">(47,724)<span></span>
</td>
<td class="num">(129,528)<span></span>
</td>
<td class="num">(127,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
<td class="nump">1,759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,029)<span></span>
</td>
<td class="num">(47,043)<span></span>
</td>
<td class="num">(126,809)<span></span>
</td>
<td class="num">(125,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive loss</a></td>
<td class="num">$ (34,047)<span></span>
</td>
<td class="num">$ (46,987)<span></span>
</td>
<td class="num">$ (126,748)<span></span>
</td>
<td class="num">$ (125,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
<td class="num">$ (3.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">42,239,327<span></span>
</td>
<td class="nump">36,779,305<span></span>
</td>
<td class="nump">40,462,658<span></span>
</td>
<td class="nump">35,847,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue From Collaborative Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,617<span></span>
</td>
<td class="nump">$ 1,076<span></span>
</td>
<td class="nump">$ 43,670<span></span>
</td>
<td class="nump">$ 3,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue From Government Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="nump">$ 657<span></span>
</td>
<td class="nump">$ 1,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750911072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (126,809)<span></span>
</td>
<td class="num">$ (125,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">5,268<span></span>
</td>
<td class="nump">5,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,168<span></span>
</td>
<td class="nump">11,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,328)<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(1,164)<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(9,293)<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="num">(1,465)<span></span>
</td>
<td class="num">(2,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">9,460<span></span>
</td>
<td class="nump">9,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestructuringReserve', window );">Lease exit liability</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(1,176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(5,807)<span></span>
</td>
<td class="num">(2,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="num">(738)<span></span>
</td>
<td class="nump">6,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(126,006)<span></span>
</td>
<td class="num">(97,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(120,039)<span></span>
</td>
<td class="num">(89,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturities of marketable securities</a></td>
<td class="nump">155,848<span></span>
</td>
<td class="nump">177,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(24,239)<span></span>
</td>
<td class="num">(18,645)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by investing activities</a></td>
<td class="nump">11,570<span></span>
</td>
<td class="nump">69,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">103,259<span></span>
</td>
<td class="nump">34,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">104,516<span></span>
</td>
<td class="nump">34,989<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(9,920)<span></span>
</td>
<td class="nump">6,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">211,727<span></span>
</td>
<td class="nump">84,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">201,807<span></span>
</td>
<td class="nump">90,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash operating and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FairValueOfWarrantsReceived', window );">Fair value of warrants received, including change in value</a></td>
<td class="nump">$ 6,130<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FairValueOfWarrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FairValueOfWarrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6736608128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2017 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2018.</span></div><div style="margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="text-indent:18pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">With the exception of the adoption of Accounting Standards Update (ASU) No. 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> and all related amendments (collectively ASC 606) during the nine months ended September 30, 2018, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Effective January 1, 2018, the Company adopted ASC 606 using the modified retrospective transition method. Under this method, results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">accounting standards in effect for the period presented</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The Company applied the modified retrospective transition method only to contracts that were not completed as of January 1, 2018, the effective date of adoption for ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company also enters into manufacturing service agreements.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Licenses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Research, Development and/or Manufacturing Services. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Customer Options. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement, and the potential payments that the Company is eligible to receive upon exercise of the options are excluded from the transaction price. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Milestone Payments. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Royalties. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 5, Collaboration and Other Agreements.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">Recently Adopted Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2014, the Financial Accounting Standards Board (FASB) issued ASC 606. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts that were not completed as of January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with available practical expedients.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Comparative prior period information continues to be reported under the accounting standards in effect for the period presented. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:52.465593%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.678477%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Pre-Adoption</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">ASC 606 Adjustment</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Post-Adoption</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, current</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,202&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">540&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,742&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, net of current portion</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13,637&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,939&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,576&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accumulated deficit</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(312,340)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,479)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(318,819)</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The transition adjustment resulted primarily from changes in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">the pattern of revenue recognition for upfront fees and the accounting for milestones.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:232%;">The following table shows the impact of adoption to our consolidated statement of income and balance sheet (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:42.199706%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.096916%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.942731%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.292217%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,617&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,482&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">135&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,029)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,164)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(135)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43,670&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43,265&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">405&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(126,809)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(127,214)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(405)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.13)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.14)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01&#160;</span></td></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, current&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,377&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,348&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,029&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14,134&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,090&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,044&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(445,627)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(439,554)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,073)</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents changes in the Company&#8217;s contract liabilities during the nine months ended&#160;September&#160;30, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:41.024963%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.397944%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.572687%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.271659%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at Beginning of Period&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at End of Period&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160; Deferred revenue (current and non-current)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,318&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">500&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,307)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,511&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the nine months ended&#160;September&#160;30, 2018, the Company recognized $6.3 million in revenue as a result of changes in the contract liability balance.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the FASB issued ASU 2017-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation &#8211; Stock Compensation (Topic 718): Scope Modification Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The new standard is intended to reduce the diversity in practice and cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard was effective beginning January 1, 2018. The adoption of this standard did not have a material impact on the Company&#8217;s financial position or results of operations upon adoption. </span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">Recently Issued Accounting Standards</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued&#160;ASU 2018-11,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases (Topic 842): Targeted Improvements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Codification Improvements to Topic 842, Leases,</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#8217;s fiscal year beginning January 1, 2019. Although early</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> adoption is permitted, the Company has not elected to do so.  The Company plans to</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:115%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> carryforward of the historical lease classification.</span> Based on its anticipated election of practical expedients, the Company anticipates the recognition of right of use assets and related lease liabilities on its consolidated balance sheets related to its leases.  The Company has engaged a professional services firm to assist in the implementation of ASC 842, and is completing its analysis of the impact of adopting ASC 842 on its consolidated statements of income and comprehensive income and consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904852672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued expenses and common stock warrants.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The carrying amount of accounts receivable, accounts payable&#160;and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;    Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:28.633284%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at September 30, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">99,808&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">99,808&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,996&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,996&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,477&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,477&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,863&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,863&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,130&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,130&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">164,274&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">99,808&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,336&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,130&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:29.323529%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,990&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,990&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,990&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,990&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,418&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,418&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">b</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">155,910&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">94,398&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(a) Total assets measured at fair value at September&#160;30, 2018 includes approximately $99.8 million reported in cash and cash equivalents and $6.1 million reported in other assets on the balance sheet.</span></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $62.5 million reported in cash and cash equivalents on the balance sheet.</span></div><div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model.  There were no transfers between levels during the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6736558608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Available-for-sale marketable securities as of September&#160;30, 2018 and December&#160;31, 2017 were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:52.344624%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.751105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,996&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,996&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,477&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,477&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,863&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,863&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,336&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,336&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:52.344624%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.751105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,995&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,989&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,998&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,462&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,414&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,455&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(63)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,394&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All available-for-sale marketable securities held as of September&#160;30, 2018 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable securities in an unrealized loss position as of September&#160;30, 2018 and December&#160;31, 2017 were in a loss position for less than twelve months.&#160; There were no unrealized losses at September&#160;30, 2018 or December&#160;31, 2017 that the Company determined to be other-than-temporary.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904852672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' EquityIn April 2017, the Company entered into a definitive agreement with an institutional healthcare investor to purchase 1,100,000 shares of the Company's common stock at a purchase price of $21.50 per share in a registered direct offering.<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Proceeds to the Company, before deducting estimated offering expenses, were $23.7 million. The shares were offered pursuant to the Company&#8217;s effective shelf registration </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">on Form S-3 that was filed with the SEC on November 2, 2016</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $75.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended.  The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 2, 2016. During the year ended December&#160;31, 2017, the Company sold 599,284 shares of common stock under the sales agreement, resulting in net proceeds of $10.8 million related to the ATM Offering. No shares of common stock were sold under the sales agreement during the&#160;nine months ended September 30, 2018. </span></div>On April 2, 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold 4,500,000 shares of its common stock at a price of $21.25 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 675,000 shares of the Company's common stock at a price of $21.25 per share.  Upon closing, the Company received net proceeds of approximately $103.0 million from this offering, net of underwriting discounts and commissions and other offering expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6736558608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text">Collaboration and Other Agreements <div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Incyte</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012 (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a $150.0 million upfront payment from Incyte when the transaction closed in the fourth quarter of 2017.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. As of September 30, 2018, the Company has recognized $10.0 million in development milestones under this agreement.  If commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study&#160;and will continue to fund certain related clinical activities.&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The Company evaluated the Incyte Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">During the three months ended September 30, 2018, it became probable that a significant reversal of cumulative revenue would not occur for two development milestones totaling $10.0 million related to MGA012 meeting certain clinical proof-of-concept criteria. During the three months ended</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> September 30, 2018, the associated consideration was added to the estimated transaction price and was recognized as revenue and recorded as accounts receivable on the Company&#8217;s consolidated balance sheet.&#160;Subsequent to September 30, 2018, a third proof-of-concept milestone was achieved and an additional $5.0 million will be recognized in the fourth quarter of 2018.</span></div><div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company recognized the $150.0 million allocated to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">license when it satisfied its performance obligation and transferred the license to Incyte in December 2017.  The $4.0 million allocated to the clinical activities is being recognized over the period from the effective date of the agreement until such time as the clinical activities are transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs.  These clinical activities were substantially completed as of June 30, 2018, although certain minimal work is ongoing.  Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606.  The Company recognized revenue of $10.5 million and $13.6 million&#160; under the Incyte Agreement during the three and nine months ended September 30, 2018, respectively, including $10.0 million in development milestones and the remainder&#160;related to clinical activities.&#160;&#160;</span></div><div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company&#160;also has an agreement with&#160;Incyte under which the Company is to perform manufacturing services for Incyte&#8217;s&#160;clinical needs of MGA012.  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement - to perform services related to manufacturing the clinical supply of MGA012.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.   During the three and&#160;nine months ended September 30, 2018, the Company recognized revenue of&#160;$6.1 million&#160;and $16.0 million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Roche</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In December 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets  (Roche Agreement).  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate.  Roche would then further develop and commercialize any such product candidate.  Each company will be responsible for their own expenses during the research period. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $10.0 million which was received in January 2018. The Company will also be eligible to receive up to $370.0 million in potential milestone payments and royalties on future sales.&#160;As of September 30, 2018, the Company has not recognized any milestone revenue under this agreement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period.  The Company determined that the license is capable of being distinct, but is not distinct in the context of the contract because it has limited value to Roche without the research activities required to be performed by the Company.  Therefore, the Company concluded that there is one performance obligation under the agreement.  The Company determined that the transaction price of the Roche Agreement was $10.0 million.  The potential milestone payments are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and have been excluded from the transaction price.  Any consideration related to sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore have also been excluded from the transaction price. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The $10.0 million transaction price is being recognized over the expected research period, which is 30 months, using a cost-based input method to measure performance.   Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606. The Company recognized revenue under this agreement of $1.0 million and $3.0 million during the three and nine months ended September 30, 2018, respectively.  At September&#160;30, 2018, $7.0 million of revenue was deferred under this agreement, $4.0 million of which was current.&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Les Laboratoires Servier </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In September 2012, the Company entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). During 2014, Servier exercised its exclusive option to develop and</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> commercialize flotetuzumab, and during 2016 Servier notified the Company that it did not intend to exercise the option for the third DART molecule.  Servier retains the option to obtain a license for MGD007.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon execution of the agreement, Servier made a nonrefundable payment of $20.0 million to the Company. In addition, if Servier exercises the remaining available options and successfully develops, obtains regulatory approval for, and commercializes a product under each license, the Company will be eligible to receive up to $25.0 million in license grant fees, $53.0 million in clinical milestone payments, $188.0 million in regulatory milestone payments (excluding the $10.0 million for the flotetuzumab and MGD007 INDs noted below) and $420.0 million in sales milestone payments. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options.  The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package.  The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights.  As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company determined that the $20.0 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;Two milestones were achieved in 2014 when the INDs for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA).  Upon achievement of each milestone, the constraint related to the $5.0 million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenue associated with each performance obligation is being recognized as the research and development services are provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.  The full transaction price allocated to flotetuzumab and the third DART molecule was recognized as revenue prior to the adoption of ASC 606 on January 1, 2018 as the option periods had ended. The development period for MGD007 was estimated to be 75 months, ending in December 2018, therefore the transaction price allocated to MGD007 is being recognized through that date.  Upon the adoption of ASC 606 on January 1, 2018, the pattern of revenue recognition for the upfront fee and the accounting for the milestones received in 2014 changed, but there was no material impact to revenue recognized during the three and nine months ended September 30, 2018.  The Company recognized revenue of $0.5 million and $1.4 million during the three and nine months ended September 30, 2018, respectively, related to the MGD007 option.  At September&#160;30, 2018, $0.5 million of revenue related to the MGD007 option was deferred, all of which was current. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $15.0 million license grant fee.  Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808.  The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan.  </span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license.  The Company evaluated its performance obligation to provide Servier with an exclusive license to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">develop and commercialize flotetuzumab and determined that its transaction price is equal to the upfront payment of $15.0 million and Servier consumes the benefits of the license over time as the research and development activities are performed.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Therefore, the Company will recognize the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The additional potential clinical, regulatory and sales milestones are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and have been excluded from the transaction price.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company will follow its policy to record expense incurred as research and development expense and reimbursements received from Servier will be recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period.  During the three and nine months ended September 30, 2018, the Company recorded approximately $2.1 million and $4.9 million, respectively, as an offset to research and development expense under this collaborative arrangement.</span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The Company recognized revenue of $0.3 million and $0.9 million, respectively, during the three and nine months ended September 30, 2018 related to the flotetuzumab option exercise.  At September&#160;30, 2018, $12.9 million of revenue related to the flotetuzumab option exercise was deferred, $2.2 million of which was current.  The deferred revenue balance related to the flotetuzumab option exercise as of December 31, 2017, prior to the adoption of ASC 606, was $7.4 million. The adoption of ASC 606 increased that balance by approximately $6.4 million. The adoption of ASC 606 did not have a material impact on revenue recognized during the three and nine months ended September 30, 2018, however it will increase the revenue to be recognized in the future as the pattern of revenue recognition has changed.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provention</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2018, the Company entered into a License Agreement with Provention Bio, Inc. (Provention), pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications.  As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. &#160;As of September 30, 2018, the Company has not recognized any milestone revenue under this agreement.&#160; If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;Also in May 2018, the Company entered into an Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement).  As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share.  The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones.  If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase 2,432,688 shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company recognized revenue of $6.1 million when it satisfied its performance obligations and transferred the MGD010 license and teplizumab assets to Provention during May 2018.  The warrants are reported in other assets on the balance sheet at September&#160;30, 2018, and there was no material change in the valuation of the warrants from May 2018 through that date.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NIAID Contract</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.</span></div>This contract includes a base period of up to $7.5 million to support development of MGD014 through IND application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September&#160;15, 2015 through September&#160;14, 2022. In 2017, NIAID exercised the first option in the amount of up to $10.8 million.  The Company recognized $0.2 million and $0.4 million in revenue under this contract during the three months ended September 30, 2018 and 2017, respectively.  The Company recognized $0.6 million and $1.5 million in revenue under this contract during the nine months ended September 30, 2018 and 2017, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6736532880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2018, 20,231 shares of common stock were purchased under the 2016 ESPP for net proceeds to the Company of approximately $0.5 million. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Option Plans</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of 2,051,644 shares of the Company's common stock. Between 2006 and 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased to 4,336,730. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the Company's 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2018 there were options to purchase an aggregate of 826,333 shares of common stock outstanding at a weighted average exercise price of $1.93 per share under the 2003 Plan.</span></div><div style="text-indent:39pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the provisions of the 2013 Plan, the number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the nine months ended September&#160;30, 2018, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 8,244,131.&#160;&#160; As of September&#160;30, 2018, there were options to purchase an aggregate of 4,521,942 shares of common stock outstanding at a weighted average exercise price of $25.61 per share under the 2013 Plan.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table shows stock-based compensation expense for stock options, RSUs and ESPP (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:32.117647%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.794118%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.029412%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.441176%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.411765%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,440&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,006&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,347&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,512&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,133&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,995&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,821&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,552&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,573&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,001&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,168&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,064&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:63.491924%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.767988%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.005874%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">67.8% - 72.2%&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">66.7% - 68.3%&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4% - 3.1%&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% - 2.3%&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes stock option and restricted stock unit (RSU) activity during the nine months ended September&#160;30, 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:26.970588%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise Price&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value<br/> (in thousands)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,504,642&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19.79&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,230,244&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27.43&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(205,902)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.47&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(180,709)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24.25&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, September 30, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,348,275&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21.95&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,762&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2018:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,365,982&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19.70&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18,892&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,138,801&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21.79&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,671&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2018 was $18.07. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2018 was approximately $4.0 million, and the total cash received for options exercised was approximately $0.9 million. The total fair value of shares vested in the nine months ended September&#160;30, 2018 was approximately $11.9 million. As of September&#160;30, 2018, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was approximately $28.0 million, which the Company expects to recognize over a weighted-average period of approximately 2.65 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6591712048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants. 5,348,275 stock options (common stock equivalents) were excluded from the calculation of diluted loss per share for the three and nine months ended September&#160;30, 2018 because their inclusion would have been anti-dilutive. 4,533,794 stock options were excluded from the calculation of diluted loss per share for the three and nine months ended September&#160;30, 2017 because their inclusion would have been anti-dilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6643814976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2017 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2018.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Effective January 1, 2018, the Company adopted ASC 606 using the modified retrospective transition method. Under this method, results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">accounting standards in effect for the period presented</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The Company applied the modified retrospective transition method only to contracts that were not completed as of January 1, 2018, the effective date of adoption for ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company also enters into manufacturing service agreements.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Licenses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Research, Development and/or Manufacturing Services. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Customer Options. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement, and the potential payments that the Company is eligible to receive upon exercise of the options are excluded from the transaction price. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Milestone Payments. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Royalties. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">Recently Adopted Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2014, the Financial Accounting Standards Board (FASB) issued ASC 606. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts that were not completed as of January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with available practical expedients.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Comparative prior period information continues to be reported under the accounting standards in effect for the period presented. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:52.465593%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.678477%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Pre-Adoption</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">ASC 606 Adjustment</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Post-Adoption</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, current</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,202&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">540&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,742&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, net of current portion</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13,637&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,939&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,576&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accumulated deficit</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(312,340)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,479)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(318,819)</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The transition adjustment resulted primarily from changes in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">the pattern of revenue recognition for upfront fees and the accounting for milestones.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:232%;">The following table shows the impact of adoption to our consolidated statement of income and balance sheet (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:42.199706%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.096916%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.942731%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.292217%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,617&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,482&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">135&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,029)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,164)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(135)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43,670&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43,265&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">405&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(126,809)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(127,214)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(405)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.13)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.14)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01&#160;</span></td></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, current&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,377&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,348&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,029&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14,134&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,090&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,044&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(445,627)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(439,554)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,073)</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents changes in the Company&#8217;s contract liabilities during the nine months ended&#160;September&#160;30, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:41.024963%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.397944%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.572687%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.271659%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at Beginning of Period&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at End of Period&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160; Deferred revenue (current and non-current)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,318&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">500&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,307)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,511&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the nine months ended&#160;September&#160;30, 2018, the Company recognized $6.3 million in revenue as a result of changes in the contract liability balance.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the FASB issued ASU 2017-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation &#8211; Stock Compensation (Topic 718): Scope Modification Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The new standard is intended to reduce the diversity in practice and cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard was effective beginning January 1, 2018. The adoption of this standard did not have a material impact on the Company&#8217;s financial position or results of operations upon adoption. </span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">Recently Issued Accounting Standards</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued&#160;ASU 2018-11,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases (Topic 842): Targeted Improvements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Codification Improvements to Topic 842, Leases,</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#8217;s fiscal year beginning January 1, 2019. Although early</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;"> adoption is permitted, the Company has not elected to do so.  The Company plans to</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:115%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:115%;">elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> carryforward of the historical lease classification.</span> Based on its anticipated election of practical expedients, the Company anticipates the recognition of right of use assets and related lease liabilities on its consolidated balance sheets related to its leases.  The Company has engaged a professional services firm to assist in the implementation of ASC 842, and is completing its analysis of the impact of adopting ASC 842 on its consolidated statements of income and comprehensive income and consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750564016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of Effect of New Accounting Pronouncement</a></td>
<td class="text"><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:52.465593%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.678477%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Pre-Adoption</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">ASC 606 Adjustment</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Post-Adoption</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, current</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,202&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">540&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,742&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, net of current portion</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13,637&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,939&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,576&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accumulated deficit</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(312,340)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,479)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(318,819)</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The transition adjustment resulted primarily from changes in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">the pattern of revenue recognition for upfront fees and the accounting for milestones.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:232%;">The following table shows the impact of adoption to our consolidated statement of income and balance sheet (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:42.199706%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.096916%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.942731%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.292217%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,617&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,482&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">135&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,029)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,164)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(135)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="height:19pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43,670&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43,265&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">405&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(126,809)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(127,214)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(405)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.13)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.14)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01&#160;</span></td></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances without adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, current&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,377&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,348&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,029&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14,134&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,090&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,044&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(445,627)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(439,554)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,073)</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Contract Liabilities</a></td>
<td class="text"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents changes in the Company&#8217;s contract liabilities during the nine months ended&#160;September&#160;30, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:41.024963%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.397944%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.572687%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.271659%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at Beginning of Period&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at End of Period&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160; Deferred revenue (current and non-current)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,318&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">500&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,307)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,511&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22580-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e725-108305<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6741585024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:28.633284%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at September 30, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">99,808&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">99,808&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,996&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,996&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,477&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,477&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,863&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,863&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,130&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,130&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">164,274&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">99,808&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,336&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,130&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:29.323529%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,990&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,990&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,990&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,990&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,418&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,418&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">b</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">155,910&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">94,398&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(a) Total assets measured at fair value at September&#160;30, 2018 includes approximately $99.8 million reported in cash and cash equivalents and $6.1 million reported in other assets on the balance sheet.</span></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $62.5 million reported in cash and cash equivalents on the balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6741535072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Available-for-sale marketable securities as of September&#160;30, 2018 and December&#160;31, 2017 were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:52.344624%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.751105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,996&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,996&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,477&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,477&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,863&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,863&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,336&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,336&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:52.344624%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.751105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,995&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,989&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,998&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,462&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,414&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,455&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(63)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,394&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904827456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table shows stock-based compensation expense for stock options, RSUs and ESPP (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:32.117647%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.794118%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.029412%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.441176%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.411765%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,440&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,006&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,347&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,512&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,133&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,995&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,821&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,552&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,573&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,001&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,168&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,064&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:63.491924%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.767988%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.005874%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">67.8% - 72.2%&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">66.7% - 68.3%&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4% - 3.1%&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% - 2.3%&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock', window );">Stock Option and Restricted Stock Unit Activity</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes stock option and restricted stock unit (RSU) activity during the nine months ended September&#160;30, 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:26.970588%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise Price&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value<br/> (in thousands)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,504,642&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19.79&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,230,244&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27.43&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(205,902)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.47&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(180,709)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24.25&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, September 30, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,348,275&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21.95&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,762&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2018:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,365,982&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19.70&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18,892&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,138,801&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21.79&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,671&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752029584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">$ 7,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742<span></span>
</td>
<td class="nump">$ 7,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">14,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,576<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">445,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,819<span></span>
</td>
<td class="nump">312,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">20,798<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">44,327<span></span>
</td>
<td class="nump">$ 5,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,029)<span></span>
</td>
<td class="num">$ (47,043)<span></span>
</td>
<td class="num">$ (126,809)<span></span>
</td>
<td class="num">$ (125,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
<td class="num">$ (3.50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Change in Contract with Customer, Liability [Roll Forward] [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 21,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Calculated under Revenue Guidance in Effect before Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">6,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">9,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">439,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (127,214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">$ 1,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">5,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(6,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue From Collaborative Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,617<span></span>
</td>
<td class="nump">$ 1,076<span></span>
</td>
<td class="nump">$ 43,670<span></span>
</td>
<td class="nump">$ 3,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue From Collaborative Agreements | Calculated under Revenue Guidance in Effect before Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">20,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue From Collaborative Agreements | Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751039664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 11,065<span></span>
</td>
<td class="nump">$ 1,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">99,800<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">164,274<span></span>
</td>
<td class="nump">155,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">99,808<span></span>
</td>
<td class="nump">61,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">58,336<span></span>
</td>
<td class="nump">94,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">99,808<span></span>
</td>
<td class="nump">61,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">99,808<span></span>
</td>
<td class="nump">61,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">3,996<span></span>
</td>
<td class="nump">3,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">3,996<span></span>
</td>
<td class="nump">3,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">5,477<span></span>
</td>
<td class="nump">11,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">5,477<span></span>
</td>
<td class="nump">11,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">48,863<span></span>
</td>
<td class="nump">78,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">48,863<span></span>
</td>
<td class="nump">78,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Common stock warrants | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Common stock warrants | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Common stock warrants | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">$ 6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752175216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 58,336,000<span></span>
</td>
<td class="nump">$ 93,455,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(63,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">58,336,000<span></span>
</td>
<td class="nump">93,394,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,996,000<span></span>
</td>
<td class="nump">3,995,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,996,000<span></span>
</td>
<td class="nump">3,989,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,477,000<span></span>
</td>
<td class="nump">11,998,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">5,477,000<span></span>
</td>
<td class="nump">11,991,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">48,863,000<span></span>
</td>
<td class="nump">77,462,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 48,863,000<span></span>
</td>
<td class="nump">$ 77,414,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751678880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2018</div></th>
<th class="th"><div>May 03, 2017</div></th>
<th class="th"><div>Apr. 26, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,259<span></span>
</td>
<td class="nump">$ 34,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At the Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Common stock maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_PublicOfferingandOverAllotmentOptionMember', window );">Public offering and over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_PublicOfferingandOverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_PublicOfferingandOverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751503200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Incyte (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 44,327<span></span>
</td>
<td class="nump">$ 5,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Proceeds from royalties (percent)</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Proceeds from royalties (percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6903738192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Roche (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 44,327<span></span>
</td>
<td class="nump">$ 5,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,202<span></span>
</td>
<td class="nump">7,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member', window );">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement', window );">Potential milestone payments and royalties on future sales under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Upfront payment recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753028752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Les Laboratoires Servier (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2012 </div>
<div>USD ($) </div>
<div>performance_obligation </div>
<div>exclusive_license</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>component</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,798,000<span></span>
</td>
<td class="nump">$ 1,663,000<span></span>
</td>
<td class="nump">$ 44,327,000<span></span>
</td>
<td class="nump">$ 5,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742,000<span></span>
</td>
<td class="nump">$ 7,202,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfExclusiveOptionsToLicense', window );">Number of exclusive options to license | performance_obligation</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfComponentsInLicenseAgreement', window );">Number of components in license agreement | component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialLicenseFee', window );">Potential license fee</a></td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement', window );">Potential clinical milestone payments</a></td>
<td class="nump">53,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Potential regulatory milestone payments under agreement</a></td>
<td class="nump">188,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement', window );">Potential sales milestone payments under agreement</a></td>
<td class="nump">420,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfExclusiveOptionsToLicense', window );">Number of exclusive options to license | exclusive_license</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMilestonesAchieved', window );">Number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts', window );">Offset to research and development costs under the collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_LesLaboratoiresServierMGD007Member', window );">Les Laboratoires Servier MGD007 | Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFeeRecognitionPeriod', window );">Option exercise fee recognition period</a></td>
<td class="text">75 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Calculated under Revenue Guidance in Effect before Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,202,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Calculated under Revenue Guidance in Effect before Topic 606 | Servier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606 | Servier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Les Laboratoires Servier MGD007 | Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfComponentsInLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfComponentsInLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfExclusiveOptionsToLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfExclusiveOptionsToLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFeeRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFeeRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialClinicalMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialSalesMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_LesLaboratoiresServierMGD007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_LesLaboratoiresServierMGD007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904192928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements Collaboration and Other Agreements - Provention (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>performance_obligation </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,798,000<span></span>
</td>
<td class="nump">$ 1,663,000<span></span>
</td>
<td class="nump">$ 44,327,000<span></span>
</td>
<td class="nump">$ 5,383,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioInc.Member', window );">Provention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Number of shares available under warrants (in shares) | shares</a></td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember', window );">License Agreement | Provention | Provention PRV-3279</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Warrant to purchase shares of common stock, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">$ 65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Provention | Provention PRV-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Warrant to purchase shares of common stock, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">$ 170,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential milestone payments to third parties</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Provention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751265840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - NIAID Contract (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>USD ($) </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,798,000<span></span>
</td>
<td class="nump">$ 1,663,000<span></span>
</td>
<td class="nump">$ 44,327,000<span></span>
</td>
<td class="nump">$ 5,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Commercialization of molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FundedValueOfBasePeriod', window );">Base period</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement', window );">Additional development funding options under agreement</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement', window );">Proceeds from additional development funding options under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">Revenues From Grants | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FundedValueOfBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FundedValueOfBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904074832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Feb. 28, 2003</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,348,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,348,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,504,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,573<span></span>
</td>
<td class="nump">$ 4,001<span></span>
</td>
<td class="nump">$ 12,168<span></span>
</td>
<td class="nump">$ 11,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Payroll deduction discount</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent of the fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,336,730<span></span>
</td>
<td class="nump">2,051,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,244,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,244,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Potential annual increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,521,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,521,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,440<span></span>
</td>
<td class="nump">2,006<span></span>
</td>
<td class="nump">$ 6,347<span></span>
</td>
<td class="nump">5,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">$ 1,995<span></span>
</td>
<td class="nump">$ 5,821<span></span>
</td>
<td class="nump">$ 5,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6740665024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.80%<span></span>
</td>
<td class="nump">66.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.20%<span></span>
</td>
<td class="nump">68.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752172640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">4,504,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">1,230,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in shares)</a></td>
<td class="num">(205,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired (in shares)</a></td>
<td class="num">(180,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">5,348,275<span></span>
</td>
<td class="nump">4,504,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares)</a></td>
<td class="nump">3,365,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest (in shares)</a></td>
<td class="nump">5,138,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 19.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">27.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">5.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</a></td>
<td class="num">(24.25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</a></td>
<td class="nump">21.95<span></span>
</td>
<td class="nump">$ 19.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">19.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 21.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 19,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">18,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 19,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 18.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received for options exercised</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</a></td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750174736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,348,275<span></span>
</td>
<td class="nump">4,533,794<span></span>
</td>
<td class="nump">5,348,275<span></span>
</td>
<td class="nump">4,533,794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>42
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*FR]-GOSCXTO@ET+O^ZB^P)02P,$%     @ VX!G39E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " #;@&=-D;G[96\"  !Y"   &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'U6VXZ;,!#]%<0'+-A<DJP(4I*J:J56BK9J^^PD3D!K,+6=
ML/W[VH:EU![Z KZ<,V?&GF$H>BY>946I"MX:ULIM6"G5/4>1/%>T(?*)=[35
M.U<N&J+T5-PBV0E*+I;4L C'<1XUI&[#LK!K1U$6_*Y8W=*C".2]:8CXO:>,
M]]L0A>\++_6M4F8A*HN.W.@WJKYW1Z%GT63E4C>TE35O T&OVW"'G@\H,P2+
M^%'37L[&@0GEQ/FKF7R^;,/8>$09/2MC@NC7@QXH8\:2]N/7:#2<- UQ/GZW
M_M$&KX,Y$4D/G/VL+ZK:ANLPN- KN3/UPOM/= PH"X,Q^B_T09F&&T^TQIDS
M:9_!^2X5;T8KVI6&O WONK7O?MA)DY$&$_!(P!,!I_\E)",AF0C($J+!,QOJ
M!Z)(60C>!V*XK8Z8I$#/B3[,LUFT9V?W=+12KS[*N(@>QLR(V \(/$.@"1%I
MVY, A@3VV*/C?P4./B*!!1(P@L32DQD]A>DI2$\M/9W1,^< ?$0."V2@0.;1
M5XZ CUC# CDHD'OTC2/@(U ,*ZQ A97/1X[$ ,DLI!VN.48+8:Q!D;4OXF3*
M?H#D<\A"JFQ B8TOD3H2 "2#)5 ,%U3L6\C=DHJ]TT((9TFZ)+50N\B7<G,+
MPBQ<"P(+>(>P;\%-, "#%S(,P56,$M^"FV, 9BD4N-:17\K8S3$ LR0"USOR
MRQDGSB=OQ,P3(,4XV\1K]]2BV8>\H>)F>YX,SOS>VH8[6YWZZ@[;1O 7/C3E
MKT3<ZE8&)ZYT.[$?_2OGBFJ'XB?M2J7_ Z8)HU=EABL]%D,S'":*=V.CCZ:_
MC?(/4$L#!!0    ( -N 9TV;NT6=T0,  *P1   8    >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&ULA9C=CJ-&$$9?!7&_"U7] XQL2S%1E$B)--IHDVO&;H^M
M!>, ,]Z\?1K,6+BJ>G-C _ZJ^W0#QPVK:]M]ZX_.#='WIC[WZ_@X#)>G).EW
M1]=4_>?VXL[^ET/;-=7@=[O7I+]TKMI/14V=8)K:I*E.YWBSFHX]=YM5^S;4
MI[-[[J+^K6FJ[M^MJ]OK.H;XX\"7T^MQ& \DF]6E>G5_NN'KY;GS>\F]E?VI
M<>?^U)ZCSAW6\4_P5&(Q%DR)OT[NVB^VHW$H+VW[;=SY;;^.TY'(U6XWC$U4
M_NO=E:ZNQY8\QS]SH_&]S[%PN?W1^B_3X/U@7JK>E6W]]VD_'-=Q'D=[=ZC>
MZN%+>_W5S0,R<32/_G?W[FH?'TE\'[NV[J?/:/?6#VTSM^)1FNK[[?MTGKZO
M<_L?97(!S@5X+P#]PP(U%RA2D-S(IJ'^7 W59M6UUZB[G:U+-5X4\*3\9.[&
M@]/<3;_YT?;^Z/L&]2IY']N9(]M;!)>1QT0I),P]DOC^[Q H0N!4KY;U5JY7
M8KV:ZO6R/B.#N$6R*7*^15+(4Q(KA1A MFCM@4:+-)K3Y(3F%C&+;DRNE"4P
M/%4H56B9Q8@LAK,4A,6P7C MLI2P\!0HJY7,8D46RU@4Z65K62]:@2$H/.0S
M()-D(DG&28"09'Q6@-P8)<^H/# CN<B1<PYR:VUSSI$;J^D=R&,*$8M<IBE$
MFH+3*$)3"->MU>2**GE*%T5H9B"5O91R&B:FE%^4D%IZO4@QFV( )Z!)X#B&
MX@ _"<8H0V]K*9>I/#A!LC.!2U,%I FR-8%K4U%MSID'!^5L0#R$.G1'@BQ-
MX-94U)K A:ARG5&'BS&3AWAD<0(WIZ+F!"[%3'$<(87!RT]6)W!W:NI.X%Z$
M%*C'Q90.> )D?0+WIZ;^!"Y'AB(X-F0LD 4*W*!4C5O@;H2,.>+'H4<669_
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MSK]L['^#Z,!+26[\"'7^@RV&A,:%XYT_FVG,)L-A/_\@MGSC\A=02P,$%
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MCF">?4Z1KJ4XIO_ TW7X=E7A-L*W?RC<KQ/L5@EVD6#WWQ+78C[]E80M>JK
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MR6Y$R.9V<%"MGPN-*CD*/Y,;[SIZ#XF_7?_@\]Q^HZKMA487:>P=]3>ID=*
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MC-\'OAU?#F4]$"SFY_C%?K?E7^?'O/H*KEKVQ]2>BF-V&N7V^7[\ +.M,+5
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MK7QGDVHI#C;>7S\2^US6KZ9ZS]N[Y/:CS,[=/7EPO:Q?_ ]02P,$%     @
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M;L]^K)F*E^%'%VC0/%\T_$;#[Q4;H%!72=@F<,V"PRQXOU[<99'@  (&$'T
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MCR O!TUY&AZOAM=GO.O_ 5!+ P04    " #;@&=-6A6'<TX#   +#P  &0
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MY7O3M6?=0/"#:3V#OO]=_ -02P,$%     @ VX!G3;YOD5GV @  X@P  !D
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M2GT;J?NJ.74W \E+\T7AM)\UBW]02P,$%     @ VX!G359TR;%< P  X0X
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M+IB,WK^3D[67]\WN(V=;H5YC^5ZUEZ[V0_"#OE!ZW:UV]@]02P,$%     @
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MO5?MU-LNI#B:B3[H_JV8_0502P,$%     @ W(!G3?^@E0JF!   TA@  !D
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MN1Y35_%]@3UG5HIO"[RA.:,PQ178%G@]0J-ZKB'4#05CGBF^-/.K#+[@2B3
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M>^/PR)F"@57@X:'2@-+K?._BD3BPC3$!^H>&<8C;P!A-=!##EL>NYPDAPV"
MZ\ET--A^&/!?,K*W,6Q _ D'8MB"&/"@VTCZB4;"/L20$9U&ND[$"9JL+6Q&
M#+C1[21@Q_]T$G8DABPY/,=:4"^W<"(6@;U+$! K&I& O4OP[;N&C'Q=75LZ
M7T<"N!(\5H.KBXR][/Y@\I"5RGL5VMR)ZIO+7@C-C2BZ,]TZFOMU-\CY7MO7
MQ+S+YI+9#+2HV@MTT-WBE_\ 4$L#!!0    ( -R 9TT>-0#8A@(  'D)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;)56ZV[:,!1^E2@/T-BY.50!
M:5#H)FT2:K7MMP$#49,XLPUT;S_;<2DD!Y3](;;S77R.SR'.3UR\R3UCRGNO
MREJ._;U2S6,0R/6>550^\(;5^LV6BXHJ/16[0#:"T8TE5640(I0&%2UJ?Y+;
MM:68Y/R@RJ)F2^')0U51\7?*2GX:^]C_6'@I=GME%H))WM =>V7J9[,4>A:<
M539%Q6I9\-H3;#OVO^#'9QP9@D7\*MA)7HP]$\J*\S<S^;89^\CLB)5LK8P$
MU8\CF[&R-$IZ'W^<J'_V-,3+\8?ZP@:O@UE1R6:\_%ULU'[L9[ZW85MZ*-4+
M/WUE+J#$]USTW]F1E1IN=J(]UKR4]M=;'Z3BE5/16ZGH>_LL:OL\M6_2D:/!
MA- 1PC,AO$^('"'Z)."[A-@1XJ&$Q!&2H834$=*A!.((I$,(VNS:XWJBBDYR
MP4^>:"NNH::P\2/1!;$VB_;\[3M]8E*O'B<A2?+@:(0<9MIBPBM,>HV9 1@<
M7V.>($Q'9SY 9S% YQG Q)]Q!3HGY\2$8&)"*Q!=F1!8( (%(BL07PBD82=I
M+8182-UZ(#+*$$*=S/6!.$VC'F[>Q\5Q%)(><-$')E%V)7@580Q&&/<B#,F-
M%"6@0#(\QRDHD ([R#K5VV*2RR3#%@2T((#%J&-!>MDD"4(WLYF!1EG?*.L<
MVS3KQ8()NN,T IU&@!/N.(WZI1G?BPDC^.\% 5YAMU=1O[Q1=L_LQG\9!LRB
M&Q)PU^/_:'L,]ST>T/@8ZGS4[WL %P.X.8!+ =P"P&'P5(.+[X>YE/R@8E?4
MTEMQI3]%]H.QY5PQ+8H>=#WN]3WH/"G95IDAT6/17@;:B>*-N^@$Y]O6Y!]0
M2P,$%     @ W(!G34@\ #X=!   @Q,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&ULC5AK;^(Z$/TK47X \3L) J062EMI5ZIV=>_]G()Y:).8FYBR
M^^\W#Y?%]F1)/Y3$G)DY'L\<&\\NJOI1'Z34P<\B+^MY>-#Z-(VB>G.0159/
MU$F6S3<[5169;EZK?52?*IEM.Z,BCPA"(BJR8QDN9MW86[68J;/.CZ5\JX+Z
M7!19]>M1YNHR#W'X.?#MN#_H=B!:S$[97GZ7^I_36]6\15<OVV,AR_JHRJ"2
MNWGX@*>OE+0&'>+?H[S4-\]!.Y5WI7ZT+Z_;>8A:1C*7&]VZR)J/#[F4>=YZ
M:GC\;YR&UYBMX>WSI_=U-_EF,N]9+9<J_^^XU8=YF(3!5NZR<ZZ_J<N+-!/B
M86!F_T5^R+R!MTR:&!N5U]W_8'.NM2J,EX9*D?WL/X]E]WDQ_C_-8 -B#,C5
MH(G]-P-J#.A8 V8,V!\#]E<#;@SXV C"&(BQ$6)C$(\U2(Q!,M8@-0:I8Q#U
MZ]<5Q"K3V6)6J4M0]35]RMK6P=.T*;E-.]A56/==4Q-U,_JQ( F;11^M(X-Y
M[#'D%H.)C5GZ&)[:D"<?@J^(J"%Y94H@IH_$9Y%PAP6 L1$K'R&0P_.ND_5]
M)\^ $X?L"S0A86->(4P,9XV"ZTL[!]1RD, .&.B =0Z8Y<!9V66/X1VF[!>?
MLH3$SHR?1N*>?1SCB E&8.(<),Y]XJFS2LL>D]P$(GB2NK1'H9Y]%$XG<0I3
M%B!EX2]6.M C,>@@!N;L=FJ/B:WDQM1I$P"$$';RXH,PP2)QF@5 8208/*T$
MG%8"3(O"#E+003J^"S""=1(!'#RA1%[A)JC]&P@U(,D8",7=4!!(#,0!!?4!
M$\!%[,:!0$.I@R4(4\"%MSE0+W4$$3I0_1C6*NR+%46NO!O0;4'RP16"I07[
MVD+1$%6XU3'0ZX,E"3<[AKK=*<D7 [*TE%(14R<MKP"0((X%&^A4#+<J!GK5
MVR\,R.H3(BBE[E+=Q=F4X.;'Z8B=P( L^9ZD'J$[*/L8 RL)\96$HH&=C< *
M0?#XXB%P\Q.HKYWB61J0G7_&,'5W@A% FQ2L%,17"HJH2\I7"IP*Y&T\3R.
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M$.[+S8&RQ9'+TH") ^X@@#B(\-4&ZZ\,*F4>8L(M!! +$;Z,'&A94YH%7A:
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M*7AFQL^WC/5RE19WV?HN>EWD#]4BNLI7FV3=&%2>OEDERV7T?%MFZ[1L -A
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M$R&2PC-)B-5>+9+U'9RGOQB2B&BNQX@_]$)^2.1X?PP0#AT)7YW][UQO@>
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M4WOF=/?@,7M-<>T"0G-@%J()[)!]!P4CT-_3TAA. =QP$9"23^5J1OEME61
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M^@O8&=TS@:>1OXRZ@?2IH3/:7U$')1$J1PI"#]\">YMG"B@R$4D3S,7QI(U
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MF_YWR%]]Y28Y:+<)VED5H.M&=4: -@2I\B8\S16VB+#/0&0LY+Y6XXVA$-J
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MO" -0/I"@;$+V,''0TYAG<L,= /(,#E#*[Q&U0-:?QF_4[.O$R_WQD6HHOV
MR_3)DZ>LCM?.)A;=U#?C.3N8M7V@/P7N@+$U9T"(D\+%T?,:+)WI1A\$SDNL
MCHG)GV293<ENP4DH3O'1!\O+28[(JR8S'[IZC-8L$ $:*$5K*K+)4^H=^9]P
M0HS&YRMK,JAM##\:C*:2A/I'$$7N\4G A?_8+G>*-068Q'FGWW?7G GL^6B
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M<?"%HLINML]J703U#I7MM'QSN)V)W,7"%C-WD"<A_%!O42+$7F-5*QAZ9I5
M  ('9^;S.=I#]F&$F<S2][;.>*K;C]SD39$NL%<M7G>LVJ285!-OGS3*DY,\
M_&(!@WJ8YZA[T1;E^6CH*%]X*[<Z4E0>^JOLM:_RJR7G.JWWZ*Q(H$;F:Y><
M^P.WM#VB\[[!:Y(TG-'@0.P *X^UIFDF)^<Q,[-1,% VYY#.&W/\T<2I,,WV
M6H;ODFV>3&,L=\DZ;W>-XI?'C':X3==3:G8Q]FW!\%LK49C=>&)#E;=D(W&$
MHPDTWZ\)HQPC*BQ5\L*D//S>E;DZWQL*TBC*PQ*'&NEYEL<2^^R^/8V]"D[-
M# <3[:$&:M3>J=6=@0$W.4N10BA,,=%FW8L7O7XO.@'$3C <[_KCGSO#P>0"
M:^Q$5R^&@^?1C_#OY.)YS5XCD84\>CISUGF,U#?D.-E6>;9:8?Z.JFM#.BG)
MHU2THI[(C:.HO3; &NM?;9R9IU%*666O)IRK^>1>5]EUM7)PZI*J>G!>.3B^
M(V8J(,(4XI,SMDP0?P=G5$%%+?<)PQ#,23TZY&!\]A/KU0SJ00L_N5[-3X@H
M_BD5:MC/)3[\AM]>HB$]Q=$O2N'"O:2$FRE/SWX J:'+U7:Y^:"CE[<%.[\+
M(,CK+\5V4TVMA\EEMF/IP)U&(.,LY)A<&I1Y!08*3>N!R8PXM<@LH8V4=,PL
M08T/=V6Y3"G#&!\"!.0F Q(7(#M',T[E1R.HB HT_U$_+*)_(B[8]$DS@1D#
M:WQ2 XJCJ.R:JW]'U^9:MU/;)E55/R93$X_LIO+2!JB7!8(JW0!:<0B;)I*]
M89]H9*CLV%&TL=IMTJ@/_#2Y3;$=PTG;QDZ/H)=M[_Y&*RVM[*%T]4A2V:\G
M6#P9;?RER9:"*^7$X97CFAXNRLF5!E=V5&U-0LTQ/'GL%ZBR\=0@JP'YX!H8
M=WAL>L&FH5:#9MF"G@%GM*WK61->^S6=1:HEZ-O"B7,F[T+O-VR\9>*FFG(K
M(&8E]W B[WFM &?;9>Q&KS@+*ZZ-I),CZ@%G23/:#%:'G6NE49VMC% /2V G
M/)%IKHZD'3;P]%K:F$K3&)&5V>R.(K+-DI+;4^-$)/-*50$$XKXPMGWB')U6
M*U$_)MPM8+_=J>@6\6()'::08@EPL3DN]62B/96^K+4WJ>S[+:6^2++V4H"H
MWA&=C>4J/R$E1;,SAZ2D&*ITTMB/B_"KY*L&3SRF;4BBV<$@'@T'\?C\/,@8
M:M64G[S(4K3>DO@(D[;4;?6D&U572N]!Q>K*'G\K&?3?LV209_W<_;<K\'.$
M_4XGDS^F:HI4<:B531%"YD5).J%8ZFXBFW#D2.P]1J#WI#^S[T<T>PD7R5?Q
MI8TX RDF)ZI..Y4C)##+C (A%^_?7+YY ? 61N&QN'HFD#QCJV>_-Z6)3:H/
MNP9!T"CN=I)O0J5@T'[_ L1G;BA-4X)NX>K$U/L4],\( F>QKAQAPLSK9 P7
M-[LG8++@A-RMGMOC9#PZ[9$7+&]V%A"?C=NL,J&E?N8X6Z0X)+__W:!>7E$,
M<T6R2;<5^M'O.(4A5,05+_IZNA/J1=9$HTV5,7OPJ&(#E7;&VS/G7#]Z>0&H
M"K< +5$YUF]'USV,=9\5 /F3/[[Y\ZF\0*9//G-;>\*(W7<YQA#IT@N6A!B8
M;%N %O#&N-(60AUE6C9EJCC]>GBV&IL28+<5ONZ[G[GK-(;7!9L_=)X3R<6E
M8&(S[KK^G.O7BN/I)VT+R2MTK<71#?)D(>+7ACNV5R-O6T#T<K59YKLTC>@)
M)PM>8ZA$6ZL!JY26JO6$+;A+3U(ZU=[!3]QC-]?7ITRM[-]45[0JMA1Y+T4W
MJ<<K$=/4#,R2B&LBL4Q,!O*-R-FCP= 5V:2R)4L;_'@%:,G- L['NEF +:^"
MF***]S8%8OS&[O)CBB'+1 +>K)'9F+X$.]>58#*J\Q+JXC&+SANM,SQAB]I/
MEJCP3%,EGEMXU<%G6MX;1=9 K&RQ.(1.MV%R<$TQ#<T&P:S(B2)1BPV!"E.\
M?N\;&3DKW$*F"OO\RLC2_ISC](W-VM^5!!>83E@_=LB1$=EF'B;D4,($Q=(!
M2A2>I^VG,.S9F%]I=\,B/V;SF1]J0\8*@%1<6C3H.B0!2N=G9MO<5$LJA]K>
M6@<A+;QXF93(#IUYTE^1YS0]SJDSZ,4#@,6^-@QF/[,0CA'4O180O@V!S)6^
M?4"%V'7KY. #>[FNJ>7]2\MV7Z6WA53HZ U]YI=A>2"\7Y;(](:FFQ?<.!2#
M[@UUH=_PXZG<9@[,EAO.PK4A6+ZI]ML:7:.PO=Z9P449%E@28#05Z>;+IBR.
M5IM/.%2*3%ALCR6+KK*U8*F^N'?6C\>CT5%M<[K1<^F:-NB))N[2I5<)@'Z[
M.JR[)=MJ 1OXNXVQE32CFM%:(X'9]P.U';;.S3P:88NN>#+L=>5@3<Z!L7R&
M1A'3O1CK,WMXI3>":OPB*PO3\),W'Z].J<4W%@]Q?,(;C;(> 5:"5/Z.G ^!
MT66=V^(]<HBR8@&4LI!0[!9J7"VPUC2.APH!A!.CR$0;N]5PV_)"G!,/:.PM
MR1].;>[CB%KI+O$3X-X\I?PF:D;O+K+Q74CK'E+'6(6VX:<QOZ.SB:0*O]T$
M&]=Y\['1#HG'N<S?%A[E\!B!+SC2O*Y]>UW%TFCR&V /=7QN]W(9S82:-;G<
M?$NGZY?O?# &]!VVG1W*>9BX0XY<Y( /*1KHD(!(=:J $;[?O1BJ_E6!TVZ/
M]1."RX_%QQEBK SA'0"7,]J".)M0I]CESGGQ==2ZQPM9N/8CVD>1:]\T4SJ+
M]]1@&)LKBDW9>+W8];0?7XQ[<7]LK%@QM1 ==:UP(+%D!W>ICR)?Z_ -9W:'
M[S@ $[N$SF [N"?"[I/IZ7' ]+N;D^TNATM+$2/4>"S'KIV/YKT_-W7NMU'G
M\W@P&L7]8?^ 9_@QEV84GPW@7$>#)[TV@[/NN-]R;_KFWB /5LTAN/7@ D5=
MFEDT(BUDVD MDADU0XBCCS>?V?I"XDV]V^8G"IIYQT?[,G"T[_'H]_Q.!(F:
M"+I/']OBR9ZAP7?4HW^1LV/OZ.%H@DTPJ:OPZW0-H%NRY*(RV^[14MP'$M:G
MYI9G,<B4^,K90-I,'@3,,SS0R9#^[?7ZV-)X0#?V&;:W[(U'@0ZQ+"2S!$=<
MC4S KKT>R["FU"X+1(]I&JMK\*/'9V/2"UBPKF$ 'JU!7+DKC6:R)A8FG7W_
MB(-[::H7S3+4/ #VNPR;;4H/T&_<!_OD?8XIGY0".9YTS[^).M%DT!U\$XW'
MW0G^-3[O#K^)/F;EE\X<,<PZOJE@S* [PH>&W?XW$7 2_#S Y^WX2)^B<7=P
M1M2MU!^#MV.[ A6$'+(:^\78#CB432LK*FW7(">?P+4X-3&QN\?V7ON>;1-E
M]!>Y\QWWZ5)N_Z6E)A\<I8@#S3<!,7LCD(VQ/VK_HCNYB+ \T6L1+/N@S_20
MOD6#27<$JH#-IP%YXBR^Z U.H[,NW*%76CAB(0N>Z9_WXDGOXC0:C!"$WE("
M^' &UQ&HZ>0L&L"YG-%*<%7Q9#QHI:W?FT7160SCX1C6=3Z@S?0BK#8*]/?\
M8A#].:4^$W@JMF(6T&#LM@8S]X?P%%Q-F%E@ /..)WTV\1KP&N)*UZU#E\^_
MM77)_)%'*^77SKL]J=G-K#O#8D#K,ILV)W(93E\S5;WGEZ[-:K,::0G4']Q%
M0"MRX%80&%%%V.H-^4 3'G?/!R04Z&OWT._K*??':O%BL'FM]3<$Z;?R[:#Z
M(PNML;HU)[^;9T5=0$NCH=IE'%KPX%Q#O1DGR<A:^LDE7#^VB9A"B1MV@D%W
M+"2L83I]#^M^BR'DUVC4PZ-H=,U-"BQ!I)[88PAM#O<\0<SEWL(4N\!R#+>>
M+6OR('$!#LHHT=H#B'^[K8PU2,M QGH@,EL#%$X(U#.6GNC4X&&QBT3SO'MU
M^0LC&^Y1!L8LC!?9DJHJV"W:O2$V;:O:SDB$?_K=U=?E;505@[9E-RO;P9M>
ME5P66/56)%M[,BQJX"Y1&&('3M.(XC$_(H  &T?3?</#2=NR3]LJ*8#*,:7V
M''P<LS#0736-(^*Q_^U_]<>]'RPU45V_LH+UL)(<-11RX3S$&!#7,>#H(@L=
M#N/)Q:BVQ5]I'Y.OW$?](N.UE9 (D*C7E2N6?:.\[I<NE_H:$V_0M7UB/IT>
M->9Q$R/&8L@+81O7@DQ 36:.@>[1E9\_,\<*GIPK:3)IN!Q^,BUR$/6S:6F"
MUA4:GRKP@+;+B5F!,@^?NS?=Z(X5!K1/3K'K2#K3J>4@;</\&Y2_3UY?7EYS
M$UBS5K>\;,V%KRV+#*[<I/UB0C3WS)(R9[I\X9IKYJ]Q/$ITVQ9$W]0+IRX
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MDNF*$'L?8GQ,[[#2 <+J15:@#OL!%5ZX)(VNN+9=J]DCFWW1BP# (6\!_])
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M0T%:IN]MB2Z8X,G^;(5'RW'7:J1(\&1_@9RV_,HEG!Z%Z0]02P,$%     @
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M+G)E;'-02P$"% ,4    " #;@&=-)^B'#H(   "Q    $
M@ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -N 9TT5YK!Q[P
M "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( -N 9TV97)PC$ 8  )PG   3              "  ;<"  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ VX!G39&Y^V5O @  >0@  !@
M             ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( -N 9TV;NT6=T0,  *P1   8              "  9T+  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #;@&=-ZSPQR^@!  #U
M!   &               @ &D#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ VX!G3:O"1>P"!   ?1$  !@              ( !PA$
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( -N 9TVJ"F\P
M#00  /H1   8              "  ?H5  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #;@&=-8;$MYK$!  #0 P  &
M@ $]&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ VX!G
M354ZI4JS 0  T@,  !@              ( !)!P  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( -N 9TVA_1#WM $  -(#   8
M      "  0T>  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #;@&=-1E9//K4!  #2 P  &               @ 'W'P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ VX!G36 /MQRT 0  T@,  !D
M             ( !XB$  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #;@&=-2M=KS;0!  #2 P  &0              @ '-(P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( -N 9TVMBB+UM $
M -(#   9              "  ;@E  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ VX!G3;G,'I+- 0  G 0  !D              ( !
MHR<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #;@&=-
M/1*:]<(!   W!   &0              @ &G*0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( -N 9TUG\[;SM0$  -(#   9
M      "  : K  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ VX!G38E]'ZNV 0  T@,  !D              ( !C"T  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #;@&=-K"DG#]0!  "<!
M&0              @ %Y+P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( -N 9TWN)R$%N00  +@7   9              "  80Q  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ VX!G32%U-B//
M!   [QT  !D              ( !=#8  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #;@&=-6A6'<TX#   +#P  &0
M@ %Z.P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( -N
M9TV^;Y%9]@(  .(,   9              "  ?\^  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ VX!G359TR;%< P  X0X  !D
M         ( !+$(  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " #<@&=-O$B,. X#  !B#   &0              @ &_10  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -R 9TW_H)4*I@0  -(8
M   9              "  01)  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ W(!G3:D0G)?6 @  T0L  !D              ( !X4T
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #<@&=-'C4
MV(8"  !Y"0  &0              @ 'N4   >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( -R 9TU(/  ^'00  (,3   9
M  "  :M3  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MW(!G30$ 4I]4 @  ( @  !D              ( !_U<  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #<@&=-  ![)I8#  "4#P  &0
M            @ &*6@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( -R 9TU3A.^*#0(  )P%   9              "  5=>  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ W(!G3=E%![X+7
MGH<! !0              ( !FV   'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @ W(!G36Y8M7\S @  (0H   T              ( !V+P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #<@&=-[*LK@2<#  #H%   #P
M        @ $VOP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ W(!G356@
M+.EL 0  'Q,  !H              ( !BL(  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ W(!G36F&>SB( 0  U!,  !,
M     ( !+L0  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "< )P"#"@
&Y\4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>160</ContextCount>
  <ElementCount>170</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2105102 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2306302 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2309303 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Collaboration and Other Agreements - Incyte (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails</Role>
      <ShortName>Collaboration and Other Agreements - Incyte (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Collaboration and Other Agreements - Roche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails</Role>
      <ShortName>Collaboration and Other Agreements - Roche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CollaborationandOtherAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Collaboration and Other Agreements - Les Laboratoires Servier (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails</Role>
      <ShortName>Collaboration and Other Agreements - Les Laboratoires Servier (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Collaboration and Other Agreements Collaboration and Other Agreements - Provention (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails</Role>
      <ShortName>Collaboration and Other Agreements Collaboration and Other Agreements - Provention (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20180930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Net Loss Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/NetLossPerShareNarrativeDetails</Role>
      <ShortName>Net Loss Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mgnx-20180930.htm">mgnx-20180930.htm</File>
    <File>exhibit31-1q32018.htm</File>
    <File>exhibit31-2q32018.htm</File>
    <File>exhibit32-1q32018.htm</File>
    <File>exhibit32-2q32018.htm</File>
    <File>mgnx-20180930.xsd</File>
    <File>mgnx-20180930_cal.xml</File>
    <File>mgnx-20180930_def.xml</File>
    <File>mgnx-20180930_lab.xml</File>
    <File>mgnx-20180930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>48
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20180930.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 160,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20180930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20180930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20180930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20180930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20180930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20180930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 286,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 14,
    "http://xbrl.sec.gov/dei/2018-01-31": 10,
    "total": 24
   },
   "keyCustom": 38,
   "keyStandard": 132,
   "memberCustom": 25,
   "memberStandard": 17,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20180930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://macrogenics.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Collaboration and Other Agreements",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreements",
     "shortName": "Collaboration and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Stock-Based Compensation",
     "role": "http://macrogenics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Net Loss Per Share",
     "role": "http://macrogenics.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306302 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309303 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i160748b7708d470795cebd2e08cb1b72_I20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRevenueCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)",
     "role": "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i6bab00c844a44b45bc42e1f5791cae02_I20180101",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredRevenueNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i160748b7708d470795cebd2e08cb1b72_I20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Fair Value of Financial Instruments (Details)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i723d050a26224f16a353738eb4442e04_I20180930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i160748b7708d470795cebd2e08cb1b72_I20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i160748b7708d470795cebd2e08cb1b72_I20180930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i160748b7708d470795cebd2e08cb1b72_I20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i160748b7708d470795cebd2e08cb1b72_I20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ib8b8d6b8d41d4fd494c10b56288a758f_D20170426-20170426",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Collaboration and Other Agreements - Incyte (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
     "shortName": "Collaboration and Other Agreements - Incyte (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2c2f267ad6954342818988358aaec05a_D20171001-20171231",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Collaboration and Other Agreements - Roche (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
     "shortName": "Collaboration and Other Agreements - Roche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i304e6e07763f45adac1a934bb867bb1b_D20180101-20180131",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Collaboration and Other Agreements - Les Laboratoires Servier (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
     "shortName": "Collaboration and Other Agreements - Les Laboratoires Servier (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i061c41caf2584f488de00de72d70d359_I20120930",
      "decimals": "INF",
      "lang": null,
      "name": "mgnx:NumberOfExclusiveOptionsToLicense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "performance_obligation",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Collaboration and Other Agreements Collaboration and Other Agreements - Provention (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
     "shortName": "Collaboration and Other Agreements Collaboration and Other Agreements - Provention (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ia27a68ad905842ba80b4de3e9d1b929e_I20180531",
      "decimals": "INF",
      "lang": null,
      "name": "mgnx:NumberOfPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "performance_obligation",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i37dd7fb511794c24a17635ae2714c9c4_D20150915-20150915",
      "decimals": "INF",
      "lang": null,
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i160748b7708d470795cebd2e08cb1b72_I20180930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ibd438d154f414b74a7d87ac6e9098fa3_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Net Loss Per Share - Narrative (Details)",
     "role": "http://macrogenics.com/role/NetLossPerShareNarrativeDetails",
     "shortName": "Net Loss Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ia82ecdeb6ebc4f96800d4d4e63e8e834_D20180701-20180930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105102 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i2148cf3272754e1f879d4823913b518d_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 45,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "mgnx_A2003StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A2003StockIncentivePlanMember",
        "terseLabel": "2003 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2003StockIncentivePlanMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "AdditionalDevelopmentFundingOptionsUnderAgreement",
        "terseLabel": "Additional development funding options under agreement"
       }
      }
     },
     "localname": "AdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AssetPurchaseAgreementMember",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AtTheMarketOfferingMember",
        "terseLabel": "At the Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in Contract with Customer, Liability [Roll Forward]",
        "label": "Change in Contract with Customer, Liability [Roll Forward]",
        "terseLabel": "Change in Contract with Customer, Liability [Roll Forward] [Roll Forward]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20180930",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Collaboration And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Collaboration and Other Agreements"
       }
      }
     },
     "localname": "CollaborationAndOtherAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborationArrangementOffsetToResearchAndDevelopmentCosts",
        "terseLabel": "Offset to research and development costs under the collaboration agreement"
       }
      }
     },
     "localname": "CollaborationArrangementOffsetToResearchAndDevelopmentCosts",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
        "terseLabel": "Warrant to purchase shares of common stock, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
        "terseLabel": "Number of shares available under warrants (in shares)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborativeAgreementTransactionPrice",
        "terseLabel": "Collaborative agreement transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
        "terseLabel": "Potential annual increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CommonStockMaximumAmountAvailableForIssuance",
        "terseLabel": "Common stock maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ContractWithCustomerLiabilityIncreasefromCashReceipts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ContractWithCustomerLiabilityIncreasefromCashReceipts",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreasefromCashReceipts",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Development and regulatory milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document and entity information.",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://macrogenics.com/20180930",
     "xbrltype": "stringItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Payroll deduction discount"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
        "terseLabel": "Proceeds from additional development funding options under agreement"
       }
      }
     },
     "localname": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member",
        "terseLabel": "F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc."
       }
      }
     },
     "localname": "F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FairValueOfWarrantsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "FairValueOfWarrantsReceived",
        "terseLabel": "Fair value of warrants received, including change in value"
       }
      }
     },
     "localname": "FairValueOfWarrantsReceived",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FundedValueOfBasePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "FundedValueOfBasePeriod",
        "terseLabel": "Base period"
       }
      }
     },
     "localname": "FundedValueOfBasePeriod",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseInDeferredRent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteCorporationMember",
        "terseLabel": "Incyte Corporation"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementClinicalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteMGA012AgreementClinicalActivitiesMember",
        "terseLabel": "Incyte MGA012 Agreement - Clinical activities"
       }
      }
     },
     "localname": "IncyteMGA012AgreementClinicalActivitiesMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteMGA012AgreementMember",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteMGA012AgreementServicesMember",
        "terseLabel": "Incyte MGA012 Agreement - Services"
       }
      }
     },
     "localname": "IncyteMGA012AgreementServicesMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LesLaboratoiresServierMGD007Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LesLaboratoiresServierMGD007Member",
        "terseLabel": "Les Laboratoires Servier MGD007"
       }
      }
     },
     "localname": "LesLaboratoiresServierMGD007Member",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "MilestonePayment",
        "terseLabel": "Milestone Payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "NonRefundableUpfrontFees",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfComponentsInLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfComponentsInLicenseAgreement",
        "terseLabel": "Number of components in license agreement"
       }
      }
     },
     "localname": "NumberOfComponentsInLicenseAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfExclusiveOptionsToLicense": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfExclusiveOptionsToLicense",
        "terseLabel": "Number of exclusive options to license"
       }
      }
     },
     "localname": "NumberOfExclusiveOptionsToLicense",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfMilestonesAchieved",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "NumberOfMilestonesAchieved",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
        "terseLabel": "Commercialization of molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfPerformanceObligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "OptionExerciseFee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "OptionExerciseFee",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OptionExerciseFeeRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "OptionExerciseFeeRecognitionPeriod",
        "terseLabel": "Option exercise fee recognition period"
       }
      }
     },
     "localname": "OptionExerciseFeeRecognitionPeriod",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
        "terseLabel": "Potential annual increase in shares reserved for future issuance as percentage of outstanding share"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialClinicalMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialClinicalMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential clinical milestone payments"
       }
      }
     },
     "localname": "PotentialClinicalMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialCommercialMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential commercial milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential development and regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialLicenseFee",
        "verboseLabel": "Potential license fee"
       }
      }
     },
     "localname": "PotentialLicenseFee",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
        "terseLabel": "Potential milestone payments to third parties"
       }
      }
     },
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement",
        "terseLabel": "Potential milestone payments and royalties on future sales under agreement"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialRegulatoryMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialSalesMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialSalesMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential sales milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialSalesMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProceedsfromRoyaltiesPercent",
        "terseLabel": "Proceeds from royalties (percent)"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
        "verboseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProventionBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionBioInc.Member",
        "terseLabel": "Provention"
       }
      }
     },
     "localname": "ProventionBioInc.Member",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionLicenseAgreementMember",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "ProventionLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV031Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionPRV031Member",
        "terseLabel": "Provention PRV-031"
       }
      }
     },
     "localname": "ProventionPRV031Member",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV3279Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionPRV3279Member",
        "terseLabel": "Provention PRV-3279"
       }
      }
     },
     "localname": "ProventionPRV3279Member",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PublicOfferingMember",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_PublicOfferingandOverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PublicOfferingandOverAllotmentOptionMember",
        "terseLabel": "Public offering and over-allotment option"
       }
      }
     },
     "localname": "PublicOfferingandOverAllotmentOptionMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RegisteredDirectOfferingMember",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueFromCollaborativeAgreementsMember",
        "terseLabel": "Revenue From Collaborative Agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueFromGovernmentAgreementsMember",
        "terseLabel": "Revenue From Government Agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "Revenues From Grants"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenuesFromLicenseAgreementsMember",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivity [Table Text Block]",
        "terseLabel": "Stock Option and Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_ServierDARTMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ServierDARTMember",
        "terseLabel": "Servier DART"
       }
      }
     },
     "localname": "ServierDARTMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ServierMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ServierMember",
        "terseLabel": "Servier"
       }
      }
     },
     "localname": "ServierMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "StockIncentivePlan2013Member",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "TotalPotentialValueUnderAgreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UpfrontPaymentRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UpfrontPaymentRecognitionPeriod",
        "terseLabel": "Upfront payment recognition period"
       }
      }
     },
     "localname": "UpfrontPaymentRecognitionPeriod",
     "nsuri": "http://macrogenics.com/20180930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r29",
      "r58"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r77",
      "r107",
      "r110",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Accounting Standards Update 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r14",
      "r108"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss), after tax, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r116",
      "r136",
      "r141"
     ],
     "calculation": {
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ShareBasedCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r75",
      "r168",
      "r174"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r28"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Current",
        "terseLabel": "Available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r79",
      "r82"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "terseLabel": "Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.",
        "label": "Calculated under Revenue Guidance in Effect before Topic 606 [Member]",
        "terseLabel": "Calculated under Revenue Guidance in Effect before Topic 606"
       }
      }
     },
     "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r20",
      "r54"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaboration And Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 42,248,075 and 36,859,077 shares outstanding at September 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r104",
      "r105",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r113",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r24",
      "r160"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r26",
      "r160"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r52",
      "r74"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.",
        "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]",
        "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606"
       }
      }
     },
     "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r102",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based compensation awards.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r157",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r157",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r155",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r152",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r153",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r153",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r153",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r153",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair Value Measurements, Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRestructuringReserve": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.",
        "label": "Increase (Decrease) in Restructuring Reserve",
        "terseLabel": "Lease exit liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r166",
      "r172",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r169",
      "r176"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r49",
      "r50",
      "r53"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r34",
      "r36",
      "r38",
      "r53",
      "r66",
      "r171",
      "r179"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash operating and investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r60",
      "r71",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r11",
      "r167",
      "r173"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r35",
      "r37",
      "r147",
      "r148",
      "r149"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r24"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments, Available-for-sale Securities",
        "terseLabel": "Other-than-temporary unrealized losses"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r44",
      "r46",
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r117",
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name pertaining to equity-based compensation arrangements.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the equity-based compensation arrangement plan.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r86"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r44",
      "r45",
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received for options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r87",
      "r177"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r143",
      "r182"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserveCurrent": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Lease exit liability"
       }
      }
     },
     "localname": "RestructuringReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r101",
      "r175"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount",
        "terseLabel": "Variable consideration recognized"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r41",
      "r72",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r116",
      "r135",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r116",
      "r135",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]",
        "terseLabel": "Schedule of Effect of New Accounting Pronouncement"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r117",
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Valuation Assumptions Using the Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r27",
      "r59",
      "r91",
      "r92",
      "r93",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r121",
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted-average exercise price of stock options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share instruments newly issued under a share-based compensation plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "negatedTerseLabel": "Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r131",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent of the fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r94",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued or sold (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r94",
      "r101",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r78"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsCollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r113",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r113",
      "r115",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r183": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(b)(6))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  }
 },
 "version": "2.0"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001125345-18-000097-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-18-000097-xbrl.zip
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M:6>T_L+1)]]#VFI!CKTU3:!1FW3[#WYWJ?U,;TG%][5._P-02P,$%     @
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MH&&3=7MW?HFJ^4RO:\47QT[_!%!+ P04    " #<@&=-;*3S9.8#  !K$@
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MVLN[)QJ/'G0\L,#FM2P:C8/U3A-\]>'(^MX>P]@#H=%O4$L#!!0    ( -R
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MN,+;!P2?/3>XYX%-*BUKB[T5\\<//FM8W9M3#7^^,O@+4$L#!!0    ( -R
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M!J=UB/F ,2NJ+:(,,2J!^ZB@$"(:@SU5O,:S?%Z(RWV0&$H(Y*SD!COD&7:
M $R)=8)8*\%F^?K.$)](?0TX?6XZ2T?IQ&I=R_OJ]9>'W6$'OA^'U1@#1-X
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M0I;Y0(/V&.)$'5X,7.LB$$49H0;CM(,?XPY;YX'4(6X#C6!1Q P,FSRV(7G
M?/2LC&B<+Q4H.L$-.S]8*; ^/GKC\7<JO9?1<HRE9HXP@Z6@W 0B,7/:L0J5
M'#@<SR8?9@R5[2JG,MI)/B^'93+WG4[H[YV"7UKKI=1(7@P'*SDXJ\&#EYOA
M"0R87P<WETZ]RX@M)R%@@XQ-4J7,6&,MPP2$S'D4?@8V^YTI(3_)_K_"&^DD
M^/@8#/,J6J2#3WMU<>>D073V_<O]"OD^O<];H(_/QN5<7!P4E"(8HGMK!=-2
MV" X5H%HAQWA:&(ZQJB2#:IF#57R^JB2]X8JHK3&C JG<62,.A5\T&"E2-KO
M32 Q U,S&E35;B(%9\9HE1:](I0FSRLC(M8N54R0!DC-)9K3H&K64'4C7G5?
MJ J2JV 0BM1"W.Z5,5'@&*4T!EO/1WD_6<=$RB3'];YC>I> M/VUV-X'I)B>
MW\I/RA!ZJ]VC3G$:0K7?[23IE:Y\X,D0]Y5>2:FM*&)$W#A&)%,X3:02!D?,
MN.!HK/Q\HOR-O&ZM@_SZ.GA/N7=+L)$$^*>CD47&E8@.;'L46D059FHJ9ZV%
M^R1NV\>TTQD)(%R3YI8K:207AA+#,3(.)0.+*")$S9!,EU*;*_&M]5QZPO&#
M&U-$L[2_NKH'8VJYBEQR)D/:=]0JH%*<$D6)-!$X.Q^5AJECGJA>(L'DWB;[
M220\=R%2[#RC*"@J.-@_S+UW$)K'^L\2KHE([F\*+Z?!,0944%'+0"Y6!T^$
M5$PKSZ.6,RF2[Z4!+T%G12):!,$<5XJF:JQ$ZPCZP16GWDLB9IPG/)9HGIX2
MI.)USF.:JJ@S':220..%\MH+)@*>A?U/SJ?WNJ(+1 YZ(EWYKAC-\;TXA_?J
MF1*K)T=I3/,YII41#C)"4(TM,HR" )T)1! .89OR'ID92"O/C("?),.;RN<K
M)=,6"!Q\([*&*>Z%=(Z+Z+6:(4M<>P$_S:HU+#1API, 'I=[8AF.C H$1MI)
M/=DVH=;)UID1\-/D/8641&FB'(G,2J>)X$)A@:*-UC+RW'SPV] +?=-)"V1\
M-^_E@[(_6GWS?+TP<\1)9:*.DC"+0,I14!I [EX@[=ES\\)/*^(G\<,AR. =
MX\0HS\ E&XFI8%)Y89R19!9&6F=(Q$_BB9EDP+.XUA@Y"'J9(58(8->,(B*9
M%\_-$S^Y%C^^+Q8^Y6(-<DXHYA$Q!L)A:12.FL#_P@QH<1I+WDR3[$?"3%_7
M07C=8?<YZB0GEEME360&W*I#1G',C>3<26ZXFP6S>Y7 S,ES%5A0P'FDD9HI
MP8P6&HMH:*0F;0R'D)X!(_ID&O8D)A$,GV5(4(=%8)13S:()W/DT^&\5)3,J
ML$?1L(<7V*O\Y'4_#(IAWX7!Z.M^,+YJO,^/%_^$_XSD^ 5]28.(Y[\.RM-.
M$D'(]_;+UU@=E7]\S7VY_QK4\/_^,5>=M/CGX,CT%O^T_5=PZ>CSZ [?W2>U
M)S.=?*_W.B7.0S_=(ETQ.<$:=[C7+X8]G[FB4_1?]_?L;X3S^<E?"RV@W_\8
M'?L'JO[W1X07S:+IYIW3U]L@T4&K';ZV-HNNZ8V.#?)O8=3XZNO7T=M(N+23
M]T(V>3M2O=+']MKVZDIK:WMI>W7KXOO,V)MLK2Y_W%S;7EO=:BVU5UJK_U[^
MUU+[[6IK>6-]?6UK:VVC7<_70]=[O<]+6_]::[_=WFC/MU86EA=:!'&F;_!*
M7=/?RWM961R]%O#(\5=;E&71K7ZIGTC?;&RNM_X$!>X5O?:P"PKO6F,]WPPQ
M3>;%3+E(B222LX"CDMHS1:C&-.U1YJ_B.JV>27;6A_SU2N&&R8REE9ASXQDA
M]-.I72F.WY'-XQVZ/O0'J\>[;_7!QL&GP_:W-;*QXOC&VT^=]95-^//Y3O?#
MR>[G#ZC=7?NVN^T/=SZOL7>TW=GY5N#=%7?:/MBC&]O[G=WM)01_=*?[]^'Z
M9[C7RFZ^3C[2W;=O\HTWZN0=V3W=^>S$[L%NOKNRRM:_[1^N;[</VV_73N"/
MK!^LT9V#]:_KJ1TKG;S];>_8O_W$_+_^[NR2SK$]..JVT[VW][YMO/UPLDX^
MH)V#5?C;.5T_\/GZMZ73-K1SX_,:A>?A]LHA;6]_9.OI[V#IB[?44@JLQJ@8
M,D:CS[3C-E,6NI,1@JET<ZTP<.8HH:L_#'.+&&4?*OMZ+I[%'P+R.O KC>V$
M2Q=T0BQ?FV%93"[I5PBI?K%%'^QZ@F?'' W"Z\F'/Z;0GZX??<][R6&^3OKF
M\\%1QYR^SGL5ZJKGCDV]U@N*IUVL*H-?@M<H_:1)8V>P,'(&KTK__4&ZP 45
M^B=G_/3RGQ[49(%10?%UKW]5M7[T!M U23#_G*-SDRN.C/=Y;Z\2"3DZ^6/R
M?2R3]-,U;<#E[CX._3)WIC/^#1YP=O-*G!A$,/EA)$X\ L#W>!DWIK*23VB4
MV64#-2($__4/+9GXXQ(/& MF9KJ\1KYNU*T?/BYM;J]NOMMI;:Z^W]C<;KW_
MN+GU<:F]W=K>:(&?WP9GWL*TM;'9POPW_WMKXTUK^U^KK2D*<.;^EY:WTV&L
M*;M"3)6*O*KT?^:<Z#6)PYNBWRKW0^M_AT"U0[]SVAHQYQ80ZN!;6^&HK+C]
M?_T#"_0'1?.MY"I'WV:47ERS9S8V&V_5>*L7YJU8XZWNV5MM;RZUM]8JG]2X
MJWMS5^59S<F)OXK]HMN:=$JM6EUUO \N[=\"#7[=&J:JLNFT2NN2)[W[?VOY
MYG.+K;)HA/),=7&YZ';S0<H8M][DP'4@R >B^+J%$,ZHP)C,YNL3=KW77U]:
MWMQXN]I>6]Z:;ZVUEQ=F\W6O*^W?5D^,*ZOT6*N(K7[8J\:W>V7+#%J#H^#2
M6(-OY;U67@Y:;K\*)WY_Z12:Z06AJ&3J(3@T$PL4"\+)2^#0]<["C[C>2NB8
MKZ8?9IQ#SU*7(Y%AKK' ]$>$N : ']WP>0K@MVI25 MX>9$*9+8.AOU\X'-7
M<?,BSNBHVNC=\A[PPZ,Q1:Q>L;]G>OFWZOOO]=/R9XVSM87-A:V%UG@%>G^F
M@;4VGIPQFD78:A<+5Z'I%^9K?$L*CWP"^/P$[S5H6&/Y'Q[$6B+66@\^O6YK
MN6IE:Z6?'X>95LW-PAT>YYU.F&^MF_YIQ_3\TQKZ<4_=!5C37?R+'OE99U[L
M]FN^R=PB08JC2PF1.NGHL^7&ORUYWP^#08K7C_I 9O(CT-1P$MPP34N'G\$#
MA4$-B<SS%<EN?@0]Z\,/_?WSSM_3-->*XXQC.:/IP6OGRS;/,F3_/6B5H1..
M]HM>:/6J+.E\"]2Q,TQX;IE^,%=AXG*/C!-6=*H':M,A5W3 6B\Q P@-[6G+
M[0=WV()6'K:^[H<J3DRC.%-)Q-_P[R,7L6\&K9AW@F^93@?.@/"K',"__SO,
M^_!C6;1L&)\ -]ZJ"@OV1I=BFF*TT2 :F+ST!#@.\6B90]M73]Q^FM/<6G)E
M.IP&T5H>CH((TJE'_>!")1!,6EUXO?U!ZS>X7X2_P=#MMP;[1<II3@:<RGU3
M7GZ+K^9B4U,[1Q>/7^3W^180BM9O9.IM;0@@IZ$]@'=)%U7GPY6I*>.;587C
MJY94+36#LJ51RYO3P<*/QAYVPN#BC]5<I._/:Q??G79Y$/A% 3%)!(31S<L2
M9 AJZ\I^T4N^J7/:"N"G3EMKR2895_G0%5.:T?#')8B>WR,)_*@8I(]'P_Y@
MF)X"YVP.X2*&>,(BV(IJ2SV(!;>R[8=&Y:AI9^TZ QQ0@09.]PRG?- RK0Z\
M1F@9YP!._;2O:-7;_60+KORUU2MZV14'0.:F->B:5%EU;%$2,ES1A2XY70!K
M%UH^Q+Q7C8Q7O&_N^]O,M>9^T*"Y"A-S/WS"7!K>J7"+B<W(Q,A.6]:%UF_+
M5:> K_O]]4L?_L%B03*DF'Z(X1].%P052HN'N#E!"YQ)KMA#W!P.@O60>,;&
MK6Z:S*G=%*]W2>U'EGE*]T<_5 :@?I'@;1-H-9]R1^H]07SFD;[4P+LF\+YR
M1FDSLM$TK!D+FC6CVKXJ*FEL:DULZHSU>HUZ=H3NK5'4.Z(+9Z'OZ.LX_IW]
M7G\F6+\>?Q!U]89-PV:I85>"3=Q$UR>PYD_S%G6TMJO=D"S07@O:\;7<GV08
M6^E_-_5QD_Q=KZA6;UP#3D\EB9JW[!H#T-/)^JGG'PP'91Y/I_/WK![9^IB2
M[.%JM*51V"N3^7F\:EBH&@P"WMLKJ@&<X2!49T$OC!9+7[$HK>A7S^J<IH=_
MS>'1">0]>($BY=>/\T'%HWNFYW+321GYM,=:.CEM->!-WP]:1_WB./>71H_&
M Y\M3'\SOU^9B)\>A[E:I5[>0,Q@/W0Z9[;F-Y!I-5PR6K?R\X&-FPV-L1^N
M";MB@.QR!O"&XR1/+(:E:IRI71Q/U0D@HS(!\U4OCF8\I).*85G!NL+WONF'
MP:2G^].3)4 ^W2*]4N$.YUM'IM\Z-IUA:/TGM!TGU1I=/%\-;(X+ +VI!F3A
MJK2A>%7^9_2 N8LE@82@P3*)TA:?C'ED$2/,81U4,!9Q-]H9!6-$Y@ :+H>8
M8/#/N;7VF[FDRUU3PCU.RM?P2KXHQR=,UPQ:K2J=+5<O4.V*L56U8N/\Q<'@
M@XF&T]'+JBETL@%M^:(1=3HRFE'N>,8HIID)E&<8V4@4(I@$,K?("&!5SR.%
M)@6$)N)='./FQXOMKJLQ5]5HFZ[]1N15Q=]^.#5I_  ]]J:7KSLJ1H[A=3]T
MJIJPTZ7C?EI1[KL[&#LH.L,R_#%^)/KQ-3^<$?>CE[_-==/_W>^?L^*]D-E^
M,(>9B7"'UZ;SU9P.4M_L]Z^JI\?X56]_IWIZ5XJF9M/$MI?^>K>:UO0O;[2W
M5]O;/ZZR5^<Q<HFD0.1V8^2$+&!-^<,LD91T02'!9FZ)Y Q-[WZ_M+G=6ENX
M8H+W+/7A/<3(;][<ZV3AGU8H^-/,1#M;^_U$N_Z1'"H'Q_YFK;W47EY;>M<"
M2K6QN;ZT717>-)=M^_5S?$\5+U]3Y]C#Z-PUU*SIG[JM,[FR_T@].W"M#-T6
M;HSZ'8SEE8G/&AKU&[=SVJ@+ 4;]+'UUMC_&H-8VO:8ZUQCU^S/J#7H:(]T8
MZ;&1EBH5Z^H-BD[NJXD[?YD.6.S0VMH/H1RT3'E>Y[4U*?':^FW8,T.?P_F_
M5\L"5H(;GX&K,V1CXQL;W]CXFJ&GL?$OT\9CQ"X9^7,RG@;9-H["Z Z#RI@O
M%]VC?MA/&_X<A]:[8G"^NK2$NX;JI!X\9;+F\%(Y\',WD4[\[F<Y[3T:/]'X
MB<9/U P]C9]XH7X"BY_ZB64SV&^]Z11?SQU"XP;JK,B-&VC<0.,&&C=P0S=
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MZ4LU?Z_?JJE(Q7!@JLD 8>3;JLUI1X-TDUV*J]&TWV=R5T\N,$/L=KMZ<K5
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M5X=?Z\&OF\7Z._RZ;?QJU9/B*NI46<8JIQ#75".#<SDYXA537"OJMYZS;?(
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MN;$<N'N@#G'!!-* YXBHH)2DV!#*MYXKW8=_'RN!O[4JC&. %%_3]]+4U09
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M[=[']?^<N0#1C3-T-T@<KP#X((V2*RLE5IY+++5PP7H:L'(6B$,%^#>+!G:
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M+V>V#/\[2SUKWETU[@*:^2ATH)&D:?VPV9F*D4.3\.6W@W$2\O&W$3PSC>W
M#T >^NU;>N__7^_WP>$@3_O.<%@UJ&[JXCWID=.)&965H5^VU UD[A#:6W6F
MU8]&+T"0+NY<>GZV2^&";#WWRH/Q;.CA%?"Y:1[]>3:JO$]9F:=G*5UZ6O44
MN&02IN-F\/)S6AKS?\M>\D#U=D9 (X:]M^%H/ &M&O5^!57L$8S^'[Q@"+?-
MW[<X5JTJ8_9/':A*)?L&99G:]N3=JQ=/\T."G<R2 E+93^]1)\3X)+]9;2"(
M31#JR_E!9H>'J;L@E!=2NTNH,U&+GF_,0*SH]E^-;(1_TFK20E;CQ_._6Z,
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M>%2RK>#1U0,!C&MN61L3E;634#IM/:EE.D%EYH"I-:MMNILO-E2D_]YPZEH
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MZ.?^>.-]=N(O)5JEV%[EZ*^,8S--.X 65M<3\K3*+FJ;"R=CKZD8<L7/YWN
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M>[,R_>6&T,@%/7"305Y=*EF%I:Y7SFQ:B: M0WA3.0!5,)-FF6S:,%]8M]>
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MH$I0)KPN(F>%4H6+U.:L:16%4BNLCA51FEJ=V$8D0+2P]/^V@U6#Q<!F'$K
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M$:,9"8TQ2+,$P"@#5L1+L+%M,::U>?1EL[OI1>VZC^\(HFDIL9&!,I4$CUP
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M% F3U.=R+X>) >JE/'?4)*KJH,B;N 1_B/X)<_?QY$4]<N=)0\?Q.W]U"H?
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M%J=YII?Q4:-@\E1M[2+2,4DDB:#,BT23S8/%]OE7[X6PMVKJU8A<P>L#=DH
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M?7\5E)\\[]I5!(-C<#G[N$JQ9*^RD>18\B;./ZX!,!!ADP07 "W+G_[MG@%
M\!1/$9#'N[$E$L=,3_>OC^GN67GLN:$3-XA,PS% @3 ]<ATO)*YA>KH);JD;
M+L32F09@<1;T$SR27IQ#QH99D>'&<UQX#VR>RH:1MK"L/[J!(?S:3X(OQQ:S
MS[>EF)E_G_YQ=P6??_P<Z"!N&HA([^KMV=WE]R_&Q^]_?[[X\\W@8O#A_F).
MS$)X[@GY^.=O\>7W_X"X_?'M\NT9^0COO;KY^_/EX.+;QS\_WO]]<_X-Q,R\
M/+TUX9GPW OC\O3#)XI'6ALN54,;^V ZGJWZ#C-4+?)-S;==#V!P-AW"\'V0
M48M$%$,'$?6-R(?%T4/+=#5PP)XI#(!LA-'H= SRRC,,5;X$2GV59L]6GV;V
MA3'BAU\]/50]#%V=@I8@OD8<TZ7H#H*GZ!,G#-PH:-@Y+_,;M@O$ZFPPZB?W
M8 AQNDXR_]_UZ9/I\>5,A;^JPG">O-A+^H#K65&$6P09X!Y;6449Y?GDLNMW
M[UZ(>$GU.\9 ,F#7 -/XQ)D8"IY0)JH:6/E@D3U9I4CRTSF%FKDN"EJ(8989
M!%APE6)HL%#P,)V0[^SHGFN+1O(#KGA$ED)QF$@V]C_7.C),UV[@)]4LW[,\
M3D5>Y/D0L^-P$*#?\GOE),C%BQPR9_CBSM>J2HV%><N8(,6HID4F")(5NI1&
MMAY%CD/!P0\M4<;F;)>W7*+Y!*GK*%$[\>#7^SDP/\$ UG36\LDX[R4IFO;-
MV5U^=*3_X_[B]A,X)0:Q6:":C&(/=6P,Z6JF:D1VY !TZEH4/GOE:EH'9'=5
M[O)4[C#N!L<9%IU-A1(K49J5+$QAOLLFU:6E,&5+&D(L$ORYCA#\ &H>0RR#
MDR-ZGR9\-QNWKTN!>2!]0B1*S_*ZR3R@4*19-""&0UP=.RW;5(]T8MF65MC^
M5FG[/] EHI17#DHE)B$D7=!O\6 \.!F"BNOSA)O8'_.1OV-I>=<[46]7L;)J
M_'"\_/'^XH]/H6&'NF\[JN\:@4J"T%7]R#54WR(D]'5/\QT+ XIS;/R_!4_%
MZ80%@QJ^=.J(BPC)0;T?#T #%WLVT_Q<G. ITB*R^)O*?0@\$82EDSQF[E/@
MKT73"5/G('\)&JOP,'!</ 7ZGM%4M)/G59/#L/IFYIF=FNQ@EEQ9T#PK1" @
MQ^+X*2SW'\9R?Q;+*P'!+'%NU9<U*E(2OM\:5R>?+-V(&#&H2OEFD1;!3YX7
MJIIE1[;#'-?0**#ZO(]<2H(241 &, "_L)SG/;*U8+=(O>S3#!,?)^VPIGET
M^O"N%3[V;*+F9O:(;^@4E)OG!&9$(F*Y=A38D1[9GAVY[,&S.A[),!$&R3DH
M2Q:>#V=2/7X\H^2+!>SK.J$+F&VH%J5X(K81JFY@:6KH!#30#4I"@@U^M(YA
M+DA<7F*3W&&";PF#X2*KA*,U]JP ^ X8"[.93A"\A]K671YV9,>-PH7OB@F\
M29.! $906 T*'CXZ6YU]NSB]_61&/K4]/5"IXU.5N-16/<9T57-LS0UA)4*/
M'QBT:@N]X>&V#2,#8FN:>[]9NP,#9U5N]1OFIV.:8I! ,Z=S9&*8/4?C*B2@
MF<K9?\?H#X-_C!D17\M8 /\.?WQ1^-ZYJ+84_KBHWBO#"],-&O\Q$X6(,?5!
MLTHCL7BL @XH4)%B>@_W?VI-^JHF%SSY(A,1:]&%D?=QK+6D@=\W4XMA9##/
M-1C@$,5SRUR'.I9-38-:ND8##=UTS=0P&"W=]"9 U_>KFS\^.<QP3 86G6^%
MODHBW54]V[!4!XQOSP!KVZ&8_M/1++UCDP5;J0N=Y[DRXU]9?H?EG, "=KFQ
M80@9&@A7].'"85JM6I'D''/C9K:+:5T!ER*! E8[:&2%5[[8XK/<R,*M9F:&
MQ/==ZE++-%S3<&@4>+K%(U#&;+:/9.VCL;8.S_OD!BP$E\11@9\Q#\AS5$J#
M2 U]\#)=W]9U7WOVBG1,T^XXYKSWWBUT69$567487<1@19O?HK%O7$%^-O4$
M<?H6+STOF'9QG/;Y^?O7H!UX\]ZA.HD%3SVMY>UQ1=Y>H4>G)772+%EHR&&B
M1**!5*FW"G(7 %#K-@2/Z/(B]B484H^WB$<M6DU>8"<Z=W8FH^$+@K$/7A5X
M)[)F\2BMD/'CU *,2O;Q)Q#Z"%A!5(FG;.(<E$V:>_0KNJF\PGTZ$3?LB'NP
M&0!>@HF^/ FW-@G1@E=,OE,6W/,@//U*XSX/S2R)E$[P&8E?,/B\A:)7%DK1
M@TY!(T$PX2Q.EPVW9WI[3_O891TD_E5*0SUZM)OIX6AV: 4L,O4@)*;&7-.V
MP.K6K3 ,?)M$BP^G>R1\+K(TK\8Y-@; N-QE$0?[8?'Y_/[RYLLG2V,TTCU=
M==T0O7'756E@!BJS7=T',Q&X$/#9-6Q Z 5-[Y9(>#*ALXC6BT0!M*R_LA1[
MQ^VGG_-V/&<<D*W^+"9Z(N8YU>3Y1V:V[Q??@T\.@+L?,$/U-3SBQ8D"U0N=
M4(55C'3-MS18/DSO\19P6M7;>9&R6%,--_7 Z@_#Q9WZB@"6F&-GO<X^U?[N
ME/+A^@G/@0*<Q=K-_OWD/#6X]3<ZY$ZU/K4G(8H"JN^X$ID447&WN:HXG;K*
M,#NE;=7''C!\O,_IBPTUBF6R@) H<ES3)R#BOL="PW9<XKFA%7G.+AJEZ)55
M;2Z\IB.,JPC[_2(>HC=T7E#H?"@^?E^0]DV2ON'M?LX+\O[(@FU<G'[X%%'+
M"$.+J@%PJTJP<SMU?$UU/=?#@B)B,JRFZGBVUM'MI6VR.LIS?P63+-RZLCR;
MV22P7-<TB:X9GA=9/+_<#$/'L!^*O)K3S72KYJ:E*R?RRL!:RVK,4L-[WE=W
M*9N4#,(%O(K5_L@[6.=XF.FGT+5",P(S0]<<!Q1!X*NNH8&32'3B>K Z-C'!
M*UQ0?%?M88E*IP?AL&Z)P(>UTW$G;:OA,_X]+LHP!-Q#\.,NP//@Q7JH6VM"
M60#?KPE65N&!O.# !'F29MTM-\8.'9_1]Q.?.21:R_C, 231NOQ\_HD:'G,\
MSU)=2IE*(A:J/L.Z'::Y%@5A-#T=[/^.04A'7[ A5SB>Z[B?G</ZGXWF/^E_
MSO'?Q=W%YP^?#$/#TF-=#2P#\X]]HE)*(M77J:=K&O4TW<#XH&6 ]4 6E(L=
MV0/=CNND!_KX[/;MXO3B$QB)U'4\7S48;A)'V&7"T$*P/GR;$NI@1<*S5X;5
MM1?D'BQV0?6%+N@>FK3(%I/+6TR2IK>87*/PX+"E,==!CX7C/C@R5?ZIZ'BT
M!&I$GV'XZ2IZ7]5&BHPE7D8CBV;*HID_/CF %H%G::JEX7XM-4%I$<-7;3_R
M8-5-S]>BV2*8UNT-83Y#E&#N O=9^(9&UL-,;JYABQ;$]4Q:W*WA32!Y8FQ]
MFZRCO+_^(/I'\ERLY[P-1#+.X)/LQ<O-TFZ*H4Q=T6=1_A+C6R4I^0$BXA,_
M20&MD6Y].LK8R_*'7VK(AO?_4E\6)$H89Z,^O7\9#SEY^'L+>/"\+M$M0[,X
M2.2 )GE8#JD D*X D)_S</Y+T^CJNF,39_DE*^]?_:75=3RBZ^Z6]VM=?=67
MEFD9'MGR]M4#!X<?'JT;K1NXV24$%[1U S>Z?-S6FO?_S#E=<#N($4HM#Z%-
MJU'=!.%9$[%F91",5AZ@+CX3DO_+"/LL#6^%F.OP]/(#(>9Z83 5XZ]&YE4C
M*Z_/D]%+8_2MNK] %OQHM\$7IM$NPZ_C_0/%MJN0?5H'K#D3A'OLK7 A(E)G
M\^70,_7-LZ2>,$&)FF#;L(6KLM6EDK7:RUJ7&.ML &<]@%Y-8"MS$[;:,RL5
M=A*^$(:G@(,8ATJYV&W@,W2%UF"CO:[S'H@FF6#/3. \-A/(=9;"+IF@"<+^
M@(K?AL3_$P2,1=%#+ */W"_)R&%(AMD)- UZQ?&?53O+Q5;8X>FV%2L>G8H_
M+84>8]_,QGEG%ZHUB/DV.3=;PWX5NAGZMD4\+"'0(]UV0R^TB<UT[:&^G>8&
MV[HGY2%[BV/C9R*L66V>F2T-@7_\\[?L[YO$NCK]^.WOFUMR85P8,"8-KM(_
M#B[(%8SI\GL GYU]OS#.C8O[XIZ_?NOY@[!_]?D+N?S\IG]U>OL=GAW_??I^
M</']/_''[[?6I?&'>0F??;RY^/[Q\\?O?WT_SR^NM6^_WYSE%R>?=,,CE+!0
M-0/-5HFG:WC*1:A2QL)0#ZAC.HR?HTCF4W[6]@]WA*#-%+A$1HF,QT%&36=.
M1#5-]S5*3$"^@#+#-BSBZFX8:O2A1K<2&8^/C/<5,@(L6B2,(C6DS%%)%%DJ
MU4Q=]0+?9+[K&;X1\-I/;;Z[J41&B8P2&6MG6IBZ[[J.9I' (J:N^92X5F@[
M06#94>BY#W7AD,AX=&2\G-B,GA:$U-1,U=&]2"4:9EE8KJ-JD4<]YOJ!1MQG
MK^R.21R)C!(9)3*N0$8=V_$3.S08LXD5&C[1(V)B8QPO<#Q'?ZB=N43&XR/C
MQ&9T#9,:ND;5P(C 9M1-3Z4V]50]P.,N/*81/'3!ZECZ?,+T F0\0-!TJRA[
M6T*H;]F0I;0ON@2%@W@89WG*$W+75CL'H>DJ;&L#73? ,V8[C@'.D0L20'PG
M\ S;LET@?N1'OD\,&1UL.)Y=U*.#Q @UV_ #-3)-3266&ZF>:1/5<<'HLR)J
M>3IFY7?T!2T(MK?TGMZ.[P\$ "0P L>ED1<Y!J;8^TYDFR8#5 AMS0N)#((U
M'P F!HWIN1[570H63&"I) #3Q@^IKH9XEI<&^$[=D->/>_/=&R4 _)  P)C#
MPH!8!K &T7TLL &5X;BA30/J& ^>Q"4!X.@ 4(OUA!I8<]0(5$I [ FV>/?=
M(%!-+S!M2[>H'47HT;C&?%V>!( ?$@"(0QS-LCQ/UP*B:X0:OFT[$26F9C@D
MM&5(H_D ,+$ ?&)K1F3X*K5(J!+;,E37LB+5LKU(<QQ/<[$.W.I8UK%"&D\L
M#XR?ROU@*5^3L\**+XNWF?!]F(RQ-% &NG<)=*]-U@8Q\P9J@[H&"T+FV\P/
M2.39KJ:%)"3,-IG+7)/L,W*T6%M(-;&1FOBC'BG"_#^#6;I*31,<Q<@)5==W
M394&S+"IY;C,)+Q=B+//2-'3WQ.46"JQ=',L-0+-T0W-#B(G(H;I^;KM8 LW
MS;0< UZZSR"<Q-+]8.G$Y+9!$_J>9:N6Z]HJ(2:@JJY;8 V&H>/KKLT\WGI)
MT_;I<TLLE5@JL70!EF[3\D=BZ3&QM!:_- -B>[Y'5=^T#<#20%<]AVFJ;5J@
M]T(WLHCS[)5N+.Q^*\%4@JD$TWV"::A'(3.H1CQJ$=\U/-^(+&H HAJZ%=!@
MG[%A":;[ =-:>AN+ #5M5Z5>&*G$,!P TR!4(\_3+-W4=&II *9Z1[/GS\):
M%@S^F;?OJK=GG#3?>[Q>?$N.">5-Q46KM/_0ON@C>))EXX'X[ :'+AOPE0WX
M+C[!:@2Z ^I6-R--):8=J:X6$16TK 9,$MB6:3V-!GQX4F]U1*\X$UJ<ZLA/
M3E+B#&:9\Q-+P_* WK!HGRS.&1QG<=%R_-<^S$$%7DSZV#"7/T;%YK=XP2 )
M6;]V,9UPGQ*+Y\XV \0N?V4;YZ++>#AI<"Y. X9[PYCOG+6SR9]EZT0CVS7Y
ML\TN\73/6-&Y;;<F?[;CN0=K\@>:\F!-_C3+==:EBFPYMU5KCS9T[Y!]P9J2
M-O+DN\3(5D&2"62KH U)AFE- 1J68*S%8#"%RGW,^N$#N+SW(,?!^%)8&0T-
M:BP\[&K'(/'<82??69J$-.OM[3B*-^"OH ?+:MYKR4:G!1>]!W>@_4=@B?C(
MJ/?QYN+;Y<VM>?']/Y^O3B^TOS]_-#_>_&%=?+\E?Y_VOER^_?O+Q<U'_3*>
MB8\,WO0NOI_I,*_OEW]>D(OO[P>7G\/>Y>F7[U=PW]7;/[2_88Z7GS\8,\UT
M3!<\7OB?"BONJT1S-94&FJ,&@6EJAFF&(9;__;__<0W=^&7^!*W'R.EZ2F6V
MS0S/2[Q]!+S=,8XL\;;%>'M?*T[P0P,/#;)\:JG$,PS5"ZF#J<J:;EF!0SQ7
MXNTA\596J&]IN7]-\*2H?IS?'[<T_?%B50>BJ.UTW?]55,4QNL82B9:AHW:N
MK-UU<&5MMVLN6ED9)WBPI7"<?5$C/#XD1EY@6:ZD8',<%'$VM5O;0$>C2Y 1
MS:Z^ \(\BL\AUVYV[?2NAVMG/!J&_!CV"YZJ+2V7?7B\^\MMJ3FT:L:"E^$X
MQ0/3%_JT_L,^K;^)3WL#_*!+#W8-#_;#5(,=QZ"Z1QQ5<]U()3JS58^XKFHZ
M++*"P';TB( EU#6LV<PH!9<VDZ;NDX>"K4)=$@I: @6U8);EVQ'Q;-4UB*X2
M+PI5JIM4=5S;M2@Q0]LTUX:"HV56#FZ'WQ:F5=89K)Y6>3(,WX-C F/ +@[X
MQ8=AG&<G01Y_C?-[F6$YE6%Y_DDS+9L$9J#2T",JT:@!;!+ 0G@DC$S/-6GD
M/8T,R]DCCL<#&"K<59QS7.5;#D,EK3BH^ YW#Y3G[Z\_O%!HP4GU',@A)C@-
M1((3FTYP$D:MJ77P!'FWG<F1NYR ;-A=S]&LK?,7'TJ.-/#9[3M(6 Z\X0.7
MN8*M3SOEQD(F8_A/:$G_Y$]GH?I//_WYU0E,A-XR_O/9-Y8&<<:4=Z"XUP])
MRT5OT:+7U_L]&] 8[*Y;_MMK>"ONPX]I7T%_D7_X_"/Z,2\D+SPA7CBYO4W9
M+<T%$YS#JL?#+ [X;SR P']2GO-2IF2<@36_D /D9M]#E+X:YUD.Y(-A=913
M%A3E&CIW9-8Y>;DI&2]-)O+2++6,VRXS66I^2$PWU"T2$9WX#J%.Z#HTL)FG
M>6Y$S4_GN#2Z8>HKD].VJ')>(T.MB+_4V.:RR+0K,M*TED9;B@+I;Q>? ^OR
MIA?_?=KK?81W??S^Z^#CS2VY^O-R</GYHW9U^N'^X^=?OUR\GBV0/KN'Y^I7
M;W_[ N_LP;P^7[S]NW=U>FM]-#X:EY__()<WO\47;_^X^^O[63V<'_F18[N&
M!5P7^2IA3H %TKKJN9X>L<#QO,#B7= TTK')6@TS&["[W(R&$[*?Q!-)(US5
M+N(=2SE:[05(C0-B96GC%B9NZ<UP9T8BZ*8(6FLW;/F4NKJM@@&CJ\3V'97J
MGJ>&IAGI8608A'G/7NE>U_%:@I[2TMK[EJ@5:A1>ZVB.ZY+ T $#=)-Y9JB;
M ;6":&9+5.#"H;=$'\2(R@.N.;_H^[8[\?_Q4*+6U<O2 MUQ?%,%O:"IQ+&H
MZC-= Z@((\^U@"$8>_;*Z6ISNY[-!X='M:&:*/BMR,^SFTF\M]A:ACU4"2S/
MNMBCD[_OTM^#>ON</[+SX3O>!$@:JANIH*E:7]VU0]>-B!IX&KCZ-OSEF091
M=<_Q24")'U@FGHQEF%K'(&NU0_MAH]Q/%C"6>[0[HL;FKFVV$3)(]W:?J#%Q
M;PT?W%J-NJJF>V"X!EZD4D\W5&H:0129E! "AJOA=,F3.5#S"*-ID ';&)HT
M:S0-6J$&[2PVU*DHT?^P;L6& :XV\-GS)GL2F"=[SKN#GO+$6*'X10Y6/4&[
M6GVI]S?2^U,':7N.Y@:NKJG,]#V5.*ZENJX3J:9EZ&ZDVRX+*+9"LSJ>-K\M
M^*(%82LI\D_&%2@E7GH#!T&%FC<0.FY@$4VU+!JJA!E$I0Z!90[TT @TSS:L
M\-DKJTN<]NYU/<K[&V1.RE5HPBK(?8/-B/<F22,6\U[U*1XQ&Z=R$^$)V_X[
M[B(4W#).F=Q*V,X,F#H[U7%L-S0=6_69BT=LNY[J>I&G.EY@.IK);%?'K017
MZSC:?-;+5LZ!W$-H&EX\!<=A 2Y(UV&?F#%Q'?3 #T.'>:H1AK9*3,)4G_B>
M&IF1SP+3"(FM/WMED%J[ +F1T#9(D"O4IA5JT$9"0\DU5:(T=:2,LN91(#)S
M=M_I2Z *'.+ZCJ.Y(7$TQ[,"YH<&T]S UWW'X*GU1_8W9(W2;I;#5,NQP'"H
M%>B:J@<$+ ?JN& Y,%]UW- "BU*CE@?>AM4QB=L!P[*]D4>Y([&M8[$=)LAR
MF[: 06T'PK&9:S!+=2EX$$3'+$;/8ZI)?,WW_8BRP ,W0N]Z$@B>"!"TI]^H
MK*@Y,!#4*FHBDU&J^41U&*,J882JU""AJFN:I9'(=PT$@A94U#Q:L;*L1WZ
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M)! \#2!HW1;*<AA8MH72[@.<'@\(:ELHOA5&Q/:H&C"T"EB(K0M-6PT !NS
MH)X?:7B 4^.W4*3\MV@?83^H,+V/H,N-A$UA8&(/1);E!PR<@]!T M'BQ4=[
M@)#0,%R3>L1'>\#MN-ZQ-A*>="G;?UB&=6QX+!BK3JM-E*_PL:QHDT&1.@ *
M5CD9AM71E0E^)---=X/#VWJLQ#9-4W<C%ZTB7R4:,537UCW5]&S+UG5J^3[!
M=%/=!$34]*=2K"(1Y$G%41Y&"AE>V2=^3,PI-_+MT+,-U621IX)_!?BA1XYJ
M:GX0@GM%+8?R#-6]-H27V-%0[&A=Z&5CY) 1F=VPHQ:1<:(PI-0&L(@B327
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M0171M0R#3GQ#7!F/\!%P_WA(QR$_)1 #<7@PAMA!K1Z;@2$J3HH2UDA8YA7
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M)VR$6J;X\&2,GW#7I_IDE]-9Q9FOXACF[9[A=&JGT_?O.\HHC8'00 TEA)G
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M\_'W\5)WX'"T:[L):.YTG-/3HX?DG'4I9>]D%LI& ,>QC5S9"* UMI%ER48
MCVL;/;E(Z9M^DK-',8V>7G3,ZAHR6O@(IM'3HY2Q9\YIG&GT]);,W*FME0P=
M'2,NO:1WG(P?R?C11KO)O!A6!HXVHYHK T<R<+2EJMUE%UX&CH[1]GJGMD,R
M>'0$ZTA?$IV5$2090=K,.CK5]/4;\QW?-VD$U?:=,]-V>DC.61NX&Q^(D$LV
M%^YK:(*<C!TM6S%OB9#)V)&,'6U"LJNTG^1T0'WE>92D Y;V[Q6TF#1O_?*6
MXSLLC2#E;ILF3X\>DG/6-YGVRSF-,YF>XI(U_109&5":B?<?H+NNC"?]B/&D
MUYKNRGC2IL;1?J,";:>'Y)SU.:>AIZK()5N:^*MUYZNB&K-<,I8TLUJZ+&&3
M8:3=-]FT];,BCN^1-()J,F(D(T;;AA]D[5K+EDS;R8Z5$:,C"-D!\K-EQ.C'
MBQB]2UG0CX<X>"4>#,9#I@0]%GP9)?$P5T9I<IO2028C2IL:3[OD;S\]>DC.
M>9S\;1E1.DJ,HFO+B%);#*?G1$:49$1IQ\2DO,=2,(XFIA.>J%;]4EI-'7X&
M9'D H Q ;49D>\^53&VGA^2<]0NJ9,I2RY;,Z%H-7S(9@)J!YP,D><L 5(,#
M4(<Z #')P61ZZ+C;(S>BW\_9\UMT.#X0T1O2X7@_9&T0,Q.[J<V)I*A(46F6
MJ#2V%E.*BA251HG*OGLE-LXY.L;Z[L.U.M!Z+^L(T382-TB$%CAF/^<4!@W_
MAO'75_^$O\K1<1K%PQ#<CY>F#>,;T/0V'I83]@H9F+UME&1Q'B= 6-:G&/+]
MY2X.\QY,$7BJ.**.6'!S[>-GBY] ?:#X.&>_%*_4EM\S?Y#=#*W7)-$T75>M
MP,SB]>,A4\L3^ P^OMK1T)Q(];][Z82-;YGJIXQ^46D$ W])^W?T/D/2]M*I
M.:XDGICMJW_ZZ<^O%KUVXX4],O&NQNF#WK 2):F2]QC\ES*F#."AO4QA,+-0
MN6:CG U\EBJFUE&,JAPH+DZ##Q7_7OD)5$IY5B"@^&!$4_@B3]9^:!&:'Z4Q
MT! FJH1CN#%Y.;T"2VBOZFX-=SD0.T9#ET-5X,^$=L4"9 H7\@G-XB%(+D7A
M59)(T":_2\0/0%\_'HHOLWP<QG![$BFB,R(0+@4JK+^:'046"][5!Z(G492Q
M'!<T9.4(@R3+YX97O L>G>#6%1W=\Y'<*W>]&-CLCF9*GM)A%K&T8(3S87"?
ML_KH1BR-D_"7I[["-7'[&1XPCFB0"R+,4;:@ZG-!1!"AA4N3P@.'(!TI"Y+;
M(8PD5&!Z3 AP0>9JZS ;CT9P-[T%3L AO'CR]%XF40$\* :ZP17#-.GW.?[%
M(%[CM)(O95 [J[*2+01-N$J):NW9)Q3.4UB@7V8,K%6TG2=M8W5'2=HQE^*%
M2/"N!U17]$+\.0QA"[(:$!10!K< M04LQ6FH_'<,O U<"[<@_C]-VDU@=!E;
MYO$ L0"HL @<^,<3EOQAB!2ER6!&Z['ZP5$SXI<]3<(@\$R K<=H&, @<F0=
MQ/4DS6>89M:\HY@J M+'LNY2 BV</7=E9J[@!*/C/"D))MPQ_DGAPF%Z"AUE
M[&7YPUR4H+X<./7R6.5XR(G WUO8Y)[7]3PD);?,BVVO8DB%U=X5W\WXL^)+
MT^QZ-O%T8_DE*^]?_:79)9ZC.?:6]VM=?=67EJEY'MGR]F,.W'2)XUDM''AS
M*/[ )N]N9]/O/U+G;1*IVVWP13RBO5O3EP!QRH5PQ\[FW;&U8[*'.>%><E9[
M.>N\L!)^?GY:&%/K=[3;E9L> *PFL-)N.3*[L<_2T'<K& LC1-OL$NVRR+M2
M3"[_/I??>>SEWWF1V\*,<IS;CG,]&]ELB"%S^($=</$E+24MY<":.+"6!0H,
M7?ISZQ>5AAA 37'SI-Q6SQ[/HVO3I4^K)N)0'<MJ>TA'KGS8(<OT0,1I2)9I
M ]G&TO?<=J3E8B2%1@K-PPU7K!^^#D&R:WO85;>;AO'-6*(&5TH3>93Z$2JE
M#^\R'Y> 9_7\JH/VEGF0DFUO/J'O= #$4V<TR55;<I6U2Q_DI[?KWO;U?&YV
MO:W:_!TC>-O8I6R"008?[K,%X%[(U2!&?\I-; Y$LC>U4A/9*WE#/6DV[1"E
M)VEO/4'.(8T/A<@EFUDR3[:R:)FQ9!A$AJ]D^&K_AW)A[;2,6^UD.7F[*,"G
MSF&2JXZ@HF78JGG+V:XHI Q=K81\;<GIWL>F68,X7L:OMCHB=5G7.>G,+J.:
MT[3,H2=I<#U!QB$[G78@ U>M.Z!"!JZ.D TMTZYDW&KO!+Q*^TE.L:75\RA)
M!RSMW_,6:IJW?KU/TQR;1A!V)V/JJ7.=9*HMD_N;'2"5R[GI<LI8UM,QT'1C
M_Q::C&7)6-;;UU73<QF26-M;ZJY/LA^ B23CK&^W[Z"392SK./G/75T>6-\6
M,^FYX<@#ZV4,:\^[?=KZAZLWS7=I! UW.NCSJ3.89*IM]P7;%=^0R[DZP+%+
M88L,5S7,#C.6:,QCDZQ!#"^C51N3[%W*JK-QXL%@/&1*T&/!EU$2#W-EE":W
M*1UD,IJU:31K2=&*C&9)QEF=7]OX C6Y9K,!$M)U93BK+6;4<R+#63*<M=>4
M+#S2%DREB2&%Y^I5OY0V5 ?IV6=XQ![KW\OHUTYJ4F9KR?#7_KG*W,5LE_&O
MIJVGV5V2X-/0Y93Q+QG_:K8I=\30Q(%.SKA)<K#14I8QF@:]N1.1BQ.FCWP(
MPM(SAOA4Q9?%VTSX/DS&>!QS><'<,AR=Z UIK[T?LC:(F76R4X;RDV@F+V5%
MRLJ:G0R:&FJ5LB)EI5&R8EK=]=.U?H P]Y[E9@=?ZU +OB1QI&TD;I ,+?#-
M?LXI#!K^#>.OK_X)?Y6CXS2*AR%X("]-&\8WH.EM/!34L":_3P@P.[\UAS4]
MEU6SGB%8/QXRM3QTT> LJUR-TP<=*25*4B7O,64(#U &\-!>IC"8::A<LU'.
M!CY+%5/K*'B0N!(7Q]2'BG^O_(0H5)YN"((_&-$4OLF3=9_G=)11&@/I8'Y*
M.&9PZ\MJ458M@>[6A)1+;7U1BD7P&K$(J@)_D!X!7!H/QT '-DR3?I\O0CQ4
M$EBD_"Y1!K4C_F"\XS"&-^&BX051K9WT9",C3V/:_V4MBJGS)'.,)I-LPFDU
MIOT9'C".:)"/4Y@&D#3+,^#P/LT%W]5[2#Z_Z\7(]BE3@"]SH!0P61)%&<N1
M>5-X*JP&_!LDMT,83JC ')F0A?-A<)^S":&S\6@$=]/;E#$<QXLG3_0"'::H
MBY0!@@ I<Q3X).)\"W+OQT/Q4<FV\)58"I!JOE+K DQGX5J%K!S6W(KC@XM7
MP:,3W/BCHWL^D'M%<, =S4!2Z#"+6%K@4[&^M<&-6!HGX7K+VC;T@54=\YDO
MI-Z['E!6T0N2\97#UE\UXA5K#K< 7.$M>2].0^6_8U@J6#NX!;'\:=)NPGJ5
M1$1I,N"<S^H'+LV@<O8TR8'Z: (2/4;#  :1(R\A1B9IKDQ#]*S507&W'=B)
M9=VE!%HX^[FK1DD6(^B\Y/P<?V6_W,5AWH/QPW"+H1,TS6H?/UO\!.J#-3O.
MV2_%*[7E]\R?47W\E=&]:5+6_^ZE$Q?AEJD^K-P7E48P\)>T?T?O,R1M+YV:
MXTKBB=F^^J>?_OQJT6L?6L<CTVK:BWK,P8A?\5TOXQPX*)CS<18,]RT;@D(3
M^2LGX0 0)@-5AMRNG D\6@MF&@LJ-SUT0/K]Y [!(F4C=%>&H*1HX4_$F; T
MT B^K1&#3A-CUIG)>V"I\0M76!V"%RK?!J]&1;;<!5E(0>XRSES!D9R.\Z0D
MNG![^2>%JXRI1W24L9?E#W/1F/H"(OG*T]/C(2<D?V\AGY[7]3Q<#BZEQ0YC
M,:1"@KOBNYFX@?C2M+N69Q-/7W[)ROM7?TFZID,,V]OR?JV[8EA:US(USR-;
MWO[0P%W=<&WK, ,W7>)X*YZ]P\"UKJ-[AN>VCN)ZEUB:X1EKWO_ ?GH)-1B-
M:4(VB;=)1'2WP1>V28NS #B 7PC</IOW%M<.?I>H.4R&[(&4K0TNE:S57M8Z
M+_R71V.A!V"J"?QSX+S%E3RS<F.A#0R%UN-C)S3N@6B2"?;,!$Y+LEI;R9)R
MJ+L-M55*J)$4; /A)'!O7GX88@ FQ6V.<B\[6[]S=[.67XZF>:-Y6DG_!ZJ3
M>/M@:/?("?\[I%8>B&0-2:UL(#-YNU29/8DT8LFM[>%6MVF=:22W2FY=T<&N
MH24:QUVA!E?IZO*T]MUROY?F32Q*@ODQL@5,C6BKMH!_S&R!0P[\@-D"1E<S
M+<UM7[: UG5MBWB.S!;XT;=T+S')2R8+2,Z2R0)RNZ'9#"63!203R&2!-FW*
M_H!#;942:B0%VT X"=PR64".IE&CD<D",EE ;F@]:DM:;9?&U7+_5;+KX_;<
M)4W=@)7L*MEUCC*R35W;T@4,F2ZP6[K RE9Q3>W^]+!)76O[LE&3A4GON-D&
M<1O=7L#(;+NXVJA&- >2JT5W(W%YU;.'G_\"OOJXG\=%5QK>*ZIHB51U2)KM
M=C48]7G#KZKC%?:A& )A>90#1I-A![$,/@V8,NK3X1 ?__SL_;L72G:?P1RZ
M,^+4N"8I6_4E$2?LG ]A35O>@43,).8SF6EOJ'7-JKLA<@Q\X%4?'$4(.LAL
MH_+$HDXI!$# <N08F(J1-UF6E[-B-!W"XQ+\YBM\C@R=/<27<XOW0-)3'/[?
ML_B3]LDTO6>-9?/53/U[_-]Q',;Y/5^/UW2$\J"\+\0[:S>?_\F4'@4X[P&R
M)REJ70#1*![28<!$C\EDQ%*.<UFM*R?P9S*^[2FCL0_0P D#7WX%D,3^? Q[
M?/%V?PQ(EP-'CD=1"F-1(L:R#@H+\%LRQ!:,]P/1V >> $_B*B49<5C%:T57
M-9[=YB<PC"05EZ8L'OCC-.,H7(WF-@'38<@_NDUI^5CLL)G2H.+M^M_*"1_F
MDMX_'>4.R0,B;MA:5Z^$'(0IH%FOP__F<_Q*^]4T@$1?6)'0QT"!B+9F@(H*
M6C!\:B"<2%KV#:B.FF'3I_&!80M+!A92C-_!$U,6,-3,Y5OX<1EU,G%:XGNG
MZ-E!/.B/T;8J6EU^A35.QMD"<B;IA)H=CG4!V&H4Z+&TGVS&TJ^PKMA?$!_.
MPDY]@$LX 3@ )*?ZK*O\*[F#9Z8=/GSJQWT4Q]J< 3.!<18\+<Y@-"/&I1"X
M,!G./B$;@QF:9=$8&1]AN,^ B1%-XRCFJG_)Q"8MZT3[NPP'D3(@"@,ZEG2A
MR)WX'4CFAJWM&J_MW\!PD&O>(\^FG,>>"!H.D[QH*X96'QU.^L)R&1JE23@.
M@+=!3C-DHA"!CS-(PN]% S/@[0_A@RP!?LAC;!<+;(2,H- ,!3CQ"]&Y'?=1
M%$'!C.#1(/V(20*Z!@.6!C&LR'>X'A@;1&Z '%;8G.5( K@ZQE& K)QD)3IP
MZW68 V,7'3JGFU$"H>DM?U2-KP$.<N4.@$[Q00S03N C]@5CW[':W&C0BQD7
MOKB0@1S%8,+\>0_8'V\!T>7/["I_3AY0?,G?579!KMON=>T#7%89[8B^R7"(
MY@Z(\UV<]X RMPDWX''J\#CXMP8R,RTX"VTU.06R+M5 C'F:EOV81_&((==,
M32.9#'X:6[E]F )PWK()LO'9]I/D"T?/^B"G[DMXT\SQL- =\#H8>++LG>!%
MP]6<$T> ]N,I';!($Q;-2H$C/G2ONW6@QYFFO-]QHD3CE%O!R8I^X<!N_;S'
MM:]8_3".HC@ AXJ/!O ^A@'S7M4%6J0UM.@H/C>K*V N.+:V[.@]"74'$PYB
M=.<$Z^RD0)%#5NG]&B--+TRE6*9')/00C*2C9$"-/G;SYJ\<9X*2PSEC"LSQ
M!#16J!J:H>$;L_$ IU*(-3^*M%BUV@"0L;^B<<:'5LDWKBP#W85X)3NH[DL=
M&)KLH+H_<^$U2N>;?G+7<B-ANCFI0):I%J4@R##N^U)'<U2*<-[K'*KPI+J/
M6K9.-+)=/9%-NIKC&:NJ6W:J)[(\TR ':N)IF<30#U5/M-' 977+DZU!:$IU
M2ZNR0F5RHRQ-D$RPA]*$]11+4_3*X0=V6(Z5Y#Q,R8*T?]IK_^R6=']@JZ=E
M*=F',E%9+MQ?#&O'H=A ?S[.^)E1+UXV/ ?L1WS_(=@ZXG^>4*7!516=GFP"
M[C\];C>R'9U(!\M^G:=+R](&G^N&#3]MA7L'D"7)JY)7E_.JYW3)BTT\OY99
M/@>BVSE/J5M'11R.A#NDG#>"AKK>U(ZM<LV6K9GM+2Q$DF;E&K1[P],N'Q,S
MME-/3::AKI&NM0-H'-"^DHNVM-C66EAL^[0,C4.&6'J89%:F)8NDH9E4J".7
MOJ\,YQ9?%F\SX?LP&6/^PM)X[]&IWI#2SOV0M4'<_-SK>MLYQD^AA%E*B922
MM8SLKKM,76[>KOIX.8.+RNZJR.I)90*W.UNPV@(I=CUJJ<VU"I*417W&BVKH
M(,$D8)YXG?>PCJK#4P;A\S&F%_+'8.7+N,B8?B"Y??*2KH*9B_6*P.%:8PO'
M*4]T7)VWN+R6<9T*1N6.ULO+YJIX9PH7)J/K8,8[V#]8&)!$RH#F3- !4RW+
MJEQ8J7$$]XB)9..XJ-:8/+_':!@@@45)$,^^G[EM>?U/5T'*UFJA^99D5:]P
MQU(L2 )DXL5U211E0'?_GA.')XZ/>-T!_OJ3#@Q8U9F557-%TKG(VG^?!'#A
MAHL"0VQ3\=$".9H$U)X<,M0W1^,%<<.-)3!>($L@&67M Y>31441BYAT1KP6
MUE+P*HLO7+9 [<812"IP:Q]%H9?T0ZR7ARD653!%[2,(%M;@<1&>%"#B%/UQ
MW _59)R7"=0+Q5<4@*#<_G<,PV9IIO23@-=(%'6>BG(H"CN/3.%6%0XN*A2L
M EM/6G:C!?&[=5+^5PLNK]LK7@5F;YA-ZGAYN>X=\$C.AF4I=EE^K=SUXJ '
MBC,I=/L)/+E?*H/%HK'K!!;+Q8H)I.PVSK K :C6.,72MFKXO.5(SF\6,E%]
M!<-_@[5S_;X"YDJ<A/A.7GR!Q<4+Y\"+YP3*L)EA9'D2?"E+SMDWK+8L.X/P
M"K/!J)_<,U9<5\HJ+TOK+M>I6[=)L/2VMDFXBB+U5]KGM6G7/08+=E(K?FRW
MN/_)RLI>7AZ,!<' C:I?3#?CTZW7>O(*PI !,V)U(Z^JY];>N,_*!@:\Z)=7
M]!6VW_6T1CW[5H3U7B>#09QEJ-A6,(YMUAEGK9.(9*%?5>BGMZC0KQ&U76;7
MLAW#TK>L[>HZ%B[;(4J[7*]K;/+P ^PR'#YQ^+CQI_.;LPO%G&T5],CU%BVG
MX1\?3BYOSF].;L[_<Z:<7)XJ\,'OY>^GY]>O?[^Z_O#^[%HY^?7JPXUR<?+^
MWV<WROOSZW]O'/IKA8J]XF7OL2B<]3^+9E9@Q#+>[2$#$Y6;A6B33=I5U6V\
M."LZ#F#'&;0X19^FZ88&<V7X!1.7#18RQKX(7^Y;/,">&T6OK,IBK;7*XJTG
MT$VM2O?KWF\:9U^F&@Y=U=H;U&8P2L!JOR]&+SY'.@RQL4!?=.X(&=>SPBRH
M.9-@%(R%X;ZHDX-HR $WW3)X&+K9;R=?7H]@[@G:W6>3CG7\2C#;F0_&-C@3
MMX)$'5B =(3]!]C<=\+W3X;LOK32XV&6I^-Z+S'Q]WJ-EC;NXP#/G&[.U)U0
MNV0G]@WH-TX+)YV/$E<':5YK[">LK6RJ4UK*.ZK4IW$Z\6FR7I+F*EPYF'']
MJZ+O-5M1P#?XO'YR)\8%#DH4]]DD_+&P Q1V=QL,6!CCNH!Y@:TTT/U*8/2U
M'>'IN2AWO#G%Q)*M(J;81(0[8*)33$3C\LT*3&',-I\8;UO"W\+CUY.62SPF
MM'1F1;.<@J3W'=$VA=6Z*TTWV:&UR58\.#5G;%533&ZJHPQ<,NX77:TF-?J\
M<=[]E"R'[#9EB]HW5=:W8V]L?4O;3MIV#;1+N&U'I&VW"PU?7UW>O+_Z_9K;
M=>_>7[T^.T53KJ5[MJO#/J=QAC%&5*^OL;U44NQ!OL,H6P@?MSST<R4V(*@(
M[-3W*D2CIL)2P]!A,.8V:X(-L,#@+)IB%M\7<4G>VXU_WP'=F"D,E:LP04!)
M"AT,#QFRK#(EP@F%@SJ%1Q6%5W>SZBI7:SX%=2M#Q2<LHB(TK.">9B+:6:&I
MF_*8%^_!Q9LA#T$I#T1WK**W%[_;9^4[B[UE)!>/U\8!]LOA'<O0S@E%#S<>
M CM[K3SG;?)H)MK*O8%G@W6C_O&"D\MGX _P+GE 62!;'SOS!:@$PXZ82I;A
MCZ(%#ZQK6$3;\'7%FXI>>+RM71E GO1[++Y].!CWCZP6SD,29)W"E /"\#G4
M*8,=\H)@/!CWBY:"HKG?&'>U"P,T.1RGH4V##8OXI#$R#[/-N/V>LEN:UONR
MA35.Z2J_\MUQ81."05AP:ZWI]:[,V=EU<L+"A'?SX'XXZ0VW)L-7(E?N-BSD
M]CYN_#=]&^Z!]EL3_^8<[6/L#5@@]K8([>XZ4</"_^T>G.<+.;P%T>$"3)51
MCS/N?*-VRA-"SMZ_*_JP=XI],MZ7$6"B3P/>9),->WSARU:6<4FRB@$[]6R9
MJG&\>&HFV)#WX$04X9DK0L+]<18+=)_$(!3EK.+"W^APC$ZK7FP)WK&J*VVX
MI/E\.<9H/ R*IH\4N;C<6,#9SMP%0O"Y:L)9.$=X:0FAQ00P\I+'^3AG1?"C
M($(A4 H&%&HB*6"V) C'[QA;6/(>F[B/QF,/!:DYVBAYL1>/NXS3VJ]HZHP!
M%J'%,'L)W,0$99COP173FYG:'>_96%(,R/+;&!"OV/>\J/"5JY.<?F'(NFS$
M_3XV%&$"3I2)DJGA1UU#\@!+^6[\';0Y!5::689RF--\APJ!#6F _1I7Y.8<
M6@#WLSM6JF_V+6"CDBN7<!Z0#T3"1WKYP#X=X=>+)*GA5!0&'_ :<\F&]__(
M-N ]H0&"XNB&37-G^-U<IY21$> >(2%H6.#&<UI3$O=*/_Z"*E4D@)0W"%;N
M;#N'5:$&U]U/J*%AZNG=R?L;Y?P<C-6;?YV]5\XOWUR]OSBY.;^Z7$X+HFE/
M*NSBZ":QM&W#+JYGF)9]H+"+KCDV6='14(9==@R[H$[03V3<91<BOL?H^1M0
MJDFZJ.#IB>R251%[OED0B>D*TZ3N;R-'"2+H)Z6W=C($XQ+/+N'YS:"-2_?Z
MWU6:USVC::$=3UE0]]B$1>IP0RPM(OO<'Q].5%^EOZL&XU.#'*7L*QXM@2[H
M;&Q@>FQK#V?9>365CM"-UB;&J&#NJO I]FQ_6705;@ 3&H;,EME,M1M=P]*)
M;6RGVJTN(2[QUM6^&WWI:5W+TBUM7;M!JO;M5+LM-?LN-#S[UHO]>&$9\V*M
MWG)?P.MZ7K7/N3%@@))V75,C6S<97_6EXW9UW?8L3R+&P?HAZ%V]Y7!1B>#V
M=LJ;-]N&&,ALB $%B<\NQ,TB'HAZ*=*R\3(<+VW#.*?L028@\9=G2B]ET?\]
M*WXW=57_K\G#G;U\ #[1&-!,-ZFJD^?TA?(:UQ336LHPW;MJ:^6LVGJY$ELK
M__R9SII<&[3416ONAY/<->15TN> _5V>.OU ,RQJK]4F DK-<#S-8&RG&=Y4
M.Q12,TC-(#5#$^EG&M)GD)IA2\U@3/L,U\79JKII:=)CD'JA,?21>F$;O2 ]
M!JD7MM4+QC9Z0?H+4B](O=!L^NF:WCV_7%23)&FX+@W_^O7][\KY,,MYJOAI
M$O"ZY\T[64M!ED G@>Z 0'?]^E\2Z'8%NNN@QP94PIR$.0ESS:,?PMSKD]\E
MS.T*<Z]I/RA:\RF_Q\,O/I::2="3H"=!KW'T0] [/7LC06]7T#O%5J6QQ#R)
M>1+S&DX_Q+S?3WZ5F+<KYOU.?=;/)-Y)O)-XUV#Z(=Z]>W\F\6Y7O'LG#DF0
MGJU$O6.@WN9=#A\Z+(,84UU7E]=1+WQ#8ZN^&U#@;1ZDP%MW%Q%O@P+O-5?V
M,:E7%Z6%G6U6I@I=G[^]/+G!WJ#M;I+Y;IQF8RI.SQ,]]'AW+]$F??YXDZJ;
MX@D_\4?1/9-TBAOQ0*"4%OVY0FS=%5!QYF&/]^OFW2%$>\FB#Q=V5\RQ-62/
M]J.R&SJG<MG*$OM5C(=P$W\>'>>]A/>&W+"A7T,J@QW-L;4M6PD0N^LYIJTY
MAZ@,-KJV9VBN<8AG$](U36+JZY8T-]MVF;,:[$W,UQ_:L+@X>?W^ZNW9Y?GK
MZXYR?OEZ_;X*I50-$Y&FN0Z?-($WI&NSBA]^_?A2NH8[T._G[&?E.H#Q*O].
MV#"^W=P/;):,-&LTC\UQ2X\Z;P4OUOFPHUQT3[L=Y5T/_I%,V6:F; /K87 L
M#LMSDU[W8A;-E[=)-I1L>%@V?+ZBN/)%V]E/+K@T7P]AOOY&\5'_IFG*^DL[
MQ+5%2)HU&FF_;L*,DA&?#".V@=VNP4]*4N4_8!PHB^S7N3+<5K!D@_8M&T,3
M*1C;6M%S,K"%%2U)/$_B4SRU[*5RF7P5YZ<XXOB4M6W99@G1L4:SKQ,)'LR4
M,+UM,R66]:!O;/I$4YOF$YE3L3WUSO[ZU_FOYS?*^>7IV5]K[MK;C=JUWZF?
MM]<EGFX8[D'Z>=M=2W,=9]UM^U8JRSVT$-H^+VAA:YZJI[U0F>] \,5/EV-4
MJ NZY310=36'#=H=.) -WY%>LDF7;/B^5[.^"2-K&$ZV! UERT*)AK+)N43#
M1@CSD=%0-O:6:"@;>TLL;(0H'QT+I64HL5 VLY98^#1$>>]!Y:*M\]KA8TG9
M=2F[N-FS! ()!(UDUZ+ML02"PP#!3#-D"0,2!AK)K$5;8 D#AX&!E<V")2A(
M4&@DZQ9M<R4H' 845C73E9@@,:&1G%NTE968<!A,6-9L5N*!Q(-&<FW1=E7B
MP6'P8'4SUJU1P6DJ*!QS8(NK;%97SLBBEK6*6JSE12T_^TEXCW4K^:#_ZO\#
M4$L#!!0    ( -R 9TW^G=2<'0T   ]_   1    ;6=N>"TR,#$X,#DS,"YX
M<V3M75N3VC@6?L^O\/*RNU5#8S=T^E+I3!&@$ZKHA@(RF;<I80M0Q5B,)/=E
M?OT>R3:8BV6;R^(9.I5*P-8Y1T>?SDV2S:=?7V>N\8P9)]2[+UD79LG GDT=
MXDWN2]^'#^6;TJ^?/WSX]*]R^?<O_8[1I+8_PYXP&@PC@1WCA8BI\</!_*<Q
M9G1F_*#L)WE&Y?)G1=2@\S=&)E-A7)K6]?I==C>ZKEH?:]5:V:PBLUS#-S=E
MA*JC,KZY':'+D6.-;/.7R=W5"#LF-FME-+JY+M<^.D[YQKFZ+=]61]B\&MFU
MFZJMF+[R.VY/\0P9H)C'[U[Y?6DJQ/RN4GEY>;EXJ5Y0-JE<FJ95^?VQ,U!-
M2V';V<1[7;2>(9O1"?:(S2]L.@,2Z\:\K9I1X]<1<\D*;WDEXEZM$(\+Y-DX
M:N]1S_-GVPD<P2KB;8XKT*@,K3 C]H(NG6B5P"7>3TV_Y.T1XM O) 0C(U_@
M!\IF33Q&OBON2[[WIX]<,B;8@:G@8@GV2H/8;8'8!(LG-,-\CFR</G:?/QB&
MA(C,YI0)P]N@'",^4GWE3"BRLFF5JU;)"$#M4!L)-5/#]DJW#:(*=@67W\I+
M%A>OW"E5LG? Y^4)0O/\G8@3!AT)K^3O3&S&6K>WMY57"5YB-S:Q5NW+\F/9
MNLPG-FDR9Y<-W\H1W2'ZL)RX^?H0T>W9A^TVFJ4K<<JG@%#VY5;VQ?JX7U]V
MZ\>NG5"L.+8O)O2YXF"2:AP\B4A^2+2'T.L8Q+DO29_\1Q1TZI[3\@01;VUO
M#"Y)":J/N&#(%N#/PD_W)<%\F":R__>E;+0><5TT<G%$J[S[W1R&B3I#&+/[
MDN,S10.*^D!&A"^_?674G]^7@N9$X!DX1=4\N +L(9"VX;IDHM&P@WD'C2B(
MH(1A/L#LF6#V^+5IFM>/>#;"+$F_+)0'URX(9G<.G2'B95 /ICUTI#M^I"ZV
M?1?S(?V"F_@9NW2.'8"F06<P)VT"H>4O['SW',SJ$X85F[CF8^3RA>I[<CT2
MYL03>()9AE'I^2.7V-WQ&,M9@CRG"XE8W76ID.VZ<RE,#WX>#B>?!.'4;-;[
M0[U66QJ>O/-]F%:>CQ\@Q6U0V1=I<>09+^83U^N4G?[DJF[O7X-ZG( !*<E]
M;&.XJ0R,>@-![9\_$&,(U(B,<C!%X(X2;?>P0M+'+,A$1#[OK;AG,60JX#NX
MF4<"7DA0#_?0FVPRI,,I84X/,4$PAS2Z#<[!!6\E((GN,7!33+QE]':'%9)C
MQ();(^3*3.Z^9#/LD'P#"?!AJ!7>,@QEZU4Z; [NVP$IP!JYH4=7A8COR<HT
M<&P\X\#MPS*/,:Z-DX-'QQLF6;@Z$/)"$_@"^:VTDSGVN.J-LI90)PB$?2PS
M$1OJ=77CNT<$K]M@>I /#:5^0_PJOKAP*W$4CRCQ6!Y/1"(R#&C0\VBJ/&"<
M.!!;6A;5F,*@PV74^:H<9Z8@M:7]R8,2^+%GZ?ZH]X70MF=?I"1&2<U/K@B$
M.-7?'T1,&S[X<<A0.P2-B*MJ$Y@08%ER):V!^%2%P+G0A=&=N.WAUHX[8Q=!
MKD-L\"Q:0]S:=G=3/*J_CJ4[4'9Z3MCE9?:75L;F8'#J6O;AXAL=CV?(\SJH
M3R%L=(1S ;7)VM5T(]Z!T<G-NS6;N_0-8Q7U>CZSIV" /9ABC^B5S/Q9'=@A
M5YFM7'N5T;*'640%'VUM*G,8[H<?)1BB><#]V 5&%'A[D%U(C50V<IPR(T'4
ML49/L<\P?##?WP1^_%HWK<N%2JIFMG%*@,]$>G(;6EW5R+,"4A@5&E/D3< S
M:>-S'R8GE&LOB#F);C\WGU-[_V7FU>O_5KV\OLV:J*TU/SF$T1H#&+Y:,(8D
MH0MS;:)D)F=D:63'6:K(ONAXN+KZ'U1.PRRT,7:XS)3[] VY<B4E+1CKB4X<
M8U4< W<O;>M9I0B7IE5-67?5TA3&(!?K7[QN3PE,/2=]AV +R<F7_Q\08;\A
MU\?=<;2N&>4BB0II:0IK75&AUL<3WT6"LK?U-<RL/F<75G^'U9F-<B[[0DTB
MZ<D-=FNVV7")1VSDAHN!9*>4-9E)091N4#8/B_4LZFUI7A!%U@9^!ZP*HU 8
MFM$D6L/FW;%<P4;>&X\5?UU?2&\@LQBUEQ*LH;6]@*2/.91+V)&W./>EGU#^
M)JC(P6\DNZ[_D_@3)Q[@F D7&#QGDS!LBVQE7!K5Z2=/%'B69PKVCF$Y6!4U
MABW+M_4PE+7L2Z([.>)USK&(UM@RJJ6G.;E*\8HEOE^WW"'UG-:@UXLT2*YR
M=^!4U.ST22X!CJ%LE9W[/@>-H(K%&MV3"0J[K5(7PRE^1.PGSNB/-00GG\7A
MD(>N$LH?.O'40D1/]2$1MU2Z(U6$$=$^!TDX9 2+-0;J/?C"9WB H)&_Y^F1
M[)R+&H-6M\9D43Q1+6#B@C<>4IDS(7!#X))B"U4-RK7[JGOP+*P;6-]$[(II
M#&'>)-QV*0?\TX^#[,*J".<\8IEVM&<VH[XGZL^(J,[%,FN-\GF8%#7PK7N"
M1'4W&Q95I>CT<Y;CI86)9\MZ(%S5V+^PR,JHJ"Z]+I_5V%R.3LE9]$0GQ_D)
M!;LE;2_@C;OCNNMB-GD#_]GVQE#V$NI+URDK_I1EL1V9G7P08JZS@>9$(#=8
MV'B$&0M^5+/>$60F>7SSG@**<J@XEF#(7.UP:^@[,RZJVQA2@'NAGMHGR3@F
M&2@+F]7)+5?LA+M"\EQN2AV4V+ZH47WCQ&WVFB\+:0'*OO@A"+-JY3@R$6M]
M<M\>[;:V7FW7YQ!^PT6A(0T7^5+W:364ISXW,7RAPRE$5/"4 _(J,/:2#^-I
MX=N!T<F1C:)F$T?1LXG'F(%;Z^N\:AI941W.(A"H=9"]XVPV+D4-JMN/4 X9
M\CBRE1>2QR-SGL#<)"_HP>W8<WM?P>TR3][>X:$_'?')S3MROW([$H8&NM;>
MV)=)]=UZXE.[[UBN6\^1ZX;IPE^:(SD'X%R4U!)Y'N3!DH6\$EZ;SXDWIL$%
MN"1?IW 7O5.AC\?1ZU V7CNRY<45ZK\[Q&Q&I;*ZQI5Y\. BP3SVYH> P93A
M<0!K.7JSR!\V<B^@)U&3#0%2]>6+(>3M"I#8$BNU";G0)^(0C!@G$)O#$2JR
M^@X>YU4?2$B0"/_MM0?CR:L]D&#W;Z_XG.&\B@,)EP7_#L!+>NDPE%>-WJN!
MMKQ7HV3(IM_[[<0W JFN:%E$HB/AR^GZV31-"_X:Y>7;J&(?@9L1L#-B_#Y5
MUKFL\?<Y=KK>9_5Y?8Q"XK")AG#-I62F6[7%K63AQ0@##3*-[M.@VVDWZ\-6
M\TN]4W]JM ;?6JWA(",LR?0:3"R%R24 ,8!QPR$H<59&R,L(F+T#,AST$ .M
MIEC(Q?I]T5EEIH=*NH/L4!G_6>']WS.%;C"$?Q];3\-!]Z';:_7KPS;<K3\U
M&]W'7K_UK?4T:/_6ZG0'NQA:#N9Z:*NF6=-!NQ1D=!^,I2@#9!DKP@PI[1WK
MAT9]\.VAT_VQ+ZQ+/GH$:Z9YE1U!R=50;,\(JB^($T['O9@2:CD-"JHQN"BH
MQ&Q;;L@3;]*C+K&)/)V5";Q=.&O@O+1,RPI2E<6)"/BBI!AT;,3EJ,PE)LE8
MBC(B6>\8ZY X/M:9,+\TX>_A,(?P&WXZI\B[ SCJO3)'!#_DKX.^:E:K!X4^
MD/D.O!:8)A:(N$=$/A*@@[YFUFH'A3X4>D[8+QYOI.,' JC(9R/D"1>F2ONL
M *=QT<?K*TN5L2LH2HZ&8BFA7# U8ES?48I&(I<;SL9+[W(_5G="[!R=:\IP
MYW.D&9GIG>9U;4?PSM ]!@]DR$D[P+;/U(.O&;':2JIWA#>66B1:06;)QECR
M.7,$<OD[#0.]D[NM9D3C'-W:ME'-Y\MT'+0.S#)KF8$Y0Y>ESC1-J>M@QEM_
M^D2\901D"Z'67<$?M?"Y@D.<R;^-@,U9#WX^HTBFUYN$K(6R0'&6%K'RY!3:
M>'(JZR)S"A>]K50MM<2\ M *1U6A*I[&DND[2-%(!"^ZR&=,N5CJ[:M6VP4^
M:!0(>3>[S>%7;Q(]** K'/5X7M7,CSOAJ62\P[DY^-M_%>6@^.I%Z '_"'7O
M3H"#4",NU0C%OL^!38!2;B\?HSCHM,@M53]3KFOFS0XS)=-D6O;E??IL(O74
MKK>;T7M7#SI%MG+63X.;FGF[D\-0LHQ(V%GBK"J/C=^KR%,";1+KT^M;:S.>
M*T9EQ<F(LSI[('(MGVE9:!?0+LUJ0E&Z!91S7$/;/K3;K[9>Y<><^?(> K3.
M\=*J669F9#6W0J'O3G(Q),%CF/()+>)-ZIS[L^"YS$, G\9;CSG$Q(V]=@WF
M@3 CE&;$Q+VCO>TGG**?:CJ8A6]GJ\>X6K,VM@;3[#I".I)TEO ^8=&AG"]_
MLB(3>NM4VAQ';GQLE+# P9 L#.!A*";G.^A/\O7<\IG7?":4QD5O,5<U:V,O
M:A,4>3'B^T^WCT^5U6<8@^^QYQS5A>"WBS]_^!]02P,$%     @ W(!G354O
M_&6_$@  E+4  !4   !M9VYX+3(P,3@P.3,P7V-A;"YX;6SE75M3&TFR?I]?
MP?&^GAKJ?IF8F0V,\0X1C"&,9V??%'4U?49TL]T"F_WU)TL"FXM 0JH">?V
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M+)&& ZF5EU5F]&7 /;' J:Y+_8*D*F[(BA2[7;XU$M1*$T!L;&G.ZAH.$I,
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MY77R..J;.KH:[/*+ Y[]^L/_ U!+ P04    " #<@&=-US;^^;4^   +I (
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M,8R3+] _K4*_'(X^P"E^P'0Q(I1H6N;_N1A/JC(OA]K3&5&(X%C67M X!++
M>6)<:J=LTM(9O6L^KC. W1-R+PQ:@\7-X&_@7&^IRYYU1G$'A3852RN!$L!\
M#8J/)AO(*KLHW &NID^D;0UV U__!8P&9'R.W^'HPV>2Z!<8]U,]LNJ?7DPP
M]R)71?.D6?9DF^A<-(L\<99"Y@(R)[^ER4'0/7(=)]>Z!*O!]OTOK+E F$^^
MD$OS"=]<5(V^+5-1WUY,:IY,33VZ(7610LL"S'@D/5@DC613F$45)1E%*MLF
MR]UFXAXG\W8 [=+SC?_\>4'59#/_N^, ZF<G'_[Q\O7;?W4:*_WMH>W"HI<(
MOA !72 &9Z2TGJ.6%H(@FTA:IX-4O"354SH;9;-CRMG =(PUPL!R,IO(I<W%
M!Q_MQE'KE17C87DWPG'-*:EC)[I\Z'\:]$L_ 5$TI>'%H!Z"O!N>]A,9=9O
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M-)*5&,!L'.=PC^2O!NEK#<_?./1AK><W!^*.X2Q6M<@%N):@$B:=I(!Z4A?
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MT:E>_HYC)\266K_EA(UOQ89%JZB7N)"VLK)6*6(Z*Y(K8&">C",PIF3N5^/
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M1/\SQU[)>BT@-ZI/O D*>ZMDO8JPCX0JZU:R/@RFM#<Z?^D/7PW23Y=F4(Z
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M:4+LF2^'OC^\[X___7*$^*HV(</Q9#K !,GPD#C#*#G3WI,A2[]C!CUDG[2
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MA6?M3D/Y'6ASL]G"!AWNJSIL:GU5:_GU62T[D[:[PGQ2KT/ODQ*HNU8.:7!
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MRF^9,V+_W>?(&7$4_8F<$<>?G>OY;;>S2T.4*41AE')M&J8T@IHD),08):G
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M]-:U!K"YTGZ[K<VW2+@VZEC H(RI@AB;BV>&A"8<_:.D08##X+**A@YHYD9
M'703>% '(ICSF:*>;3OU#2\M;^@R7';,-=D@3'1*?E $<3,L'W:&I2'!K9O.
M6XL!\E 8<8!BQZV5Z +HF<LG#M#=^8J*0QH=1KR[\Y*D",49HU!2(36-QA$D
M.. P"424L!"%(4,NL1Q#27&RZ(W!_.?.9O/DIE'X962V>+:Y;S&3_<W+W;P
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M?/^C,F$7-RL3ZJ7[NN;K_+$.\#.W$/GJ0?_N_;ULKGFK12Q%FB$N8:+I >)
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MN-LBC$G&,$D@RR(*,5)([VM2#M-0I#3$:8!#:>T]ZMK[W*AK@Q_P5@!PUTD
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M7:*MIR;51:T-+DKP^]^O@S#:.(=W/N3;\-+649%J2XG'',,H20C$RF3>E8+
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M'XW%9S)E=N&=&,<\C#!,B2FP2F0 J<0I5"@4E.$T2NT*K-IT-C<2[+!J#NS
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M#WAKT\A$H"3,- U(D6AZU:S 0B&A$B$*(Y:*B%K5ASK?U=S(UO36U#$&&[3
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MM3WG@(&K1Y[(E^G_AVH K=3$9G\L#:. 2N5&L(1CB(00D)%(P) H3P(SF>/
MJF+ZX(ASHX5*8,MDD6%<S6C!*5J>&:*2]:Y=7J:5UNUCW]$8':>'U(.#3GL
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MYVMA>$06+-,@4TV>JYT2@[ "G"0R0O ^VD[.EX<(&L@ITXX%:47J T!/;8I
M!-3Q%:]H TQFJWZL:ZY&45JIF4+@/-61%8'5.:0!A*,-(A2Y=]T4SCU*5;\V
MIQW%W^U3T9(6!@"I7W"*\S A7D[RZ7BZ&IM=H[Y+=CQ&%M%%2%A+E66@#9@L
M!\T9MTE@2**3)_,GZ.K7/'4"JS8U,0!@;<IH5*NW;#$6A!$&E'$6@@P6,-=)
ME9I%=I@3KM\7S$Z@LY>L!Y!6_>$,*]:G7Z\K#T:)F)>.97"6>9*'Y"0*F<!X
M;VT1TC+1"5SNH:7?"I!.$+.OQ(< FEJW\GXVG=UFY=)<DCET44H'B(Z!TB2B
M0%]"]#G9J+EUW22P/DY6OW4=W4"I/3T,X-AZC\L;6X*.6QM8;9[!/!$?/(*K
M$Y69-%%6(YM4)_7?MZCHMW:C$\SL+N6A&)X'"N8NB^$^SN8K!2V7\W$\7]:[
MTB^SB_J&ZUY5UDL6,@<A:NV39J9>B@=R[8IDQCB#OKMF</O3WW<F6*LW!'WH
M= #6KK7:3Y41.?<6LG*<^.98YT0D8$)9:9(2MINZMX,6^79V3=$+^K;8 9U!
M8>!;H('L1\9JR6PH=/B9FA[* SB3,T2==<@RVXXJW?>DN]\+E*$#OFW%#\!K
MN>Q7<5EX\2(LQJE>88XGYTO,H\AD42PIR*Z6WN:B:F$L@^0SXR$SB@D[N>A[
M@JY^O8PAX+1-Q0W WOX-QU^_$=TGWRE<_(KOSVN"R(>R8NU&VOT=+HO@2I0
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MHXMQ)MM.DO'W+/CL#'K]P:1YD><V.AL$^G8H^)-1&2:U 1[J_5$)"GS6 E)
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MUU@140I;!XIU<L/5E,!^DRO[PVDK"AN J;T(#KZ%Z1<\K1'F_,?;T[,PGM?
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MU8\6(UUX3-:03=6.@2H1:4\X#5;J*&,JL6 G#;B:D==OS-4"#NY[D6A7*4.
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M3Z^3AE,P.229(+E:AQ=5 1>(&V=TD"7FQ-S&,_X#@? #"_3HIG2CQUG+0AU
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MOB_:FF0-"E&XP;@JR$RTCU@"'Q59_%!XK3ZSIC1[-CW2E,RM]+EM2N8VPAU
M8'J2_]_Y8KEBX,UL_AY_/TFIINVL2A1G4_HRK8WU:C*0RRHKF2!SS#7JKG/H
M@H,<F63)"V9=)SDE6U'Y[)(Z=SGWNM?O ,!;F_9^*"=Y=G:S5[]R7-$NA&3K
MMC-10ZRM+V-1P=44,(=-$CRWQNA]Q/3K@G6H^UG+BA@ F*Z%\[DV40OSO/CM
M+(<EDKX5\Y<3DC*+V2H!:&@'*F$]>*\-<!D3<E3,YM")!6Q"7;]PVQ\$F[:K
M=8T, &9OZUM;F)R<G4W&*5P_N[T\/ZT-T.@L>%T*IHMC8/4L=U%HA(Y<61U
M*QW)F<@1O%8%R,F0W*28@^OD-6(W<I]=WN8^1_ !-'Z4N+Y,!Y>)ET3[UX3
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M '(PK\9&D0UG6J<(1=5&"-I:"G%E[5R6"TO%)Z\ZR9_<:HP7?[YW\7LI9 !
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M8@0A-$=KN(N\3]]YHJ!7DWX;@J,M47ANWN[C<(M.;G51.1>0F&IU,Y,@6A=
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M4$L! A0#%     @ W(!G38YE&>8?!P  DR8  !4              ( !6 <
M &5X:&EB:70S,2TR<3,R,#$X+FAT;5!+ 0(4 Q0    ( -R 9TULI/-DY@,
M &L2   5              "  :H.  !E>&AI8FET,S(M,7$S,C Q."YH=&U0
M2P$"% ,4    " #<@&=-9-9U5=@#  "Z$0  %0              @ '#$@
M97AH:6)I=#,R+3)Q,S(P,3@N:'1M4$L! A0#%     @ W(!G3<]PO!^D1@$
MB70. !$              ( !SA8  &UG;G@M,C Q.# Y,S N:'1M4$L! A0#
M%     @ W(!G3?Z=U)P=#0  #W\  !$              ( !H5T! &UG;G@M
M,C Q.# Y,S N>'-D4$L! A0#%     @ W(!G354O_&6_$@  E+4  !4
M         ( ![6H! &UG;G@M,C Q.# Y,S!?8V%L+GAM;%!+ 0(4 Q0    (
M -R 9TW7-O[YM3X   ND @ 5              "  =]] 0!M9VYX+3(P,3@P
M.3,P7V1E9BYX;6Q02P$"% ,4    " #<@&=-TXZ99::   #V>@4 %0
M        @ ''O $ ;6=N>"TR,#$X,#DS,%]L86(N>&UL4$L! A0#%     @
MW(!G3<RM8G.M5@  CP,$ !4              ( !H#T" &UG;G@M,C Q.# Y
@,S!?<')E+GAM;%!+!08     "@ * )8"  " E (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
